WO2008039023A1 - Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists - Google Patents

Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists Download PDF

Info

Publication number
WO2008039023A1
WO2008039023A1 PCT/KR2007/004754 KR2007004754W WO2008039023A1 WO 2008039023 A1 WO2008039023 A1 WO 2008039023A1 KR 2007004754 W KR2007004754 W KR 2007004754W WO 2008039023 A1 WO2008039023 A1 WO 2008039023A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazol
dichlorophenyl
chlorophenyl
methyl
oxadiazole
Prior art date
Application number
PCT/KR2007/004754
Other languages
French (fr)
Inventor
Jinhwa Lee
Jeong Min Kim
Chong-Hwan Jonathan Chang
Suk Ho Lee
Hee Jeong Seo
Suk Youn Kang
Kwang-Seop Song
Jong Yup Kim
Min Ju Kim
Sung-Han Lee
Kwang-Woo Ahn
Myung Eun Jung
Original Assignee
Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/541,269 external-priority patent/US20080081815A1/en
Application filed by Green Cross Corporation filed Critical Green Cross Corporation
Priority to EP07833072A priority Critical patent/EP2097410A4/en
Priority to KR1020097008743A priority patent/KR101100028B1/en
Priority to JP2009530273A priority patent/JP5269795B2/en
Priority to CN2007800363304A priority patent/CN101528740B/en
Publication of WO2008039023A1 publication Critical patent/WO2008039023A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to a novel heteroaryl-pyrazole compound which is effective as a cannabinoid CB 1 receptor inverse agonist or antagonist.
  • CB 1 cannabinoid receptor belongs to G-protein-coupled receptor (GPCR) type and is coupled to inhibitory G proteins (G(i/o)) to inhibit certain adenylyl cyclase isozymes, leading to decreased cAMP production, decreased Ca 2+ conductance, increased K + conductance, and increased mitogen-activated protein kinase activity (See Di Marzo et al., Nat. Rev. Drug Discovery 2004, 3, 771-784; Rhee, M. H. et al., J Neurochem. 1998, 71, 1525-1534).
  • GPCR G-protein-coupled receptor
  • cannabinoids in the central nervous system (CNS) and neuronal tissues
  • CNS central nervous system
  • CB 1 receptors located on distinct types of axon terminals throughout the brain
  • the CB 1 receptor is mainly expressed in several brain areas including the limbic system (amygdala, hippocampus), hypothalamus, cerebral cortex, cerebellum, and basal ganglia. In the cerebellum and basal ganglia cannabinoids modulate the locomotor activity.
  • cannabinoids influence learning, memory, emotion, and motivation, and through activation of CBi receptors in the limbic system-hypothalamus axis, cannabinoids have an important role in the control of appetite.
  • lower levels of CB 1 receptors can also be found in peripheral tissues including urinary bladder, testis, prostate, GI tract, heart, lung, adrenal gland, parotid gland, bone marrow, uterus, ovary, and adipose tissue (See Cota, D. et al., J. Clin. Invest. 2003, 112, 423-431; Ravinet Trillou, C. et al., Int. J. Obes. Relat. Metab.
  • CBi receptor antagonists can influence energy homeostasis by central and peripheral mechanisms and may represent promising targets to treat diseases that are characterized by impaired energy balance.
  • rimonabant SR141716
  • rodents See Arnone, M. et al., Psychopharmacology (Berlin) 1997, 132, 104-106
  • primates See Simiand, J.; Keane, M.; Keane, P. E.; Soubrie, P. Behav. Pharmacol. 1998, P, 179-181
  • CB 1 antagonists are currently the subject of intense studies, which were published in several reviews (See Adam, J. et al., Expert Opin.Ther. Patents, 2002, 12(10), 1475-1489; Hertzog, D. L. Expert Opin.Ther. Patents, 2004, 14(10), 1435-1452; Lange, J. H. M. et al., Drug Discov. Today, 2005, 10, 693-702; Bishop, M. J. J Med. Chem., 2006, 49(14), 4008-4016).
  • Fig. 1 shows chronic effects of compounds of Examples 132, 155 and 502, and rimonabant in DIO mice.
  • Ri is hydrogen, C 1-5 alkyl, substituted Ci -5 alkyl, C 2-4 alkenyl, substituted C 2-4 alkenyl, C 2-4 alkynyl, substituted C 2-4 alkynyl, halogen, or -(CH 2 ) n -C 3-5 carbocycle, n being O or l;
  • R 2 is hydrogen, NR 3 R 4 , carbocycle, substituted carbocycle, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, Ci -8 alkyl optionally substituted with hydroxy, acyloxy, Ci -6 alkoxy, substituted Ci -6 alkoxy; C 3-5 alkenyloxy, substituted C 3-5 alkenyloxy; C 3-5 alkynyloxy, substituted C 3-5 alkynyloxy; aryloxy, substituted aryloxy; heteroaryloxy, substituted heteroaryloxy or halogen, C 2-6 alkenyl optionally substituted with alkoxy or halogen, C 2-6 alkynyl optionally substituted with alkoxy or halogen, -(CH 2 ) m -C 3-6 carbocycle optionally substituted with alkoxy or halogen, or -(CH 2 ) m -R 5 , m being 1 or 2;
  • R 3 and R 4 are each independently hydrogen, Ci -6 alkyl, substituted Ci -6 alkyl, C 3-7 cycloalkyl, substituted C 3-7 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl; or R 3 and R 4 , together with the nitrogen atom to which they are bonded, form a 4- to
  • 10-membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more Ci -3 alkyl, benzyl, phenyl, Ci -3 alkoxy or halogen;
  • R 5 is phenyl, furanyl, benzofuranyl, thienyl, benzothienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridizinyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, 1 ,4-benzodioxanyl or benzo[l,3]dioxolyl, each being optionally substituted with one or more halogen, C 1-3 alkyl or C 1-2 alkoxy, each optionally having one to three fluorine substitutes;
  • R 6 , R 7 , Rg, R 9 , Rio and Rn are each independently hydrogen, halogen, Ci -3 alkyl, Ci -3 alkoxy or trifluoromethyl;
  • Ri 2 and Ri 3 are each independently hydrogen, NR 3 R 4 , carbocycle, substituted carbcycle, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, Ci -8 alkyl optionally substituted with alkoxy or halogen, C 2-6 alkenyl optionally substituted with alkoxy or halogen, C 2-6 alkynyl optionally substituted with alkoxy or halogen, -(CH 2 ) m -C 3-6 carbocycle optionally substituted with alkoxy or halogen, or
  • R 2 and Rj 2 are bonded together to form a 4- to 10-membered saturated or unsaturated carbocyclic or heterocyclic ring which is optionally substituted with one or more Cj -3 alkyl, benzyl, phenyl, Cj -3 alkoxy or halogen.
  • aromatic heterocycles formed by X, Y, Z, Q and T encompass, for example, oxazole, isoxazole, thiazole, isothiazole, pyrazole, triazole, oxadiazole, thiadiazole and tetrazole.
  • the present invention also includes a pharmaceutically acceptable salt and an addition salt of the inventive compound, such as a hydrochloride, hydrobromide or trifluoroacetate addition salt and a sodium, potassium and magnesium salt.
  • a pharmaceutically acceptable salt and an addition salt of the inventive compound such as a hydrochloride, hydrobromide or trifluoroacetate addition salt and a sodium, potassium and magnesium salt.
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are incorporated within the scope of the present invention.
  • One embodiment of the present invention is to provide a compound of formula (Ia) or a pharmaceutically acceptable salt thereof:
  • Ri, R 2 , R 6 , R 7 , R 8 , R 9 , Ri 0 , and R 1 have the same meanings as defined in claim 1; with the proviso that when Ri is C 1-5 alkyl, R 2 represents (i) or (ii):
  • R la is Ci -6 alkyl, substituted Ci -6 alkyl; C 2-4 alkenyl, substituted C 2-4 alkenyl; C 2-4 alkynyl, substituted C 2-4 alkynyl; CN, carboxy, aminocarbonyl; aryl, substituted aryl; heteroaryl, substituted heteroaryl;
  • Ri b is hydrogen, acyl, Ci -6 alkyl, substituted Ci -6 alkyl; C 3-5 alkenyl, substituted C 3-5 alkenyl; C 3-5 alkynyl, substituted C 3-5 alkynyl; aryl, substituted aryl; heteroaryl, substituted heteroaryl.
  • Another embodiment of the present invention is to provide a compound of formula (Ib) or a pharmaceutically acceptable salt thereof: wherein Ri, R 2 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 have the same meanings as defined above.
  • a further embodiment of the present invention is provide a compound of formula (Ic) or a pharmaceutically acceptable salt thereof:
  • a still another embodiment of the present invention is to provide a compound of formula (Id) or a pharmaceutically acceptable salt thereof:
  • R 1 , R 2 , R 6 , R 7 , R 8 , R 9 , R 10 , Rn and R 13 have the same meanings as defined above.
  • the present invention also provides a compound of formula (Ie) or (If) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 6 , R 7 , Rg, R 9 , Rj 0 , Rn and Ri 3 have the same meanings as defined above.
  • a further embodiment of the present invention is to provide a compound of formula (Ie) or (If) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 6 , R 7 , Rg, R 9 , Rj 0 , Rn and Ri 3 have the same meanings as defined above.
  • a further embodiment of the present invention is to provide a compound of formula (Ie) or (If) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 6 , R 7 , Rg, R 9 , Rj 0 , Rn and Ri 3 have the same meanings as defined above.
  • a further embodiment of the present invention is to provide a compound of formula (Ie) or (If
  • a still another embodiment of the present invention is to provide a compound of formula (Ih) or a pharmaceutically acceptable salt thereof:
  • R 1 , R 2 , R 6 , R7, R 8 , R 9 , Ri 0 , Rn and Ri 2 have the same meanings as defined above.
  • alkyl refers to a straight or branched chain saturated hydrocarbon radical.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl and hexyl.
  • substituted alkyl refers to a straight or branched chain saturated hydrocarbon radical, which is optionally substituted with one or more substituents selected from the group consisting of C 1-3 alkyl optionally having one to three fluorine substituents, C 2-3 alkenyl, C 2-3 alkynyl, Ci -2 alkoxy optionally having one to three fluorine substituents, sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, ureido, nitro, cyano and halogen.
  • substituents selected from the group consisting of C 1-3 alkyl optionally having one to three fluorine substituents, C 2-3 alkenyl, C 2-3 alkynyl, Ci
  • alkenyl refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond.
  • alkenyl as used herein include, but are not limited to, ethenyl and propenyl.
  • substituted alkenyl refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond, which has optional substituents selected from the group consisting of Cj -3 alkyl optionally having one to three fluorine substituents, amino, aryl, cyano and halogen.
  • alkynyl refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond. Examples of “alkynyl” as used herein include, but are not limited to, acetylenyl and 1-propynyl.
  • substituted alkynyl refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond, optionally having one or more substituents selected from the group consisting of Ci -3 alkyl optionally having one to three fluorine substituents, amino, aryl and halogen.
  • halogen refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
  • carbocycle refers to a non-aromatic cyclic hydrocarbon radical composed of three to seven carbon atoms. Five-to seven-membered rings may contain a double bond in the ring structure.
  • exemplary "carbocycle” groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cycloheptyl.
  • substituents selected from the group consisting of Ci -3 alkyl optionally having one to three fluorine substituents, C 2-3 alkenyl, C
  • aryl refers to an optionally substituted benzene ring or refers to a ring system which may result by fusing one or more optional substituents.
  • exemplary optional substituents include substituted Ci -3 alkyl, substituted C 2-3 alkenyl, substituted C 2-3 alkynyl, heteroaryl, heterocyclic, aryl, alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, or ureido.
  • Such a ring or ring system may be optionally fused to aryl rings (including benzene rings) optionally having one or more substituents, carbocycle rings or heterocyclic rings.
  • aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, indanyl, anthracyl or phenanthryl, as well as substituted derivatives thereof.
  • heteroaryl refers to an optionally substituted monocyclic five to six-membered aromatic ring containing one or more heteroatomic substitutions selected from S, SO, SO 2 , O, N, or N-oxide, or refers to such an aromatic ring fused to one or more rings such as heteroaryl rings, aryl rings, heterocyclic rings, or carbocycle rings (e.g., a bicyclic or tricyclic ring system), each having optional subsituents.
  • optional substituents are selected from the group consisting of substituted Ci -3 alkyl, substituted C 2-3 alkenyl, substituted C 2-3 alkynyl, heteroaryl, heterocyclic, aryl, Ci -3 alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen or ureido.
  • heteroaryl groups used herein include, but are not limited to, benzoimidazolyl, benzothiazolyl, benzoisothiazolyl, benzothiophenyl, benzopyrazinyl, benzotriazolyl, benzo[l,4]dioxanyl, benzofuranyl, 9H-a-carbolinyl, cinnolinyl, furanyl, furo[2,3-b]pyridinyl, imidazolyl, imidazolidinyl, imidazopyridinyl, isoxazolyl, isothiazolyl, isoquinolinyl, indolyl, indazolyl, indolizinyl, naphthyridinyl, oxazolyl, oxothiadiazolyl, oxadiazolyl, phthalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl
  • heterocyclic refers to a three to seven-membered ring containing one or more heteroatomic moieties selected from S, SO, SO 2 , O, N, or N-oxide, optionally substituted with one or more substituents selected from the group which includes substituted Ci -3 alkyl, substituted C 2-3 alkenyl, substituted C 2-3 alkynyl, heteroaryl, heterocyclic, aryl, C 1-3 alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen,
  • Such a ring can be saturated or have one or more degrees of unsaturation.
  • Such a ring may be optionally fused to one or more "heterocyclic" ring(s), aryl ring(s), heteroaryl ring(s) or carbocycle ring(s), each having optional substituents.
  • heterocyclic moieties include, but are not limited to, 1,4-dioxanyl, 1,3-dioxanyl, pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, imidazolidine-2,4-dionepiperidinyl, piperazinyl, piperazine-2,5-dionyl, morpholinyl, dihydropyranyl, dihydrocinnolinyl, 2,3-dihydrobenzo [1,4] dioxinyl,
  • alkoxy refers to the group -OR 3 , where R a is alkyl as defined above.
  • alkoxy groups useful in the present invention include, but are not limited to, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and t-butoxy.
  • alkenyloxy referes to the group -OR b , where R b is alkenyl as defined above.
  • alkynyloxy referes to the group -OR c , where R 0 is alkynyl as defined above.
  • aralkoxy refers to the group -OR 3 R d , wherein R 3 is alkyl and Ra is aryl as defined above.
  • aryloxy refers to the group -OR d , wherein R d is aryl as defined above.
  • heteroaryloxy refers to the group -OR e , where R e is heteroaryl as defined above.
  • mercapto refers to the group -SH.
  • sulfonyl refers to the group -SR f , wherein R f is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • sulfonyl refers to the group -S-(O)R f , wherein R f is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • sulfonyl refers to the group -S(O) 2 R f , wherein R f is5 substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • hydroxyl refers to the group -OH.
  • amino refers to the group -NH 2 .
  • the amino group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or0 heterocyclic, as defined above.
  • cyano refers to the group -CN.
  • aminosulfonyl refers to the group -S(O) 2 NH 2 .
  • the aminosulfonyl group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • sulfonylamino refers to the group -NHS(O) 2 R f wherein Rf is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • carboxyamide refers to the group -NHC(O)R f wherein R f is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined O above.
  • carboxy refers to the group -C(O)OH.
  • the carboxy group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • aminocarbonyl refers to the group -C(O)NH 2 .
  • the aminocarbonyl group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • ureido refers to the group -NHC(O)NHR g wherein R g is hydrogen, alkyl, carbocycle or aryl as defined above. 5
  • acyl refers to the group -C(O)R h , wherein R h is alkyl, carbocycle, or heterocyclic as defined herein.
  • aroyl refers to the group -C(O)R d , wherein R d is aryl as defined herein. 0
  • heteroaroyl refers to the group -C(O)R e , wherein R e is heteroaryl as defined herein.
  • acyloxy refers to the group -OC(O)R h , wherein R h is alkyl, carbocycle, or heterocyclic as defined herein.
  • aroyloxy refers to the group -OC(O)R d , wherein R d is aryl5 as defined herein.
  • heteroaroyloxy refers to the group -OC(O)R e , wherein R e is heteroaryl as defined herein.
  • Preferred compounds useful in the present invention are selected from the group O consisting of:
  • the compound of formula (Ia) may be prepared by (i) reacting a carboxylic acid derivative (5) with a hydrazide compound (7) or a semicarbazide compound (12) in the presence of a coupling agent, e.g., l-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDCI), 4-dimethylaminopyridine (DMAP), and (ii) cyclizing the resulting product using a dehydrating agent to obtain an 1,3,4-oxadiazole compound of formula (Ia), as shown in Reaction Scheme 1.
  • a coupling agent e.g., l-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDCI), 4-dimethylaminopyridine (DMAP), and (ii) cyclizing the resulting product using a dehydrating agent to obtain an 1,3,4-oxadiazole compound of formula (I
  • R 1 to R 4 have the same meanings as defined above.
  • the cyclization may be conducted using Burgess reagent as a dehydrating agent while applying microwave irradiation thereon (See Leber, J. D. et al., WO 2005/032550), or using triphenylphosphine with carbon tetrachloride and a base such triethylamine in a suitable solvent such as acetonitrile and THF.
  • the carboxylic acid derivative (5) used as a starting material in preparing the compound of formula (Ia) may be prepared by a conventional method, e.g., by treating an acetophenone derivative (1) with an organic base such as lithium hexamethyldisilazide (LHMDS) to produce a corresponding alkali metal salt (2), reacting the resulting salt with an equimolar amount of diethyl oxalate to provide a ketoester salt (3), reacting the salt (3) with a hydrazine derivative in refluxing acetic acid to obtain a pyrazole-3 -carboxylic ester (4), and transforming the ester (4) into an acid form (5) using an alkaline agent such as potassium hydroxide or lithium hydroxide, followed by acidification (See Barth, F. et al., U.S. Patent No. 5,462,960), as shown in Reaction Scheme 2.
  • Reaction Scheme 2 See Barth, F. et al., U.S. Patent No.
  • the hydrazide compound (7) which may be used in preparing the compound of formula (Ia) may be prepared by treating an ester or a carboxylic acid with hydrazine, and also, the semicarbazide compound (12) may be prepared by treating carbamyl chloride or isocynate with hydrazine, as shown in Reaction Scheme 3.
  • the compound of formula (Ib) may be prepared by (i) reacting a carboxylic acid derivative (5) with a hydrazide compound (7) in the presence of coupling agents, e.g., EDCI, DMAP, and (ii) cyclizing the resulting product using a Lawesson's reagent, which can be conducted with microwave irradiation (See Kiryanov, A. A., Sampson, P., Seed, A. J., J. Org. Chem. 2001, 665, 7925-7929), as shown in Reaction Scheme 4.
  • coupling agents e.g., EDCI, DMAP
  • a Lawesson's reagent which can be conducted with microwave irradiation (See Kiryanov, A. A., Sampson, P., Seed, A. J., J. Org. Chem. 2001, 665, 7925-7929), as shown in Reaction Scheme 4.
  • the acylhydrazide intermediate (9) is also available through a coupling of the hydrazide (A) with a corresponding acid in the presence of coupling reagents: DMAP, EDCI; EDCI, 1-hydroxybezotriazole (HOBt), N-methyl morpholine (NMM)
  • the requisite hydrazide (A) is prepared by treating ester (4) with hydrazine in refluxing ethanol (EtOH).
  • the compound of formula (Ic) may be prepared by (i) reacting a nitrile intermediate (19) with hydroxylamine in a solvent, e.g., MeOH, (ii) acylating the resulting N-hydroxyamidine (20) with an activated carboxylic acid in the presence of a coupling agent, e.g., dicyclohexylcarbodiimide (DCC), EDCI or 1,1-carbonyldiimidazole (CDI), and (iii) cyclizing the acylated compound (21) in the presence of a base by heating, e.g., microwave irradiation, as shown in Reaction Scheme 5.
  • a coupling agent e.g., dicyclohexylcarbodiimide (DCC), EDCI or 1,1-carbonyldiimidazole (CDI)
  • step (i) may be conducted in heated methyl alcohol.
  • the acylation of step (ii) may be conducted in the presence of a suitable base such as triethylamine (TEA) or N-methyl morpholine (NMM) in a solvent such as methylene chloride, THF or acetonitrile.
  • TAA triethylamine
  • NMM N-methyl morpholine
  • the cyclization step (iii) may be conducted in a solvent such as acetonitrile or THF, and exemplary bases which may be used in this step include pyridine, N,N-diisopropylethylamine or tetrabutylammonium fluoride.
  • N-acyloxyamidine (21) may be omitted, in case N-hydroxyamidine (20) was converted to 1,2,4-oxadiazole (Ic) in a continuous process (See, Colandrea, V. J. et al., WO 2005/058848).
  • the nitrile intermediate (19) used in preparing the compound of formula (Ic) may be prepared by [3+2] cycloaddition reaction disclosed in J. Med. Chem. 1999, 42, 769-776, as shown in Reaction Scheme 6.
  • Reaction Scheme 6 l ammonia solution CHJCI 2
  • the compound of formula (Id) may be prepared by reacting a nitrile intermediate (19) with a hydrazide compound (7) in the presence of a catalyst such as potassium carbonate in a suitable solvent such as 1-butanol under a reflux condition, to obtain a triazole, as shown in Reaction Scheme 7.
  • a catalyst such as potassium carbonate
  • a suitable solvent such as 1-butanol
  • R 2 has the same meaning as defined above.
  • the compound of formula (Ie) or (If) may be prepared by reacting a nitrile intermediate (19) with sodium azide in the presence of a base (e.g., ammonium chloride) in a solvent (e.g., N,N-dimethylformamide: DMF) with microwave irradiation, according to
  • RX is a primary alkyl halide
  • the alkylation can be conducted at room temperature.
  • the reaction is preferably conducted at 80 ° C .
  • the alkylation of the tetrazole may be conducted using an aliphatic alcohol in the presence of diisopropylazodicarboxylate (DIAD) and triphenylphophine (PPh 3 ) in THF at 0 ° C , as shown in Reaction Scheme 9.
  • DIAD diisopropylazodicarboxylate
  • PPh 3 triphenylphophine
  • the compound of formula (If) may be prepared by treating acyl chloride (17) with an amine in the presence of triethylamine in methylene chloride to produce an amide (26) and reacting the resulting amide with hydrazoic acid in the presence of phosphorus pentachloride in toluene as shown in Reaction Scheme 10.
  • Reaction Scheme 10 Reaction Scheme 10
  • R cyPropyi , oyBut ⁇ , cyHept ⁇ , t Bu , n Hexjrt , n Octyl . adamant. cyHexyl
  • the compound of formula (Ig) may be prepared by (i) reacting a carboxylic acid intermediate (5) with an aminoketone (27) in the presence of a coupling reagent, e.g. EDCI, DMAP, and (ii) cyclizing the resulting product (28) using a dehydrating agent to obtain an oxazole compound of formula (Ig), as shown in Reaction Scheme 11.
  • a coupling reagent e.g. EDCI, DMAP
  • R 2 and R 12 have the same meanings as defined above.
  • R 12 (27) (32) The aminoketone compound (27) or (32) which may be used in preparing the compound of formula (Ig) may be prepared as shown in Reaction Scheme 12.
  • the starting iV-Boc protected aminoacid (29) is converted into the corresponding Weinreb amide (30) using N, 0-dimethylhydroxylamine hydrochloride in the presence of coupling reagents such as EDCI, HOBt, NMM in an appropriate solvent such as dichloromethane (DCM) or DMF.
  • the Weinreb amide (30) may be transformed into a corresponding ketone (31) by action of a Grignard reagent in an appropriate solvent such as ether or THF under N 2 atmosphere.
  • final deprotection of Boc group using either trifluoroacetic acid (TFA) or HCl may provide a corresponding aminoketone (27) or (32) in a salt form, respectively.
  • the compound of formula (Ih) may be prepared by (i) reacting a carboxylic acid intermediate (5) with an aminoketone (27) or (32) in the presence of a coupling reagent, e.g.
  • a bromide of structure (33) may be utilized to provide the corresponding cyanide
  • a bromide of structure (33) may be further utilized by reacting a bromide (33) with various primary or secondary amines in the presence of a suitable base such as diisopropylethylamine (DIPEA) in a suitable solvent such as acetonitrile to afford the corresponding amines of structure (40) as described in Reaction Scheme 16.
  • DIPEA diisopropylethylamine
  • bromide of structure (33) may be conducted on a bromide of structure (33) by reacting a bromide (33) with a pyrrole or various azoles including pyrazole, imidazole, 1 ,2,4-triazole, 1,2,3-triazole, tetrazole in the presence of a base such as sodium hydride in an appropriate solvent such as THF.
  • a derivatization may come from alkylation of the anion of pyrrolidin-2-one, succinimide, or oxazolidini-2-one with a bromide of structure (33) to lead to the corresponding alkylated products (42), (43), or (44), respectively as depicted in Reaction Scheme (18).
  • Reaction Scheme 18
  • Another derivatization may come from alkylation of the anion of hydroxyl-aryl or hydroxyl-hetero-aryl such as phenol or pyridin-2-ol with a bromide of structure (33) to produce the corresponding alkylated products (45) or (46), respectively as demonstrated in Reaction Scheme 19.
  • Another derivatization may result from a nucleophilic sulfur reagent such as potassium thioacetate or sodium thiomethoxide with a bromide of structure (33).
  • a bromide (33) is smoothly converted to a thioacetate (47) in a suitable solvent such as DMF at ambient temperature.
  • a thioacetate of structure (47) may be used to prepare the corresponding thiol.
  • An alcohol of structure (35) can be alkylated with an alkyl iodide or an alkyl bromide in the presence of a suitable base such as sodium hydride (Williamson ether synthesis conditions) to furnish the corresponding ether of structure (49).
  • a suitable base such as sodium hydride (Williamson ether synthesis conditions)
  • an alcohol of structure (35) may be converted into the corresponding fluoride of structure (50) by action of a fluorinating agent such as diethylaminosulfur trifluoride (DAST) in an appropriate solvent such as methylene chloride at ambient temperature.
  • DAST diethylaminosulfur trifluoride
  • Burgess reagent may convert an alcohol of structure (35) to the corresponding carbamate of structure (51) as described in Reaction Scheme 21.
  • An aldehyde of structure (36) previously prepared as shown in Reaction Scheme 14 may be treated with a fluorinating agent such as DAST to provide the corresponding difluoromethyl-pyrazole (52).
  • a fluorinating agent such as DAST
  • an aldehyde of structure (36) may be treated with a Grignard reagent such as methylmagnesium bromide to afford the corresponding alcohol of structure (53), which is further alkylated with an alkyl iodide or an alkyl bromide in the presence of a suitable base such as sodium hydride (Williamson ether synthesis conditions) to furnish the corresponding ether of structure (54).
  • an alcohol of structure (53) may be treated with Burgess reagent to furnish a carbamate (56) as well as an olefin of structure (55). Also, an alcohol of structure (53) may be oxidized by an appropriate oxidizing agent such as Dess-Martin periodinane to give the corresponding ketone of structure (57). Finally, an alcohol of structure (53) may be treated with a fluorinating agent such as DAST to give a fluoride of structure (58) as described in Reaction Scheme 22.
  • a fluorinating agent such as DAST
  • a ketone of structure (57) may be further reacted with a Grignard reagent such as methylmagnesium bromide to provide the alcohol of structure (59), which may be dehydrated by using a suitable dehydrating agent such as Burgess reagent to give the corresponding olefin of structure (60) as demonstrated in Reaction Scheme 23.
  • a Grignard reagent such as methylmagnesium bromide
  • a suitable dehydrating agent such as Burgess reagent
  • the compounds containing 1 ,2,4-triazole at C-4 on pyrazole may be obtained by a series of reaction sequence involving a key intermediate bromide of structure (61).
  • a bromide of structure (61) which is obtained by reaction of a pyrazole of structure (4) with N-bromosuccinimide (NBS) in the presence of a catalytic amount of AIBN, may be reacted with lH-l,2,4-triazole in the presence of a suitable base such as sodium hydride in a suitable solvent such as THF to furnish 1,2,4-triazole of structure (62).
  • Hydrolysis of an ester (62) may provide the corresponding acid of structure (63).
  • Activation of an acid of structure (63) followed by coupling with a hydrazide in the presence of an appropriate base such as triethylamine may produce an acylhydrazide of structure (64).
  • an appropriate base such as triethylamine
  • hydrazynolysis of an ester (62) may provide the corresponding hydrazide, which may be coupled with a particular acid in the presence of coupling reagents such as EDCI, HOBt and NMM to provide an acylhydrazide of structure (64).
  • the cyclization may be conducted using Burgess reagent as a dehydrating agent while applying microwave irradiation thereon, or using triphenylphosphine with carbon tetrachloride and a base such as triethylamine in a suitable solvent such as acetonitrile and THF, or alternatively using phosphorus(III) oxychloride in a solvent such as acetonitrile or 1,4-dioxane at reflux temperature to give an oxadiazole of structure (65).
  • a compound of formula (66) may be prepared by cyclizing the acylhydrazide intermediate (64) using a Lawesson's reagent, which may be conducted with microwave irradiation as shown in Reaction Scheme 24.
  • Reaction Scheme 24
  • the 4-cyclopropyl-pyrazole compound may be prepared as shown in Reaction
  • 4-bromo-pyrazole of structure (68) which may be prepared by following a generic procedure (Andrew G. Horti et al, J. Med. Chem. 2003, 46, 642-645), may be coupled with a cyclopropylboronic acid under Suzuki-Miyaura coupling reaction conditions to afford a 4-cyclopropyl-pyrazole of structure (69).
  • the ester (69) may undergo a series of reaction sequence previously described to give rise to an oxadiazole of structure (72).
  • the thiadiazole compound of formula (73) may be prepared by cyclizing the acylhydrazide intermediate (71) using a Lawesson's reagent, which may be conducted with microwave irradiation as shown in Reaction Scheme 25.
  • Reaction Scheme 25
  • the 4-ethynyl-pyrazole compound of structure (75) may be prepared through two steps from a starting aldehyde of structure (36).
  • an aldehyde of structure (36) prepared in Reaction Scheme 14 may be converted to a corresponding 4-(2,2-dibromovinyl)-pyrazole (74), which could be treated with a suitable base such as potassium hexamethyldisilazane (KHMDS) at -78 0 C in an appropriate solvent such as THF to afford a 4-ethynyl-pyrazole of structure (75).
  • KHMDS potassium hexamethyldisilazane
  • a compound of structure (75) may be further alkylated by action of a base such as lithium hexamethyldisilazide (LHMDS) with an alkylating agent such as methyl iodide in an appropriate solvent such as THF to produce 4-(prop-l-ynyl)-pyrazole of structure (76) as shown in Reaction Scheme 26.
  • a base such as lithium hexamethyldisilazide (LHMDS)
  • an alkylating agent such as methyl iodide
  • THF 4-(prop-l-ynyl)-pyrazole of structure (76) as shown in Reaction Scheme 26.
  • the requisite cyclopropanecarboxylic acid (80) as a coupling partner of a hydrazide such as structure (70) for the preparation of an oxadiazole as well as a thiadiazole may be prepared by following a known procedure involving three steps starting from a benzyl bromide of structure (77) : i) cyanation, ii) cyclopropanation, iii) hydrolysis of the resulting cyanide of structure (79) [Imbimbo, B. P., J Med. Chem. 2005, 48, 5707-7520] as described in Reaction Scheme 27.
  • A is carbon or nitrogen;
  • R is halogen, C 1 -C 6 alkyl, Ci-C 4 alkoxy, NRjRj, carbocycle, heterocycle, aryl, or heteroaryl; and Rj and Rj are independently hydrogen, Ci -4 alkyl or C 3-5 carbocycle.
  • a requisite cyclopropanecarboxylic acid such as structure (85) may be provided by following a known method [Krawczyk, H., Synlett., 2005, / 7, 2648-2652].
  • a commercially available 3-bromodihydrofuran-2(3H)-one (81) may undergo Arbuzov reaction to afford diethyl 2-oxotetrahydrofuran-3-ylphosphonate (82), which could be alkylated with an alkyl bromide or an alkyl iodide in the presence of a suitable base such as lithium diisopropylamide (LDA) in an appropriate solvent such as THF to give a compound of structure (83).
  • a suitable base such as lithium diisopropylamide (LDA) in an appropriate solvent such as THF
  • a pyrazole of structure (88) may be prepared by treatment of 1,3-dione of structure (87) with hydrazine at reflux temperature.
  • a 1,3-dione of structure (87) in equilibrium with a keto-enol of structure (88) may be obtained by treating an ester of structure (4) with a methyl ketone such as 3,3-dimethylbutan-2-one (86) in the presence of a base such as sodium amide.
  • an isoxazole (90) or its isomer (91) may be prepared by treatment of 1,3-dione of structure (87) with hydroxylamine. These two isomers may be separated by preparative HPLC as shown in Reaction Scheme 29. Reaction Scheme 29
  • Reaction Scheme 30 bromination may be achieved by NBS in the presence of either benzoyl peroxide or AIBN. Subsequently, hydroxyl group is introduced by reacting a bromide of structure (92) with sodium acetate followed by subsequent hydrolysis of the acetate (93). Oxidation of the alcohol (94) to aldehyde (95) may be achieved by action of a mild oxidant such as Dess-Martin periodinane. Reaction Scheme 30
  • the inventive heteroaryl-pyrazole compound of formula (I) is effective as a cannabinoid CB 1 receptor inverse agonist or antagonist, thereby preventing or treating obesity and obesity-related metabolic disorders.
  • the present invention provides a pharmaceutical composition for preventing or treating obesity and obesity-related metabolic disorders, which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier. Further, the present invention provides a method for preventing or treating obesity and obesity-related metabolic disorders in a mammal, which comprises administering the compound of formula (I) of claim 1 to the mammal.
  • the present invention provides a method for inhibiting cannabinoid CBi receptor in a mammal, which comprises administering the compound of formula (I) of claim 1 to the mammal.
  • obesity-related metabolic disorders refers to chronic diseases that require treatment to reduce the excessive health risks associated with obesity and exemplary disorders include type 2 diabetes mellitus, cardiovascular and hypertension, hyperlipidaemia, fibrinolytic abnormalities.
  • the pharmaceutical composition may be administered orally, intramuscularly or subcutaneously.
  • the formulation for oral administration may take various forms such as a syrup, tablet, capsule, cream and lozenge.
  • a syrup formulation will generally contain a suspension or solution of the compound or its salt in a liquid carrier, e.g., ethanol, peanut oil, olive oil, glycerine or water, optionally with a flavoring or coloring agent.
  • a liquid carrier e.g., ethanol, peanut oil, olive oil, glycerine or water
  • any one of pharmaceutical carriers routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose.
  • any of the routine encapsulation procedures may be employed, e.g., using the aforementioned carriers in a hard gelatin capsule shell.
  • any of the pharmaceutical carrier routinely used for preparing dispersions or suspensions may be prepared using an aqueous gum, cellulose, silicate or oil.
  • the formulation for intramuscular or subcutaneous administration may take a liquid form such as a solution, suspension and emulsion which includes aqueous solvents such as water, physiological saline and Ringer's solution; or lipophilic solvents such as fatty oil, sesame oil, corn oil and synthetic fatty acid ester.
  • composition is formulated in a specific dosage form for a particular patient.
  • Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg of the compound of Formula (I) or its pharmaceutically acceptable salt.
  • the suitable daily dosage for oral administration is about 0.01 mg/Kg to 40 mg/Kg of the compound of Formula (I) or its pharmaceutically acceptable salt, may be administered 1 to 6 times a day, depending on the patient's condition.
  • TFA trifluoroacetic acid
  • TEA triethylamine
  • Boc tert-butyloxycarbonyl
  • mCPBA metal-chloroperbenzoic acid
  • NMM N-methyl morpholine
  • BOP bis(2-oxo-3-oxazolidinyl)phosphinic chloride
  • HBTU O-Benzotriazolel-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • DIPEA diisopropylethylamine
  • NaSMe sodium thiomethoxide
  • Microwave reaction was conducted with a Biotage microwave reactor.
  • Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d(doublet), t (triplet), q (quartet), quint
  • Mass spectra were obtained with either a Micromass, Quattro LC Triple Quadruple Tandem Mass Spectometer, ESI or Agilent, 1100LC/MSD, ESI.
  • Step 1 N-butanoyl-N'-[5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazole- 3 -carbonyl] -hydrazine
  • Step 2 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-propyl- 1,3,4-oxadiazole
  • N-butanoyl-N' -[5-(4-Chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazole-3 -carbonyl] -hydrazine (0.35 g, 0.75 mmol) obtained in Step 1 was added to a microwave reactor containing Burgess reagent (0.45 g, 1.88 mmol) in THF (2 mL). The capped reactor was placed in a microwave reactor and the mixture was irradiated at 140 ° C for 15 min. The reaction product was purified by preparative HPLC to provide the title compound (0.21 g, 0.46 mmol, 61%) as yellow solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

Description

HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CBI RECEPTOR ANTAGONISTS
FIELD OF THE INVENTION
The present invention relates to a novel heteroaryl-pyrazole compound which is effective as a cannabinoid CB1 receptor inverse agonist or antagonist.
BACKGROUND OF THE INVENTION
The World Health Organization (WHO) recently reported that obesity has become a global epidemic, posing a serious threat to public health because of the increased risk of associated health problems (See Report of a WHO Consultation on Obesity: Obesity-Preventing and Managing a Global Epidemic; World Health Organization: Geneva, 1997). Obesity is characterized by excess body fat, especially visceral fat, and constitutes a pro-inflammatory state eventually leading to serious health consequences. There are growing evidences that obesity as a chronic disease cannot be cured by short-term dieting or exercise alone, but additional pharmacological treatments would lead to higher success rates.
CB1 cannabinoid receptor belongs to G-protein-coupled receptor (GPCR) type and is coupled to inhibitory G proteins (G(i/o)) to inhibit certain adenylyl cyclase isozymes, leading to decreased cAMP production, decreased Ca2+ conductance, increased K+ conductance, and increased mitogen-activated protein kinase activity (See Di Marzo et al., Nat. Rev. Drug Discovery 2004, 3, 771-784; Rhee, M. H. et al., J Neurochem. 1998, 71, 1525-1534). The major physiological effect of cannabinoids (in the central nervous system (CNS) and neuronal tissues) is the modulation of neurotransmitter release via activation of presynaptic CB1 receptors located on distinct types of axon terminals throughout the brain (See Howlett, A. C. et al., Neuropharmacology 2004, 47 (Suppl. 1), 345-358). The CB1 receptor is mainly expressed in several brain areas including the limbic system (amygdala, hippocampus), hypothalamus, cerebral cortex, cerebellum, and basal ganglia. In the cerebellum and basal ganglia cannabinoids modulate the locomotor activity. In the limbic system, cannabinoids influence learning, memory, emotion, and motivation, and through activation of CBi receptors in the limbic system-hypothalamus axis, cannabinoids have an important role in the control of appetite. Moreover, lower levels of CB1 receptors can also be found in peripheral tissues including urinary bladder, testis, prostate, GI tract, heart, lung, adrenal gland, parotid gland, bone marrow, uterus, ovary, and adipose tissue (See Cota, D. et al., J. Clin. Invest. 2003, 112, 423-431; Ravinet Trillou, C. et al., Int. J. Obes. Relat. Metab. Disord. 2004, 28, 640-648; Galiegue, S. et al., Eur. J. Biochem. 1995, 232, 54-61; Howlett, A. C. et al., Pharmacol. Rev. 2002, 54, 161-202).
Many preclinical in vitro and in vivo experiments have shown that CBi receptor antagonists can influence energy homeostasis by central and peripheral mechanisms and may represent promising targets to treat diseases that are characterized by impaired energy balance. Already the first published studies with rimonabant (SR141716) in both rodents (See Arnone, M. et al., Psychopharmacology (Berlin) 1997, 132, 104-106) and primates (See Simiand, J.; Keane, M.; Keane, P. E.; Soubrie, P. Behav. Pharmacol. 1998, P, 179-181) showed clear differentiation, i.e., marked effects on sweet food intake versus marginal effects on regular chow intake or water drinking. Many other preclinical "proof of concept" studies have been performed in the meantime with several CB agonists and antagonists to further uncover the amount and mode of contribution of cannabinergic system modulators to energy homeostasis. Almost all of those studies have been recently reviewed (See Smith, R. A. et al., IDrugs 2005, 8, 53-66).
Considering the important impact of obesity on public health and the lack of any efficient and viable drug to cure it, it is no surprise that CB1 antagonists are currently the subject of intense studies, which were published in several reviews (See Adam, J. et al., Expert Opin.Ther. Patents, 2002, 12(10), 1475-1489; Hertzog, D. L. Expert Opin.Ther. Patents, 2004, 14(10), 1435-1452; Lange, J. H. M. et al., Drug Discov. Today, 2005, 10, 693-702; Bishop, M. J. J Med. Chem., 2006, 49(14), 4008-4016).
SUMMARY QF THE INVENTION
It is a primary object of the present invention to provide a novel heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof, which is effective as a cannabinoid CBi receptor inverse agonist or antagonist, useful for preventing or treating obesity and obesity-related metabolic disorders.
It is another object of the present invention to provide a method for preparing the inventive compound.
It is another object of the present invention to provide a pharmaceutical composition for preventing or treating obesity and obesity-related metabolic disorders, comprising the inventive compound as an active ingredient.
BRIEF DESCRIPTION OF DRAWINGS
The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawing, which show:
Fig. 1 shows chronic effects of compounds of Examples 132, 155 and 502, and rimonabant in DIO mice.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with one aspect of the present invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof and a method for preparing same:
Figure imgf000005_0001
wherein: Ri is hydrogen, C1-5 alkyl, substituted Ci-5 alkyl, C2-4 alkenyl, substituted C2-4 alkenyl, C2-4 alkynyl, substituted C2-4 alkynyl, halogen, or -(CH2)n-C3-5 carbocycle, n being O or l;
R2 is hydrogen, NR3R4, carbocycle, substituted carbocycle, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, Ci-8 alkyl optionally substituted with hydroxy, acyloxy, Ci-6 alkoxy, substituted Ci-6 alkoxy; C3-5 alkenyloxy, substituted C3-5 alkenyloxy; C3-5 alkynyloxy, substituted C3-5 alkynyloxy; aryloxy, substituted aryloxy; heteroaryloxy, substituted heteroaryloxy or halogen, C2-6 alkenyl optionally substituted with alkoxy or halogen, C2-6 alkynyl optionally substituted with alkoxy or halogen, -(CH2)m-C3-6 carbocycle optionally substituted with alkoxy or halogen, or -(CH2)m-R5, m being 1 or 2;
R3 and R4 are each independently hydrogen, Ci-6 alkyl, substituted Ci-6 alkyl, C3-7 cycloalkyl, substituted C3-7 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl; or R3 and R4, together with the nitrogen atom to which they are bonded, form a 4- to
10-membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more Ci-3 alkyl, benzyl, phenyl, Ci-3 alkoxy or halogen;
R5 is phenyl, furanyl, benzofuranyl, thienyl, benzothienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridizinyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, 1 ,4-benzodioxanyl or benzo[l,3]dioxolyl, each being optionally substituted with one or more halogen, C1-3 alkyl or C1-2 alkoxy, each optionally having one to three fluorine substitutes;
R6, R7, Rg, R9, Rio and Rn are each independently hydrogen, halogen, Ci-3 alkyl, Ci-3 alkoxy or trifluoromethyl;
X, Y and Z are each independently selected from the group consisting of -C(Ri2)=, -O-, -N=, -N(Ri3)- and -S- to form an aromatic heterocycle together with Q and T;
Y N
Q and T are each independently ■*»- or ^ , with the proviso that both Q
and T can not be simultaneously ^ ; and
Ri2 and Ri3 are each independently hydrogen, NR3R4, carbocycle, substituted carbcycle, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, Ci-8 alkyl optionally substituted with alkoxy or halogen, C2-6 alkenyl optionally substituted with alkoxy or halogen, C2-6 alkynyl optionally substituted with alkoxy or halogen, -(CH2)m-C3-6 carbocycle optionally substituted with alkoxy or halogen, or
-(CH2)m-R5, m being 1 or 2, and R3, R4 and R5 having the same meaning as defined above; or R2 and Rj2 are bonded together to form a 4- to 10-membered saturated or unsaturated carbocyclic or heterocyclic ring which is optionally substituted with one or more Cj-3 alkyl, benzyl, phenyl, Cj-3 alkoxy or halogen.
The aromatic heterocycles formed by X, Y, Z, Q and T encompass, for example, oxazole, isoxazole, thiazole, isothiazole, pyrazole, triazole, oxadiazole, thiadiazole and tetrazole.
It is to be understood that the present invention also includes a pharmaceutically acceptable salt and an addition salt of the inventive compound, such as a hydrochloride, hydrobromide or trifluoroacetate addition salt and a sodium, potassium and magnesium salt. The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are incorporated within the scope of the present invention.
One embodiment of the present invention is to provide a compound of formula (Ia) or a pharmaceutically acceptable salt thereof:
Figure imgf000007_0001
wherein Ri, R2, R6, R7, R8, R9, Ri0, and R1] have the same meanings as defined in claim 1; with the proviso that when Ri is C1-5 alkyl, R2 represents (i) or (ii):
Figure imgf000007_0002
(i) wherein, Rla is Ci-6 alkyl, substituted Ci-6 alkyl; C2-4 alkenyl, substituted C2-4 alkenyl; C2-4 alkynyl, substituted C2-4 alkynyl; CN, carboxy, aminocarbonyl; aryl, substituted aryl; heteroaryl, substituted heteroaryl;
Figure imgf000007_0003
(ϋ)
wherein Rib is hydrogen, acyl, Ci-6 alkyl, substituted Ci-6 alkyl; C3-5 alkenyl, substituted C3-5 alkenyl; C3-5 alkynyl, substituted C3-5 alkynyl; aryl, substituted aryl; heteroaryl, substituted heteroaryl.
Another embodiment of the present invention is to provide a compound of formula (Ib) or a pharmaceutically acceptable salt thereof:
Figure imgf000008_0001
wherein Ri, R2, R6, R7, R8, R9, R10 and R11 have the same meanings as defined above. A further embodiment of the present invention is provide a compound of formula (Ic) or a pharmaceutically acceptable salt thereof:
Figure imgf000008_0002
wherein R1, R2, Rg, R7, R8, R9, R10 and R11 have the same meanings as defined above. A still another embodiment of the present invention is to provide a compound of formula (Id) or a pharmaceutically acceptable salt thereof:
Figure imgf000008_0003
wherein, R1, R2, R6, R7, R8, R9, R10, Rn and R13 have the same meanings as defined above.
The present invention also provides a compound of formula (Ie) or (If) or a pharmaceutically acceptable salt thereof:
Figure imgf000009_0001
wherein R1, R2, R6, R7, Rg, R9, Rj0, Rn and Ri3 have the same meanings as defined above. A further embodiment of the present invention is to provide a compound of formula
(Ig) or a pharmaceutically acceptable salt thereof:
Figure imgf000009_0002
wherein R1, R2, R6, R7, R8, R9, Ri0, Rn and R12 have the same meanings as defined above. A still another embodiment of the present invention is to provide a compound of formula (Ih) or a pharmaceutically acceptable salt thereof:
Figure imgf000009_0003
wherein R1, R2, R6, R7, R8, R9, Ri0, Rn and Ri2 have the same meanings as defined above.
As used herein, the term "alkyl" refers to a straight or branched chain saturated hydrocarbon radical. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl and hexyl.
As used herein, the term "substituted alkyl" refers to a straight or branched chain saturated hydrocarbon radical, which is optionally substituted with one or more substituents selected from the group consisting of C1-3 alkyl optionally having one to three fluorine substituents, C2-3 alkenyl, C2-3 alkynyl, Ci-2 alkoxy optionally having one to three fluorine substituents, sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, ureido, nitro, cyano and halogen.
As used herein, the term "alkenyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond. Examples of "alkenyl" as used herein include, but are not limited to, ethenyl and propenyl.
As used herein, the term "substituted alkenyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond, which has optional substituents selected from the group consisting of Cj-3 alkyl optionally having one to three fluorine substituents, amino, aryl, cyano and halogen. As used herein, the term "alkynyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond. Examples of "alkynyl" as used herein include, but are not limited to, acetylenyl and 1-propynyl.
As used herein, the term "substituted alkynyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond, optionally having one or more substituents selected from the group consisting of Ci-3 alkyl optionally having one to three fluorine substituents, amino, aryl and halogen.
As used herein, the term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
As used herein, the term "carbocycle" refers to a non-aromatic cyclic hydrocarbon radical composed of three to seven carbon atoms. Five-to seven-membered rings may contain a double bond in the ring structure. Exemplary "carbocycle" groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cycloheptyl.
As used herein, the term "substituted carbocycle" refers to a non-aromatic cyclic hydrocarbon radical composed ρ= by three to seven carbon atoms, which is optionally substituted with one or more substituents selected from the group consisting of Ci-3 alkyl optionally having one to three fluorine substituents, C2-3 alkenyl, C2-3 alkynyl, Ci-2 alkoxy optionally having one to three fluorine substituents, sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, nitro, ureido, cyano and halogen.
As used herein, the term "aryl" refers to an optionally substituted benzene ring or refers to a ring system which may result by fusing one or more optional substituents. Exemplary optional substituents include substituted Ci-3 alkyl, substituted C2-3 alkenyl, substituted C2-3 alkynyl, heteroaryl, heterocyclic, aryl, alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, or ureido. Such a ring or ring system may be optionally fused to aryl rings (including benzene rings) optionally having one or more substituents, carbocycle rings or heterocyclic rings. Examples of "aryl" groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, indanyl, anthracyl or phenanthryl, as well as substituted derivatives thereof. As used herein, the term "heteroaryl" refers to an optionally substituted monocyclic five to six-membered aromatic ring containing one or more heteroatomic substitutions selected from S, SO, SO2, O, N, or N-oxide, or refers to such an aromatic ring fused to one or more rings such as heteroaryl rings, aryl rings, heterocyclic rings, or carbocycle rings (e.g., a bicyclic or tricyclic ring system), each having optional subsituents. Examples of optional substituents are selected from the group consisting of substituted Ci-3 alkyl, substituted C2-3 alkenyl, substituted C2-3 alkynyl, heteroaryl, heterocyclic, aryl, Ci-3 alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen or ureido. Examples of "heteroaryl" groups used herein include, but are not limited to, benzoimidazolyl, benzothiazolyl, benzoisothiazolyl, benzothiophenyl, benzopyrazinyl, benzotriazolyl, benzo[l,4]dioxanyl, benzofuranyl, 9H-a-carbolinyl, cinnolinyl, furanyl, furo[2,3-b]pyridinyl, imidazolyl, imidazolidinyl, imidazopyridinyl, isoxazolyl, isothiazolyl, isoquinolinyl, indolyl, indazolyl, indolizinyl, naphthyridinyl, oxazolyl, oxothiadiazolyl, oxadiazolyl, phthalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl, phenazinyl, pyrazolyl, pyridyl, pyrazolopyrimidinyl, pyrrolizinyl, pyridazyl, pyrazinyl, pyrimidyl, 4-oxo-l,
2-dihydro-4H-pyrrolo[3,2,l-ij]-quinolin-4-yl, quinoxalinyl, quinazolinyl, quinolinyl, quinolizinyl, thiophenyl, triazolyl, triazinyl, tetrazolopyrimidinyl, triazolopyrimidinyl, tetrazolyl, thiazolyl, thiazolidinyl, and substituted versions thereof.
As used herein, the term "heterocyclic" refers to a three to seven-membered ring containing one or more heteroatomic moieties selected from S, SO, SO2, O, N, or N-oxide, optionally substituted with one or more substituents selected from the group which includes substituted Ci-3 alkyl, substituted C2-3 alkenyl, substituted C2-3 alkynyl, heteroaryl, heterocyclic, aryl, C1-3 alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, and ureido. Such a ring can be saturated or have one or more degrees of unsaturation. Such a ring may be optionally fused to one or more "heterocyclic" ring(s), aryl ring(s), heteroaryl ring(s) or carbocycle ring(s), each having optional substituents.
Examples of "heterocyclic" moieties include, but are not limited to, 1,4-dioxanyl, 1,3-dioxanyl, pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, imidazolidine-2,4-dionepiperidinyl, piperazinyl, piperazine-2,5-dionyl, morpholinyl, dihydropyranyl, dihydrocinnolinyl, 2,3-dihydrobenzo [1,4] dioxinyl,
3,4-dihydro-2H-benzo[b][l,4]-dioxepinyl, tetrahydropyranyl, 2,3-dihydrofuranyl, 2,3-dihydrobenzofuranyl, dihydroisoxazolyl, tetrahydrobenzodiazepinyl, tetrahydroquinolinyl, tetrahydrofuranyl, tetrahydronaphthyridinyl, tetrahydropurinyl, tetrahydrothiopyranyl, tetrahydrothiophenyl, tetrahydroquinoxalinyl, tetrahydropyridinyl, tetrahydrocarbolinyl, 4H-benzo[ 1,3] -dioxinyl, benzo[l,3]dioxonyl,
2,2-difluorobenzo-[l,3]-dioxonyl, 2,3-dihydro-phthalazine-l, 4-dionyl, and isoindole-1 ,3-dionyl.
As used herein, the term "alkoxy" refers to the group -OR3, where Ra is alkyl as defined above. Exemplary alkoxy groups useful in the present invention include, but are not limited to, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and t-butoxy.
As used herein, the term "alkenyloxy" referes to the group -ORb, where Rb is alkenyl as defined above. As used herein, the term "alkynyloxy" referes to the group -ORc, where R0 is alkynyl as defined above.
As used herein, the term "aralkoxy" refers to the group -OR3Rd, wherein R3 is alkyl and Ra is aryl as defined above.
5 As used herein, the term "aryloxy" refers to the group -ORd, wherein Rd is aryl as defined above.
As used herein, the term "heteroaryloxy" refers to the group -ORe, where Re is heteroaryl as defined above.
As used herein, the term "mercapto" refers to the group -SH. 0 As used herein, the term "sulfonyl" refers to the group -SRf, wherein Rf is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "sulfonyl" refers to the group -S-(O)Rf, wherein Rf is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "sulfonyl" refers to the group -S(O)2Rf, wherein Rf is5 substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "oxo" refers to the group =0.
As used herein, the term "hydroxyl" refers to the group -OH.
As used herein, the term "amino" refers to the group -NH2. The amino group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or0 heterocyclic, as defined above.
As used herein, the term "cyano" refers to the group -CN.
As used herein, the term "aminosulfonyl" refers to the group -S(O)2NH2. The aminosulfonyl group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above. 5 As used herein, the term "sulfonylamino" refers to the group -NHS(O)2Rf wherein Rf is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "carboxyamide" refers to the group -NHC(O)Rf wherein Rf is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined O above.
As used herein, the term "carboxy" refers to the group -C(O)OH. The carboxy group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "aminocarbonyl" refers to the group -C(O)NH2. The aminocarbonyl group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "ureido" refers to the group -NHC(O)NHRg wherein Rg is hydrogen, alkyl, carbocycle or aryl as defined above. 5 As used herein, the term "guanidine" refers to the group -NHC(=NH)NH2.
As used herein, the term "acyl" refers to the group -C(O)Rh, wherein Rh is alkyl, carbocycle, or heterocyclic as defined herein.
As used herein, the term "aroyl" refers to the group -C(O)Rd, wherein Rd is aryl as defined herein. 0 As used herein, the term "heteroaroyl" refers to the group -C(O)Re, wherein Re is heteroaryl as defined herein.
As used herein, the term "acyloxy" refers to the group -OC(O)Rh, wherein Rh is alkyl, carbocycle, or heterocyclic as defined herein.
As used herein, the term "aroyloxy" refers to the group -OC(O)Rd, wherein Rd is aryl5 as defined herein.
As used herein, the term "heteroaroyloxy" refers to the group -OC(O)Re, wherein Re is heteroaryl as defined herein.
Preferred compounds useful in the present invention are selected from the group O consisting of:
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (pyridin-4-yl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-methyl- 1,3,4-thiadiazole 5 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentyl- 1 ,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3 ,4-thiadiazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)- 1 -ethyl-0 lH-tetrazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (furan-2-yl)- 1 ,3,4-oxadiazole
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l- cyclopentyl- 1 H-tetrazole 5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- cyclopentyl-2H-tetrazole
1 -benzyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- lH-tetrazole 2-benzyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-
2H-tetrazole
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- cyclohexyl-2H-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclohexyl-lH-tetrazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- cyclobutyl- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (pyrazin-2-yl)- 1 ,3 ,4-oxadiazole 2-(5-(4-chlorophenyl)-l -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5-
(pyrazin-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (thiophen-2-yl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (thiophen-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (pyridin-2-ylmethyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- isopropyl- 1 ,3 ,4-thiadiazole 2-benzyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-
1,3 ,4-thiadiazole
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-l H-pyrazol-3-yl)- 1-propyl- lH-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-2-propyl- 2H-tetrazole
3-((5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H- tetrazol- 1 -yl)methyl)pyridine
3.((5.(5.(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2H- tetrazol-2-yl)methyl)pyridine 2-((5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H- tetrazol- 1 -yl)methyl)pyridine
2-((5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2H- tetrazol-2-yl)methyl)pyridine 4-((5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H- tetrazol- 1 -yl)methyl)pyridine
4-((5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2H- tetrazol-2-yl)methyl)pyridine
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l- (furan-2-ylmethyl)-l H-tetrazole
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- (furan-2-ylmethyl)- 1 H-tetrazole
2-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)- 1,3,4-thiadiazole 5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 -
(furan-3-ylmethyl)- 1 H-tetrazole
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- (furan-3-ylmethyl)-2H-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 -phenyl- 1 H-tetrazole
1 -butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H-tetrazole
2-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)- 2H-tetrazole 5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 -pentyl-
1 H-tetrazole
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-pentyl- 2H-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - isopropyl-1 H-tetrazole
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- isopropyl-2H-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - (cyclohexylmethyl)- 1 H-tetrazole 5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- (cyclohexylmethyl)-2H-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - (thiophen-3-ylmethyl)- 1 H-tetrazole 5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-2-
(thiophen-3-ylmethyl)-2H-tetrazole
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-l H-pyrazol-3-yl)- 1- cycloheptyl- 1 H-tetrazole
1 -tert-butyl-5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3 -y I)- 1 H-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 -octyl- 1 H-tetrazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-phenyl- 1,3,4-thiadiazole 5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 -hexyl-
1 H-tetrazole
1 -Adamantyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-m ethyl- 1 H-pyrazol-3- yl)- 1 H-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclopropyl- 1 H-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - phenethyl- 1 H-tetrazole
5 -(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-2- phenethyl-2H-tetrazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-
(cyclopentylmethyl)- 1 ,3 ,4-thiadiazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclobutyl- 1 H-tetrazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentyl-lH-l,2,4-triazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (tetrahydro-2H-pyran-4-yl)- 1 ,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (tetrahydrofuran-2-yl)-l,3,4-thiadiazole 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- IH-1 ,2,4-triazole
3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5-phenyl- lH-l,2,4-triazole 2-(benzofuran-2-yl)-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-pentyl- 1,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cycloheptyl-l,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2,4-dichlorophenyl)- 1 ,3 ,4-thiadiazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (thiophen-2-yl)- 1 H- 1 ,2,4-triazole 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cycloheptyl- IH-1 ,2,4-triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (fiιran-2-yl)- 1 H- 1 ,2,4-triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- propyl- 1 H- 1 ,2,4-triazole
3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- isopropyl- IH-1 ,2,4-triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopropyl- IH-1 ,2,4-triazole 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-
(cyclopropylmethyl)- IH-1 ,2,4-triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclobutyl- IH-1 ,2,4-triazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclopentylmethyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (tetrahydro-2H-pyran-4-yl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3 ,4-oxadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclobutyl-l,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3,4-thiadiazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-
(tetrahydrofuran-2-yl)-l,3,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentyl- 1 ,3,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (l-phenylethyl)-l,3,4-thiadiazole
2-sec-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3- yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (pentan-2-yl)- 1 ,3,4-thiadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-N- cyclohexyl- 1 ,3 ,4-thiadiazol-2-amine
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclohex-3-enyl)-l ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclohex-3-enyl)- 1 ,3 ,4-thiadiazole
5-sec-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3- yl)-lH-l,2,4-triazole 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 -isopropyl- IH-1 ,2,4-triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopropyl- 1 -methyl- IH-1 ,2,4-triazole
4-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclopentyl- IH-1 ,2,3 -triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentyl- 1 -methyl- IH-1 ,2,4-triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 -methyl- IH-1 ,2,4-triazole 2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclopropylmethyl)- 1 ,3,4-thiadiazole
2-(4-tert-butylcyclohexyl)-5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-l,3,4-thiadiazole 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3- yl)- 1 ,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclopropylmethyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl-l,3,4-thiadiazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopropyl- 1 -ethyl- IH-1 ,2,4-triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopropyl- 1 -isopropyl- 1 H- 1 ,2,4-triazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- cyclohexyl-1 ,3,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5 - (cyclopent-3-enyl)- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclopent-3-enyl)-l,3,4-thiadiazole
5-sec-butyl-3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 -methyl- 1 H- 1 ,2,4-triazole
5-sec-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazol-3-yl)- 1 -ethyl- 1 H- 1 ,2,4-triazole 5-sec-butyl-3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 -isopropyl- IH-1 ,2,4-triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- isopropyl- 1 -methyl- IH-1 ,2,4-triazole
3 -(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 -ethyl-5- isopropyl- 1 H- 1 ,2,4-triazole
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-l H-pyrazol-3-yl)- 1,5- diisopropyl- IH-1 ,2,4-triazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- yclopentyl- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cycloheptyl- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (hexan-2-yl)-l ,3,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dicMorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (hexan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -phenylpropan-2-yl)- 1 ,3 ,4-thiadiazole
5-butyl-2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3- yl)oxazole 2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ethyloxazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- isobutyloxazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- isobutylthiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -cyclobutylpropan-2-yl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyloxazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexylthiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3,4-thiadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3,4-oxadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (hexan-2-yl)-l ,3,4-thiadiazole
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)- 1,3,4-thiadiazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5,6- dihydro-4H-cyclopenta[d]thiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-4,5,6,7- tetrahydrobenzo [d] oxazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-4,5 ,6,7- tetrahydrobenzo [d] thiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentyloxazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentylthiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (l-cyclopentylethyl)-l,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (1 -cyclopentylethyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -cyclohexylethyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -cyclohexylethyl)- 1 ,3 ,4-thiadiazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-
(2-cyclopentylpropan-2-yl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-cyclopentylpropan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-cyclohexylpropan-2-yl)-l ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-cyclohexylpropan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2 ,2-dichloro- 1 -methy lcyclopropyl)- 1 , 3 ,4-oxadiazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3 ,4-thiadiazole 2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- cyclopentyl- 1 ,3 ,4-thiadiazole
5-tert-butyl-2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3- yl)oxazole
5-tert-butyl-2-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 - yl) thiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- cycloheptyl- 1 ,3 ,4-thiadiazole 2-sec-butyl-5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3 - yl)-l,3,4-thiadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- sec-butyl-1 ,3,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- cycloheptyl- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-phenylpropan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-(4-chlorophenyl)propan-2-yl)- 1 ,3 ,4-thiadiazole 2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- sec-butyl- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (2-phenylpropan-2-y I)- 1 , 3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-(pyridin-2-yloxy)propan-2-yl)- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-(5-(trifluoromethyl)pyridin-2-yloxy)propan-2-yl)-l,3,4-oxadiazole
2-tert-butyl-5-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)- 1,3,4-thiadiazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-methylhexan-2-yl)- 1 ,3 ,4-thiadiazole
2-sec-butyl-5-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)- 1,3,4-thiadiazole 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-
1,3,4-thiadiazole
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl- 1,3,4-thiadiazole
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (hexan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (pentan-2-yl)- 1 ,3 ,4-thiadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-
(pentan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (pentan-2-yl)- 1 ,3,4-thiadiazole
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-methylhexan-2-yl)- 1 ,3 ,4-thiadiazole
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-phenylpropan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)- 1 -(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole 2-(5-(4-bromophenyl)-l-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- sec-butyl- 1 ,3 ,4-thiadiazole
2-(l -(allyloxy)-2-methylpropan-2-yl)-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 4-methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-methoxypropan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-methoxypropan-2-yl)- 1 ,3,4-oxadiazole
2-( 1 -(2,4-dichlorophenyl)-4-methyl-5 -phenyl- 1 H-pyrazol-3 -yl)-5-tert-pentyl- 1 ,3 ,4- thiadiazole 2-tert-butyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,3,4- thiadiazole
2-sec-butyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,3,4- thiadiazole 2-cyclobutyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,3,4- thiadiazole
2-(5-(4-bromophenyl)-l-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole
2-(5-(4-bromophenyl)-l-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- tert-butyl-l,3,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3,4-thiadiazole 2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- sec-butyl- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole
(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyl acetate
(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyl benzoate 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-
( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole 2-tert-butyl-5-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3- yl)- 1 ,3,4-thiadiazole
2-sec-butyl-5-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3- yl)- 1 ,3,4-thiadiazole
2-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-ethoxypropan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-ethoxypropan-2-yl)-l,3,4-oxadiazole 2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(fluoromethyl)- 1 H- pyrazol-3-yl)-l ,3,4-oxadiazole
2-(4-(butoxymethyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-oxadiazole
(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methanol
2-( 1 , 5 -bis(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5 - ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole 2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(methoxymethyl)- 1 H- pyrazol-3 -yl)- 1 ,3 ,4-oxadiazole
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-butyl-l,3,4-thiadiazole
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-sec-butyl-l,3,4-thiadiazole
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-thiadiazole
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl-l,3,4-thiadiazole
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(phenoxymethyl)- 1 H- pyrazol-3-yl)-l ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-propoxypropan-2-yl)- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-propoxypropan-2-yl)- 1 ,3,4-thiadiazole
3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazole-4-carbaldehyde
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-((pyridin-2-yloxy) methyl)- 1 H-pyrazol-3-yl)- 1 ,3,4-oxadiazole
2-(4-chloro-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3-yl)-5- cyclobutyl-1 ,3,4-oxadiazole 2-(4-chloro-5-(4-chlorophenyl)-l -(2,4-dichlorophenyl)- lH-pyrazol-3-yl)-5- cyclobutyl-1 ,3,4-thiadiazole
2-(4-chloro-5-(4-chlorophenyl)-l -(2,4-dichlorophenyl)- lH-pyr azol-3-yl)-5- tert-pentyl-1 ,3,4-oxadiazole
2-(4-chloro-5-(4-chlorophenyl)-l -(2,4-dichlorophenyl)- lH-pyr azol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole
2-(4-chloro-5-(4-chlorophenyl)-l -(2,4-dichlorophenyl)- lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3 ,4-oxadiazole
2-(4-chloro-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3 -yl)-5 - cyclohexyl- 1 ,3 ,4-thiadiazole 2-sec-butyl-5-(4-chloro-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)- 1 ,3,4-oxadiazole
2-sec-butyl-5-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-3-yl)- 1 ,3,4-thiadiazole
2-tert-butyl-5-(4-chloro-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)- 1 ,3,4-oxadiazole
2-tert-butyl-5-(4-chloro-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-l ,3,4-thiadiazole
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(difluoromethyl)- 1 H- pyrazol-3-yl)-l,3,4-oxadiazole 2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(l -methoxyethyl)- 1 H- pyrazol-3-yl)-l ,3,4-oxadiazole l-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanone
2-tert-butyl-5-(l-(2,4-dichlorophenyl)-5-(4-(methylthio)phenyl)-4- (methylthiomethyl)- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(piperidin- 1 -ylmethyl)- lH-pyrazol-3-yl)-l,3,4-oxadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3 -yl)-5 - (1 -phenylcyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3 -yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole 2-(bicyclo[2.2.1]heptan-2-yl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4- ethyl- 1 H-pyrazol-3 -yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- isopropyl- 1 ,3,4-thiadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (pentan-3-yl)-l,3,4-thiadiazole
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -methylcyclohexyl)- 1 ,3 ,4-thiadiazole
Methyl (3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l- (2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methylcarbamate N-((3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl)-N-methylethanamine
5'-tert-butyl-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H, 1 Η-3 ,3'- bipyrazole
2-(4-(( 1 H-imidazol- 1 -yl)methyl)-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l ,3,4-oxadiazole
5-tert-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3- yl) isoxazole
3-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3- yl) isoxazole 2-( 1 -(benzyloxy)pentyl)-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 ,3,4-oxadiazole
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-l,3,4-oxadiazole
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-l,3,4-thiadiazole
1 -(5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4- oxadiazol-2-yl)pentan- 1 -ol
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(pyrrolidin- 1 -ylmethyl)- lH-pyrazol-3-yl)-l,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- IH- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole
1 -((3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl)pyrrolidine-2,5-dione 1 -(3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-
1 H-pyrazol-4-yl)ethanol
2-tert-butyl-5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-( 1 -fluoroethyl)- 1 H- pyrazol-3-yl)-l ,3,4-oxadiazole l-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methyl)pyrrolidin-2-one
3-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl)oxazolidin-2-one
S-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methyl ethanethioate 4-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-
1 H-pyrazol-4-yl)methyl)morpholine
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-oxadiazole
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole
2-(4-bromo-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3-yl)-5 - sec-butyl- 1 ,3 ,4-oxadiazole
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- sec-butyl- 1 ,3 ,4-thiadiazole 2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- cyclobutyl-1 ,3,4-oxadiazole
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3,4-oxadiazole
2-(4-bromo-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3 -yl)-5- cyclohexyl-1 ,3,4-thiadiazole
2-(4-bromo-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3-yl)-5- tert-pentyl-l,3,4-oxadiazole
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- tert-pentyl-1 ,3,4-thiadiazole
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- (2-(4-chlorophenyl)propan-2-yl)- 1 ,3 ,4-oxadiazole 2-(4-bromo-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3 -yl)-5-
(2-(4-chlorophenyl)propan-2-yl)- 1 ,3 ,4-thiadiazole
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)- 1,3,4-oxadiazole
2-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)propan-2-ol
(( 1 R,2S)-2-(5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3- yl)- 1 ,3 ,4-oxadiazol-2-yl)cyclopropyl)(piperidin- 1 -yl)methanone
2-(2-butoxypropan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazol-3-yl)-l ,3,4-oxadiazole 2-(2-butoxypropan-2-yl)-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)-l ,3,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5 - ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-
( 1 -p-tolylcyclopropyl)- 1 ,3 ,4-oxadiazole
2-tert-butyl-5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(prop- 1 -en-2-yl)- 1 H- pyrazol-3-yl)- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -p-tolylcyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-(pentyloxy)propan-2-yl)- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-(pentyloxy)propan-2-yl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethy^cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(trifluoromethy^cyclopropyl)- 1 ,3 ,4-thiadiazole 5-tert-butyl-3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3- yl) isothiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
(3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-4-yl)methanethiol
2-(4-(( 1 H-pyrazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole 2-(5-(4-bromophenyl)-l -(2-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-
( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl acetate
(5-(4-bromophenyl)-3 -(5 -tert-butyl- 1 ,3 ,4-oxadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-4-yl)methyl acetate
2-(4-((l H-pyrrol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole 2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-
(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole
2-(4-bromo-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3-yl)-5- (1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethyl)cyclobutyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethyl)cyclobutyl)- 1 ,3 ,4-thiadiazole
2-(2-(benzyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4- methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2,2,2-trifluoroethyl)- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2,2,2-trifluoroethyl)-l,3,4-thiadiazole 2-(5-(4-chlorophenyl)- 1 -(2,3-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5-
( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3,4-oxadiazole
2-(l-(4-chlorophenyl)cyclopropyl)-5-(l-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)- 4-methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)- 1 -(2,3-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (1 -(4-chlorophenyl)cyclopropyl)-l ,3,4-oxadiazole
2-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)acetonitrile
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-
(1 -(4-chlorophenyl)cyclobutyl)- 1 ,3,4-oxadiazole
N-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl)-2-methylpropan-2-amine
N-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methy l)propan-2-amine
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 , 3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -p-tolylcyclopropyl)- 1 ,3 ,4-oxadiazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-
( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(2,4-dichlorophenyl)cyclopropyl)-l,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethytycyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(3-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(3-chlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole
2-(l -allylcyclopropyl)-5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H- pyrazol-3-yl)- 1 ,3,4-oxadiazole 5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclopentyl- 1 H-tetrazole
5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclohexyl- 1 H-tetrazole
5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cycloheptyl-1 H-tetrazole
2-(l-(2-bromophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-( 1 -(2-bromophenyl)-5 -(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole 2-(5-(4-chlorophenyl)- 1 -(2,6-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5-
( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,6-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole
(5-(4-bromophenyl)-3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-4-yl)methanol
5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)- 1 - cyclopentyl- 1 H-tetrazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-(fluoromethyl)- 1 H-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-oxadiazole 5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)- 1 - cyclopentyl- 1 H-tetrazole
5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH- pyrazole-4-carbaldehyde
2-(4-((1H- 1 ,2,3-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-oxadiazole
2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,5-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,5-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclobutyl)-l,3,4-oxadiazole 2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethynyl- 1 H-pyrazol-3- yl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -propylcyclopropyl)- 1 ,3 ,4-oxadiazole
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(prop- 1 -ynyl)- 1 H- pyrazol-3-yl)-l,3,4-oxadiazole
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(3-(trimethylsilyl)prop- 2-ynyl)- 1 H-pyrazol-3-yl)- 1 ,3,4-oxadiazole
2-(4-(( 1 H-tetrazol- 1 -yl)methyl)-5 -(4-chlorophenyl)- 1 -(2 ,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole 2-(4-((l H-tetrazol-5-yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-oxadiazole
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(propa- 1 ,2-dienyl)- 1 H- pyrazol-3-yl)-l ,3,4-oxadiazole
2-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)propan-2-ol
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-(prop- 1 -en-2-yl)- 1 H-pyrazol-3 -yl)- 5-tert-butyl-l ,3,4-oxadiazole
2-( 1 -(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-
( 1 -(trifluoromethyOcyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (l-p-tolylcyclopropyl)-l,3,4-oxadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-( 1 -fluoroethyl)- 1 H-pyrazol-3-yl)-5- tert-butyl-l,3,4-oxadiazole l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanol
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3,4-oxadiazole Methyl l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-
(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethylcarbamate l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanone l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)ethanone
1 -(5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 ,3,4- oxadiazol-2-yl)cyclopropanecarbonitrile
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(pyridin-2-yl)cyclopropyl)- 1 ,3 ,4-oxadiazole 2-(5-(4-chlorophenyl)-l -(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5-
( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5- (1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5- (1 -(4-chlorophenyl)cyclobutyl)- 1 ,3,4-oxadiazole
(5-(4-bromophenyl)-3-(5-tert-butyl- 1 ,3,4-thiadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-4-yl)methyl acetate (5-(4-bromophenyl)-3-(5-tert-butyl- 1 ,3,4-thiadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-4-yl)methanol
2-(l -benzylcyclopropyl)-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 ,3,4-oxadiazole
2-(l-benzylcyclopropyl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH- pyrazol-3-yl)-l ,3,4-oxadiazole
2-( 1 -benzylcyclopropyl)-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- IH- pyrazol-3-yl)-l ,3,4-thiadiazole
2-(l -benzylcyclopropyl)-5-(5-(4-bromorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H- pyrazol-3-yl)-l,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-methylcyclopropyl)-l,3,4-oxadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -methylcyclopropyl)- 1 ,3 ,4-thiadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-
( 1 -methylcyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -methylcyclopropyl)- 1 ,3,4-thiadiazole
2-(l-(4-chlorobenzyl)cyclopropyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4- methyl- 1 H-pyrazol-3 -yl)- 1 ,3 ,4-oxadiazole
2-(l-(4-chlorobenzyl)cyclopropyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4- methyl-1 H-pyrazol-3 -yl)-l, 3, 4-thiadiazole
2-( 1 -(4-chlorobenzyl)cyclopropyl)-5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4- ethyl- 1 H-pyrazol-3 -yl)- 1 ,3 ,4-oxadiazole 2-( 1 -(4-chlorobenzyl)cyclopropyl)-5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4- ethyl-lH-pyrazol-3-yl)-l,3,4-thiadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-(methoxymethyl)- 1 H-pyrazol-3-yl)- 5-tert-butyl-l ,3,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -p-tolylcyclopropyl)- 1 , 3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-thiadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-
( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- 5 ( 1 -p-tolylcyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole 0 2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5-
(1 -(4-chlorophenyl)cyclobutyl)-l ,3 ,4-thiadiazole
(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)-l- (2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methyl acetate
(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)-l- 5 (2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methanol
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(fluoromethyl)- 1 H-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole
5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)-l- (2,4-dichlorophenyl)- 1 H-pyrazole-4-carbaldehyde 0 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-
( 1 -methylcyclopropyl)- 1 , 3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (1 -methylcyclopropyl)- 1 ,3,4-thiadiazole
1 -( 1 -(5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5 1,3 ,4-oxadiazol-2-yl)cyclopropyl)ethanone
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-(fluoromethyl)- 1 H-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-((5-(trifluoromethyl)pyridin-2- yloxy)methyl)- 1 H-pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-thiadiazole o 2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-thiadiazole
5.(4.bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH- pyrazole-4-carbaldehyde
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-cyclobutyl- 1 ,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-cyclohexyl-l,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -phenylcyclopropyl)- 1 ,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-p-tolylcyclopropyl)-l,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-methoxyphenyl)cyclopropyl)-l,3,4-oxadiazole 2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -(2,4-dichlorophenyl)cyclopropyl)-l ,3,4- oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-cyclobutyl-l,3,4-thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-cyclohexyl-l,3,4-thiadiazole
2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-( 1 -phenylcyclopropyl)- 1 ,3,4-thiadiazole 2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-p-tolylcyclopropyl)-l,3,4-thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-methoxyphenyl)cyclopropyl)-l,3,4-thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(2,4-dichlorophenyl)cyclopropyl)-l,3,4- thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(trifluoromethyl)cyclopropyl)-l,3,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (1 -ethylcyclopropyl)- 1 ,3,4-oxadiazole 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-
(l-ethylcyclopropyl)-l,3,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -ethylcyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopentyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopentyl)- 1 , 3 ,4-thiadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopentyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopentyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-thiadiazole 2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5-
(l-ethylcyclopropyl)-l,3,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -ethylcyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (1 -ethylcyclopropyl)- 1 ,3 ,4-thiadiazole
1 -(5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- lH-pyrazol-3-yl)- 1 ,3,4- oxadiazol-2-yl)cyclopropanecarbonitrile l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,3,4- thiadiazol-2-yl)cyclopropanecarbonitrile 2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -(trifluoromethyl)cyclobutyl)- 1 ,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclobutyl)-l,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -phenylcyclopentyl)- 1 ,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclopentyl)-l,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3 -yl)-5 -( 1 -(trifluoromethyl)cyclobutyl)- 1 , 3 ,4-thiadiazole 2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclobutyl)-l,3,4-thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-phenylcyclopentyl)-l,3,4-thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclopentyl)-l,3,4-thiadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-fluorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (1 -(4-fluorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (l-(3-chlorophenyl)cyclopropyl)-l,3,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(3-chlorophenyl)cyclopropyl)-l,3,4-thiadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-
(l-(3-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-^-chlorophenyrjcyclopropyrH^^-thiadiazole
5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH- pyrazole-4-carbaldehyde
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-(prop- 1 -en-2-yl)- 1 H-pyrazol-3-yl)- 5-tert-butyl- 1 ,3 ,4-thiadiazole
2-(4-((2H-tetrazol-2-yl)methyl)-5 -(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole 2-(4-(( 1 H-tetrazol- 1 -yl)methyl)-5 -(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-fluorophenyl)cyclopropyl)-l,3,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (1 -(4-fluorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)- 1 ,3 ,4-oxadiazol-2-yl)cyclopropyl)propan-2-ol
1 -(I -(5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazol-2-yl)cyclopropyl)ethanol 2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4- oxadiazol-2-yl)-2-methylpropyl acetate
2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4- oxadiazol-2-yl)-2-methylpropan- 1 -ol
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-(2-fluorobenzyloxy)propan-2-yl)- 1 ,3,4-oxadiazole
2-(2-(3-Chlorobenzyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l- (2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-oxadiazole
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl- lH-pyrazol-3-yl)-l,3,4-oxadiazole
3-(2-(5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)- 1,3,4- oxadiazol-2-yl)propan-2-yloxy)propan- 1 -ol
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3 -y I)- 1 ,3 ,4-oxadiazole 2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-((2-methyl-2H-tetrazol-
5-yl)methyl)- 1 H-pyrazol-3-yl)- 1 ,3,4-oxadiazole
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-((l-methyl-lH-tetrazol- 5 -y l)methyl)- 1 H-pyrazol-3 -yl)- 1 ,3 ,4-oxadiazole
2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)- 1 -(2-chlorophenyl)-5-(4-chlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1,3 ,4-oxadiazole l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanol
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-( 1 -fluoroethyl)- 1 H-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3,4-thiadiazole
Methyl 1 -(5-(4-bromophenyl)-3-(5-tert-butyl- 1 ,3,4-thiadiazol-2-yl)- 1 - (2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethylcarbamate
1 -(5-(4-bromophenyl)-3 -(5-tert-butyl- 1 ,3 ,4-thiadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- lH-pyrazol-4-yl)ethanone
2-( 1 -(Benzyloxy)-2-methylpropan-2-yl)-5 -(5-(4-chlorophenyl)- 1 - (2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-oxadiazole l-(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)-l- (2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanol 2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(difluoromethyl)- 1 H-pyrazol-3 -y I)-
5-( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethy^cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-propyl- 1 H-pyrazol-3 -yl)-5 - ( 1 -(trifluoromethy^cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethy^cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-( 1 -fluoroethyl)- 1 H-pyrazol-3-yl)-5- (1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole 1 -(5-(4-chlorophenyl)-3-(5-( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazol-2-yl)- 1 -
(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanone
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (1 -(2-fluorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(2-fluorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3 -yl)-5 -tert-butyl- 1 ,3 ,4-oxadiazole 2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)- 1 -(2-chlorophenyl)-5 -(4-chlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3 ,4-thiadiazole
(3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyl acetate
(3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methanol
2-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-vinyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
Methyl l-(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)-l- (2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethylcarbamate
2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4- oxadiazol-2-yl)propan-2-yl acetate
2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4- oxadiazol-2-yl)propan-2-ol 2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -methylcyclopropyl)-! ,3,4-oxadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(trifluoromethyl)cyclopropyl)-l,3,4-oxadiazole 2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole
2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3 -yl)-5-( 1 -methylcyclopropyl)- 1 ,3 ,4-thiadiazole
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(trifluoromethyl)cyclopropyl)-l,3,4-thiadiazole
2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-thiadiazole
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-methyl- 1 -(4-(trifluoromethyl)benzyloxy)propan-2-yl)- 1 ,3 ,4-oxadiazole 2-( 1 -(4-Chlorobenzyloxy)-2-methylpropan-2-yl)-5-(5-(4-chlorophenyl)- 1 -
(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-oxadiazole
2-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -( 1 -fluoroethyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (1 -(cyclopropylmethyl)cyclopropyl)- 1 ,3,4-oxadiazole
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(cyclopropylmethyl)cyclopropyl)- 1 ,3 ,4-oxadiazole
2-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)propan-2-ol 1 -(3-(5-tert-butyl- 1 ,3,4-thiadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-
1 H-pyrazol-4-yl)ethanol
GENERAL SYNTHETIC SEQUENCE
The following synthetic schemes are merely illustrative of the methods by which the compounds of the invention may be prepared and are not intended to limit the scope of the invention as defined in the appended claims.
The compound of formula (Ia) may be prepared by (i) reacting a carboxylic acid derivative (5) with a hydrazide compound (7) or a semicarbazide compound (12) in the presence of a coupling agent, e.g., l-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDCI), 4-dimethylaminopyridine (DMAP), and (ii) cyclizing the resulting product using a dehydrating agent to obtain an 1,3,4-oxadiazole compound of formula (Ia), as shown in Reaction Scheme 1.
Reaction Scheme 1
Figure imgf000044_0001
wherein, R1 to R4 have the same meanings as defined above. The cyclization may be conducted using Burgess reagent as a dehydrating agent while applying microwave irradiation thereon (See Leber, J. D. et al., WO 2005/032550), or using triphenylphosphine with carbon tetrachloride and a base such triethylamine in a suitable solvent such as acetonitrile and THF.
The carboxylic acid derivative (5) used as a starting material in preparing the compound of formula (Ia) may be prepared by a conventional method, e.g., by treating an acetophenone derivative (1) with an organic base such as lithium hexamethyldisilazide (LHMDS) to produce a corresponding alkali metal salt (2), reacting the resulting salt with an equimolar amount of diethyl oxalate to provide a ketoester salt (3), reacting the salt (3) with a hydrazine derivative in refluxing acetic acid to obtain a pyrazole-3 -carboxylic ester (4), and transforming the ester (4) into an acid form (5) using an alkaline agent such as potassium hydroxide or lithium hydroxide, followed by acidification (See Barth, F. et al., U.S. Patent No. 5,462,960), as shown in Reaction Scheme 2. Reaction Scheme 2
Figure imgf000045_0001
The hydrazide compound (7) which may be used in preparing the compound of formula (Ia) may be prepared by treating an ester or a carboxylic acid with hydrazine, and also, the semicarbazide compound (12) may be prepared by treating carbamyl chloride or isocynate with hydrazine, as shown in Reaction Scheme 3.
Reaction Scheme 3
0
R2 CO2Me NH2NH2 R2AN;NH2
(6)
(7)
Figure imgf000045_0002
(1 1) (1 2)
Figure imgf000045_0003
(12) wherein, Ri to R4 have the same meanings as defined above. The compound of formula (Ib) may be prepared by (i) reacting a carboxylic acid derivative (5) with a hydrazide compound (7) in the presence of coupling agents, e.g., EDCI, DMAP, and (ii) cyclizing the resulting product using a Lawesson's reagent, which can be conducted with microwave irradiation (See Kiryanov, A. A., Sampson, P., Seed, A. J., J. Org. Chem. 2001, 665, 7925-7929), as shown in Reaction Scheme 4.
Reaction Scheme 4
Figure imgf000046_0001
(Ib) wherein, R1 and R2 have the same meanings as defined above.
Figure imgf000046_0002
As demonstrated above, the acylhydrazide intermediate (9) is also available through a coupling of the hydrazide (A) with a corresponding acid in the presence of coupling reagents: DMAP, EDCI; EDCI, 1-hydroxybezotriazole (HOBt), N-methyl morpholine (NMM) In turn, the requisite hydrazide (A) is prepared by treating ester (4) with hydrazine in refluxing ethanol (EtOH).
The compound of formula (Ic) may be prepared by (i) reacting a nitrile intermediate (19) with hydroxylamine in a solvent, e.g., MeOH, (ii) acylating the resulting N-hydroxyamidine (20) with an activated carboxylic acid in the presence of a coupling agent, e.g., dicyclohexylcarbodiimide (DCC), EDCI or 1,1-carbonyldiimidazole (CDI), and (iii) cyclizing the acylated compound (21) in the presence of a base by heating, e.g., microwave irradiation, as shown in Reaction Scheme 5.
Reaction Scheme 5
Figure imgf000047_0001
wherein, R1 and R2 have the same meanings as defined above. In Reaction Scheme 5, step (i) may be conducted in heated methyl alcohol. The acylation of step (ii) may be conducted in the presence of a suitable base such as triethylamine (TEA) or N-methyl morpholine (NMM) in a solvent such as methylene chloride, THF or acetonitrile. The cyclization step (iii) may be conducted in a solvent such as acetonitrile or THF, and exemplary bases which may be used in this step include pyridine, N,N-diisopropylethylamine or tetrabutylammonium fluoride. Also, the process of isolating N-acyloxyamidine (21) may be omitted, in case N-hydroxyamidine (20) was converted to 1,2,4-oxadiazole (Ic) in a continuous process (See, Colandrea, V. J. et al., WO 2005/058848).
The nitrile intermediate (19) used in preparing the compound of formula (Ic) may be prepared by [3+2] cycloaddition reaction disclosed in J. Med. Chem. 1999, 42, 769-776, as shown in Reaction Scheme 6. Reaction Scheme 6 l ammonia solution CHJCI2
Figure imgf000048_0001
The compound of formula (Id) may be prepared by reacting a nitrile intermediate (19) with a hydrazide compound (7) in the presence of a catalyst such as potassium carbonate in a suitable solvent such as 1-butanol under a reflux condition, to obtain a triazole, as shown in Reaction Scheme 7.
Reaction Scheme 7
Figure imgf000048_0002
wherein, R2 has the same meaning as defined above.
The compound of formula (Ie) or (If) may be prepared by reacting a nitrile intermediate (19) with sodium azide in the presence of a base (e.g., ammonium chloride) in a solvent (e.g., N,N-dimethylformamide: DMF) with microwave irradiation, according to
[3+2] cycloaddition reaction, to obtain a tetrazole, which may be alkylated by a reaction with an alkyl halide in the presence of potassium carbonate in DMF to obtain alkyl tetrazoles, as shown in Reaction Scheme 8.
Reaction Scheme 8
Figure imgf000049_0001
In Reaction Scheme 8, when RX is a primary alkyl halide, the alkylation can be conducted at room temperature. However, when a secondary alkyl halide is used, the reaction is preferably conducted at 80 °C .
Also, the alkylation of the tetrazole may be conducted using an aliphatic alcohol in the presence of diisopropylazodicarboxylate (DIAD) and triphenylphophine (PPh3) in THF at 0°C , as shown in Reaction Scheme 9. Reaction Scheme 9
Figure imgf000049_0002
Alternatively, the compound of formula (If) may be prepared by treating acyl chloride (17) with an amine in the presence of triethylamine in methylene chloride to produce an amide (26) and reacting the resulting amide with hydrazoic acid in the presence of phosphorus pentachloride in toluene as shown in Reaction Scheme 10. Reaction Scheme 10
PCIE, Toluene, lOmin; HN3, 1 day rt; reflux
Figure imgf000050_0001
Figure imgf000050_0002
OO (26) (lf-2)
R = cyPropyi , oyBut^ , cyHept^ , t Bu , n Hexjrt , n Octyl . adamant. cyHexyl
The compound of formula (Ig) may be prepared by (i) reacting a carboxylic acid intermediate (5) with an aminoketone (27) in the presence of a coupling reagent, e.g. EDCI, DMAP, and (ii) cyclizing the resulting product (28) using a dehydrating agent to obtain an oxazole compound of formula (Ig), as shown in Reaction Scheme 11.
Reaction Scheme 11
Figure imgf000050_0003
wherein R2 and R12 have the same meanings as defined above.
Reaction Scheme 12
Figure imgf000050_0004
O
TFA or HCI HCI R R- 2 ' 12 NH'TFA°' %-V NH
R12 (27) (32) The aminoketone compound (27) or (32) which may be used in preparing the compound of formula (Ig) may be prepared as shown in Reaction Scheme 12. The starting iV-Boc protected aminoacid (29) is converted into the corresponding Weinreb amide (30) using N, 0-dimethylhydroxylamine hydrochloride in the presence of coupling reagents such as EDCI, HOBt, NMM in an appropriate solvent such as dichloromethane (DCM) or DMF. The Weinreb amide (30) may be transformed into a corresponding ketone (31) by action of a Grignard reagent in an appropriate solvent such as ether or THF under N2 atmosphere. Then final deprotection of Boc group using either trifluoroacetic acid (TFA) or HCl may provide a corresponding aminoketone (27) or (32) in a salt form, respectively.
The compound of formula (Ih) may be prepared by (i) reacting a carboxylic acid intermediate (5) with an aminoketone (27) or (32) in the presence of a coupling reagent, e.g.
EDCI, DMAP, and (ii) cyclizing the resulting product (28) using a Lawesson's reagent, which may be conducted with microwave irradiation (See Kiryanov, A. A., Sampson, P.,
Seed, A. J., J. Org. Chem. 2001, 665, 7925-7929), as shown in Reaction Scheme 13.
Reaction Scheme 13
Figure imgf000051_0001
Further derivatization may be started with activated 4-pyrazole intermediate such as the bromomethyl derivative (33) as illustrated in Reaction Scheme 14. Thus, hydroxyl group is introduced by reacting the bromo derivative (33) with sodium acetate, and subsequent hydrolysis of the acetate (34). Oxidation of the alcohol (35) to aldehyde (36) is achieved by action of an oxidant such as Dess-Martin periodinane. Reaction Scheme 14
Figure imgf000052_0001
A bromide of structure (33) may be utilized to provide the corresponding cyanide
(37) by reaction with sodium cyanide in a mixture of acetonitrile and water. A bromide (33) also undergoes acetylenylation to afford a 4-(3-(trimethylsilyl)prop-2-ynyl)-pyrazole (38), which is further desilylated in the presence of TBAF to provide a 4-(prop-2-ynyl)-pyrazole (39) as shown in Reaction Scheme 15.
Reaction Scheme 15
Figure imgf000052_0002
A bromide of structure (33) may be further utilized by reacting a bromide (33) with various primary or secondary amines in the presence of a suitable base such as diisopropylethylamine (DIPEA) in a suitable solvent such as acetonitrile to afford the corresponding amines of structure (40) as described in Reaction Scheme 16.
Reaction Scheme 16
Figure imgf000053_0001
Further derivatization may be conducted on a bromide of structure (33) by reacting a bromide (33) with a pyrrole or various azoles including pyrazole, imidazole, 1 ,2,4-triazole, 1,2,3-triazole, tetrazole in the presence of a base such as sodium hydride in an appropriate solvent such as THF.
Reaction Scheme 17
Figure imgf000053_0002
A derivatization may come from alkylation of the anion of pyrrolidin-2-one, succinimide, or oxazolidini-2-one with a bromide of structure (33) to lead to the corresponding alkylated products (42), (43), or (44), respectively as depicted in Reaction Scheme (18). Reaction Scheme 18
Figure imgf000054_0001
Another derivatization may come from alkylation of the anion of hydroxyl-aryl or hydroxyl-hetero-aryl such as phenol or pyridin-2-ol with a bromide of structure (33) to produce the corresponding alkylated products (45) or (46), respectively as demonstrated in Reaction Scheme 19.
Reaction Scheme 19
Figure imgf000054_0002
Another derivatization may result from a nucleophilic sulfur reagent such as potassium thioacetate or sodium thiomethoxide with a bromide of structure (33). For example, a bromide (33) is smoothly converted to a thioacetate (47) in a suitable solvent such as DMF at ambient temperature. A thioacetate of structure (47) may be used to prepare the corresponding thiol. Another example includes reacting a bromide of structure (33, X = Cl) with sodium thiomethoxide in heated DMF to generate a disulfide of structure (48) as shown in Reaction Scheme 20. Reaction Scheme 20
Figure imgf000055_0001
An alcohol of structure (35) can be alkylated with an alkyl iodide or an alkyl bromide in the presence of a suitable base such as sodium hydride (Williamson ether synthesis conditions) to furnish the corresponding ether of structure (49). Also, an alcohol of structure (35) may be converted into the corresponding fluoride of structure (50) by action of a fluorinating agent such as diethylaminosulfur trifluoride (DAST) in an appropriate solvent such as methylene chloride at ambient temperature. On the other hand, Burgess reagent may convert an alcohol of structure (35) to the corresponding carbamate of structure (51) as described in Reaction Scheme 21.
Reaction Scheme 21
Figure imgf000056_0001
An aldehyde of structure (36) previously prepared as shown in Reaction Scheme 14 may be treated with a fluorinating agent such as DAST to provide the corresponding difluoromethyl-pyrazole (52). Also, an aldehyde of structure (36) may be treated with a Grignard reagent such as methylmagnesium bromide to afford the corresponding alcohol of structure (53), which is further alkylated with an alkyl iodide or an alkyl bromide in the presence of a suitable base such as sodium hydride (Williamson ether synthesis conditions) to furnish the corresponding ether of structure (54). In addition, an alcohol of structure (53) may be treated with Burgess reagent to furnish a carbamate (56) as well as an olefin of structure (55). Also, an alcohol of structure (53) may be oxidized by an appropriate oxidizing agent such as Dess-Martin periodinane to give the corresponding ketone of structure (57). Finally, an alcohol of structure (53) may be treated with a fluorinating agent such as DAST to give a fluoride of structure (58) as described in Reaction Scheme 22. Reaction Scheme 22
Figure imgf000057_0001
A ketone of structure (57) may be further reacted with a Grignard reagent such as methylmagnesium bromide to provide the alcohol of structure (59), which may be dehydrated by using a suitable dehydrating agent such as Burgess reagent to give the corresponding olefin of structure (60) as demonstrated in Reaction Scheme 23. Reaction Scheme 23
Figure imgf000058_0001
The compounds containing 1 ,2,4-triazole at C-4 on pyrazole may be obtained by a series of reaction sequence involving a key intermediate bromide of structure (61). Thus, a bromide of structure (61), which is obtained by reaction of a pyrazole of structure (4) with N-bromosuccinimide (NBS) in the presence of a catalytic amount of AIBN, may be reacted with lH-l,2,4-triazole in the presence of a suitable base such as sodium hydride in a suitable solvent such as THF to furnish 1,2,4-triazole of structure (62). Hydrolysis of an ester (62) may provide the corresponding acid of structure (63). Activation of an acid of structure (63) followed by coupling with a hydrazide in the presence of an appropriate base such as triethylamine may produce an acylhydrazide of structure (64). As an alternative, hydrazynolysis of an ester (62) may provide the corresponding hydrazide, which may be coupled with a particular acid in the presence of coupling reagents such as EDCI, HOBt and NMM to provide an acylhydrazide of structure (64).
The cyclization may be conducted using Burgess reagent as a dehydrating agent while applying microwave irradiation thereon, or using triphenylphosphine with carbon tetrachloride and a base such as triethylamine in a suitable solvent such as acetonitrile and THF, or alternatively using phosphorus(III) oxychloride in a solvent such as acetonitrile or 1,4-dioxane at reflux temperature to give an oxadiazole of structure (65). On the other hand, a compound of formula (66) may be prepared by cyclizing the acylhydrazide intermediate (64) using a Lawesson's reagent, which may be conducted with microwave irradiation as shown in Reaction Scheme 24. Reaction Scheme 24
Figure imgf000059_0001
Figure imgf000059_0003
Figure imgf000059_0002
The 4-cyclopropyl-pyrazole compound may be prepared as shown in Reaction
Scheme 25. Thus, 4-bromo-pyrazole of structure (68), which may be prepared by following a generic procedure (Andrew G. Horti et al, J. Med. Chem. 2003, 46, 642-645), may be coupled with a cyclopropylboronic acid under Suzuki-Miyaura coupling reaction conditions to afford a 4-cyclopropyl-pyrazole of structure (69). The ester (69) may undergo a series of reaction sequence previously described to give rise to an oxadiazole of structure (72). The thiadiazole compound of formula (73) may be prepared by cyclizing the acylhydrazide intermediate (71) using a Lawesson's reagent, which may be conducted with microwave irradiation as shown in Reaction Scheme 25. Reaction Scheme 25
Figure imgf000060_0001
The 4-ethynyl-pyrazole compound of structure (75) may be prepared through two steps from a starting aldehyde of structure (36). Thus, an aldehyde of structure (36) prepared in Reaction Scheme 14 may be converted to a corresponding 4-(2,2-dibromovinyl)-pyrazole (74), which could be treated with a suitable base such as potassium hexamethyldisilazane (KHMDS) at -78 0C in an appropriate solvent such as THF to afford a 4-ethynyl-pyrazole of structure (75). A compound of structure (75) may be further alkylated by action of a base such as lithium hexamethyldisilazide (LHMDS) with an alkylating agent such as methyl iodide in an appropriate solvent such as THF to produce 4-(prop-l-ynyl)-pyrazole of structure (76) as shown in Reaction Scheme 26. Reaction Scheme 26
Figure imgf000061_0001
The requisite cyclopropanecarboxylic acid (80) as a coupling partner of a hydrazide such as structure (70) for the preparation of an oxadiazole as well as a thiadiazole may be prepared by following a known procedure involving three steps starting from a benzyl bromide of structure (77) : i) cyanation, ii) cyclopropanation, iii) hydrolysis of the resulting cyanide of structure (79) [Imbimbo, B. P., J Med. Chem. 2005, 48, 5707-7520] as described in Reaction Scheme 27.
Reaction Scheme 27
Figure imgf000061_0002
(79) (80) wherein A is carbon or nitrogen; R is halogen, C1-C6 alkyl, Ci-C4 alkoxy, NRjRj, carbocycle, heterocycle, aryl, or heteroaryl; and Rj and Rj are independently hydrogen, Ci-4 alkyl or C3-5 carbocycle.
Alternatively, a requisite cyclopropanecarboxylic acid such as structure (85) may be provided by following a known method [Krawczyk, H., Synlett., 2005, / 7, 2648-2652]. Thus, a commercially available 3-bromodihydrofuran-2(3H)-one (81) may undergo Arbuzov reaction to afford diethyl 2-oxotetrahydrofuran-3-ylphosphonate (82), which could be alkylated with an alkyl bromide or an alkyl iodide in the presence of a suitable base such as lithium diisopropylamide (LDA) in an appropriate solvent such as THF to give a compound of structure (83). Treatment of a lactone compound of structure (83) with in situ generated sodium ethoxide in refluxed THF would afford a cyclopropanecarboxylic ester of structure (84), which in turn could be hydrolyzed to a corresponding cyclopropanecarboxylic acid (85) as shown in Reaction Scheme 28.
Reaction Scheme 28
Figure imgf000062_0001
(81) (82) (83)
Figure imgf000062_0002
(84) (85)
As an alternative scaffold, a pyrazole of structure (88) may be prepared by treatment of 1,3-dione of structure (87) with hydrazine at reflux temperature. In turn, a 1,3-dione of structure (87) in equilibrium with a keto-enol of structure (88) may be obtained by treating an ester of structure (4) with a methyl ketone such as 3,3-dimethylbutan-2-one (86) in the presence of a base such as sodium amide. On the other hand, an isoxazole (90) or its isomer (91) may be prepared by treatment of 1,3-dione of structure (87) with hydroxylamine. These two isomers may be separated by preparative HPLC as shown in Reaction Scheme 29. Reaction Scheme 29
Figure imgf000063_0001
Further derivatization on a thiadiazole compound may be done in a similar fashion as done on an oxadiazole compound as illustrated in Reaction Scheme 14. Thus, as shown in
Reaction Scheme 30, bromination may be achieved by NBS in the presence of either benzoyl peroxide or AIBN. Subsequently, hydroxyl group is introduced by reacting a bromide of structure (92) with sodium acetate followed by subsequent hydrolysis of the acetate (93). Oxidation of the alcohol (94) to aldehyde (95) may be achieved by action of a mild oxidant such as Dess-Martin periodinane. Reaction Scheme 30
Figure imgf000064_0001
All the other transformations demonstrated in Reaction Scheme 15-24, and Reaction Scheme 26 can be applied on a thiadiazole compound to prepare inventive compounds in a similar way.
The inventive heteroaryl-pyrazole compound of formula (I) is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, thereby preventing or treating obesity and obesity-related metabolic disorders.
Accordingly, the present invention provides a pharmaceutical composition for preventing or treating obesity and obesity-related metabolic disorders, which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier. Further, the present invention provides a method for preventing or treating obesity and obesity-related metabolic disorders in a mammal, which comprises administering the compound of formula (I) of claim 1 to the mammal.
Also, the present invention provides a method for inhibiting cannabinoid CBi receptor in a mammal, which comprises administering the compound of formula (I) of claim 1 to the mammal.
As used herein, the term "obesity-related metabolic disorders" refers to chronic diseases that require treatment to reduce the excessive health risks associated with obesity and exemplary disorders include type 2 diabetes mellitus, cardiovascular and hypertension, hyperlipidaemia, fibrinolytic abnormalities.
The pharmaceutical composition may be administered orally, intramuscularly or subcutaneously. The formulation for oral administration may take various forms such as a syrup, tablet, capsule, cream and lozenge. A syrup formulation will generally contain a suspension or solution of the compound or its salt in a liquid carrier, e.g., ethanol, peanut oil, olive oil, glycerine or water, optionally with a flavoring or coloring agent. When the composition is in the form of a tablet, any one of pharmaceutical carriers routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. When the composition is in the form of a capsule, any of the routine encapsulation procedures may be employed, e.g., using the aforementioned carriers in a hard gelatin capsule shell. When the composition is formulated in the form of a soft gelatin shell capsule, any of the pharmaceutical carrier routinely used for preparing dispersions or suspensions may be prepared using an aqueous gum, cellulose, silicate or oil. The formulation for intramuscular or subcutaneous administration may take a liquid form such as a solution, suspension and emulsion which includes aqueous solvents such as water, physiological saline and Ringer's solution; or lipophilic solvents such as fatty oil, sesame oil, corn oil and synthetic fatty acid ester.
Preferably the composition is formulated in a specific dosage form for a particular patient.
Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg of the compound of Formula (I) or its pharmaceutically acceptable salt.
The suitable daily dosage for oral administration is about 0.01 mg/Kg to 40 mg/Kg of the compound of Formula (I) or its pharmaceutically acceptable salt, may be administered 1 to 6 times a day, depending on the patient's condition.
SYNTHETIC EXAMPLES
As used herein the symbols and conventions used describing the processes, schemes and examples of the present invention are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification.
Hz (Hertz) TLC (thin layer chromatography)
Tr (retention time) RP (reverse phase)
MeOH (methanol) /-PrOH (isopropanol)
TFA (trifluoroacetic acid) TEA (triethylamine)
EtOH (ethanol) THF (tetrahydrofuran)
DMSO (dimethylsulfoxide) EtOAc (ethyl acetate)
DCM (dichloromethane) HOAc (acetic acid)
DMF (7V,7V-dimethylformamide) Ac (acetyl)
CDI (1,1-carbonyldiimidazole) Bn (benzyl)
HOSu (N-hydroxysuccinimide)
HOBT (1-hydroxybenzotriazole)
Boc (tert-butyloxycarbonyl) mCPBA (meta-chloroperbenzoic acid)
FMOC (9-fluorenylmethoxycarbonyl)
DCC (dicyclohexylcarbodiimide)
Cbz (benzyloxycarbonyl)
NMM (N-methyl morpholine)
HOAt (l-hydroxy-7-azabenzotriazole)
TBAF (tetra-n-butylammonium fluoride)
THP (tetrahydro-2H-pyran-2-yl)
DMAP (4-dimethylaminopyridine)
HPLC (high pressure liquid chromatography)
BOP (bis(2-oxo-3-oxazolidinyl)phosphinic chloride);
EDCI (l-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride)
HBTU (O-Benzotriazolel-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate)
AIBN (α,α'-azobis(isobutyronitrile))
MeI (iodomethane)
LDA (lithium diisopropylamide)
DIPEA (diisopropylethylamine)
NaSMe (sodium thiomethoxide) All references to ether are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in°C (degrees
Centigrade). All reactions are conducted under an inert atmosphere at room temperature unless otherwise noted, and all solvents are of the highest available purity unless otherwise indicated.
Microwave reaction was conducted with a Biotage microwave reactor.
1H NMR spectra were recorded on either a Jeol ECX-400, or a Jeol JNM-LA300 spectrometer. Chemical shifts were expressed in parts per million (ppm, δ units).
Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d(doublet), t (triplet), q (quartet), quint
(quintet), m (multiplet), br (broad).
Mass spectra were obtained with either a Micromass, Quattro LC Triple Quadruple Tandem Mass Spectometer, ESI or Agilent, 1100LC/MSD, ESI.
For preparative HPLC, ca 100 mg of a product was injected in 1 mL of DMSO onto a SunFire™ Prep C18 OBD 5 urn 19x100mm Column with a 10 min gradient from 10% CH3CN to 90% CH3CN in H2O. Flash chromatography was carried using Merck silica gel 60 (230-400 mesh). Most of the reactions were monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light using a 5% ethanolic phosphomolybdic acid or p-anisaldehyde solution.
Preparation of l,3<4-oxadiazole (formula (Ia))
Example 1 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-propyl-l,3,4 -oxadiazole
Step 1: N-butanoyl-N'-[5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazole- 3 -carbonyl] -hydrazine
Added to a solution of 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazole-3-carboxylic acid (0.40 g, 1.05 mmol), N-butanoyl-hydrazine (0.11 g, 1.05 mmol) and EDCI (0.24 g, 1.26 mmol) dissolved in DCM (11 ml), was DMAP (0.15 g, 1.26 mmol) in one portion at room temperature. The reaction mixture was stirred at room temperature for 6 hrs, and then treated with 10% aq. HCl. The organic layer was collected, and evaporated under a vacuum. The crude mixture was further purified by preparative HPLC, to obtain 0.38 g (0.81 mmol, 77%) of the title compound as yellow solid.
1H NMR (400 MHz, CDCl3) δ 7.40 (br s, IH), 7.31-7.27 (m, 4H), 7.08-7.03 (m, 2H), 2.33 (s, 3H), 2.31 (t, J = 7.8 Hz, 2H), 1.72 (m, 2H), 0.97 (t, J = 7.3 Hz, 3H). MH+ 463.
Step 2: 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-propyl- 1,3,4-oxadiazole
N-butanoyl-N' -[5-(4-Chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazole-3 -carbonyl] -hydrazine (0.35 g, 0.75 mmol) obtained in Step 1 was added to a microwave reactor containing Burgess reagent (0.45 g, 1.88 mmol) in THF (2 mL). The capped reactor was placed in a microwave reactor and the mixture was irradiated at 140°C for 15 min. The reaction product was purified by preparative HPLC to provide the title compound (0.21 g, 0.46 mmol, 61%) as yellow solid.
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.3 Hz, IH), 7.34-7.28 (m, 4H), 7.09-7.13 (m, 2H), 2.90 (t, J = 7.6 Hz, 2H), 2.45 (s, 3H), 1.88 (m, 2H), 1.03 (t, J = 7.6 Hz, 3H). MH+ 447.
The following compounds of Examples 2 to 344 were obtained by using corresponding starting materials and repeating the procedure of Example 1.
Example 2
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pyridin-4-y l)-l,3)4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 8.78 (d, J = 7.43 Hz, IH), 8.01 (d, J = 5.04 Hz, IH), 7.41 (d, J = 1.84 Hz, IH), 7.37- 7.29 (m, 4H), 7.11 (d, J = 8.72 Hz, 2H), 2.48 (s, 3H). MH+ 482.
Example 3
2-(5-(4-chlorophenyl)-l-(2,4-dichloroplienyl)-4-metliyl-lH-pyrazol-3-yl)-5-methyl-l,354 -oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 1.84 Hz, IH), 7.37- 7.29 (m, 4H), 7.11 (dt, J = 2.28, 8.24 Hz, 2H), 2.63 (s, 3H), 2.46 (s, 3H). MH+ 419.
Example 4
2-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3»4-o xadiazole
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 1.84 Hz, IH), 7.37- 7.29 (m, 4H), 7.12 (dt, J =
2.28, 8.24 Hz, 2H), 2.94 (t, J = 7.56 Hz, 2H), 2.46 (s, 3H), 1.85 (m, 2H), 1.45 (m, 2H), 0.96
(t, J = 7.36 Hz, 3H).
MH+ 461.
Example 5
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopentyl-
1,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 1.84 Hz, IH), 7.37- 7.29 (m, 4H), 7.11 (dt, J = 2.28, 8.24 Hz, 2H), 3.39 (m, IH), 2.45 (s, 3H), 2.14 (m, 2H), 2.04 (m, 2H), 1.84 (m, 2H),
1.71 (m, 2H).
MH+ 473.
Example 6 2-(5-(4-chIorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 1.84 Hz, IH), 7.37- 7.29 (m, 4H), 7.11 (dt, J = 2.28, 8.24 Hz, 2H), 3.00 (m, IH), 2.44 (s, 3H), 2.16-2.12 (m, 2H), 1.87-1.81 (m, 2H), 1.78-1.65 (m, 3H), 1.44-1.28 (m, 3H). MH+ 487.
Example 7
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopropyl- l,3*4-oxadiazole MH+ 445.
Example 8
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazoI-3-yl)-5-(furan-2-yl)- 1 ,3,4-oxadiazole MH+ 471.
Example 9
2-(5-(4-chIorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l ,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 2.3 Hz, IH), 7.34-7.28 (m, 4H), 7.13-7.09 (m, 2H), 4.01 (m, IH), 2.62-2.52 (m, 2H), 2.49 (s, 3H), 2.47-2.39 (m, 2H), 2.20-2.00 (m, 2H). MH+ 459.
Example 10
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pyrazin-2-y I)-1 ,3,4-oxadiazoIe
1H NMR (400 MHz, CDCl3) δ 9.53 (s, IH), 8.76 (m, IH), 7.43 (d, J = 1.84 Hz, IH), 7.39 (d, J = 8.68 Hz, IH), 7.36- 7.30 (m, 4H), 7.15 (d, J = 8.24 Hz, 2H), 2.55 (s, 3H). MH+ 483.
Example 11
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-metliyl-lH-pyrazol-3-yl)-5-(tliioplien-2- yl)-l,3,4-oxadiazole MH+ 487.
Example 12
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pyridin-2-y
Imethyl)-l,3;4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 8.55 (d, J = 4.12 Hz, IH), 7.66 (dt, J = 1.84, 7.80 Hz, IH), 7.41 (d, J = 1.84 Hz, IH), 7.35-7.29 (m, 5H), 7.20 (dd, J = 5.04, 7.32 Hz, IH), 7.13-7.09 (m, 2H), 4.52 (s, 2H), 2.45 (s, 3H). MH+ 496.
Example 13
2-(5-(4-chlorophenyl)-l-(2,4-dichloroplienyl)-4-methyl-lH-pyrazoI-3-yl)-5-isopropyl-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.28 Hz, IH), 7.38-7.29 (m, 4H), 7.13-7.09 (m, 2H), 3.28 (m, IH), 2.44 (s, 3H), 1.46 (d, J - 6.88 Hz, 6H). MH+ 447.
Example 14
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pentan-3-yl )-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 2.28 Hz, IH), 7.38-7.30 (m, 4H), 7.13-7.10 (m, 2H), 2.96 (m, IH), 2.46 (s, 3H), 1.93-1.79 (m, 2H), 0.94 (t, J = 7.32 Hz, 3H). MH+ 475.
Example 15
2-Benzyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazoI-3-yl)-l,354 -oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 1.84 Hz, IH), 7.38-7.27 (m, 9H), 7.12-7.08 (m, 2H), 4.29 (s, 2H), 2.43 (s, 3H). MH+ 495.
Example 16
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-phenyl-l,3»
4-oxadiazole 1H NMR (300 MHz, CDCl3) δ 8.22-8.18 (m, 2H), 7.57-7.49 (m, 3H), 7.45-7.44 (m, IH), 7.41-7.32 (m, 4H), 7.16-7.12 (m, 2H), 2.51 (s, 3H). MH+ 483.
Example 17 2-(4-ChIorophenyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol -3-yl)-l,3.4-oxadiazole
1H-NMR (300 MHz, CDCl3) δ 8.16-8.12 (m, 2H), 7.52-7.48 (m, 2H), 7.45-7.44 (m, IH), 7.37-7.32 (m, 4H), 7.16-7.12 (m, 2H), 2.50 (s, 3H). MH+ 517.
Example 18
2-(Benzofuran-2-yI)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol
-3-yl)-l,3>4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.70 (d, J= 7.7 Hz, IH), 7.64-7.62 (m, 2H), 1 Al-I Al (m, 2H), 7.40-7.38 (m, IH), 7.36-7.30 (m, 4H), 7.16-7.13 (m, 2H), 2.53 (s, 3H). MH+ 521.
Example 19 2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-pentyl-l,3,4 -oxadiazole
1H-NMR (400 MHz, CDCl3.) δ 7.43-7.42 (m, IH), 7.37-7.30 (m, 4H), 7.13-7.10 (m, 2H), 2.93 (t, J = 7.8 Hz, 2H), 2.46 (s, 3H), 1.90-1.83 (m, 2H), 1.45-1.32 (m, 4H), 0.91 (t, J = 7.3 Hz, 3H). MH+ 475.
Example 20
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-cycloheptyl
-l,3)4-oxadiazole 1H-NMR (400 MHz, CDCl1) δ 7.43-7.41 (m, IH), 7.37-7.29 (m, 4H), 7.13-7.10 (m, 2H), 3.23-3.16 (m, IH), 2.45 (s, 3H), 2.21-2.14 (m, 4H), 1.98-1.89 (m, 2H), 1.85-1.79 (m, 2H), 1.68-1.53 (m, 4H). MH+ 501.
Example 21
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2,4-dichlor opheny I)-1 ,3,4-oxadiazole
1H-NMR (400 MHz, CDCla) δ 8.04 (d, J = 8.4 Hz, IH), 7.60 (d, J = 1.8 Hz, IH), 7.44 (d, J = 2.2 Hz, IH), 7.41 (d, J =2.2 Hz, IH), 7.39-7.31 (m, 4H), 7.15-7.12 (m, 2H), 2.51 (s, 3H). MH+ 548.
Example 22
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclopenty lmethyl)-l,3,4-oxadiazole 1H-NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.3 Hz, IH), 7.37-7.29 (m, 4H), 7.14-7.10 (m, 2H), 2.93 (d, J = 7.3 Hz, 2H), 2.46 (s, 3H), 2.45-2.39 (m, IH), 1.90-1.82 (m, 2H), 1.71-1.63 (m, 2H), 1.61-1.54 (m, 2H), 1.35-1.26 (m, 2H). MH+ 487. Example 23
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(tetrahydro
-2H-pyran-4-yl)-l,3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.37-7.30 (m, 4H), 7.13-7.10 (m, 2H), 4.08-4.03 (m, 2H), 3.59-3.52 (m, 2H), 3.29-3.21 (m, IH), 2.45 (s, 3H), 2.10-2.05 (m, 4H). MH+ 489.
Example 24
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclohexyl methyl)-l,3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.37-7.29 (m, 4H), 7.13-7.10 (m, 2H),
2.82 (d, J = 7.3 Hz, 2H), 2.46 (s, 3H), 1.98-1.87 (m, IH), 1.79-1.63 (m, 4H), 1.31-1.03 (m,
6H).
MH+ 501.
Example 25
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(tetrahydro furan-2-yl)-l,3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.45-7.42 (m, IH), 7.34-7.29 (m, 4H), 7.13-7.10 (m, 2H), 5.28-5.24 (m, IH), 4.10-4.04 (m, IH), 3.99-3.96 (m, IH), 2.45 (s, 3H), 2.42-2.33 (m, 2H),
2.25-2.14 (m, IH), 2.11-2.00 (m, IH).
MH+ 475.
Example 26 2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl- 1,3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.42 (d, J = 2.3 Hz, IH), 7.36 (d, J = 8.7 Hz, IH), 7.33-7.30 (m, IH), 7.07-7.04 (m, 2H), 3.86-3.77 (m, IH), 2.61-2.51 (m, 2H), 2.49-2.41 (m, 2H), 2.45 (s, 3H), 2.16-2.00 (m, 2H). MH+ 503.
Example 27
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopentyl-
1,3,4-oxadiazole 1H-NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.42 (d, J = 2.3 Hz, IH), 7.36 (d, J = 8.2 Hz, IH), 7.32-7.29 (m, IH), 7.07-7.03 (m, 2H), 3.43-3.35 (m, IH), 2.45 (s, 3H), 2.19-2.11 (m, 2H), 2.08-1.99 (m, 2H), 1.89-1.80 (m, 2H), 1.75-1.67 (m, 2H). MH+ 517.
Example 28
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl- 1,3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.42 (d, J = 2.3 Hz, IH), 7.36 (d, J = 8.2 Hz, IH), 7.32-7.29 (m, IH), 7.06-7.03 (m, 2H), 3.03-2.96 (m, IH), 2.45 (s, 3H), 2.17-2.12 (m, 2H), 1.88-1.83 (m, 2H) 1.76-1.66 (m, 4H), 1.45-1.26 (m, 2H). MH+ 531.
Example 29 2-sec-Butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l, 3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.36 (d, J = 8.2 Hz, IH), 7.34-7.30 (m, 3H), 7.13-7.09 (m, 2H), 3.16-3.07 (m, IH), 2.45 (s, 3H), 2.00-1.89 (m, IH), 1.80-1.70 (m, IH), 1.43 (d, J = 6.9 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H). MH+ 461.
Example 30
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(peiitan-2-y
I)-l,3)4-oxadiazole 1H-NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.38-7.30 (m, 4H), 7.13-7.09 (m, 2H), 3.24-3.15 (m, IH), 2.45 (s, 3H), 1.95-1.86 (m, IH), 1.71-1.63 (m, IH), 1.46-1.32 (m, 5H), 0.92 (t, J = 7.4 Hz, 3H). MH+ 475.
Example 31
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(hexan-2-yl )-l,3?4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.38-7.30 (m, 4H), 7.13-7.09 (m, 2H), 3.22-3.13 (m, IH), 2.45 (s, 3H), 1.95-1.89 (m, IH), 1.73-1.64 (m, IH), 1.42 (d, J = 6.9 Hz, 3H), 1.38-1.25 (m, 4H), 0.91-1.87 (m, 3H). MH+ 489.
Example 32 2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-butyl-l ,3,4-oxadiazoIe
1H-NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.42-7.41 (m, IH), 7.39-7.37 m, IH),
7.33-7.30 (m, IH), 7.05-7.03 (m, 2H), 2.45 (s, 3H), 1.50 (s, 9H).
MH+ 505.
Example 33
2-tert-Butyl-5-(5-(4-chIorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyrazol-3-yl)-l,
3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.38 (d, J = 8.2 Hz, IH), 7.34-7.30 (m, 3H), 7.12-7.09 (m, 2H), 2.45 (s, 3H), 1.52 (s, 9H).
MH+ 461.
Example 34
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclopropy lmethyl)-l, 3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.37-7.30 (m, 4H), 7.13-7.09 (m, 2H),
2.87 (d, J = 6.9 Hz, 2H), 2.45 (s, 3H), 2.29-2.24 (m, 2H), 1.29-1.21 (m, IH), 0.64-0.60 (m,
2H), 0.36-0.32 (m, 2H).
MH+ 459.
Example 35
2-(4-tert-Butylcyclohexyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-p yrazol-3-yl)-l,3?4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.37-7.30 (m, 4H), 7.13-7.09 (m, 2H), 2.92-2.85 (m, IH), 2.45 (s, 3H), 2.28-2.24 (m, 2H), 1.94-1.91 (m, 2H), 1.71-1.63 (m, 2H),
1.17-1.08 (m, 3H), 0.87 (s, 9H).
MH+ 543.
Example 36 2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cycloheptyl- 1,3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.42-7.41 (m, IH), 7.36 (d, J = 8.7 Hz, IH), 7.31 (dd, J = 8.7, 2.3 Hz, IH), 7.07-7.03 (m, 2H), 3.23-3.15 (m, IH), 2.45 (s, 3H), 2.21-2.14 (m, 2H), 1.98-1.89 (m, 2H), 1.84-1.79 (m, 2H), 1.69-1.52 (m, 6H). MH+ 545.
Example 37
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclohexyl-l, 3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.41-7.40 (m, IH), 7.36 (d, J = 8.7 Hz,
IH), 7.30 (dd, J = 8.7, 2.3 Hz, IH), 7.07-7.03 (m, 2H), 3.02-2.96 (m, IH), 2.94-2.89 (m, 2H),
2.22-2.13 (m, 2H), 1.87-1.84 (m, 2H), 1.76-1.67 (m, 2H), 1.45-1.20 (m, 7H).
MH+ 545.
Example 38
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3
,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.42-7.41 (m, IH), 7.36 (d, J = 8.2 Hz, IH), 7.30 (dd, J = 8.2, 2.3 Hz, IH), 7.09-7.05 (m, 2H), 3.86-3.77 (m, IH), 2.91-2.85 (m, 2H),
2.61-2.51 (m, 2H), 2.49-2.40 (m, 2H), 2.19-1.99 (m, 2H), 1.25-1.21 (m, 3H).
MH+ 517.
Example 39 2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclopentyl-l, 3,4-oxadiazole
1H-NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.41-7.40 (m, IH), 7.36 (d, J = 8.2 Hz, IH), 7.32-7.29 (m, IH), 7.07-7.03 (m, 2H), 3.45-3.35 (m, IH), 2.90-2.84 (m, 2H), 2.19-2.11 (m, 2H), 2.08-1.99 (m, 2H), 1.89-1.80 (m, 2H), 1.75-1.65 m, 2H), 1.25-1.20 (m, 3H). MH+ 531.
Example 40
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-etliyl-lH-pyrazol-3-yl)-5-tert-butyl-l,3,
4-oxadiazole 1H-NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.41-7.40 (m, IH), 7.37 (d, J = 8.2 Hz, IH), 7.32-7.29 (m, IH), 7.07-7.03 (m, 2H), 2.88-2.82 (m, 2H), 1.50 (s, 9H), 1.25-1.18 (m, 3H).
MH+ 519.
Example 41
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(hexan-2-yl) -1,3,4-oxadiazole
1H-NMR (300 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.42-7.41 (m, IH), 7.37 (d, J = 8.4 Hz, IH), 7.33-7.29 (m, IH), 7.07-7.03 (m, 2H), 3.21-3.14 (m, IH), 2.45 (s, 3H), 1.96-1.89 (m, IH), 1.71-1.64 (m, IH), 1.43 (d, J = 7.0 Hz, 3H), 1.34-1.32 (m, 4H), 0.91-0.86 (m, 3H). MH+ 533.
Example 42 2-(5-(4-chIorophenyI)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-phenyleth yl)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.3 Hz, IH), 7.37-7.23 (m, 9H), 7.12-7.09 (m,
2H), 4.45 (m, IH), 2.42 (s, 3H), 1.82 (d, J = 7.3 Hz, 3H).
(M+Na)+ 531.
Example 43
4-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyrazol-3-yl)-l,3»4-oxadi azol-2-yl)morpholine
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.3 Hz, IH), 7.35-7.28 (m, 4H), 7.13-7.09 (m, 2H), 3.81 (m, 4H), 3.62 (m, 4H), 2.41 (s, 3H).
MH+ 490.
Example 44
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-N-cyclohexyl- l,3>4-oxadiazol-2-amine
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 1.8 Hz, IH), 7.34-7.27 (m, 4H), 7.13-7.09 (m, 2H), 4.62 (br d, J = 8.2 Hz, IH), 3.68 (m, IH), 2.42 (s, 3H), 2.15-2.07 (m, 2H), 1.78-1.70 (m, 2H), 1.67-1.59 (m, IH), 1.47-1.18 (m, 7H). MH+ 502. Example 45
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-(4-methylcy clohexyl)-l,3.4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 2.3 Hz, IH), 7.38-7.29 (m, 4H), 7.14-7.10 (m, 2H), 3.20 (m, IH), 2.46 (s, 3H), 2.25-2.15 (m, 3H), 1.87-1.79 (m, 2H), 1.47-1.35 (m, 2H), 0.93 (d, J = 6.4 Hz, 3H). MH+ 501.
Example 46
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(3-methylcy clohexyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 2.3 Hz, IH), 7.38-7.29 (m, 4H), 7.14-7.10 (m, 2H), 3.01 (m, IH), 2.45 (s, 3H), 2.17-2.13 (m, 2H), 1.91-1.33 (m, 7H), 0.95 (d, J = 6.4 Hz, 3H).
MH+ 501.
Example 47
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-methyIcy clohexyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 1.8 Hz, IH), 7.38-7.09 (m, 4H), 7.13-7.10 (m,
2H), 3.25 (m, IH), 2.46 (s, 3H), 2.26 (m, IH), 2.05 (m, IH), 1.92-1.57 (m, 5H), 1.49-1.40
(m, 2H), 0.92 (d, J = 6.9 Hz, 3H).
MH+ 501.
Example 48
N-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l
,3,4-oxadiazol-2-amine
MH+ 476.
Example 49
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cycloliex-3- enyl)-l,3)4-oxadiazole
MH+ 485. Example 50
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-methylcy clohexyl)-l,3,4-oxadiazole MH+ 501.
Example 51
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclopent-3
-enyl)-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 2.3 Hz, IH), 7.38-7.30 (m, 4H), 7.14-7.10 (m, 2H), 5.76 (s, 2H), 3.79 (m, IH), 2.89 (d, J = 8.2 Hz, 2H), 2.45 (s, 3H). MH+ 471.
Example 52 2-(bicyclo[2.2.1]heptan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH -pyrazol-3-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 1.8 Hz, IH), 7.38-7.30 (m, 4H), 7.14-7.10 (m, 2H), 3.34 (m, IH), 2.74 (m, IH), 2.46 (s, 3H), 2.40 (m, IH), 2.05-1.98 (m, 2H), 1.65-1.21 (m, 6H). MH+ 499.
Example 53
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-phenylpr opan-2-yl)-l,3,4-oxadiazole 1H NMR (300 MHz, CDCl3) δ 7.43 (d, J = 2.22 Hz, 2H), 7.38-7.24 (m, 5H), 7.24-7.19 (m, 3H), 7.13-7.10 (m, 2H), 3.48-3.43 (m, IH), 3.37-3.30 (m, IH), 2.95-2.88 (dd, J = 13.56, 8.79 Hz, IH), 2.45 (s, 3H), 1.40 (d, J = 6.93 Hz, 3H). MH+525.
Example 54
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-cyclobuty lpropan-2-yl)-l ,3,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.43-7.13 (m, 5H), 7.13-7.10 (m, 2H), 3.15-3.13 (m, IH), 2.46 (s, 3H), 2.26-2.33 (m, IH), 2.04-1.97 (m, 3H), 1.81-1.75 (m, 3H), 1.41 (d, J = 7.14 Hz, 3H). MH+503.
Example 55 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(cyclohexylme thyl)-l,3,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.50-7.47 (m, 2H), 7.42-7.41 (m, IH), 7.38-7.28 (m, 2H), 7.09-7.06 (m, 2H), 2.92-2.80 (m, 4H), 1.99-1.88 (m, IH), 1.80-1.62 (m, 4H), 1.26-1.04 (m, 9H). MH+ 560.
Example 56
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclohexyl methyl)-l ,3,4-oxadiazole 1H NMR (300 MHz, CDCl3) δ 7.50-7.47 (m, 2H), 7.43-7.30 (m, 3H), 7.07-7.04 (m, 2H), 2.82 (d, J=6.9 Hz, 2H), 2.46 (s, 3H), 1.99-1.87 (m, IH), 1.79-1.61 (m, 4H), 1.25-1.04 (m, 6H). MH+ 545.
Example 57
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(hexan-2-yl)-l ,3,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.41-7.40 (m, IH), 7.38-7.28 (m, 2H), 7.08-7.05 (m, 2H), 3.21-3.13 (m, IH), 2.91-2.83 (m, 2H), 1.98-1.88 (m, IH), 1.75-1.65 (m, IH), 1.43 (d, J = 6.9 Hz, 3H), 1.37-1.28 (m, 4H), 1.23 (t, J = 7.3 Hz, 3H), 0.91-0.86 (m, 3H). MH+ 547.
Example 58 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,3, 4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.42-7.40 (m, IH), 7.37-7.28 (m, 4H), 7.15-7.11 (m, 2H), 2.89-2.82 (m, 2H), 1.50 (s, 9H), 1.23 (t, J = 7.3 Hz, 3H). MH+ 475. Example 59
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,3
,4-oxadiazole 1K NMR (300 MHz, CDCl3) δ 7.42-7.40 (m, IH), 7.38-7.27 (m, 4H), 7.15-7.12 (m, 2H), 3.04-2.96 (m, IH), 2.91-2.83 (m, 2H), 2.18-2.13 (m, 2H), 1.84-1.61 (m, 6H), 1.44-1.34 (m, 2H), 1.23 (t, J = 7.3 Hz, 3H). MH+ 501.
Example 60
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl-l ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.31 (m, 5H), 7.12-7.10 (m, 2H), 2.44 (s, 3H), 1.83 (q, J = 7.6 Hz, 2H), 1.47 (s, 6H), 0.87 (t, J - 7.6 Hz, 3H). MH+ 475.
Example 61
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-cyclopent ylethyl)-l,3,4-oxadiazole 1H NMR (300 MHz, CDCl3) δ 7.43-7.12 (m, 5H), 7.13-7.11 (m, 2H), 3.15-3.13 (m, IH), 2.46 (s, 3H), 1.89-1.73 (m, IH), 1.70-1.50 (m, 4H), 1.44-1.40 (m, 4H), 1.41 (d, J = 7.23 Hz, 3H). MH+ 503.
Example 62
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-cycIohexy lethyl)-l,3,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.44-7.12 (m, 5H), 7.13-7.12 (m, 2H), 3.11-3.12 (m, IH), 2.49 (s, 3H), 1.92-1.73 (m, 2H), 1.72-1.50 (m, 5H), 1.44-1.40 (m, 4H), 1.44 (d, J = 7.21 Hz, 3H).
MH+ 517.
Example 63 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-(2-cyclopent ylpropan-2-yl)-l,3.4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.55-7.53 (m, 2H), 7.39-7.34 (m, 2H), 7.26-7.20 (m, 2H), 7.13-7.12 (m, IH), 2.51 (s, 3H), 1.92-1.73 (m, IH), 1.74-1.50 (m, 5H), 1.45 (s, 6H), 1.43-1.40 (m, 3H). MH+ 517.
Example 64
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-(2-cyclohexy lpropan-2-yI)-l,3,4-oxadiazo!e 1H NMR (300 MHz, CDCl3) δ 7.55-7.53 (m, 2H), 7.39-7.34 (m, 2H), 7.26-7.20 (m, 2H), 7.13-7.12 (m, IH), 2.54 (s, 3H), 1.97-1.88 (m, IH), 1.74-1.50 (m, 6H), 1.45 (s, 6H), 1.43-1.40 (m, 3H). MH+ 531.
Example 65
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2,2-dichlor o-l-methylcyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.31 (m, 5H), 7.14-7.10 (m, 2H), 2.69 (d, J = 7.8 Hz, IH), 2.46 (s, 3H), 1.86 (s, IH), 1.78 (d, J = 7.8 Hz, IH). MH+ 527.
Example 66
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-N-cyclohexyl-
N-methyl-l,3)4-oxadiazol-2-amine 1H NMR (400 MHz, CDCl3) δ 7.41-7.30 (m, 5H), 7.12-7.08 (m, 2H), 3.98 (m, IH), 3.04 (s, 3H), 2.41 (s, 3H), 1.88-1.80 (m, 4H), 1.70-1.05 (m, 6H). MH+ 516.
Example 67 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclopropyl)-l,3.4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.39 (m, 3H), 7.35-7.29 (m, 6H), 7.08 (m, 2H), 2.38 (s, 3H), 1.79 (dd, J = 7.1, 4.6 Hz, 2H), 1.45 (dd, J = 7.1, 4.6 Hz, 2H). MH+ 555. Example 68
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3, 4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.37-7.29 (m, 4H), 7.15-7.12 (m, 2H), 3.84-3.80 (m, IH), 2.91-2.85 (m, 2H), 2.61-2.52 (m, 2H), 2.48-2.40 (m, 2H), 2.17-2.02 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H). MH+ 473.
Example 69
2-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclopentyl-l, 3,4-oxadiazole
1U NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.38-7.29 (m, 4H), 7.15-7.12 (m, 2H), 3.43-3.35 (m, IH), 2.90-2.84 (m, 2H), 2.19-2.08 (m, 2H), 2.06-1.99 (m, 2H), 1.88-1.80 (m, 2H), 1.75-1.68 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H). MH+ 487.
Example 70
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cycloheptyl-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.40 (m, IH), 7.37-7.28 (m, 4H), 7.15-7.11 (m, 2H),
3.23-3.15 (m, IH), 2.90-2.84 (m, 2H), 2.22-2.15 (m, 2H), 1.98-1.89 (m, 2H), 1.85-1.78 (m,
2H), 1.69-1.52 (m, 6H), 1.22 (t, J = 7.3 Hz, 3H).
MH+ 515.
Example 71
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-phenylcy clopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.41-7.27 (m, 8H), 7.15-7.08 (m, 2H), 2.38 (s, 3H), 1.78 (dd, J = 7.0, 5.0 Hz, 2H), 1.48 (dd, J = 7.0, 5.0 Hz, 2H).
MH+ 521.
Example 72 2-sec-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,3,4 -oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.40 (m, IH), 7.38-7.29 (m, 4H), 7.15-7.11 (m, 2H), 3.15-3.06 (m, IH), 2.90-2.84 (m, 2H), 2.01-1.90 (m, IH), 1.80-1.69 (m, IH), 1.43 (d, J = 6.88 Hz, 3H), 1.23 (t, J = 7.3 Hz, 3H), 0.98 (t, J = 7.3 Hz, 3H). MH+ 475.
Example 73
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-sec-butyl-l,3,
4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.42-7.41 (m, 2H), 7.36 (d, J = 8.28 Hz,
IH), 7.32-7.29 (m, IH), 7.08-7.05 (m, 2H), 3.16-3.06 (m, IH), 2.90-2.84 (m, 2H), 2.01-1.90
(m, IH), 1.80-1.69 (m, IH), 1.43 (d, J = 7.32 Hz, 3H), 1.23 (t, J = 7.32 Hz, 3H), 0.98 (t, J =
7.32 Hz, 3H).
MH+ 519.
Example 74
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cycloheptyl-l,
3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.41 (d, J = 2.28 Hz, IH), 7.36 (d, J = 8.24 Hz, IH), 7.30 (dd, J = 8.24, 2.28 Hz, IH), 7.08-7.05 (m, 2H), 3.22-3.15 (m, IH),
2.90-2.84 (m, 2H), 2.22-2.15 (m, 2H), 1.98-1.89 (m, 2H), 1.85-1.79 (m, 2H), 1.68-1.53 (m,
6H), 1.23 (t, J = 7.8 Hz, 3H).
MH+ 560.
Example 75
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-sec-butyl-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.42 (d, J - 2.32 Hz, IH), 7.37 (d, J = 8.72 Hz, IH), 7.32 (dd, J = 8.68, 2.28 Hz, IH), 7.07-7.03 (m, 2H), 3.16-3.07 (m, IH), 2.45 (s, 3H), 2.00-1.90 (m, IH), 1.80-1.70 (m, 2H), 1.43 (d, J = 6.88 Hz, 3H), 0.97 (t, J = 7.32 Hz, 3H). MH+ 505.
Example 76 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(2-phenylprop an-2-yl)-l ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.45 (m, 2H), 7.37 (d, J = 2.32 Hz, IH), 7.35-7.30 (m, 4H), 7.29-7.20 (m, 3H), 7.05-7.01 (m, 2H), 2.83-2.78 (m, 2H), 1.90 (s, 6H), 1.18 (t, J = 7.32 Hz, 3H). MH+ 581.
Example 77
N-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-N -methyl-l,3,4-oxadiazol-2-amine
1H NMR (400 MHz, CDCl3) δ 7.41-7.29 (m, 7H), 7.12-7.08 (m, 2H), 3.15 (s, 3H), 2.41 (s, 3H), 1.51 (s, 9H). MH+ 490.
Example 78
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-phenylpr opan-2-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40-7.38 (d, J = 2 Hz, IH), 7.36-7.27 (m, 7H), 7.26-7.21 (m, IH), 7.10-7.07 (m, 2H), 2.42 (s, 3H), 1.90 (s, 6H). MH+ 523.
Example 79
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-(4-chloro phenyl)propan-2-yl)-l,3»4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.40-7.38 (m, IH), 7.35-7.27 (m, 6H), 7.26-7.21 (m, IH), 7.10-7.07 (m, 2H), 2.42 (s, 3H), 1.88 (s, 6H). MH+ 559.
Example 80 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-(2-(pyridin- 2-yloxy)propan-2-yl)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.90-7.89 (m, IH), 7.55-7.51 (m, IH), 7.43-7.29 (m, 5H), 7.11-7.07 (m, 2H), 6.79-6.74 (m, 2H), 2.37 (s, 3H), 1.99 (s, 6H). MH+ 542. Example 81
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-(5-(trifluo romethyI)pyridin-2-yloxy)propan-2-yl)-l,3)4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 8.00 (m, IH), 7.77-7.74 (m, IH), 7.40-7.26 (m, 5H), 7.10-7.08 (m, 2H), 6.88-6.86 (d, J = 9.2 Hz, IH), 2.41 (s, 3H), 2.02 (s, 6H). MH+ 610.
Example 82 2-tert-butyI-5-(l-(2-chlorophenyI)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3?4- oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.27 (m, 6H), 7.14-7.10 (m, 2H), 2.45 (s, 3H), 1.50 (s,
9H).
MH+ 427.
Example 83
2-sec-butyl-5-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-metliyl-lH-pyrazol-3-yl)-l,3»4- oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.27 (m, 6H), 7.16-7.11 (m, 2H), 3.12 (sextet, J = 6.8 Hz, IH), 2.47 (s, 3H), 1.95 (septet, J= 6.8 Hz, IH), 1.75 (septet, J = 6.8 Hz, IH), 1.43 (d, J =
7.2 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H).
MH+ 427.
Example 84 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,3»4 -oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.26 (m, 6H), 7.18-7.11 (m, 2H), 3.01-2.98 (m, IH), 2.47 (s, 3H), 2.41-2.20 (m, 2H), 1.91-1.83 (m, 2H), 1.80-1.65 (m, 3H), 1.48-1.24 (m, 4H). MH+ 453.
Example 85
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-methylhe xan-2-yl)-l,3.4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.38 (m, 2H), 7.34-7.30 (m, 3H), 7.15-7.09 (m, 2H), 2.44 (s, 3H), 1.78 (m, 2H), 1.47 (s, 6H), 1.25 (m, 4H), 0.87 (t, J = 7.0 Hz, 3H). MH+ 503.
Example 86 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(pentan-2-yl)- l,3)4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, 2H), 7.38-7.36 (m, IH), 7.34-7.29 (m, 2H), 7.14-7.12 (m, 2H), 3.24-3.15 (m, IH), 2.90-2.84 (m, 2H), 1.96-1.87 (m, 2H), 1.71-1.65 (m, 2H), 1.44-1.42 (m, 2H), 1.24 (t, J = 7.2 Hz, 3H), 0.93 (t, J = 7.6 Hz, 3H). MH+ 489.
Example 87
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-metliyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3,4
-oxadiazole 1U NMR (400 MHz, CDCl3) δ 7.44-7.26 (m, 6H), 7.18-7.10 (m, 2H), 3.82 (quintet, J = 8.8 Hz, IH), 2.63-2.51 (m, 2H), 2.50-2.48 (m, 4H), 2.19-2.01 (m, 2H). MH+ 425.
Example 88 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl-l,3j4 -oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.28 (m, 6H), 7.14-7.10 (m, 2H), 2.45 (s, 3H), 1.84
(quartet, J = 7.2 Hz, 2H), 1.46 (s, 6H), 0.87 (t, J = 7.6 Hz, 3H).
MH+ 441.
Example 89
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(hexan-2-yl)-l,3
,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.28 (m, 6H), 7.18-7.11 (m, 2H), 3.18 (sextet, J = 6.8 Hz, IH), 2.47 (s, 3H), 1.96-1.88 (m, IH), 1.75-1.62 (m, IH), 1.43 (d, J = 6.8 Hz, 3H),
1.39-1.28 (m, 4H), 0.90 (t, J = 7.2 Hz, 3H).
MH+ 455.
Example 90 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pentan-2-yl )- 1 ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.42 (d, J = 2.4 Hz, IH), 7.38-7.36 (d, J = 8.4 Hz, IH), 7.30 (dd, J = 8.4, 2.4 Hz, IH), 7.06-7.04 (m, 2H), 3.22-3.17 (m, IH), 2.45 (s, 3H), 1.92-1.89 (m, IH), 1.68-1.66 (m, IH), 1.43-1.42 (m, 3H), 1.41-1.37 (m, 2H), 0.93 (t, J = 7.6 Hz, 3H). MH+ 519.
Example 91 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(pentan-2-yl)- l,3*4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.41 (d, J = 2.0 Hz, IH), 7.37 (d, J = 8.4 Hz, IH), 7.32-7.29 (m, IH), 7.08-7.05 (m, 2H), 3.22-3.17 (m, IH), 2.90-2.84 (m, 2H), 1.93-1.88 (m, IH), 1.70-1.64 (m, IH), 1.44-1.42 (d, J = 6.8 Hz, 3H), 1.41-1.35 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H), 0.93 (t, J = 7.6 Hz, 3H). MH+ 533.
Example 92
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-methylhexan -2-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.27 (m, 6H), 7.30-7.11 (m, 2H), 2.45 (s, 3H), 1.83-1.74 (m, 2H), 1.47 (s, 6H), 1.33-1.18 (m, 4H), 0.88 (t, J = 6.8 Hz, 3H). MH+ 469.
Example 93
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-phenylpropa n-2-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.20 (m, HH), 7.12-7.07 (m, 2H), 2.43 (s, 3H), 1.90 (s, 6H). MH+ 489.
Example 94
2-(5-(4-bromophenyl)-l-(4-chlorophenyl)-4-methyI-lH-pyrazol-3-yl)-5-tert-pentyl-l,3,
4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 6.4 Hz, 2H), 7.22 (d, J = 6.4 Hz, 2H), 7.06 (d, J = 8.4 Hz, 2H), 2.41 (s, 3H), 1.86 (q, J = 7.2 Hz, 2H), 1.48 (s, 6H), 0.88 (t, J = 7.2 Hz, 3H). MH+ 487.
Example 95
2-(5-(4-bromophenyl)-l-(4-chlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,3»4 -oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.55-7.52 (m, 2H), 7.33-7.30 (m, 2H), 7.23-7.20 (m, 2H), 7.08-7.05 (m, 2H), 3.08-2.98 (m, IH), 2.41 (s, 3H), 2.18-2.14 (m, 2H), 1.90-1.85 (m, 2H), 1.77-1.68 (m, 2H), 1.46-1.25 (m, 3H). MH+ 499.
Example 96 2-(5-(4-bromophenyl)-l-(4-chIorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-sec-butyl-l,3,4- oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.55-7.53 (m, 2H), 7.33-7.30 (m, 2H), 7.23-7.20 (m, 2H), 7.08-7.06 (m, 2H), 3.15-3.13 (m, IH), 2.42 (s, 3H), 1.98-1.92 (m, 2H), 1.79-1.75 (m, 2H), 1.45 (d, J = 6.8 Hz, 3H), 0.99 (t, J = 7.2 Hz, 3H). MH+ 473.
Example 97
2-(l-(allyloxy)-2-methylpropan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-m ethyl-lH-pyrazol-3-yl)-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.42-7.30 (m, 5H), 7.15-7.09 (m, 2H), 4.00 (br d, 5.6 Hz, 2H), 3.67 (s, 2H), 2.44 (s, 3H), 1.56 (s, 3H), 1.51 (s, 3H). MH+ 517.
Example 98 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-(2-methoxyp ropan-2-yI)-l,3*4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.31 (m, 5H), 7.14-7.10 (m, 2H), 3.23(s, 3H), 2.45 (s, 3H), 1.74 (s, 6H). MH+ 477. Example 99
2-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-5-tert-pentyl-l,3j4-oxadi azole 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.4 Hz, IH), 7.39-7.32 (m, 3H), 7.31-7.28 (m, 2H), 7.20-7.16 (m, 2H), 2.46 (s, 3H), 1.84 (q, J - 7.6 Hz, 2H), 1.47 (s, 6H), 0.88 (t, J = 7.2 Hz, 3H). MH+ 441.
Example 100
2-tert-butyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,3>4-oxadia zole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.4 Hz, IH), 7.38-7.32 (m, 3H), 7.31-7.28 (m, 2H), 7.20-7.16 (m, 2H), 2.46 (s, 3H), 1.51 (s, 9H). MH+ 427.
Example 101
2-cyclohexyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,354-oxadi azole 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.0 Hz, IH), 7.36-7.32 (m, 3H), 7.30-7.28 (m, 2H), 7.19-7.17 (m, 2H), 3.04-2.97 (m, IH), 2.47 (s, 3H), 2.17-2.13 (m, 2H), 1.88-1.84 (m, 2H), 1.77-1.67 (m, 3H), 1.45-1.29 (m, 3H). MH+ 453.
Example 102
2-sec-butyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,354-oxadia zole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.0 Hz, IH), 7.37-7.31 (m, 3H), 7.30-7.26 (m, 2H), 7.20-7.16 (m, 2H), 3.15-3.09 (m, IH), 2.47 (s, 3H), 1.99-1.90 (m, IH), 1.81-1.72 (m, IH), 1.44 (d, J = 6.8 Hz, 3H), 0.98 (t, J = 7.6 Hz, 3H). MH+ 427.
Example 103 2-cyclobutyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,3,4-oxadi azole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.0 Hz, IH), 7.36-7.32 (m, 3H), 7.30-7.27 (m, 2H), 7.20-7.17 (m, 2H), 3.87-3.78 (m, IH), 2.62-2.52 (m, 2H), 2.49-2.41 (m, 5H), 2.17-2.03 (m, 2H). MH+ 425.
Example 104
2-(5-(4-bromophenyl)-l-(4-chIorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-butyl-l,3,4- oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.56-7.55 (m, 2H), 7.39-7.31 (m, 2H), 7.23-7.21 (m, 2H), 7.08-7.06 (m, 2H), 2.41 (s, 3H), 1.52 (s, 9H). MH+ 473.
Example 105 2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-butyl-l,3?4- oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.43 (m, 3H), 7.41-7.38 (m, IH), 7.36-7.31 (m, 2H),
7.07-7.04 (m, 2H), 2.5 (s, 3H), 1.50 (s, 9H).
MH+ 471.
Example 106
2-(5-(4-bromophenyl)-l-(2-chlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,3,4
-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.43 (m, 3H), 7.41-7.39 (m, IH), 7.38-7.34 (m, 2H), 7.07-7.05 (m, 2H), 3.02-2.97 (m, IH), 2.46 (s, 3H), 2.16-2.12 (m, 2H), 1.88-1.84 (m, 2H),
1.77-1.58 (m, 2H), 1.41-1.25 (m, 4H).
MH+ 497.
Example 107 2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3j4 -oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.42 (m, 3H), 7.41-7.39 (m, IH), 7.38-7.33 (m, 2H), 7.08-7.06 (m, 2H), 3.86-3.77 (m, IH), 2.63-2.48 (m, 2H), 2.50 (s, 3H), 2.44-2.40 (m, 2H), 2.18-1.98 (m, 2H). MH+ 469.
Example 108
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazoI-3-yl)-5-sec-butyl-l,3,4- oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.31 (m, 6H), 7.08-7.05 (m, 2H), 3.16-3.07 (m, IH),
2.49 (s, 3H), 2.01-1.90 (m, IH), 1.80-1.69 (m, IH), 1.43 (d, J = 7.2 Hz, 3H), 0.97 (t, J = 7.6
Hz, 3H).
MH+ 471 .
Example 109
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl-l,3»
4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.42 (m, 2H), 7.41-7.31 (m, 4H), 7.07-7.04 (m, 2H), 2.45 (s, 3H), 1.83 (q, J = 7.6 Hz, 2H), 1.46 (s, 6H), 0.87 (t, J = 7.6 Hz, 3H).
MH+ 485.
Example 110
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclobutyl)-l,3j4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40 (m, IH), 7.35-7.29 (m, 8H), 7.10-7.06 (m, 2H), 3.09 (m, 2H), 2.73 (m, 2H), 2.40 (s, 3H), 2.25 (s, IH), 2.02 (m, IH). MH+ 569.
Example Ul
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chlorop henyl)cyclopropyl)-l,3?4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.40 (m, 5H), 7.35-7.28 (m, 4H), 7.06-7.02 (m, 2H), 2.79 (q, J = 7.2 Hz, 2H), 1.79 (dd, J = 7.2, 4.8 Hz, 2H), 1.45 (dd, J = 7.2, 4.8 Hz, 2H), 1.16 (t, J = 7.2 Hz, 3H). MH+ 613.
Example 112 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-clilorophe nyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.25 (m, 10H), 7.12-7.08 (m, 2H), 2.39 (s, 3H), 1.79 (m, 2H), 1.44 (m, 2H). MH+ 521.
Example 113
2-tert-butyl-5-(5-(3-chIorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, IH, /= 2.4 Hz), 7.38 (d, IH, J= 8.8 Hz), 7.34-7.31 (m, 2H), 7.29-7.25 (m, IH), 7.21-7.20 (m, IH), 7.03 (dt, IH, /= 7.6 Hz, 1.2 Hz), 2.45 (s,
3H), 1.50 (s, 9H). MH+ 461.
Example 114 2-sec-butyl-5-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, IH, /= 2.4 Hz), 7.37 (d, IH, /= 7.6 Hz), 7.34-7.31 (m, 2H), 7.29-7.25 (m, IH), 7.21-7.20 (m, IH), 7.03 (dt, IH, /= 8.0 Hz, 1.2 Hz), 3.14-3.09 (m, IH), 2.46 (s, 3H), 1.98-1.91 (m, IH), 1.78-1.73 (m, IH), 1.43 (d, 3H), 0.97 (t, 3H). MH+ 461.
Example 115
2-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cycIobutyl-l
,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.43 (dd, IH, /= 2.0 Hz, 0.4 Hz), 7.36 (d, IH, /= 8.0 Hz), 7.35-7.32 (m, 2H), 7.31-7.25 (m, IH), 7.22-7.21 (m, IH), 7.04 (dt, IH, /= 7.6 Hz, 1.2 Hz), 3.82 (m, IH), 2.59-2.51 (m, 2H), 2.48-2.42 (m, 2H), 2.47 (s, 3H), 2.14-2.05 (m, 2H). MH+ 461.
Example 116
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-ethoxypr opan-2-yl)-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.32 (m, 5H), 7.14-7.10 (m, 2H), 3.40 (q, J = 7.2 Hz, 2H), 2.45 (s, 3H), 1.74 (s, 6H), 1.16 (t, J = 7.2 Hz, 3H). MH+ 491.
Example 117 2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.8 Hz, 2H), 7.31 (d, J = 8.8 Hz, 2H), 7.22 (d, J = 8.8 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 2.40 (s, 3H), 1.51 (s, 9H). MH+ 427.
Example 118 2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-sec-butyl-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.8 Hz, 2H), 7.31 (d, J = 8.8 Hz, 2H), 7.21 (d, J =
9.2 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 3.16-3.11 (m, IH), 2.42 (s, 3H), 1.99-1.92 (m, IH),
1.80-1.73 (m, IH), 1.45 (d, J = 7.2 Hz, 3H), 0.99 (t, J = 7.6 Hz, 3H).
MH+ 427.
Example 119
2-(l,5-Bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclopropy l)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 8.8 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.35-7.29 (m, 4H), 7.18 (d, J = 8.8 Hz, 2H), 7.11 (d, J = 8.8 Hz, 2H), 2.34 (s, 3H), 1.82-1.79 (m, 2H),
1.48-1.45 (m, 2H).
MH+ 521.
Example 120 2-(l,5-Bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl-l,3»4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 9.2 Hz, 2H), 7.22 (d, J =
9.2 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 2.40 (s, 3H), 1.85 (q, J = Hz, 2H), 1.48 (s, 6H), 0.88 (t,
J = 7.6 Hz, 3H).
MH+ 441.
Example 121
2-(5-(3-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyI-
1,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43(d, J = 2.4 Hz, IH), 7.36 (d, , J = 8.8 Hz, IH), 7.35-7.32 (m, 2H), 7.31-7.25 (m, IH), 7.21-7.20 (m, IH), 7.04 (dt, J = 7.2 Hz, 1.2 Hz, IH), 3.04-3.00 (m, IH), 2.46 (s, 3H), 2.17-2.13 (m, 2H), 1.88- 1.84 (m, 2H), 1.77-1.67 (m, 3H), 1.46- 1.26 (m, 3H). MH+ 487.
Example 122
2-(5-(3-ChlorophenyI)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl- 1,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, , J = 2.4 Hz, IH), 7.38 (d, J = 8.0 Hz, IH), 7.34-7.31 (m, 2H), 7.29-7.25 (m, IH), 7.21-7.20 (m, IH), 7.03 (dt, J = 7.6 Hz, 1.6 Hz IH)5 2.45 (s, 3H), 1.83 (q, 2H, J = 7.6 Hz), 1.46 (s, 6H), 0.88 (t, J = 7.2 Hz, 3H). MH+ 477.
Example 123 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-phenylcycl opropyl)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.43 (m, 3H), 7.39-7.25 (m, 7H), 7.05-7.02 (m, 2H), 2.76 (quartet, J = 7.6 Hz, 2H), 1.77 (m, 2H), 1.48 (m, 2H), 1.15 (t, J = 7.6 Hz, 3H). MH+ 581.
Example 124
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yI)-5-tert-pentyl-l,
3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.41-7.35 (m, 2H), 7.31-7.27 (m, IH), 7.07-7.03 (m, 2H), 2.84 (quartet, J = 7.6 Hz, 2H), 1.83 (quartet, J = 7.2 Hz, 2H), 1.46 (s,
6H), 1.22 (t, J = 7.2 Hz, 3H), 0.87 (t, J = 7.6 Hz, 3H). MH+ 535.
Example 125 2-(bicyclo[2.2.1]heptan-2-yl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH- pyrazol-3-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.42-7.39 (m, IH), 7.37-7.33 (m, IH), 7.31-7.27 (m, IH), 7.08-7.04 (m, 2H), 7.08-7.04 (m, 2H), 2.90 (quartet, J = 7.6 Hz, 2H), 2.56 (br d, J = 3.6 Hz, IH), 2.49-2.37 (m, IH), 2.20-2.02 (m, IH), 1.95-1.85 (m, IH), 1.70-1.18 (m, 9H). MH+ 559.
Example 126 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-isopropyl-l,3» 4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.41-7.28 (m, 3H), 7.08-7.04 (m, 2H), 3.28 (quintet, J - 6.8 Hz, IH), 2.86 (quartet, J = 6.8 Hz, 2H), 1.46 (d, J = 6.8 Hz, 6H), 1.22 (t, J = 7.6 Hz, 3H). MH+ 506.
Example 127
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(pentan-3-yl)- 1,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.50-7.45 (m, 2H), 7.41-7.27 (m, 3H), 7.08-7.04 (m, 2H),
2.99-2.91 (m, IH), 2.86 (quartet, J = 7.6 Hz, 2H), 1.94-1.74 (m, 4H), 1.22 (t, J = 7.2 Hz, 3H), 0.92 (t, J = 7.6 Hz, 3H). MH+ 534.
Example 128
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-methylcycl ohexyl)-l,3)4-oxadiazole
1B. NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.41-7.36 (m, 2H), 7.31-7.29 (m, IH), 7.07-7.03 (m, 2H), 2.85 (quartet, J = 7.2 Hz, 2H), 2.32-2.25 (m, 2H), 1.68-1.45 (m, 8H), 1.40 (s, 3H), 1.21 (t, J = 7.6 Hz, 3H). MH+ 561.
Example 129
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-metho xyphenyl)cyclopropyl)-l,3)4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.38 (m, 3H), 7.35-7.28 (m, 4H), 7.07 (m, 2H), 6.87 (m, 2H), 3.79 (s, 3H), 2.54 (s, 3H), 1.73 (dd, J = 7.2, 4.4 Hz, 2H), 1.42 (dd, J = 7.2, 4.4 Hz, 2H). MH+ 551. Example 130
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-(l-(2,4-dichl orophenyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.39 (m, 3H), 7.36-7.25 (m, 5H), 7.07 (m, 2H), 2.35 (s, 3H), 1.94 (dd, J = 7.6, 5.2 Hz, 2H), 1.48 (dd, J = 7.6, 5.2 Hz, 2H). MH+ 589.
Example 131
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-p-tolylcyc lopropyl)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.39-7.25 (m, 7H), 7.14 (m, 2H), 7.08 (m, 2H), 2.36 (s, 3H), 2.33 (s, 3H), 1.73 (dd, J = 7.2, 4.4 Hz, 2H), 1.44 (dd, J = 7.2, 4.4 Hz, 2H). MH+ 535.
Example 132
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(trifluoro methyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (br d, J = 2.0 Hz, IH), 7.38-7.30 (m, 4H), 7.10 (m, 2H), 2.42 (s, 3H), 1.63 (m, 2H), 1.61 (m, 2H). MH+ 513.
Example 133
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chloroph enyl)cyclopropyl)-l,3)4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.42-7.37 (m, 3H), 7.34-7.27 (m, 6H), 7.11-7.07 (m, 2H), 2.78 (quartet, J = 7.6 Hz, 2H), 1.79 (m, 2H), 1.44 (m, 2H), 1.16 (t, J = 7.6 Hz, 3H). MH+ 571.
Example 134 2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chloropheny l)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.40 (m, 4H), 7.39-7.34 (m, 4H), 7.33-7.31 (m, 2H), 7.05 (d, 2H, J= 8.4 Hz), 2.80 (q, 2H, /= 7.2 Hz), 1.82-1.79 (m, 2H), 1.47-1.44 (m, 2H), 1.17 (t, 3H, /= 7.2 Hz). MH+ 581.
Example 135
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(trifluoro methyl)cyclobutyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.0 Hz, IH), 7.38-7.30 (m, 4H), 7.10 (m, 2H), 2.81 (m, 4H), 2.44 (s, 3H), 2.16 (m, 2H). MH+ 527.
Example 136
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2,2,2-trifluo roethyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (br d, J = 2.0 Hz, IH), 7.36-7.30 (m, 4H), 7.11 (m, 2H), 3.84 (q, J = 9.6 Hz, 2H), 2.45 (s, 3H). MH+ 487.
Example 137
2-(5-(4-chlorophenyl)-l-(2,3-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclobutyl)-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.53-7.50 (m, IH), 7.34-7.23 (m, 9H), 7.10-7.07 (m, IH), 3.14-3.04 (m, 2H), 2.78-2.69 (m, 2H), 2.40 (s, 3H), 2.26-2.18 (m, 2H). MH+ 571.
Example 138 2-(l-(4-chlorophenyl)cyclopropyl)-5-(l-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-m ethyl-lH-pyrazol-3-yl)-l,3j4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.47 (m, 2H), 7.33-7.25 (m, 5H), 7.07-7.04 (m, 2H), 6.85-6.81 (m, 2H), 3.79 (s, 3H), 2.37 (s, 3H), 1.78 (m, 2H), 1.43 (m, 2H). MH+ 553.
Example 139
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,3-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,
3,4-oxadiazoIe
1H NMR (400 MHz, CDCl3) δ 7.54-7.49 (m, IH), 7.34-7.22 (m, 4H), 7.14-7.10 (m, 2H), 2.44 (s, 3H), 1.49 (s, 9H). MH+ 463.
Example 140 2-tert-butyl-5-(l-(2,4-dichIorophenyl)-5-(4-methoxyphenyI)-4-methyl-lH-pyrazol-3-yl)- 1,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.39 (m, IH), 7.37-7.33 (m, IH), 7.29-7.24 (m, IH),
7.11-7.06 (m, 2H), 6.86-6.83 (m, 2H), 3.79 (s, 3H), 2.42 (s, 3H), 1.49 (s, 9H).
MH+ 457.
Example 141
2-(5-(4-chlorophenyl)-l-(2,3-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l
,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 8.0 Hz, 1.6 Hz, IH), 7.33-7.24 (m, 4H), 7.15-7.10 (m, 2H), 3.85-3.75 (m, IH), 2.61-2.50 (m, 2H), 2.48-2.39 (m, 5H), 2.24-2.02 (m,
2H).
MH+ 461.
Example 142 2-(5-(4-chlorophenyl)-l-(2,3-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 8.0 Hz, 1.6 Hz, IH), 7.33-7.22 (m, 4H), 7.14-7.09 (m, 2H), 3.05-2.94 (m, IH), 2.45 (s, 3H), 2.18-2.10 (m, 2H), 1.89-1.80 (m, 2H), 1.79-1.63 (m, 2H), 1.45-1.25 (m, 4H). MH+ 487.
Example 143
2-(5-(4-chlorophenyl)-l-(2,3-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclopropyl)-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.53-7.49 (m, IH), 7.42-7.37 (m, 2H), 7.32-7.22 (m, 6H), 7.12-7.06 (m, 2H), 2.83 (s, 3H), 1.78 (m, 2H), 1.39 (m, 2H). MH+ 557.
Example 144 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-lH-pyrazoI-3-yl)-5-(l-(4-chloropheny l)cyclopropyl)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.36 (m, 4H), 7.34-7.26 (m, 6H), 7.14-7.10 (m, 2H), 2.80 (q, 2H), 1.84-1.78 (m, 2H), 1.46-1.43 (m, 2H), 1.73 (t, 3H, /= 7.2 Hz). MH+ 537.
Example 145
2-tert-butyl-5-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,354-ox adiazole 1H NMR (400 MHz, CDCl3) δ 7.45-7.42 (m, IH), 7.40-7.36 (m, IH), 7.35-7.27 (m, 4H), 7.16-7.13 (m, 2H), 2.87 (q, 2H), 1.50 (s, 9H), 1.24 (t, 3H, J= 7.2 Hz). MH+ 442.
Example 146 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3»4-o xadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.40 (m, IH), 7.39-7.36 (m, IH), 7.35-7.28 (m, 4H), 7.17-7.14 (m, 2H), 3.86-3.77 (m, IH), 2.88 ( q, 2H), 2.62-2.52 (m, 2H), 2.49-2.40 (m, 2H), 2.18-2.01 (m, 2H), 1.24 (t, 3H, J= 7.6 Hz). MH+ 439.
Example 147
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chloropheny l)cyclobutyl)-l,3)4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.41-7.35 (m, 2H), 7.34-7.26 (m, 6H), 7.27-7.25 (m, 2H), 7.13-7.09 (m, 2H), 3.12-3.06 (m, 2H), 2.81 (q, 2H), 2.78-2.70 (m, 2H), 2.30-2.19 (m, IH), 2.07-1.97 (m, IH), 1.19 (t, 3H, /= 7.2 Hz). MH+ 551.
Example 148
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-phenylpr opyl)-l,3*4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.39 (br d, J - 2.0 Hz, IH), 7.37-7.22 (m, 9H), 7.08 (m, 2H), 4.17 (t, J = 7.6 Hz, 2H), 2.42 (s, 3H), 2.37 (m, IH), 2.12 (m, IH), 0.97 (t, J = 7.2 Hz, 3H). MH+ 523.
Example 149
2-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-phenylpr opyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 2.0 Hz, IH), 7.36-7.18 (m, 9H), 7.11 (m, 2H), 3.44 (m, IH), 3.20 (m, 2H), 2.42 (s, 3H), 1.36 (d, J = 6.8 Hz). MH+ 523.
Example 150
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-phenylcycIo propyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.45 (m, 2H), 7.38-7.26 (m, 8H), 7.09 (d, J = 8.8 Hz, 2H), 2.77 (q, J = 7.2 Hz, 2H), 1.79-1.76 (m, 2H), 1.48-1.46 (m, 2H), 1.14 (t, J = 7.6 Hz, 3H).
MH+ 537.
Example 151
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-p-tolylcyclo propyl)-l,3j4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.38-7.34 (m, 3H), 7.32-7.26 (m, 4H), 7.16-7.13 (m, 2H),
7.09 (d, J = 8.4 Hz, 2H), 2.77 (q, J = 7.2 Hz, 2H), 2.33 (s, 3H), 1.76-1.73 (m, 2H), 1.45-1.42
(m, 2H), 1.14 (t, J = 7.2 Hz, 3H).
MH+ 549.
Example 152
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-methoxy phenyl)cyclopropyl)-l,3»4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.38 (m, 3H), 7.34-7.26 (m, 4H), 7.09 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 2.77 (q, J = 7.6 Hz, 2H), 1.75-1.72 (m, 2H),
1.44-1.41 (m, 2H), 1.14 (t, J = 7.2 Hz, 3H).
MH+ 565.
Example 153 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(2,4-dichlor ophenyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.42 (m, 2H), 7.39-7.27 (m, 6H), 7.09 (d, J = 8.4 Hz, 2H), 2.75 (q, J = 7.6 Hz, 2H), 1.97-1.94 (m, 2H), 1.50-1.47 (m, 2H), 1.12 (t, J = 7.6 Hz, 3H).
MH+ 605.
Example 154
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chIoroph enyl)cyclobutyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 2.0 Hz, IH), 7.34-7.25 (m, 8H), 7.09 (d, J = 8.8
Hz, 2H), 3.11-3.05 (m, 2H), 2.82-2.70 (m, 4H), 2.30-2.18 (m, IH), 2.06-1.97 (m, IH), 1.16
(t, J = 7.2 Hz, 3H).
MH+ 585.
Example 155
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(trifluorom ethyl)cyclopropyl)-l,3»4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.4 Hz, IH), 7.36-7.28 (m, 4H), 7.12 (d, J = 8.8 Hz, 2H), 2.84 (q, J = 7.6 Hz, 2H), 1.67-1.61 (m, 4H), 1.21 (t, J = 7.2 Hz, 3H).
MH+ 527.
Example 156
2-(l-(2-bromophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,3,4 -oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.59-7.57 (m, IH), 7.41-7.34 (m, 2H), 7.30-7.25 (m, 3H),
7.16-7.12 (m, 2H), 3.02-2.97 (m, IH), 2.46 (s, 3H), 2.16-2.12 (m, 2H), 1.88-1.84 (m, 2H),
1.73-1.71 (m, 2H), 1.41-1.33 (m, 4H).
MH+ 497.
Example 157
2-(l-(2-bromophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-butyl-l,3»4- oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.59-7.57 (m, IH), 7.43-7.35 (m, 2H), 7.30-7.26 (m, 3H), 7.15-7.12 (m, 2H), 2.45 (s, 3H), 1.50 (s, 9H). MH+ 471.
Example 158 2-(l-(2-bromophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chlorophe nyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.58-7.56 (m, IH), 7.42-7.36 (m, 4H), 7.34-7.25 (m, 5H),
7.13-7.09 (m, 2H), 2.39 (s, 3H), 1.80-1.77 (m, 2H), 1.45-1.42 (m, 2H).
MH+ 565.
Example 159
2-(l-(2-bromophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chlorophe nyl)cyclobutyl)-l ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.58-7.55 (m, IH), 7.37-7.25 (m, 9H), 7.18-7.09 (m, 2H), 3.12-3.06 (m, 2H), 2.78-2.70 (m, 2H), 2.41 (s, 3H), 2.27-2.20 (m, IH), 2.04-1.99 (m, IH).
MH+ 579.
Example 160
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,6-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.36-7.35 (m, IH), 7.34-7.33 (m, IH), 7.31-7.30 (m, IH), 7.29-7.28 (m, 2H), 7.22-7.19 (m, 2H), 2.43 (s, 3H), 1.49 (s, 9H). MH+ 461.
Example 161
2-(5-(4-chlorophenyl)-l-(2,6-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclopropyl)-l,3)4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.38 (m, 2H), 7.36-7.33 (m, 2H), 7.32-7.29 (m, 3H), 7.28-7.26 (m, 2H), 7.20-7.17 (m, 2H), 2.37 (s, 3H), 1.80-1.77 (m, 2H), 1.44-1.41 (m, 2H). MH+ 555.
Example 162
2-(5-(4-chlorophenyl)-l-(2,6-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclobutyl)-l,3>4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.35-7.34 (m, IH), 7.33-7.32 (m, 2H), 7.31-7.29 (m, 4H), 7.28-7.27 (m, 2H), 7.20-7.16 (m, 2H), 3.12-3.06 (m, 2H), 2.77-2.69 (m, 2H), 2.25 (s, 3H), 2.24-2.18 (m, IH), 2.05-1.97 (m, IH). MH+ 569.
Example 163
2-(l-(2-bromophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3,4 -oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.59-7.56 (m, IH), 7.40-7.30 (m, 2H), 7.29-7.27 (m, 3H), 7.24-7.12 (m, 2H), 3.83-3.78 (m, IH), 2.58-2.53 (m, 2H), 2.51 (s, 3H), 2.47-2.41 (m, 2H), 2.15-1.03 (m, 2H). MH+ 469.
Example 164 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,5-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 2.4 Hz, IH), 7.35-7.29 (m, 4H), 7.12 (d, J = 8.8 Hz, 2H), 2.43 (s, 3H), 1.50 (s, 9H). MH+ 461.
Example 165
2-(5-(4-chlorophenyl)-l-(2,5-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l
,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.0 Hz, IH), 7.35-7.30 (m, 4H), 7.13 (d, J = 8.8 Hz, 2H), 3.83-3.79 (m, IH), 2.58-2.51 (m, 2H), 2.47-2.42 (m, 5H), 2.14-2.05 (m, 2H). MH+ 459.
Example 166
2-(5-(4-chlorophenyl)-l-(2,5-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.0 Hz, IH), 7.35-7.29 (m, 4H), 7.13 (d, J = 8.8 Hz, 2H), 3.02-2.97 (m, IH), 2.45 (s, 3H), 2.16-2.12 (m, 2H), 1.87-1.83 (m, 2H), 1.76-1.66 (m, 3H), 1.44-1.29 (m, 3H). MH+ 487. Example 167
2-(5-(4-chIorophenyl)-l-(2,5-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclopropyl)-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 2.0 Hz, IH), 7.40 (d, J = 8.8 Hz, 2H), 7.35-7.28 (m, 6H), 7.10 (d, J = 8.4 Hz, 2H), 2.38 (s, 3H), 1.80-1.77 (m, 2H), 1.46-1.43 (m, 2H). MH+ 557.
Example 168 2-(5-(4-chlorophenyl)-l-(2,5-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclobutyl)-l,3*4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 2.4 Hz, IH), 7.34-7.27 (m, 8H), 7.09 (d, J = 8.4 Hz, 2H), 3.12-3.05 (m, 2H), 2.78-2.70 (m, 2H), 2.39 (s, 3H), 2.24-2.19 (m, IH), 2.05-1.18 (m, IH). MH+ 571.
Example 169
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,354-o xadiazole 1U NMR (400 MHz, CDCl3) δ 7.42-7.39 (m, IH), 7.38-7.35 (m, IH), 7.33-7.26 (m, 4H),
7.16-7.12 (m, 2H), 3.02-2.95 (m, IH), 2.88 (q, 2H), 2.16-2.12 (m, 2H), 1.87-1.83 (m, 2H), 1.76-1.66 (m, 3H), 1.44-1.26 (m, 3H), 1.23 (t, J = 7.6 Hz, 3H). MH+ 467.
Example 170
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(3,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 2.4 Hz, 2H), 7.42-7.39 (m, 2H), 7.34(d, J = 8.4 Hz, IH), 7.16-7.12 (m, 2H), 6.96 (dd, J = 8.8 Hz, 2.4 Hz, IH), 2.38 (s, 3H), 1.51 (s, 9H). MH+ 461.
Example 171
2-(5-(4-chlorophenyl)-l-(3,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l
,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 2.4 Hz, 2H), 7.42-7.39 (m, 2H), 7.34(d, J = 8.4 Hz, IH), 7.16-7.12 (m, 2H), 6.96 (dd, J = 8.8 Hz, 2.4 Hz, IH), 3.86-3.81 (m, IH), 2.59-2.54 (m, 2H), 2.51-2.45 (m, 2H), 2.40 (s, 3H), 2.18-2.07 (m, 2H). MH+ 459.
Example 172
2-(l-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-met hoxyphenyl)cyclopropyl)-l,3j4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.36 (m, 2H), 7.34-7.24 (m, 3H), 7.08-7.03 (m, 2H), 6.90-6.80 (m, 4H), 3.78 (s, 6H), 2.35 (d, J = 4.0 Hz, 3H), 1.81-1.71 (m, 2H), 1.45-1.38 (m, 2H). MH+ 547.
Example 173 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yI)-5-(l-(trifluorom ethyl)cyclopropyl)-l,3;4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.40 (br d, J = 2.0 Hz, IH), 7.37-7.28 (m, 2H), 7.07-7.04 (m, 2H), 2.83 (q, J = 7.6 Hz, 2H), 1.64 (m, 2H), 1.61 (m, 2H), 1.21 (t, J = 7.6 Hz, 3H). MH+ 571.
Example 174
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(2,4-dichlo rophenyl)cyclopropyl)-l,3»4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.47-7.25 (m, 8H), 7.04-7.00 (m, 2H), 2.74 (q, J = 7.6 Hz, 2H), 1.95 (dd, J = 7.4, 5.0 Hz, 2H), 1.49 (dd, J = 7.4, 5.0 Hz, 2H), 1.12 (t, J = 7.6 Hz, 3H). MH+ 647.
Example 175 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyI)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-methoxy phenyl)cyclopropyl)-l,3)4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.44 (m, 2H), 7.42-7.39 (m, 2H), 7.38-7.27 (m, 3H), 7.04-7.00 (m, 2H), 6.88-6.86 (m, 2H), 3.79 (s, 3H), 2.76 (q, J = 7.6 Hz, 2H), 1.74 (dd, J = 7.2, 4.8 Hz, 2H), 1.42 (dd, J = 7.2, 4.8 Hz, 2H), 1.14 (t, J = 7.6 Hz, 3H). MH+ 609.
Example 176
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-p-tolylcyclo propyl)-l,3?4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.44 (m, 2H), 7.38-7.27 (m, 5H), 7.16-7.14 (m, 2H),
7.04-7.00 (m, 2H), 2.76 (q, J = 7.6 Hz, 2H), 2.31 (s, 3H), 1.74 (dd, J = 7.2, 4.8 Hz, 2H), 1.44
(dd, J = 7.2, 4.8 Hz, 2H), 1.14 (t, J = 7.6 Hz, 3H).
MH+ 593.
Example 177
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yI)-5-(l-phenylcycl opropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.44 (m, 4H), 7.38-7.27 (m, 6H), 7.04-7.00 (m, 2H), 2.76 (q, J = 7.6 Hz, 2H), 1.77 (dd, J = 7.2, 4.8 Hz, 2H), 1.47 (dd, J = 7.2, 4.8 Hz, 2H), 1.14
(t, J = 7.6 Hz, 3H).
MH+ 579.
Example 178 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)
-1,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 2.0 Hz, IH), 7.31-7.24 (m, 4H), 7.14 (d, J = 8.8 Hz, 2H), 3.48-3.43 (m, IH), 1.49 (s, 9H), 1.26 (d, J = 7.2 Hz, 6H). MH+ 489.
Example 179
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5-cyclobuty
1-1,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 2.4 Hz, IH), 7.31-7.23 (m, 4H), 7.15 (d, J = 8.4 Hz, 2H), 3.85-3.76 (m, IH), 3.54-3.47 (m, IH), 2.60-2.40 (m, 3H), 2.18-2.00 (m, 3H), 1.27
(d, J = 7.2 Hz, 6H). MH+ 487.
Example 180 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yI)-5-cyclohexy 1-1,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 2.4 Hz, IH), 7.31-7.22 (m, 4H), 7.15 (d, J = 8.0 Hz, 2H), 3.52-3.45 (m, IH), 3.02-2.95 (m, IH), 2.16-2.12 (m, 2H), 1.87-1.83 (m, 2H), 1.75-1.65 (m, 3H), 1.44-1.29 (m, 3H), 1.26 (d, J = 6.8 Hz, 6H). MH+ 515.
Example 181
2-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-isopropyI-lH-pyrazol-3-yl)-5-(l-(4-chlo rophenyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 2.0 Hz, IH), 7.33-7.23
(m, 6H), 7.11 (d, J = 8.4 Hz, 2H), 3.40-3.33 (m, IH), 1.80-1.77 (m, 2H), 1.46-1.43 (m, 2H),
1.20 (d, J = 7.2 Hz, 6H).
MH+ 585.
Example 182
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yI)-5-(l-(4-chlo rophenyl)cyclobutyl)-l,3»4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 2.0 Hz, IH), 7.31-7.22 (m, 8H), 7.11 (d, J = 8.4 Hz, 2H), 3.43-3.36 (m, IH), 3.11-3.05 (m, 2H), 2.77-2.70 (m, 2H), 2.28-2.21 (m, IH),
2.05-1.97 (m, IH), 1.19 (d, J = 7.2 Hz, 6H).
MH+ 599.
Example 183 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-l, 3,4-oxadiazoIe
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.4 Hz, IH), 7.37-7.27 (m, 4H), 7.11 (d, J = 8.4 Hz, 2H), 2.81-2.77 (m, 2H), 1.66-1.57 (m, 2H), 1.49 (s, 9H), 0.88 (t, J = 7.2 Hz, 3H). MH+ 489.
Example 184
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,
3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.0 Hz, IH), 7.35-7.27 (m, 4H), 7.12 (d, J = 8.0 Hz, 2H), 3.82-3.78 (m, IH), 2.84-2.80 (m, 2H), 2.58-2.50 (m, 2H), 2.48-2.42 (m, 2H), 2.16-2.05 (m, 2H), 1.65-1.59 (m, 2H), 0.88 (t, J = 7.2 Hz, 3H). MH+ 487.
Example 185
2-(5-(4-chIorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5-cyclohexyl-l ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.0 Hz, IH), 7.35-7.27 (m, 4H), 7.12 (d, J = 8.4 Hz, 2H), 3.02-2.94 (m, IH), 2.83-2.79 (m, 2H), 2.17-2.12 (m, 2H), 1.87-1.83 (m, 2H), 1.75-1.57 (m, 4H), 1.44-1.25 (m, 4H), 0.88 (t, J = 7.2 Hz, 3H). MH+ 515.
Example 186
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.38 (m, 3H), 7.34-7.26 (m, 6H), 7.09 (d, J =8.8 Hz,
2H), 2.74-2.70 (m, 2H), 1.80-1.77 (m, 2H), 1.58-1.50 (m, 2H), 1.46-1.43 (m, 2H), 0.82 (t, J
= 7.6 Hz, 3H).
MH+ 585.
Example 187
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclobutyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 2.4 Hz, IH), 7.33-7.26 (m, 8H), 7.08 (d, J =8.8 Hz, 2H), 3.11-3.04 (m, 2H), 2.77-2.70 (m, 4H), 2.27-2.20 (m, IH), 2.04-2.00 (m, IH),
1.61-1.53 (m, 2H), 0.85 (t, J = 7.2 Hz, 3H).
MH+ 599.
Example 188 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-phenylcycl opentyl)-l,3,4-oxadiazole
1R NMR (400 MHz, CDCl3) δ 7.46-7.38 (m, 4H), 7.37 (d, J = 2.4 Hz, IH), 7.34-7.26 (m, 4H), 7.23-7.19 (m, IH), 7.03-6.95 (m, 2H), 2.91 (m, 2H), 2.77 (q, J = 7.6 Hz, 2H), 2.24 (m, 2H), 1.83 (m, 4H), 1.15 (t, J = 7.6 Hz, 3H). MH+ 607.
Example 189
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyI-lH-pyrazol-3-yl)-5-(l-(4-chlorop henyl)cyclopentyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.44 (m, 2H), 7.35-7.25 (m, 7H), 7.04-7.01 (m, 2H), 2.88 (m, 2H), 2.78 (q, J = 7.6 Hz, 2H), 2.19 (m, 2H), 1.83 (m, 4H), 1.16 (t, J = 7.6 Hz, 3H). MH+ 641.
Example 190
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5-(l-(trifluo romethyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (s, IH), 7.33-7.26 (m, 4H), 7.16 (d, J = 8.8 Hz, 2H), 3.48-3.41 (m, IH), 1.66-1.63 (m, 4H), 1.28 (d, J = 7.2 Hz, 6H). MH+ 541.
Example 191
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5-(l-(trifluoro methyl)cyclopropyl)-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.34 (s, IH), 7.30-7.22 (m, 4H), 7.06 (d, J = 8.8 Hz, 2H), 2.74-2.71 (m, 2H), 1.58-1.52 (m, 6H), 0.82 (t, J = 7.2 Hz, 2H). MH+ 541.
Example 192 2-(5-(4-chlorophenyl)-4-cyclopropyl-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclohe xyl-l,3.4-oxadiazole
Step 1: Ethyl 4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazole-3- carboxylate (68) To a solution of ethyl 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazole-
3-carboxylate (1 g, 2.4 mmol) in methylene chloride (30 ml) at room temperature was added bromine (4.9 ml, prepared 1.0 M solution in methylenechlordie, 4.9 mmol) dropwisely. The reaction mixture was stirred at room temperature for 1 hour and the resulting solution was diluted with ethyl ether (50 ml). The reaction mixture was quenched with saturated sodium bicarbonate solution (30 ml) and extracted with ethyl ether (50 ml twice). The organic solution was evaporated under reduced pressure, and crude residue was purified with silica gel column (hexane/ethyl acetate = 5/1) to recover starting material (401 mg, 40 %) and produce the title compound (520 mg, 45% yield) as white solid.
1R NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.0 Hz, IH), 7.37 (d, J = 8.4, 2H), 7.35-7.31 (m, 3H), 7.21-7.19 (m, 2H), 4.50 (q, J = 7.2 Hz, 2H), 1.44 (t, J = 7.2 Hz, 3H). MH+ 473.
Step 2: Ethyl 5-(4-chlorophenyl)-4-cyclopropyl-l-(2,4-dichlorophenyl)-lH-pyrazole-3- carboxylate (69)
To a solution of ethyl 4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazole-3-carboxylate (68) (500 mg, 1.1 mmol) in aqueous toluene, tetrakis(triphenylphsophine)palladium (122 mg, 0.11 mmol) and potassium carbonate (510 mg, 3.9 mmol) were added. The reaction mixture was placed under microwave irradiation with the temperature set to 140 °C. The resulting solution was filtered with syringe filter, and then solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography to obtain the title compound (283 mg, 44%) as white solid.
1H NMR (400 MHz, CDCl3) δ 7.46-7.43 (m, IH), 7.38-7.35 (m, 4H), 7.13-7.11 (m, 2H),
4.48 (q, J = 7. 1 Hz, 2H), 2.02-1.98 (m, IH), 1.44 (t, J = 7.1, 3H), 1.26-1.23 (m, IH),
0.89-0.86 (m, IH).
MH+ 436.
Step 3:
2-(5-(4-chlorophenyl)-4-cyclopropyl-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclohe xyl-1 ,3?4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.52-7.48 (m, 2H), 7.31-7.22 (m, 2H), 7.17-7.04 (m, IH), 7.02-7.00 (m, 2H), 3.08-2.98 (m, IH), 2.18-2.14 (m, 2H), 1.90-1.85 (m, 2H), 1.77-1.68 (m,
2H), 1.46-1.25 (m, 4H), 0.63-0.60 (m, 2H), 0.38-0.34 (m, 2H).
MH+ 515.
Example 193 2-tert-butyl-5-(5-(4-chlorophenyl)-4-cyclopropyl-l-(2,4-dichlorophenyl)-lH-pyrazol-3- yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.55-7.50 (m, 2H), 7.37-7.31 (m, 2H), 7.22-7.20 (m, IH), 7.15-7.10 (m, 2H), 1.45 (m, IH), 1.34 (s, 9H), 0.62-0.59 (m, 2H), 0.38-0.34 (m, 2H). MH+ 489.
Example 194
2-(5-(4-chlorophenyl)-4-cyclopropyl-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclobu tyl-l,3,4-oxadiazole 1U NMR (400 MHz, CDCl3) δ 7.54-7.51 (m, 2H), 7.33-7.31 (m, 2H), 7.20-7.17 (m, IH), 7.14-7.11 (m, 2H), 3.25-2.22 (m, IH), 1.50 (m, IH), 1.45-1.44 (m, 4H), 1.37-1.30 (m, 2H), 0.61-0.59 (m, 2H), 0.37-0.34 (m, 2H). MH+ 487.
Example 195
(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichIorophenyl)-lH-py razol-4-yl)methyl acetate
To the solution of bromide (33) (2.7g, 4.614 mmol) in DMF (20 mL) was added sodiumacetate (1.13 mg, 13.842 mmol). The reaction mixture was heated for 12 hrs at 60 °C . The reaction mixture was diluted with EtOAc and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=3/l) provided 1.75 g (76%) of desired acetate as solid.
1U NMR (400 MHz, CDCl3) δ 7.51-7.47 (m, 2H), 7.44-7.39 (m, IH), 7.40-7.38 (m, IH), 7.35-7.32 (m, IH), 7.25-7.06 (m, 2H), 5.30 (s, 2H), 2.03 (s, 3H), 1.49 (s, 9H). MH+ 563.
Example 196
(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-4-yl)methyl acetate
1H NMR (400 MHz, CDCl3) δ 7.44-7.43 (m, IH), 7.39 (d, J = 8.4 Hz, IH), 7.35-7.32 (m, 3H), 7.15-7.13 (m, 2H), 5.30 (s, 2H), 2.03 (s, 3H), 1.50 (s, 9H). MH+ 519.
Example 197
(5-(4-chlorophenyI)-3-(5-(l-(4-chlorophenyl)cycIopropyl)-l,3,4-oxadiazoI-2-yl)-l-(2,4-d ichlorophenyl)-lH-pyrazol-4-yl)methyl acetate
1H NMR (300 MHz, CDCl3) δ 7.42-7.38 (m, 3H), 7.35-7.31 (m, 6H), 7.12 (d, J = 8.4 Hz, 2H), 5.24 (s, 2H), 1.99 (s, 3H), 1.81-1.77 (m, 2H), 1.48-1.46 (m, 2H). MH+ 615.
Example 198
(3-(5-tert-butyl-l,3»4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-4-yl)methyl benzoate
1H NMR (400 MHz, CDCl3) δ 7.93-7.91 (m, 2H), 7.56-7.52 (m, IH), 7.45-7.26 (m, 7H), 7.19-7.17 (m, 2H), 5.58 (s, 2H), 1.46 (s, 9H). MH+ 581.
Example 199
(3-(5-tert-butyl-l,354-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-4-yl)methanol
To the solution of acetate (34) (1.57 g, 3.020 mmol) in
THF(9mL)/MeOH(9mL)/H2O(2mL) was added LiOH monohydrate (380 mg, 9.060 mmol).
The reaction mixture was stirred for 12 hrs at room temperature. The reaction mixture was diluted with EtOAc and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo to provide 1.37g (95 %) of desired alcohol (35) as solid. The obtained acid was used without further purification.
1H NMR (400 MHz, CDCl3) δ 7.45-7.44 (m, IH), 7.34-7.32 (m, 4H), 7.16-7.14 (m, 2H), 4.82-4.78 (m, IH), 4.72-4.70 (m, 2H), 1.51 (s, 9H). MH+ 478.
Example 200
(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH-py razol-4-yl)methanol 1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.44-7.43 (m, IH), 7.33-7.32 (m, 2H), 7.08-7.06 (m, 2H), 4.69 (s, 2H), 1.50 (s, 9H). MH+ 521.
Example 201
(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cycIopropyl)-l,3,4-oxadiazol-2-yl)-l-(2,4-d ichlorophenyl)-lH-pyrazol-4-yl)methanol
1H NMR (400 MHz, CDCl3) δ 7.43-7.39 (m, 3H), 7.35-7.30 (m, 6H), 7.12 (d, J = 8.4 Hz, 2H), 4.66 (s, 2H), 1.82-1.79 (m, 2H), 1.50-1.47 (m, 2H). MH+ 573.
Example 202
3-(5-tert-butyl-l,3j4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azole-4-carbaldehyde
To the solution of alcohol (35) (100 mg, 0.209 mmol) and Dess-Martin periodinane (132mg, 0.313 mmol) in CH2Cl2 (5 mL) was stirred at room temperature. The reaction mixture was filtered off the white solid and then diluted with CH2Cl2 (5OmL) and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=3/l) provided 78 mg (78%) of desired aldehyde (36) as solid.
1H NMR (400 MHz, CDCl3) δ 10.65 (s, IH), 7.46-7.45 (m, IH), 7.38-7.31 (m, 4H), 7.36-7.23 (m, 2H), 1.52 (s, 9H). MH+ 475.
Example 203
5-(4-bromophenyl)-3-(5-tert-butyl-l,354-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH-pyr azole-4-carbaldehyde 1H NMR (400 MHz, CDCl3) δ 10.63 (s, IH), 7.48-7.44 (m, 3H), 7.35-7.33 (m, 2H), 7.18-7.15 (m, 2H), 1.50 (s, 9H). MH+ 519.
Example 204 5-(4-chlorophenyI)-3-(5-(l-(4-chlorophenyI)cyclopropyl)-l,3,4-oxadiazol-2-yl)-l-(2,4-di chlorophenyl)-lH-pyrazole-4-carbaldehyde
1H NMR (300 MHz, CDCl3) δ 10.55 (s, IH), 7.45-7.41 (m, 3H), 7.36-7.30 (m, 6H), 7.23 (d, J = 8.6 Hz, 2H), 1.85-1.81 (m, 2H), 1.52-1.48 (m, 2H). MH+ 571.
Example 205
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(methoxymethyl)-lH-pyraz oI-3-yl)-l ,3>4-oxadiazole
To the suspension of alcohol (35) (120mg, 0.251mmol), NaH (20mg, 60% dispersion in mineral oil) in DMF (5 mL) was stirred at room temperature. After lhr, the reaction mixture was added MeI (40 μL, 0.33 mmol) and stirred for 12hrs. The reaction mixture was filtered off the white solid and then extracted with EtOAc (5OmL). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=4/l) provided 103 mg (84%) of desired ether (49)as solid.
1H NMR (400 MHz, CDCl3) δ 7.45-7.44 (m, IH), 7.36-7.31 (m, 4H), 7.26-7.23 (m, 2H), 4.66 (s, 2H), 3.48 (s, 3H), 1.50 (s, 9H). MH+ 491.
Example 206
2-(4-(butoxymethyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-tert -buty 1-1 ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.36 (m, IH), 7.34-7.31 (m, 4H), 7.28-7.26 (m, 2H),
4.70 (s, 2H), 3.60 (t, J = 6.4 Hz, 2H), 1.66-1.57 (m, 2H), 1.50 (s, 9H), 1.41-1.26 (m, 2H),
0.91 (t, J = 7.6 Hz, 3H).
MH+ 533.
Example 207 l_(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-p yrazol-4-yl)ethanol To the solution of aldehyde (36) (100 mg, 0.210 mmol) in THF (5 mL) was added methyl magnesiumbromide (200 L, 3.0M solution in diethylether). The reaction mixture was stirred for 12 hrs at room temperature. H2O (20 mL) was added to the reaction mixture and then extracted with CH2Cl2 (5OmL). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=2/l) provided 83mg (80%) of desired secondary alcohol (53) as solid.
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.34-7.29 (m, 4H), 7.13-7.10 (m, 2H), 5.72 (d, J = 11.6 Hz, IH), 4.86-4.78 (m, IH), 1.61 (d, J = 7.2 Hz, 3H), 1.51 (s, 9H). MH+ 491.
Example 208 l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3?4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH-p yrazol-4-yl)ethanol
1H NMR (400 MHz, CDCl3) δ 7.48-7.46 (m, 2H), 7.42-7.41 (m, IH), 7.31-7.29 (m, 2H), 7.06-7.03 (m, 2H), 4.83-4.78 (m, IH), 1.60-1.59 (m, 3H), 1.50 (s, 9H). MH+ 535.
Example 209 l-(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,354-oxadiazol-2-yl)-l-(2,4 -dichlorophenyl)-lH-pyrazol-4-yl)ethanol
1H NMR (400 MHz, CDCl3) δ 7.43-7.40 (m, 3H), 7.35-7.29 (m, 6H), 7.09 (d, J = 8.4 Hz, 2H), 4.78 (q, J = 6.8 Hz, IH), 1.85-1.77 (m, 2H), 1.56 (d, J = 6.8 Hz, 3H), 1.51-1.46 (m, 2H).
MH+ 587.
Example 210
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(l-fluoroethyl)-lH-pyrazol -3-yl)-l,3?4-oxadiazole
To the solution of secondary alcohol (53) (50mg, O.lOlmmol) in CH2Cl2 (3 mL) in Falcon tube was added DAST (27 L, 0.202mmol). The reaction mixture was stirred for 2 hrs at room temperature. Saturated NaHCO3 (3OmL) was added to the reaction mixture. After lhr, the organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=2/l) provided 40mg (80%) of desired product (58) as solid.
1H NMR (400 MHz, CDCl3) δ 7.42 (bs, IH), 7.32-7.29 (m, 4H), 7.25-7.22 (m, 2H), 6.49 (q, J = 6.8 Hz, IH), 1.61 (d, J = 6.4 Hz, 3H), 1.50 (s, 9H). MH+ 493.
Example 211 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-(l-fluoroethyl)-lH-pyrazol-3-yl)-5-tert- butyl-l,3)4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.46 (m, 2H), 7.41-7.40 (m, IH), 7.31-7.30 (m, 2H),
7.05-7.03 (m, 2H), 4.82-4.80 (m, IH), 1.60-1.58 (m, 3H), 1.50 (s, 9H).
MH+ 537.
Example 212
2-(5-(4-chIorophenyl)-l-(2,4-dichloroplienyl)-4-(l-fluoroethyl)-lH-pyrazol-3-yl)-5-(l-(4
-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.41 (m, 3H), 7.36-7.30 (m, 6H), 7.22 (d, J = 8.4 Hz, 2H), 6.43-6.27 (m, IH), 1.82-1.80 (m, 2H), 1.58-1.51 (m, 3H), 1.49-1.47 (m, 2H).
MH+ 589.
Example 213 l-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-lH-p yrazol-4-yl)ethanone
To the solution of secondary alcohol (53) (150mg, 0.305mmol) and Dess-Martin periodinane (155mg, 0.366 mmol) in CH2Cl2 (5 mL) was stirred at room temperature. The reaction mixture was filtered off the white solid and then diluted with CH2Cl2 (5OmL) and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=2/l ) provided 117mg (78%) of desired ketone (57) as solid.
1H NMR (400 MHz, CDCl3) δ 7.44-7.43 (m, IH), 7.35-7.30 (m, 4H), 7.23-7.19 (m, 2H), 2.40 (s, 3H), 1.50 (s, 9H). MH+ 489.
Example 214 l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH-p yrazol-4-yl)ethanone
1H NMR (400 MHz, CDCl3) δ 7.48-7.45 (m, 2H), 7.43-7.42 (m, IH), 7.32-7.31 (m, 2H),
7.15-7.11 (m, 2H), 2.39 (s, 3H), 1.49 (s, 9H).
MH+ 533.
Example 215 l-(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3»4-oxadiazol-2-yl)-l-(2,4
-dichlorophenyl)-lH-pyrazol-4-yl)ethanone
1H NMR (400 MHz, CDCl3) δ 7.36-7.34 (m, 3H), 7.28-7.23 (m, 6H), 7.12 (d, J = 8.8 Hz, 2H), 2.25 (s, 3H), 1.76-1.73 (m, 2H), 1.43-1.40 (m, 2H).
MH+ 585.
Example 216
3-(5-tert-butyl-l,3)4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-4-yl acetate
To the solution of ketone (57) (65 mg, 0.132 mmol) and 3-chloroperoxybenzoic acid (77% max) (66 mg) in CH2Cl2 (10 mL) was stirred at rt. The reaction mixture was diluted with CH2Cl2 (5OmL) and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=5/l ) provided 42 mg (63%) of desired acetate as solid.
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.4 Hz, IH), 7.45 (d, J = 2.0 Hz, IH), 7.39-7.36 (m, IH), 7.33-7.29 (m, 2H), 7.16-7.12 (m, 2H), 2.37 (s, 3H), 1.48 (s, 9H). MH+ 505.
Example 217 2-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-p yrazol-4-yl)propan-2-ol
To the solution of ketone (57) (40mg, 0.082 mmol) in THF (5 mL) was added methyl magnesiumbromide (100 L, 3.0M solution in diethylether). The reaction mixture was stirred for 12 hrs at room temperature. H2O (20 mL) was added to the reaction mixture and then extracted with CH2Cl2 (5OmL). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=2/l) provided 33mg (80%) of desired tertiary alcohol (59) as solid.
1H NMR (400 MHz, CDCl3) δ 7.39-7.38 (m, IH), 7.29-7.17 (m, 6H), 6.77 (s, IH), 1.51 (s, 9H), 1.42 (s, 6H). MH+ 505.
Example 218
2-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3»4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH-p yrazol-4-yl)propan-2-ol
1H NMR (400 MHz, CDCl3) δ 7.44-7.41 (m, 2H), 7.38 (d, J = 2.0 Hz, IH), 7.21 (dd, J = 8.4 Hz, J = 2.0 Hz, IH), 7.17 (d, J = 8.4 Hz, IH), 7.11-7.09 (m, 2H), 1.50 (s, 9H), 1.41 (s, 6H). (MH+ -H2O) 531.
Example 219
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-(prop-l-en-2-yl)-lH-pyraz ol-3-yl)-l,3,4-oxadiazole
To the solution of tertiary alcohol (59) (52mg, 0.103mmol) and Burgess reagent (50mg, 0.206 mmol) in THF (5 mL) was irradiated in a microwave reactor (Biotage) for 10 minutes at 150°C . The organic layer was washed with brine and dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=4/l ) provided 49mg (98%) of desired product (60) as solid.
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 2.4 Hz, IH), 7.39 (d, J = 8.4 Hz, IH), 7.32 (dd, J = 8.4, 2.4 Hz, IH), 7.28-7.26 (m, 2H), 7.14-7.10 (m, 2H), 5.28-5.27 (m, IH), 4.99-4.98 (m, IH), 2.02 (s, 3H), 1.48 (s, 9H). MH+ 487.
Example 220 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-(prop-l-en-2-yI)-lH-pyrazol-3-yl)-5-ter t-butyl-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.37 (m, 3H), 7.39 (d, J = 8.4 Hz, IH), 7.31 (dd, J = 8.4 Hz, J = 2.4 Hz, IH), 7.06-7.03 (m, 2H), 5.27-5.26 (m, IH), 4.98-4.97 (m, IH), 2.01 (s, 3H), 1.47 (s, 9H). MH+ 531.
Example 221
2-tert-butyl-5-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-(fluoromethyl)-lH-pyrazoI -3-yl)-l ,3,4-oxadiazole
To the solution of alcohol (35) (200mg, 0.418mmol) in CH2Cl2(5mL) in Falcon tube was added (diethylamino)sulfur trifluoride (DAST, 110 L, 0.836mmol). The reaction mixture was stirred for 2 hrs at room temperature. Saturated NaHCO3 (3OmL) was added to the reaction mixture. After lhr, the organic extract was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=4/l) provided 106mg (53%) of desired fluoride(50) as solid.
1H NMR (400 MHz, CDCl3) δ 7.47-7.46 (m, IH), 7.38-7.32 (m, 4H), 7.24-7.20 (m, 2H), 5.67 (d, J = 48.8 Hz, 2H), 1.50 (s, 9H). MH+ 479.
Example 222
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-(fluoromethyl)-lH-pyrazol-3-yl)-5-tert- butyl-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.51-7.49 (m, 2H), 7.45-7.44 (m, IH), 7.38-7.32 (m, 2H), 7.15-7.13 (m, 2H), 5.65 (d, J = 48.8 Hz, 2H), 1.48 (s, 9H). MH+ 523.
Example 223 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(fluoromethyl)-lH-pyrazol-3-yl)-5-(l-(4 -chlorophenyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.45-7.39 (m, 3H), 7.36-7.31 (m, 6H), 7.20 (d, J - 8.5 Hz, 2H), 5.67 (s, IH), 5.51 (s, IH), 1.82-1.78 (m, 2H), 1.49-1.45 (m, 2H). MH+ 575.
Example 224
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(difluoromethyl)-lH-pyraz ol-3-yl)-l,3,4-oxadiazole
To the solution of aldehyde (36) (50mg, 0.105mmol) in CH2Cl2(5mL) in Falcon tube was added (diethylamino)sulfur trifiuoride (DAST, 30 L, 0.210mmol). The reaction mixture was stirred for 2 hrs at room temperature. Saturated NaHCO3 (3OmL) was added to the reaction mixture. After lhr, the organic extract was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=4/l) provided 25mg (48%) of desired difluoride (52) as solid.
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 53.6 Hz, IH), 7.45-7.44 (m, IH), 7.37-7.30 (m, 4H), 7.27-7.24 (m, 2H), 1.50 (s, 9H). MH+ 497.
Example 225
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(difluoromethyl)-lH-pyrazol-3-yl)-5-(l-
(4-chlorophenyl)cyclopropyl)-l,3)4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.45-7.41 (m, 3H), 7.36-7.31 (m, 7H), 7.25 (d, J = 8.8 Hz, 2H), 1.83-1.80 (m, 2H), 1.51-1.48 (m, 2H). MH+ 593.
Example 226 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(l-methoxyethyl)-lH-pyraz ol-3-yl)-l,3»4-oxadiazole
To the suspension of secondary alcohol (53) (50mg, O.lOlmmol), NaH( 25mg, 60% dispersion in mineral oil) in DMF (5 mL) was stirred at room temperature. After 1 hr, the reaction mixture was added MeI ( 20μL, 0.33 mmol) and stirred for 12 hrs. The reaction mixture was filtered off the white solid and then extracted with EtOAc (5OmL). The organic extract was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: Hexane/EtOAc=2/l) provided 42mg (82%) of desired product (54) as solid.
1H NMR (400 MHz, CDCl3) δ 7.41-7.40 (m, IH), 7.30-7.22 (m, 6H), 5.27 (q, J = 6.4 Hz, IH), 3.27 (s, 3H), 1.50 (s, 9H), 1.39 (d, J = 6.8 Hz, 3H). MH+ 505.
Example 227
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)-l,3,
4-oxadiazole
To the solution of secondary alcohol (53) (50mg, 0.093mmol) and Burgess reagent
(45mg, 0.186 mmol) in THF (5 mL) was irradiated in a microwave reactor (Biotage) for lOminutes at 150°C . The organic extract was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=4/l ) provided 15mg (55, 31%) and 16mg(56, 29%) as solid.
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.34-7.28 (m, 4H), 7.20-7.18 (m, 2H), 7.12-7.04 (m, IH), 5.41 (dd, J = 18.0, 1.2 Hz, IH), 5.25 (dd, J = 11.6, 1.2 Hz, IH), 1.50 (s, 9H). MH+ 473.
Example 228
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yI)-5-tert-butyl-l,3,
4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.44 (m, 2H), 7.42-7.40 (m, IH), 7.33 (d, J = 8.4 Hz, IH), 7.29 (dd, J = 8.4 Hz, J = 2.4 Hz, IH), 7.13-7.09 (m, 2H), 7.07-7.02 (m, IH), 5.40 (dd, J = 18.0, 1.2 Hz, IH), 5.13 (dd, J = 11.6, 1.2 Hz, IH), 1.49 (s, 9H). MH+ 517.
Example 229 2-(5-(4-chIorophenyI)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)-5-(l-(4-chloroph enyl)cyclopropyl)-l,3»4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.39 (m, 3H), 7.38-7.23 (m, 6H), 7.16 (d, J = 8.8 Hz, 2H), 7.01-6.84 (m, IH), 5.39 (d, J = 18 Hz, IH), 5.22 (d, J = 12 Hz, IH), 1.81-1.77 (m, 2H), 1.50-1.42 (m, 2H). MH+ 569.
Example 230 Methyl l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyI)-lH-p yrazol-4-yl)ethylcarbamate
1H NMR (400 MHz, CDCl3) δ 7.51-7.49 (m, 2H), 7.47-7.44 (m, IH), 7.41-7.40 (m, IH), 7.31-7.29 (m, 2H), 7.23-7.21 (m, IH), 5.10-4.90 (m, IH), 3.62 (s, 3H), 1.54 (s, 3H), 1.50 (s, 9H). MH+ 592.
Example 231 Methyl l-(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3»4-oxadiazol-2-yl)-l-(2,4 -dichlorophenyl)-lH-pyrazol-4-yl)ethylcarbamate
1H NMR (400 MHz, CDCl3) δ 7.44-7.40 (m, 3H), 7.36-7.33 (m, 4H), 7.31-7.27 (m, 4H), 5.0-4.94 (m, IH), 3.60 (s, 3H), 1.85-1.74 (m, 2H), 1.50-1.40 (m, 4H). MH+ 644.
Example 232 Methyl
(3-(5-tert-butyl-l,3»4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-4-yl)methylcarbamate
1H NMR (400 MHz, CDCl3) δ 7.44-7.41 (m, IH), 7.38-7.27 (m, 6H), 6.86-6.78 (m, IH), 4.41 (d, J = 6.8 Hz, 2H), 3.60 (s, 3H), 1.50 (s, 9H). MH+ 536.
Example 233 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(phenoxymethyl)-lH-pyraz oI-3-yl)-l ,3,4-oxadiazole
To the solution of bromide (33) (150 mg, 0.277 mmol) in DMF (5mL) was added phenol (40mg, 0.415mmol), Cs2CO3 (202mg, 0.622mmol). The reaction mixture was refluxed for 12 hrs at room temperature. Reaction mixture was filtered off the white solid and then extracted with EtOAc (5OmL). The organic extract was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (eluent: hexane/EtOAc=5/l) provided 86 mg ( 56%) of desired ether(45) as solid.
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 2.0 Hz, IH), 7.39 (d, J = 8.4 Hz, IH), 7.33 (dd, J = 8.4, 2.0 Hz, IH), 7.30-7.22 (m, 6H), 6.97-6.95 (m, 3H), 5.27 (s, 2H), 1.44 (s, 9H). MH+ 553.
Example 234
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-((pyridin-2-yloxy)methyl)- lH-pyrazol-3-yl)-l,3.4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 8.11-8.09 (m, IH), 7.56-7.53 (m, IH), 7.44-7.41 (m, 2H), 7.34-7.32 (m, IH), 7.28-7.19 (m, 4H), 6.88-6.86 (m, IH), 6.73-6.71 (m, IH), 5.52 (s, 2H), 1.52 (s, 9H). MH+ 554.
Example 235
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-propoxyp ropan-2-yl)-l,3.4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.30 (m, 5H), 7.14-7.08 (m, 2H), 3.29 (t, J = 6.6 Hz, 2H), 2.45 (s, 3H), 1.74 (s, 6H), 1.53 (m, 2H), 0.87 (t, J = 7.2 Hz, 3H). MH+ 505.
Example 236
2-(l-(benzyloxy)pentyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyr azol-3-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (br d, J = 2.0 Hz, 2H), 7.39-7.26 (m, 9H), 7.14-7.10 (m, 2H), 4.75 (dd, J = 6.0, 8.0 Hz, IH), 4.66 (d, J = 11.6 Hz, IH), 4.49 (d, J = 11.6 Hz, IH), 2.46 (s, 3H), 2.09 (m, IH), 1.97 (m, IH), 1.48 (m, IH), 1.31 (m, 3H), 0.87 (t, J = 7.2 Hz, 3H). MH+ 581.
Example 237 2-(2-(allyloxy)propan-2-yI)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH- pyrazol-3-yl)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (br d, J = 2.0 Hz,, IH), 7.40-7.31 (m, 4H), 7.13-7.10 (m, 2H), 5.86 (m, IH), 5.26 (br d, J = 17.2 Hz, IH), 5.10 (br d, J = 10.4 Hz,, IH), 3.92 (dt, J = 5.2, 1.6 Hz, 2H), 2.45 (s, 3H), 1.77 (s, 6H). MH+ 503.
Example 238
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-py razol-3-yl)-l,3,4-oxadiazo!e 1H NMR (400 MHz, CDCl3) δ 7.43-7.22 (m, 5H), 7.01-6.98 (m, 2H), 5.79 (m, IH), 5.17 (dd, J = 17.2, 1.4Hz, IH), 5.03 (dd, J = 10.4, 1.4 Hz, IH), 3.86 (d, J = 6.8 Hz, 2H), 2.78 (q, J = 7.6 Hz, 2H), 1.70 (s, 6H), 1.16 (t, J = 7.6 Hz, 3H). MH+ 561.
Example 239
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-py razol-3-yl)-l,3.4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.35-7.22 (m, 5H), 7.08-7.04 (m, 2H), 5.79 (m, IH), 5.17 (dd, J = 17.2, 1.4Hz, IH), 5.03 (dd, J = 10.4, 1.4 Hz, IH), 3.86 (d, J = 6.8 Hz, 2H), 2.78 (q, J = 7.6 Hz, 2H), 1.70 (s, 6H), 1.16 (t, J = 7.6 Hz, 3H). MH+ 517.
Example 240
3-(2-(5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,3,4-oxad iazol-2-yl)propan-2-yloxy)propan-l-ol MH+ 580.
Example 241 l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,354-oxadi azol-2-yl)pentan-l-ol t
1H NMR (400 MHz, CDCl3) δ 7.42 -7.26 (m, 5H), 7.14-7.10 (m, 2H), 4.75 (dd, J = 6.0, 8.0 Hz, IH), 2.46 (s, 3H), 2.09 (m, IH), 1.97 (m, IH), 1.48 (m, IH), 1.31 (m, 3H), 0.87 (t, J = 7.2 Hz, 3H). MH+ 491.
Example 242
((lR,2S)-2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,
3,4-oxadiazol-2-yl)cyclopropyl)(piperidin-l-yl)methanone MH+ 556.
Example 243
2-(2-butoxypropan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-py razol-3-yl)-l,3?4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.40 (br d, J = 2.0 Hz), 7.37-7.29 (m, 4H), 7.12-7.09 (m, 2H), 3.31 (t, J = 6.8 Hz, 2H), 2.43 (s, 3H), 1.72 (s, 6H), 1.49 (m, 2H), 1.31 (m, 2H), 0.84 (t, J = 7.2 Hz, 3H). MH+ 519.
Example 244
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-(pentylox y)propan-2-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40 (br d, J = 2.0 Hz, IH), 7.38-7.30 (m, 4H), 7.10 (m, 2H), 3.30 (t, J = 6.8 Hz, 2H), 2.44 (s, 3H), 1.72 (s, 6H), 1.50 (m, 2H),, 1.25 (m, 4H), 0.83 (t, J = 5.2 Hz, 3H). MH+ 533.
Example 245
2-(2-(benzyloxy)propan-2-yI)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-l H-pyrazol-3-yl)-l,3»4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (br d, J = 2.0 Hz, IH), 7.37-7.20 (m, 9H), 7.10 (m, 2H), 4.43 (s, 2H), 2.43 (s, 3H), 1.83 (s, 6H). MH+ 553. Example 246
2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyrazoI-3-yl)-l,3,4-oxadi azol-2-yl)propan-2-yl acetate
1H NMR (400 MHz, CDCl3) δ 7.42-7.30 (s, 5H), 7.12-7.09 (m, 2H), 2.44 (s, 3H), 2.09 (s, 3H), 1.90 (s, 6H). MH+ 505.
Example 247
2-(5-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-oxadi azol-2-yl)propan-2-ol
1H NMR (400 MHz, CDCl3) δ 7.43-7.31 (m, 5H), 7.13-7.10 (m, 2H), 2.45 (s, 3H), 1.77 (s,
6H).
MH+ 463.
Example 248
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-l/T-pyrazol-3-yl)-5-(2-(2-fluoro benzyIoxy)propan-2-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.18 (m, 7H), 7.12-6.94 (m, 4H), 4.51 (s, 2H), 2.43 (s, 3H), 1.83 (s, 6H). MH+ 571.
Example 249
2-(2-(3-Chlorobenzyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4- methyI-l//-pyrazol-3-yl)-l,3>4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.42-7.22 (m, 6H), 7.20-7.09 (m, 5H), 4.42 (s, 2H), 2.43 (s, 3H), 1.82 (s, 6H). MH+ 587.
Example 250 Ethyl
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-oxadiazo Ie-2-carboxylate
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 2.0 Hz, IH), 7.36-7.30 (m, 4H), 7.11 (m, 2H), 4.53 (q, J = 7.2 Hz, 2H), 2.47 (s, 3H), 1.45 (t, J = 7.2 Hz, 3H). MH+ 477.
Example 251
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2,2,2-trifluo ro-l-methoxy-l-phenylethyl)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.58 (m, 2H), 7.44-7.29 (m, 8H), 7.10 (m, 2H), 3.49 (s, 3H), 2.44 (s, 3H). MH+ 593.
Example 252
2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lJΪ-pyrazol-3-yl)-l,3,4-oxadi azol-2-yl)-2-methylpropyl acetate
1H NMR (400 MHz, CDCl3) δ 7.42-7.31 (m, 5H), 7.12-7.10 (m, 2H), 4.32 (s, 2H), 2.44 (s, 3H), 1.52 (s, 6H). MH+ 519.
Example 253
2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-l^T-pyrazol-3-yl)-l,3»4-oxadi azol-2-yl)-2-methyIpropan-l-ol 1H NMR (400 MHz, CDCl3) δ 7.44-7.32 (m, 5H), 7.14-7.13 (m, 2H), 3.85 (s, 2H), 2.45 (s, 3H), 1.47 (s, 6H). MH+ 477.
Example 254 2-(l-(Benzyloxy)-2-methylpropan-2-yl)-5-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4- methyl-lH-pyrazol-3-yl)-l,3,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.43-7.23 (m, 9H), 7.17-7.04 (m, 3H), 5.11 (s, 2H), 3.93 (s, 2H), 2.12 (s, 3H), 1.21 (s, 6H). MH+ 567.
Example 255
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lJΪ-pyrazol-3-yl)-5-(2-methyI-l
-(4-(trifluoromethyl)benzyloxy)propan-2-yl)-l,3?4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.59-7.31 (m, 9H), 7.13-7.10 (m, 2H), 4.58 (s, 2H), 3.70 (s, 2H), 2.42 (s, 3H), 1.53 (s, 6H). MH+ 635.
Example 256 2-(l-(4-Chlorobenzyloxy)-2-methylpropan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorop henyl)-4-methyl-l//-pyrazoI-3-yI)-l,3,4-oxadiazoIe
1H NMR (400 MHz, CDCl3) δ 7.44-7.32 (m, 5H), 7.24-7.11 (m, 6H), 4.48 (s, 2H), 3.60 (s, 2H), 2.42 (s, 3H), 1.51 (s, 6H). MH+ 601.
Example 257
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(3-chloro phenyl)cyclopropyl)-l,3)4-oxadiazole
Step 1: 2-(3-chlorophenyl)acetonitriIe
The experimental procedure was followed by the method of Bruno P. Imbimbo et al [J. Med. Chem. 2005, 48, 5707-7520]. A solution of 3-chlorobenzylbromide (5 g, 24.3 mmol) and sodium cyanide (1.3 g, 26.8 mmol) in ethanol (50 ml) was heated to 80 °C for 2 hours. After resulting solution was cooled to room temperature and concentrated under reduced pressure. The residue was suspended in water and organic layer was extracted with ethyl acetate. The solution was evaporated and crude compound was purified by silica gel column chromatography (hexane/ethyl acetate = 5/1) to yield 2-(3-chlorophenyl)acetonitrile (3.2 g, 87 % yield) as colorless oil.
1H NMR (400 MHz, CDCl3) δ 7.36-7.32 (m, IH), 7.20-7.17 (m, 3H),7.06-7.04 (m, IH), 3.68 (s, 2H).
Step 2: l-(3-chlorophenyl)cyclopropanecarbonitrile
To a solution of 2-(3-chlorophenyl)acetonitrile (3.2 g, 21 mmol) and 1,2-dibromoethane (3 niL, 35 mmol) in toluene (20 ml), 35% sodium hydroxide and tetrabutylammonium iodide (400 mg, 1.3 mmol) were added. The mixture was vigorously stirred at room temperature for 4 hours. The resulting solution was diluted with water and extracted with ethyl acetate. The organic solution was concentrated to afford brown oil. Chromatography on silica gel (hexane/ethyl acetate = 5/1) afforded l-(3-chlorophenyl)cyclopropanecarbo nitrile (2.1 g, 56% yield) as light yellow oil.
1H NMR (400 MHz, CDCl3) δ 7.38-7.34 (m, IH), 7.21-7.18 (m, 3H),7.07-7.03 (m, IH), 0.98-0.96 (m, 2H), 0.74-0.72 (m, 2H).
Step 3: l-(3-chlorophenyl)cyclopropanecarboxylic acid
To a solution of l-(3-chlorophenyl)cyclopropanecarbonitrile (2.1 g, 11.8 mmol) in methanol (10 ml), 35% NaOH (40 ml) was added and the mixture was heated to 100 "C for 8 hours. After cooling to room temperature, the resulting solution was evaporated under reduced pressure. And the aqueous layer was washed with ethyl ether, acidified with 2N HCl, and extracted organic layer with ethyl acetate. The organic solution was dried over magnesium sulfate, evaporated volatile solvent and dried under vacuum to obtain l-(3-chlorophenyl)cyclopropanecarboxylic acid (1.8 g, 77% yield) as white solid.
Step 4:
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-(l-(3-chloro phenyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.55-7.48 (m, 4H), 7.33-7.31 (m, 2H), 7.25-7.17 (m, 3H),
7.14-7.11 (m, 3H), 2.35 (s, 3H), 1.86-1.84 (m, 2H), 1.34-1.29 (m, 2H).
MH+ 555.
Example 258
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyI-lH-pyrazol-3-yl)-5-(l-(3-chloroph enyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.56-7.48 (m, 4H), 7.33-7.32 (m, 2H), 7.25-7.19 (m, 3H), 7.13-7.10 (m, 3H), 2.85 (q, J = 7.6 Hz, 2H), 1.23 (t, J = 7.6 Hz, 3H).
MH+ 569.
Example 259 2-(l-alIylcyclopropyl)-5-(5-(4-bromophenyI)-l-(2,4-dichlorophenyl)-4-ethyI-lH-pyrazol -3-yl)-l ,3>4-oxadiazole
Step 1: 1-allylcyclopropanecarboxylic acid
The experimental procedure was followed by the method of Henryk Krawczyk et al
[Synlett 2005, 17, 2648-2652]. A solution of -diethoxyphosphoryl- -lactone (5 g, 22.5 mmol) in THF (10 ml) was added dropwise under nitrogen atmosphere at -78 "C to a stirred solution of LDA (13.7 ml, 1.8 M in tetrahydrofuran/heptane/ethylbenzene, 24.8 mmol). When the addition was completed the reaction mixture was warmed to 0 °C and stirred for 30 minutes. The reaction mixture was cooled down to -78 "C and ally bromide (2.45 ml, 18.7 mmol) was added. The stirring was continued for 1 hour at this temperature and then the reaction mixture was warmed to room temperature and stirred for overnight. The mixture was quenched and acidified using IN HCl solution and extracted with methylenechloride (30 ml twice). The crude products was purified by column chromatography (silica gel, acetone/methylenechloride = 1/5) to produce diethyl 3-allyl-2-oxotetrahydro furan-3-ylphosphonate (4.5 g, 76%) as colorless oil.
1H NMR (400 MHz, CDCl3) δ 5.71-5.70 (m, IH), 5.03-4.97 (m, 2H), 4.35-4.25 (m, 2H), 4.08-4.06 (m, 6H), 2.40-2.38 (m, IH), 2.32-2.30 (m, 2H), 1.97-1.95 (m, IH), 1.13-1.10 (m, 9H).
Step 2:
To a suspension of sodium hydride (686 mg, 60% in mineral oil, 17.2 mmol) and diethyl 3-allyl-2-oxotetrahydrofuran-3-ylphosphonate (4.5 g, 17.2 mmol) in THF (15 ml) was added dropwise under nitrogen atmosphere at room temperature a solution of ethanol
(1.1 ml, 18.9 mmol) in THF (5 ml). The reaction mixture was stirred for 30 minutes and then was heated at reflux for 10 hours. After cooling to room temperature saturated ammonium chloride was added and extracted organic layer with ethyl ether. The residue was dried with magnesium sulfate. Without further purification, the ester was hydrolyzed with sodium hydroxide (1.4 g, 34 mmol) in aqueous acetonitrile (20 ml) at 60 °C for overnight. The reaction mixture was cooled down to room temperature. After acidification of the resulting solution with IH HCl, organic layer was extracted with ethyl ether. The solution was dried with magnesium sulfate, and then it was evaporated under reduced pressure. Product was dried under vacuum to produce crude title compound (1.4 g, 65% yield) as light yellow oil.
Step 3:
2-(l-allylcyclopropyl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol -3-yI)-l,354-oxadiazoIe
1H NMR (400 MHz, CDCl3) δ 1.51-1 Al (m, 4H), 7.34-7.32 (m, 2H), 7.26-7.19 (m, 3H), 7.14-7.10 (m, 3H), 5.71-5.68 (m, IH), 5.03-4.97 (m, 2H), 2.85 (q, J = 7.6 Hz, 2H), 2.23-2.20 (m, 2H), 1.23 (t, J = 7.6 Hz, 3H), 0.84 (dd, J = 4.4, 6.8 Hz, 2H), 0.43 (dd, J = 4.4. 68 Hz, 2H).
MH+ 543.
Example 260
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethynyl-lH-pyrazol-3-yI)-l ,3?4-oxadiazole
Step 1:
2-tert-butyl-5-(5-(4-chlorophenyl)-4-(2,2-dibromovinyl)-l-(2,4-dichlorophenyl)-lJΪ-pyr azol-3-yl)-l,3?4-oxadiazole (74)
To a solution of carbontetrabromide (313 mg, 0,94 mmol) in methylene chloride (15 ml) at 0°C was added triphenylphosphine (248 mg, 0.95 mmol). The reaction mixture was stirred at 0°C for 10 minutes and then 3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4- chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazole-4-carbaldehyde (300 mg, 0.63 mmol) in methylenechloride (10 ml) was added slowly. The reaction temperature was warmed slowly to room temperature and stirred overnight. The resulting solution was quenched with saturated ammonium chloride and extracted organic layer with ethyl ether (50 ml twice). After evaporation, crude residue was purified with silica gel column (hexane/ethyl acetate = 5/1) to recover starting material (110 mg, 37 %) and produce 2-tert-butyl-5-(5-(4- chlorophenyl)-4-(2,2-dibromovinyl)- 1 -(2,4-dichlorophenyl)- lH-pyrazol-3-yl)- 1 ,3,4-oxadiaz ole (230 mg, 58% yield) as white solid.
1H NMR (400 MHz, CDCl3) δ 7.51-7.48 (m, IH), 7.47 (s, lH),7.36-7.32 (m, 2H), 7.30-7.28 (m, IH), 7.18 (d, J = 8.68 Hz, IH), 7.14-7.10 (m, 2H), 1.34 (s, 9H). MH+ 631.
Step 2:
2-tert-butyl-5-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-ethynyl-lH-pyrazol-3-yl)-l ,3>4-oxadiazole (75)
To a solution of 2-tert-butyl-5-(5-(4-chlorophenyl)-4-(2,2-dibromovinyl) -l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-l,3,4-oxadiazole (230 mg, 0.36 mmol) in tetrahydrofuran (10 ml) at 78 °C , potassium bis(trimethysilyl)amide (1.46 ml, 0.5 M solution in tetahydrofuran, 0.73 mmol) was added slowly. After stirring for 20 minutes at 78 °C, the resulting solution was quenched with saturated ammonium chloride (5 ml). After warming up to room temperature, the solution was diluted with ethyl ether, and then the organic layer was extracted with ethyl acetate (50 ml twice). After evaporation, crude residue was purified with silica gel column (hexane/ethyl acetate = 5/1) to obtain title compound (150 mg, 91% yield) as light yellow solid.
1H NMR (400 MHz, CDCl3) δ 7.54-7.49 (m, 2H), 7.34-7.31 (m, 2H), 7.20-7.17 (m, IH), 7.15-7.11 (m, 2H), 3.06 (s, IH), 1.35 (s, 9H). MH+ 471.
Example 261
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(prop-l-ynyl)-lH-pyrazol-
3-yl)-l,3,4-oxadiazole
To a solution of 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichloro phenyl)-4-ethynyl-lH-pyrazol-3-yl)-l,3,4-oxadiazole (100 mg, 0.21 mmol) in tetrahydrofuran (15 ml) at 78 °C, lithium bis(trimethylsilyl)amide (0.23 ml, 1.0 M solution in tetrahydrofuran, 0.23 mmol) was added slowly not to warm up the reaction solution. After stirring at 78 "C for 10 minutes, iodomethane (0.04 ml, 0.7 mmol) was added quickly. The resulting solution was stirred for 20 minutes, and then it was warmed up to room temperature slowly. After quenching with saturated ammonium solution, the organic layer was separated with ethyl acetate. The organic solution was evaporated in reduced pressure and the residue was purified by silica gel column chromatography (hexane/ethyl acetate = 10/1 to hexane/ethyl acetate = 5/1) to produce title compound (13 mg, 13% yield) as light yellow solid.
1H NMR (400 MHz, CDCl3) δ 7.55-7.49 (m, 2H), 7.35-7.31 (m, 2H), 7.21-7.17 (m, IH), 7.16-7.11 (m, 2H), 1.89 (s, IH), 1.35 (s, 9H). MH+ 485.
Example 262
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyI)-4-ethyI-lH-pyrazoI-3-yl)-5-(l-propylcycl op ropy I)- 1 ,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.56-7.44 (m, 4H), 7.34-7.32 (m, 2H), 7.27-7.20 (m, 3H),
7.15-7.10 (m, 3H), 2.91 (q, J = 7.8 Hz, 2H), 2.23-2.20 (m, 2H), 1.57-1.53 (m, 2H), 1.33-1.30
(m, 2H), 1.27 (t, J = 7.8 Hz, 3H), 0.98 (t, J = 7.4 Hz, 3H), 0.86-0.82 (m, 2H), 0.45-0.41 (m,
2H).
MH+ 545.
Example 263
2-tert-butyl-5-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-(3-(trimethylsilyl)prop-2-y nyl)-lH-pyrazol-3-yl)-l,3,4-oxadiazole
To a solution of ethylyltrimethylsilane (0.26 ml, 1.85 mmol) in tetrahydrofuan (10 ml) at 78 °C was added butyllithium (0.74 ml, 2.5 M in hexane, 1.85 mmol) slowly. The reaction mixture was stirred at 78 °C for 10 minutes and then 2-(4-(bromomethyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3-yl)-5-tert-but yl-l,3,4-oxadiazole (500 mg, 0.92 mmol) in tetrahydrofuan (5 ml) was added slowly at 78 °C . The reaction temperature was warmed slowly to room temperature for 5 hours and stirred 1 hour at room temperature. The resulting solution was quenched with saturated ammonium chloride and extracted organic layer with ethyl acetate (50 ml twice). After evaporation, crude residue was purified with silica gel column (hexane/ethyl acetate = 5/1) to produce 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(3-(trimethylsilyl)prop-2-ynyl)- lH-pyrazol-3-yl)-l ,3,4-oxadiazole (370 mg, 72% yield) as white solid.
1H NMR (400 MHz, CDCl3) δ 7.54-7.49 (m, 2H), 7.33-7.31 (m, 2H), 7.20-7.17 (m, IH), 7.14-7.11 (m, 2H), 4.00 (s, 2H), 1.57 (s, 9H), 0.11 (s, 9H). MH+ 559. Example 264
2-tert-butyl-5-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-(prop-2-ynyl)-lH-pyrazol-
3-yl)-l,3,4-oxadiazole
To a solution of 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichloro phenyl)-4-(3-(trimethylsilyl)prop-2-ynyl)-lH-pyrazol-3-yl)-l,3,4-oxadiazole (300 mg, 0.46 mmol) in tetrahydrofuan (5 ml) at 0 °C was added tetrabutylammonium fluoride (0.7 ml, 1.0 M in tetrahydrofuran, 0.7 mmol). After reaction mixture was warmed up to room temperature, it was stirred for 10 minutes. After the resulting solution was diluted with ether (20 ml), water was added (10 ml). Organic layer was separated with ethyl acetate (20 ml twice). After evaporation, crude residue was purified with silica gel column (hexane/ethyl acetate = 7/1 to hexane/ethyl acetate 5/1). The less polar compound 2-tert-butyl-5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(propa- 1 ,2-dienyl)- 1 H-pyrazol- 3-yl)-l,3,4-oxadiazole was obtained as light yellow solid (87 mg, 34% yield). And relatively more polar compound 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4- (prop-2-ynyl)-lH-pyrazol-3-yl)-l,3,4-oxadiazole was produced as yellow solid (140 mg, 54% yield).
1H NMR (400 MHz, CDCl3) δ 7.41-7.40 (dd, J = 0.4, 2.4 Hz, IH), 7.34-7.32 (m, IH),
7.30-7.25 (m, 3H), 7.18-7.16 (m, 2H), 6.83 (t, J = 7.2 Hz, IH), 4.59 (d, J = 6.8 Hz, 2H), 1.49 (s, 9H). MH+ 485.
Example 265
2-tert-butyI-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-(propa-l,2-dienyl)-lH-pyr azol-3-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, 2H), 7.35-7.32 (m, 2H), 7.29-7.26 (m, 3H), 3.02-2.93 (m, 2H), 1.49 (s, 9H), 1.51 (m, IH). MH+ 485.
Example 266 l-(5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,3,4-oxadiaz ol-2-yl)cyclopropanecarbonitrile 1H NMR (400 MHz, CDCl3) δ 7.49-7.41 (m, 3H), 7.36-7.30 (m, 2H), 7.07-7.04 (m, 2H), 2.84 (q, J = 7.6 Hz, 2H), 2.03-1.95 (m, 2H), 1.94-1.91 (m, 2H), 1.21 (t, J = 7.6 Hz, 3H). MH+ 528.
Example 267 l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3j4-oxadi azol-2-yl)cyclopropanecarbonitrile
1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 0.4, 2.4 Hz, IH), 7.36-7.30 (m, 4H), 7.12-7.08 (m, 2H), 2.42 (s, 3H), 2.03-1.90 (m, 4H). MH+ 470.
Example 268 l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,3»4-oxadiaz ol-2-yl)cyclopropanecarbonitrile 1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.34-7.27 (m, 4H), 7.14-7.10 (m, 2H), 2.86 (q, J = 10.0 Hz, 2H), 1.97 (dd, J = 4.6, 2.7 Hz, 2H), 1.04 (dd, J = 4.6, 2.7 Hz, 2H), 1.21 (t, J = 10.0, 3H). MH+ 484.
Example 269
2-(5-(4-chIorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazoI-3-yI)-5-(l-(pyridin- 2-yl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 8.45 (m, IH), 7.43-7.40 (m, 3H), 7.34-7.31 (m, 4H), 7.20-7.18 (m, IH), 7.12-7.08 (m, 2H), 2.43 (s, 3H), 2.02-1.92 (m, 4H). MH+ 523.
Example 270
2-(l-benzylcyclopropyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichloroplienyI)-4-metliyl-lH-pyr azol-3-yl)-l ,3,4-oxadiazole
Step 1: 1-benzylcyclopropanecarboxylic acid
A solution of cyclopropyl cyanide (2 g, 30 mmol) in THF (30 ml) was added dropwise under nitrogen atmosphere at -78 °C to a stirred solution of LDA (18 ml, 1.8 M in tetrahydroftiran/heptane/ethylbenzene, 33 mmol). The reaction mixture was stirred 20 minutes at -78 "C and then benzylbromide (7 ml, 60 mmol) in tetrahydrofuran (20 ml) was added at -78 °C . After stirring for 30 minutes, the reaction mixture was warmed to room temperature. The stirring was continued for 3 hours at this temperature and then the mixture was quenched using saturated ammonium chloride solution and extracted with ethyl ether. The organic solution was dried with magnesium sulfate. Without further purification, the nitrile compound was hydrolyzed with 35% aqueous sodium hydroxide solution (20 ml) in methanol (30 ml) at 100°C for 8 hours. After reaction complete, methanol was evaporated under reduced pressure. After washing aqueous solution with diethyl ether (30 ml twice), resulting solution was acidified using 3N HCl. With diethyl ether, the organic phase was worked-up and evaporated under reduced pressure to obtained the title compound (3.2 g, 61 %) as light yellow solid.
1H NMR (400 MHz, CDCl3) δ 7.35-7.17 (m, 5H), 2.98 (s, 2H), 1.34 (dd, J = 4, 6.8 Hz, 2H), 0.87 (dd, J = 4.0, 6.8 Hz, 2H).
Step 2:
2-(l-benzylcyclopropyl)-5-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyr azol-3-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2 Hz, IH), 7.35-7.26 (m, 6H), 7.21-7.17 (m, 3H), 7.09-7.07 (m, 2H), 3.22 (s, 2H), 2.38 (s, 3H), 1.44-1.41 (m, 2H), 1.07-1.04 (m, 2H). MH+ 535.
Example 271
2-(l-benzylcyclopropyl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyra zol-3-yl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.44 (m, 2H), 7.41 (d, J = 2 Hz, IH), 7.37-7.25 (m, 5H), 7.23-7.17 (m, 2H), 7.05-7.02 (m, 2H), 3.31 (s, 2H), 2.81 (q, J = 7.6 Hz, 2H), 1.44-1.41 (m 2H), 1.96 (t, J = 7.6 Hz, 3H), 1.06-1.05 (m, 2H). MH+ 551.
Example 272 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-fluoroph enyl)cyclopropyl)-l,3»4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.42 (m, IH), 7.34-7.30 (m, 6H), 7.20-7.11 (m, 4H), 2.86 (q, J = 9.9 Hz, 2H), 2.12 (dd, J = 9.3, 6.1, 2H), 1.98 (dd, J = 9.3, 6.1, 2H), 1.26 (t, J = 9.9 Hz, 3H). 5 MH+ 597.
Example 273
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(3-chlorop henyl)cyclopropyl)-l,3.4-oxadiazole
10 1H NMR (400 MHz, CDCl3) δ 7.47-7.44 (m, 2H), 7.40 (d, J = 2.1 Hz, IH), 7.37-7.31 (m,
2H), 7.30 (d, J = 2.4 Hz, IH), 7.27-7.23 (m, 4H), 7.05-7.03 (m, 2H), 2.77 (q, J = 7.7 Hz, 2H), 1.94 (dd, J = 9.2, 6.2 Hz, 2H), 1.46 (dd, J = 9.2, 6.2 Hz, 2H), 1.19 (t, J = 7.7 Hz, 3H). MH+ 615.
,15 Example 274
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-fluoro phenyl)cyclopropyl)-l,3)4-oxadiazole
1R NMR (400 MHz, CDCl3) δ 7.48-7.45 (m, 3H), 7.38-7.35 (m, 2H), 7.29-7.22 (m, 4H), 7.04-7.01 (m, 2H), 2.23 (s, 3H), 1.92 (dd, J = 9.2, 6.7 Hz, 2H), 1.51 (dd, J = 9.2, 6.7 Hz, 20 2H).
MH+ 539.
Example 275
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-methylcy 25 clopropy I)-1 ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2 Hz, 2H), 7.36 (d, J = 8.4 Hz, IH), 7.33-7.23 (m, 3H), 7.11-7.08 (m, 2H), 2.41 (s, 3H), 1.61 (s, 3H), 1.42-1.40 (m, 2H), 0.97-0.94 (m, 2H). MH+ 459.
30 Example 276
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-methylcycl opropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.45 (m, 2H), 7.40 (d, J = 3.6 Hz, IH), 7.35-7.27 (m, 2H), 7.06-7.04 (m, 2H), 2.83 (q, J = 7.6 Hz, 2H), 1.62 (s, 3H), 1.45-1.42 (m, 2H), 1.22 (t, J = 7.6 Hz, 3H), 0.96-0.95 (m, 2H). MH+ 517.
Example 277 2-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-ethyIcycl opropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.42 (m, IH), 7.34-7.31 (m , 4H), 7.14-7.10 (m, 2H), 2.45 (s, 3H), 1.90 (q, J = 9.7 Hz, 2H), 1.39 (dd, J = 9.3, 6.2 Hz, 2H), 1.11 (t, J = 9.7 Hz, 3H), 1.06 (dd, J = 9.3, 6.2 Hz). MH+ 473.
Example 278
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-ethylcycIop ropyl)-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.34-7.29 (m , 4H), 7.16-7.11 (m, 2H), 2.89 (q, J = 9.8 Hz, 2H), 1.90 (q, J = 9.6 Hz, 2H), 1.38 (dd, J = 9.3, 6.2 Hz, 2H), 1.27 (t, J = 9.8 Hz, 3H), 1.03 (t, J = 9.6 Hz, 3H), 1.01 (dd, J = 9.3, 6.2 Hz). MH+ 487.
Example 279
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-ethylcyclop ropyl)-l ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.42 (m, IH), 7.33-7.30 (m , 4H), 7.14-7.11 (m, 2H), 2.91 (q, J = 9.8 Hz, 2H), 1.91 (q, J = 9.6 Hz, 2H), 1.36 (dd, J = 9.3, 6.2 Hz, 2H), 1.27 (t, J = 9.8 Hz, 3H), 1.03 (t, J = 9.6 Hz, 3H), 1.01 (dd, J = 9.3, 6.2 Hz). MH+ 531.
Example 280
2-(l-(4-chlorobenzyl)cyclopropyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-meth yl-lH-pyrazol-3-yI)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.4 Hz, IH), 7.34-7.28 (m, 4H), 7.23-7.20 (m, 3H), 7.10-7.07 (m, 2H), 3.24 (s, 2H), 2.39 (s, 3H), 1.45 (dd, J = 2, 6.8 Hz, 2H), 1.07 (dd, J = 2, 6.8 Hz, 2H). MH+ 571. Example 281
2-(l-(4-chlorobenzyl)cyclopropyl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl
-lH-pyrazol-3-yl)-l,3j4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.51-7.45 (m, 2H), 7.40 (d, J = 2 Hz, IH), 7.34-7.26 (m, 3H), 7.23-7.20 (m, 3H), 7.05-6.96 (m, 2H), 3.24(s, 2H), 2.80 (q, J = 7.6 Hz, 2H), 1.46 (dd, J = 5.2, 7.2 Hz, 2H), 1.25 (t, J = 7.6 Hz, 3H), 1.06 (dd, J = 4.8, 6.8 Hz, 2H). MH+ 629.
Example 282
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(2-fluoroph enyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.38 (m, 2H), 7.34-7.27 (m, 5H), 7.16-7.06 (m, 4H), 2.74 (q, J = 7.6 Hz, 2H), 1.89-1.82 (m, 2H), 1.51-1.45 (m, 2H), 1.12 (t, J = 7.2 Hz, 3H). MH+ 553.
Example 283
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazoI-3-yl)-5-(l-methylcycl opropyl)-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J - 2.0 Hz, IH), 7.34 (d, J = 8.4 HZ, IH), 7.32-7.27 (m, 3H), 7.13-7.09 (m, 2H), 2.84 (q, J = 7.6 Hz, 2H), 1.61 (s, 3H), 1.40 (dd, J = 4.4, 6.8 Hz, 2H), 1.21 (t, J = 7.6 Hz, 3H), 0.95 (dd, J = 4.4, 6.8 Hz, 2H). MH+ 473.
Example 284
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(cyclopropy Imethyl)cyclopropyl)-l,3i4-oxadiazole
MH+ 513.
Example 285
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazoI-3-yl)-5-(l-(cycloprop ylmethyl)cyclopropyl)-l,3»4-oxadiazole
MH+ 557. Example 286 l-(l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,354-oxa diazol-2-yl)cyclopropyl)ethanone
1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 0.4, 2.4 Hz, IH), 7.36-7.30 (m, 4H), 7.13-7.09 (m, 2H), 2.46 (s, 3H), 2.35 (s, 3H), 1.78 (dd, J = 4.8, 8.4 Hz, 2H), 1.66 (dd, J = 4.8, 8.4 Hz, 2H). MH+ 487.
Example 287 2-(l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-oxa diazol-2-yl)cyclopropyl)propan-2-ol
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.0, IH), 7.35-7.28 (m, 4H), 7.10-7.08 (m, 2H),
2.42 (s, 3H), 1.39 (s, 6H), 1.33-1.30 (m, 2H), 1.27-1.23 (m, 2H).
MH+ 503.
Example 288 l-(l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-oxa diazol-2-yl)cyclopropyI)ethanoI
1H NMR (400 MHz, CDCl3) δ 7.41-7.41 (m, IH), 7.35-7.29 (m, 4H), 7.12-7.08 (m, 2H), 3.86 (q, J = 6.4 Hz, IH), 2.42 (s, 3H), 1.38 (d, J = 6.4 Hz, 3H), 1.33-1.30 (m, 2H), 1.27-1.23
(m, 2H).
MH+ 489.
Example 289 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(l-fluoroe thyl)cyclopropyl)-l,3,4-oxadiazole
MH+ 491.
Example 290 N-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyl)-N-methylethanamine
To the suspension of bromide (33) (150 mg, 0.28 mmol) in CH3CN (5 mL) was added N-ethylmethylamine (30 μL, 0.33 mmol) and DIPEA (63 μL, 0.36 mmol). The reaction mixture was stirred for 12 hrs at room temperature. H2O (25 mL) was added to the reaction mixture and then extracted with EtOAc (5OmL). The organic extract was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by Prep-LC (Gilson) provided 83mg (58%) of desired amine as solid.
1H NMR (400 MHz, CDCl3) δ 7.42-7.27 (m, 7H), 3.78 (s, 2H), 2.51-2.43 (m, 2H), 2.13 (s, 3H), 1.51 (s, 9H), 0.99 (t, J = 6.8 Hz, 3H). MH+ 518.
Example 291
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(piperidin-l-ylmethyl)-lH- pyrazol-3-yl)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.26 (m, 7H), 3.58 (s, 2H), 2.38 (br s, 4H), 1.60-1.45 (m, 15H). MH+ 546.
Example 292
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(pyrrolidin-l-ylmethyl)-lH -py razol-3-y I)- 1 ,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.45-7.29 (m, 7H), 4.91 (s, 2H), 3.60-3.49 (m, 4H), 1.99-1.90 (m, 4H), 1.51 (s, 9H). MH+ 532.
Example 293 4-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyl)morpholine
1H NMR (400 MHz, CDCl3) δ 7.43-7.41 (m, IH), 7.38-7.27 (m, 4H), 6.98-6.81 (m, 2H), 4.92 (s, 2H), 3.77-3.51 (m, 8H), 2.51-2.39 (m, 8H), 1.50 (s, 9H). MH+ 548.
Example 294
N-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyl)-2-methylpropan-2-amine
1U NMR (400 MHz, CDCl3) δ 7.47-7.28 (m, 7H), 4.01 (s, 2H), 3.03 (s, IH), 1.51 (s, 9H), 1.10 (s, 9H). MH+ 534.
Example 295 N-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyl)propan-2-amine
1H NMR (400 MHz, CDCl3) δ 7.43-7.31 (m, 7H), 3.95 (s, 2H), 3.20-3.07 (m, IH), 1.51 (s, 9H), 1.05 (s, 6H). MH+ 518.
Example 296
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-tert-butyl-l,3,4-oxadiazole
NaH (15 mg, 0.36 mmol, 60% dispersion in mineral oil) was added to the solution of
1,2,4-triazole (23 mg, 0.33 mmol) in THF (5mL) at 0°C . The reaction mixture was stirred for 30 min at 0°C . The solution of bromide (33) (150 mg, 0.28 mmol) in THF (5 mL) was added to the reaction mixture. The reaction mixture was warmed up to room temperature and stirreded for 12 hrs at room temperature. H2O (25 mL) was added to the reaction mixture and then extracted with EtOAc (5OmL). The organic extract was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by Prep-LC (Gilson) provided 70mg (47%) of desired product as solid.
1H NMR (400 MHz, CDCl3) δ 8.79 (s, IH), 7.99 (s, IH), 7.49-7.44 (m, 3H), 7.49-7.29 (m, 4H), 5.59 (s, 2H), 1.48 (s, 9H). MH+ 530.
Example 297
2-(4-((lH-imidazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol -3-yl)-5-tert-butyl-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.59 (s, IH), 7.43-7.33 (m, 5H), 7.10-7.05 (m, 2H), 7.01 (t, J = 6.8 Hz, IH), 6.92 (t, J = 1.2 Hz, IH), 5.47 (s, 2H), 1.49 (s, 9H). MH+ 527. Example 298
2-(4-((lH-pyrazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-
3-yl)-5-tert-butyl-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.78 (d, J - 2.0 Hz, IH), 7.49-7.47 (m, IH), 7.42-7.28 (m, 7H), 6.18 (t, J = 2.0 Hz, IH), 5.54 (s, 2H), 1.47 (s, 9H). MH+ 527.
Example 299
2-(4-((lH-pyrrol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3- yl)-5-tert-butyl-l ,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.27 (m, 7H), 6.45-6.39 (m, 2H), 5.92-5.85 (m, 2H), 5.53 (s, 2H), 1.51 (s, 9H). MH+ 528.
Example 300
2-(4-((lH-tetrazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol- 3-yl)-5-tert-butyl-l,3,4-oxadiazoIe
1H NMR (400 MHz, CDCl3) δ 8.43 (s, IH), 7.44-7.43 (m, IH), 7.36 (d, J - 0.4 Hz, IH), 7.33 (d, J - 2.4 Hz, IH), 7.31-7.27 (m, 2H), 7.16-7.13 (m, 2H), 6.07 (s, 2H), 1.47 (s, 9H). MH+ 531.
Example 301
2-(4-((lH-tetrazoI-l-yl)methyl)-5-(4-chloroplienyl)-l-(2,4-diclilorophenyl)-lH-pyrazol-
3-yl)-5-tert-butyl-l,3.4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 9.26 (s, IH), 7.46-7.29 (m, 7H), 5.777 (s, 2H), 1.49 (s, 9H). MH+ 531.
Example 302
2-(4-((2H-tetrazol-2-yI)methyI)-5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol- 3-yl)-5-tert-butyl-l,3»4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 8.43 (s, IH), 7.49-7.31 (m, 5H), 7.09-7.03 (m, 2H), 6.07 (s, 2H), 1.47 (s, 9H). MH+ 573. Example 303
2-(4-((lH-tetrazol-l-yl)methyI)-5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-
3-yl)-5-tert-butyl-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 9.26 (s, IH), 7.52-7.31 (m, 7H), 5.77 (s, 2H), 1.48 (s, 9H). MH+ 573.
Example 304
2-(4-((lH-l,2,3-triazoI-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-lH-pyra zol-3-yl)-5-tert-butyl-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 8.21 (d, J = 1.2 Hz, IH), 7.66 (d, J = 0.8 Hz, IH), 7.44 (dd, J = 1.6 Hz, 0.8 Hz, IH), 7.42-7.29 (m, 6H), 5.76 (s, 2H), 1.48 (s, 9H). MH+ 530.
Example 305 l-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yI)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyl)pyrrolidine-2,5-dione
To the suspension of bromide (33) (150 mg, 0.28 mmol) in acetone (10 mL) was added succimide (35 mg, 0.33 mmol) and K2CO3 (60mg, 0.42 mmol). The reaction mixture was refluxed for 12 hrs and cooled to room temperature. H2O (25 mL) was added to the reaction mixture and then extracted with EtOAc (5OmL). The organic extract was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by Prep-LC (Gilson) provided 99mg (64%) of desired product as solid.
1H NMR (400 MHz, CDCl3) δ 7.36-7.16 (m, 7H), 4.99 (s, 2H), 2.33 (s, 4H), 1.47 (s, 9H). MH+ 560.
Example 306 l-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyI)pyrrolidin-2-one
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 2.0 Hz, IH), 7.36-7.27 (m, 4H), 7.13-7.09 (m, 2H), 4.87 (s, 2H), 3.26 (t, J = 6.8 Hz, 2H), 2.12 (t, J = 8.0 Hz, 2H), 1.68-1.65 (m, 2H), 1.50 (s, 9H). MH+ 544. Example 307
3-((3-(5-tert-butyl-l,3,4-oxadiazoI-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)methyl)oxazolidin-2-one 1H NMR (400 MHz, CDCl3) δ 7.45-7.41 (m, IH), 7.37-7.28 (m, 4H), 7.18-7.15 (m, 2H), 4.75 (s, 2H), 4.13 (t, J = 8.0 Hz, 2H), 3.62 (t, J = 8.0 Hz, 2H), 1.50 (s, 9H). MH+ 546.
Example 308 S-(3-(5-tert-butyl-l,3,4-oxadiazoI-2-yl)-5-(4-chIorophenyl)-l-(2,4-dichlorophenyI)-lH-p yrazol-4-yl)methyl ethanethioate
To the solution of bromide (33) (150 mg, 0.28 mmol) in DMF (3 mL) was added
KSAc (48 mg, 0.42 mmol). The reaction mixture was refluxed for 12 hrs at room temperature. The reaction mixture was diluted with EtOAc (25mL) and washed with brine.
The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo.
Purification by Prep-LC (Gilson) provided 45mg (30%) of desired thioacetate as solid.
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.4 Hz, IH), 7.38-7.26 (m, 5H), 7.16-7.12 (m, 2H), 4.40 (s, 2H), 2.26 (s, 3H), 1.49 (s, 9H). MH+ 535.
Example 309
(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-4-yl)methanethiol
To the solution of thioacetate (47) (337 mg, 0.63 mmol) in H2O/l,4-dioxane/THF (5 mL/5 mL/5 mL) was added NaOH (100 mg, 2.52 mmol). The reaction mixture was stirred for 12 hrs at room temperature. The reaction mixture was diluted with aq. saturated NH4Cl solution and extracted with EtOAc. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by normal phase column chromatography (Biotage) provided 93 mg (30 %) of desired thiol as solid.
1H NMR (400 MHz, CDCl3) δ 7.42-7.37 (m, 2H), 7.34-7.27 (m, 3H), 7.25-7.21 (m, 2H), 4.03 (s, 2H), 3.69 (s, IH), 1.48 (s, 9H). MH+ 493.
Example 310 2-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-p yrazol-4-yl)acetonitrile
To the solution of bromide (33) (1.0 g, 1.85 mmol) in CH3CN (2OmL) was added KCN (0.24g, 3.70 mmol) and 18-crown-6 (0.20 g, 0.74 mmol). The reaction mixture was refluxed for 12 hrs. The reaction mixture was cooled to room temperature and diluted with brine. The aqueous layer was extracted with EtOAc. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by normal phase column chromatography (Biotage) provided 0.66 g (74 %) of desired cyanide as solid.
1H NMR (400 MHz, CDCl3) δ 7.45-7.32 (m, 5H), 7.21-7.18 (m, 2H), 4.05 (s, 2H), 1.51 (s, 9H). MH+ 488.
Example 311 2-tert-butyl-5-(l-(2,4-dichlorophenyl)-5-(4-(methylthio)phenyl)-4-(methylthiomethyl)-l H-pyrazol-3-yl)-l,3.4-oxadiazole
To the solution of bromide (33) (150 mg, 0.28 mmol) in DMF (3 mL) was added NaSMe (28 mg, 0.36 mmol). The reaction mixture was heated for 12 hrs at 100°C and then cooled to room temperature. The reaction mixture was diluted with EtOAc (25mL) and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by Prep-LC (Gilson) provided 51mg (35%) of desired disulfide as solid.
1H NMR (400 MHz, CDCl3) δ 7.34-7.26 (m, 5H), 7.19-7.16 (m, IH), 7.15-7.10 (m, IH), 4.03 (s, 2H), 2.47 (s, 3H), 2.08 (s, 3H), 1.49 (s, 9H). MH+ 519.
Example 312 Step : 1 ethyl 4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chIorophenyl)-l-(2,4-dichloro phenyl)-lH-pyrazole-3-carboxyIate
NaH (0.37 g, 9.21 mmol, 60% dispersion in mineral oil) was added to the solution of
1,2,4-triazole (0.51 g, 7.37 mmol) in THF (3OmL) at 0"C . The reaction mixture was stirred for lhr at 0°C . The solution of bromide (61) (3 g, 6.14 mmol) in THF (15 mL) was added to the reaction mixture. The reaction mixture was warmed up to room temperature, stirreded for lhr at room temperature and for 12 hrs at 45 °C . The reaction mixture was cooled to room temperature. H2O (100 mL) was added to the reaction mixture and then extracted with EtOAc (15OmL). The organic extract was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (Biotage, Eluent : 12% EtOAc / Hexane-* EtOAc (Gradient)) provided 1.35 g (46%) of desired triazole (62) as solid.
1H NMR (400 MHz, CDCl3) δ 8.76 (s, IH), 8.09 (s, IH), 7.41-7.27 (m, 7H), 5.48 (s, 2H), 4.44 (quartet, J = 7.2 Hz, 2H), 1.398 (t, J = 7.2 Hz, 3H). MH+ 478.
Step 2:
4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol e-3-carboxylic acid
To the solution of bromide (62) (500 mg, 1.05 mmol) in THF (5 mL) / H2O (15 mL) was added LiOH monohydrate (132 mg, 3.15 mmol). The reaction mixture was refluxed for 2 hrs and cooled to room temperature. The reaction mixture was acidified with aq. IN HCl solution and extracted with 30% MeOH / CHCl3. The organic extract was dried over anhydrous MgSO4, filtered, concentrated and dried in vacuo to provide 470 mg (100%) of desired acid (63) as solid. The obtained acid was used without further purification.
Step 3:
4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-N'-pivaloyl -lH-pyrazole-3-carbohydrazide To the solution of acid (63) (330 mg, 0.74 mmol) in CH2Cl2 (10 mL) was added oxalyl chloride (77 μL, 0.88 mmol) and the catalytic amount of DMF. The reaction mixture was stirred for 1 hr and concentrated in vacuo. The residue (crude acyl chloride) was diluted with CH2Cl2 (10 mL) and pivalohydrazide (128 mg, 1.10 mmol) and triethylamine (0.31 mL, 2.21 mmol) was added. The reaction mixture was stirred for 2 hrs at room temperature. The reaction mixture was concentrated in vacuo and diluted with EtOAc (5OmL). The organic layer was washed with aq. IN HCl and aq. sat'd NaHCO3 solution, dried over anhydrous
MgSO4, filtered, and concentrated in vacuo. Purification by Prep-LC (Gilson) provided
244mg (61%) of desired diamide as solid.
Step 4:
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-tert-butyl-l,3,4-oxadiazole
A solution of diamide (200mg, 0.37 mmol) and Burgess reagent (217 mg, 0.91 mmol) in THF (3 mL) was irradiated in a microwave reactor (Biotage) for lhr at 160°C . Purification by Prep-LC (Gilson) provided 155mg (79%) of desired oxadiazole as solid.
Example 313 2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-(4-chIorophenyl)cyclopropyl)-l,3»4-oxadiazoIe
1H NMR (400 MHz, CDCl3) δ 8.76 (s, IH), 7.99 (s, IH), 7.46-7.28 (m, 1 IH), 5.54 (s, 2H),
1.78 (m, 2H), 1.47 (m, 2H).
MH+ 624.
Example 314
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chIorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-(trifluoromethyl)cyclopropyl)-l,3»4-oxadiazole
1H NMR (400 MHz, DMSO-(I6) δ 8.43 (s, IH), 7.88 (s, IH), 7.85 (d, J = 8.0 Hz, IH), 7.80 (d, J = 2.0 Hz, IH), 7.60 (dd, J = 8.4 Hz, 2.4 Hz, IH), 7.50-7.39 (m, 4H), 5.52 (s, 2H), 1.66
(s, 4H).
MH+ 582.
Example 315 2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-cyclobutyl-l,3>4-oxadiazole
1H NMR (400 MHz, DMSO-Cl6) δ 8.45 (s, IH), 7.89 (s, IH), 7.88-7.80 (m, 2H), 7.59 (dd, J = 8.4 Hz, 2.4 Hz, IH), 7.50-7.39 (m, 4H), 5.53 (s, 2H), 3.95-3.89 (m, IH), 2.47-2.30 (m, 4H), 2.15-1.87 (m, 2H). MH+ 528.
Example 316
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-cyclohexyl-l,3,4-oxadiazole
1H NMR (400 MHz, DMSO-d6) δ 8.45 (s, IH), 7.89 (s, IH), 7.85-7.78 (m, 2H), 7.59 (dd, J
- 8.4 Hz, 2.4 Hz, IH), 7.51-7.38 (m, 4H), 5.52 (s, 2H), 3.08-2.99 (m, IH), 2.07-1.97 (m,
2H), 1.79-1.69 (m, 2H), 1.68-1.33 (m, 6H).
MH+ 556.
Example 317
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-phenylcyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, DMSO-Cl6) δ 8.38 (s, IH), 7.94 (s, IH), 7.89-7.78 (m, 2H), 7.60-7.55 (m, IH), 7.48-7.26 (m, 8H), 5.52 (s, 2H), 1.69-1.64 (m, 2H), 1.55-1.47 (m, 2H).
MH+ 588.
Example 318
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-p-tolylcyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, DMSOd6) δ 8.37 (s, IH), 7.88 (s, IH), 7.84-7.76 (m, 2H), 7.57 (dd, J
= 8.4 Hz, 2.4 Hz, IH), 7.48-7.43 (m, 2H), 7.43-7.36 (m, 8H), 7.30-7.24 (m, 2H), 7.18-7.12
(m, 2H), 5.52 (s, 2H), 2.26 (s, 3H), 1.65-1.59 (m, 2H), 1.48-1.41 (m, 2H).
MH+ 603.
Example 319
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-S-yO-S-Cl^-methoxyphenyOcyclopropyO-ljS^-oxadiazole
1H NMR (400 MHz, DMSO-(I6) δ 8.38 (s, IH), 7.88 (s, IH), 7.85-7.74 (m, 2H), 7.57 (dd, J = 8.4 Hz, 2.4 Hz, IH), 7.50-7.29 (m, 6H), 6.91-6.84 (m, 2H), 5.47 (s, 2H), 3.72 (s, 3H), 1.65-1.56 (m, 2H), 1.46-1.39 (m, 2H). MH+ 619.
Example 320
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-lH-pyra zol-3-yl)-5-(l-(2,4-dichlorophenyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, DMSO-de) δ 8.37 (s, IH), 7.87 (s, IH), 7.82 (d, J = 8.4 Hz, IH), 7.77 (d, J = 2.4 Hz, IH), 7.65 (d, J = 2.0 Hz, IH), 7.60 (d, J = 8.4 Hz, IH), 7.57 (dd, J = 8.4 Hz, 2.4 Hz, IH), 7.49-7.25 (m, 5H), 5.46 (s, 2H), 1.83-1.74 (m, 2H), 1.60-1.51 (m, 2H). MH+ 656.
Example 321
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-(trifluoromethyl)cyclobutyl)-l,3,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 8.47 (s, IH), 7.91 (s, IH), 7.89-7.79 (m, 2H), 7.61 (dd, J = 8.4 Hz, 2.4 Hz, IH), 7.51-7.39 (m, 4H), 5.54 (s, 2H), 2.81-2.63 (m, 4H), 2.15-2.03 (m, 4H). MH+ 594.
Example 322
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-(4-chlorophenyl)cyclobutyl)-l,3»4-oxadiazole
1K NMR (300 MHz, CDCl3) δ 8.42 (s, IH), 7.89 (s, IH), 7.86-7.75 (m, 2H), 7.58 (dd, J = 8.7 Hz, 2.1 Hz, IH), 7.50-7.31 (m, 8H), 5.49 (s, 2H), 3.01-2.83 (m, 2H), 2.76-2.62 (m, 2H), 2.15-1.85 (m, 2H). MH+ 636.
Example 323
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-phenylcyclopentyl)-l,3,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 8.41 (s, IH), 7.88 (s, IH), 7.85-7.76 (m, 2H), 7.57 (dd, J = 8.7 Hz, 2.1 Hz, IH), 7.50-7.31 (m, 9H), 5.48 (s, 2H), 2.73-2.65 (m, 2H), 2.21-2.11 (m, 2H), 1.80-1.65 (m, 4H). MH+ 618. Example 324 l^-^lH-ljZ^-triazol-l-y^methyO-S^-chloropheny^-l^^-dichlorophenylJ-lH-pyra zol-3-yl)-5-(l-(4-chlorophenyl)cyclopentyl)-l,3,4-oxadiazole 1H NMR (300 MHz, CDCl3) δ 8.42 (s, IH), 7.88 (s, IH), 7.86-7.77 (m, 2H), 7.58 (dd, J - 8.7 Hz, 2.1 Hz, IH), 7.52-7.31 (m, 8H), 5.48 (s, 2H), 2.74-2.63 (2H), 2.20-2.09 (m, 2H), 1.84-1.62 (m, 4H). MH+ 650.
Example 325
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-l-(2-chlorophenyl)-5-(4-chlorophenyl)-lH-pyrazol- 3-yl)-5-tert-butyl-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 8.88 (s, IH), 8.05 (s, IH), 7.49-7.32 (m, 8H), 5.64 (s, 2H), 1.51 (s, 9H), 1.45 (s, 9H). MH+ 494.
Example 326
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-methylcyclopropyl)-l,3j4-oxadiazole 1H NMR (400 MHz, DMSO-(I6) δ 8.41 (s, IH), 7.89 (s, IH), 7.83 (d, J = 8.8 Hz, IH), 7.60 (d, J = 2.4 Hz, IH), 7.59 (dd, J = 8.8 Hz, 2.4 Hz, IH), 7.50-7.76 (m, 4H), 5.50 (s, 2H), 1.50 (s, 3H), 1.26-1.19 (m, 2H), 1.05-0.99 (m, 2H). MH+ 528.
Example 327
2-(4-((lH-l,2,4-triazol-l-yI)methyl)-5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-S-ylJ-S-Cl-^rifluoromethy^cyclopropylJ-ljS^-oxadiazole
1H NMR (400 MHz, DMSOd6) δ 8.43 (s, IH), 7.89 (s, IH), 7.85 (d, J = 8.8 Hz, IH), 7.80 (d, J = 2.4 Hz, IH), 7.63-7.55 (m, 3H), 7.38-7.30 (m, 2H), 5.52 (s, 2H), 1.73 (s, 4H). MH+ 624.
Example 328
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-3-yl)-5-(l-(4-chlorophenyl)cyclopropyl)-l,3>4-oxadiazole 1H NMR (400 MHz, DMSO-Cl6) δ 8.39 (s, IH), 7.88 (s, IH), 7.81 (d, J = 8.4 Hz, IH), 7.77 (d, J = 2.4 Hz, IH), 7.63-7.43 (m, 3H), 7.47-7.39 (m, 4H), 7.35-7.29 (m, 2H), 5.48 (s, 2H), 1.70-1.63 (m, 2H), 1.53-1.46 (m, 2H). MH+ 666.
Example 329
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-3-yl)-5-tert-butyl-l,3j4-oxadiazole
1H NMR (400 MHz, DMSO-Cl6) δ 8.44 (s, IH), 7.89 (s, IH), 7.85 (d, J - 8.8 Hz, IH), 7.79 (d, J = 2.0 Hz, IH), 7.63-7.57 (m, 3H), 7.37-7.31 (m, 2H), 5.51 (s, 2H), 1.37 (s, 9H). MH+ 572.
Example 330
2-(4-((lH-tetrazol-5-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol- 3-yl)-5-tert-butyl-l,3?4-oxadiazole
To the solution of cyanide (200 mg, 0.41 mmol) in DMF (2 mL) was added NaN3 (320 mg, 4.93 mmol) and NH4Cl (264 mg, 4.93 mmol) and the reaction mixture was irradiated in a microwave reactor (Biotage) for 20 min at 180°C . The reaction mixture was cooled to room temperature and diluted with 30 % MeOH / CHCl3. The organic layer was washed with aq. saturated NaHCO3 solution. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification by Prep-LC (Gilson) provided 87mg (40 %) of desired tetrazole as solid.
1H NMR (400 MHz, CDCl3) δ 7.46-7.28 (m, 7H), 4.34 (s, 2H), 2.91 (d, J = 29.2 Hz, IH), 1.54 (s, 9H). MH+ 529.
Example 331 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-((2-methyl-2H-tetrazol-5-yl )methyl)-lH-pyrazol-3-yl)-l,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.42 (m, 3H), 7.35-7.29 (m, 4H), 4.32 (s, 2H), 4.25 (s, 3H), 1.45 (s, 9H). MH+ 543. Example 332
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-((l-methyl-lH-tetrazol-5-yl
)methyl)-lH-pyrazol-3-yl)-l,3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.42-7.37 (m, 2H), 7.31-7.23 (m, 3H)5 7.18-7.14 (m, 2H), 4.48 (s, 2H), 4.22 (s, 3H), 1.45 (s, 9H). MH+ 543.
Example 333 2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclobutyl-l, 3,4-oxadiazole
Step 1: Ethyl 4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazole-3-carboxylate To a solution of ethyl 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazole-
3-carboxylate (3.0 g, 7.6 mmol) in acetic acid (30 ml) at room temperature was bubbled chlorine gas for 10 minutes. The reaction mixture was stirred at room temperature for 2 hours and the resulting solution was quenched with water (100 ml). The organic solution was extracted with diethyl ether (100 ml x 2). With saturated sodium bicarbonate solution, remained acetic acid was removed and organic phase was evaporated with reduced pressure. The crude residue was purified with silica gel column (hexane/ethyl acetate = 5/1) to produce title compound (3.1 g, 95% yield) as white solid.
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.0 Hz, IH), 7.38 (d, J = 8.4 Hz, IH), 7.35-7.32 (m, 3H), 7.20-7.18 (m, 2H), 4.48 (q, J = 7.2 Hz, 2H), 1.44 (t, J = 7.2 Hz, 3H). MH+ 430.
Step 2: 4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazole-3-carboliydrazide
A solution of ethyl 4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH- pyrazole-3-carboxylate (3.1 g, 7.2 mmol) in ethyl alcohol (30 ml) was added hydrazine (5 ml, 64% solution in water) in one portion. The reaction mixture was refluxed 100°C for 6 hours, and then cooled down to room temperature. After volatile solvent was removed in reduced pressure, the residue was purified with silica gel column (5% methanol in methylene chloride) to obtained title compound (3 g, quantitatively) as slightly yellow solid. MH+ 415.
Step 3:
2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-lH-pyrazol-3-yl)-5-cyclobutyI-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.38 (m, IH), 7.40-7.33 (m, 4H), 7.25-7.22 (m, 2H), 4.06-4.02 (m, IH), 2.61-2.57 (m, 2H), 2.54-2.48 (m, 2H), 2.18-2.07 (m, 2H). MH+ 481.
Example 334
2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-tert-pentyl-l
,3,4-oxadiazole 1B. NMR (400 MHz, CDCl3) δ 7.45-7.44 (m, IH), 7.38-7.33 (m, 4H), 7.26-7.22 (m, 2H), 1.86 (q, J = 7.2 Hz, 2H), 1.56 (s, 3H), 1.50 (s, 3H), 0.89 (t, J = 7.2 Hz, 3H). MH+ 497.
Example 335 2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclohexyl-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.40 (m, 2H), 7.38-7.33 (m, 3H), 7.26-7.22 (m, 2H),
3.26-3.24 (m, IH), 2.20-1.86 (m, 4H), 1.58-1.44 (m, 6H).
MH+ 509.
Example 336
2-sec-butyl-5-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichloroplienyl)-lH-pyrazol-3-yl)-l,3
,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.41 (m, 2H), 7.38-7.26 (m, 3H), 7.25-7.22 (m, 2H), 3.39-3.34 (m, IH), 1.87-1.75 (m, 2H), 1.46 (d, J = 6.8 Hz, 3H), 0.99 (t, J = 7.2 Hz).
MH+ 483.
Example 337 2-tert-butyI-5-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.41 (m, 2H), 7.39-7.24 (m, 3H), 7.23-7.19 (m, 2H), 1.57 (s, 9H). MH+ 483.
Example 338
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-tert-butyl-l,
3,4-oxadiazole
Step 1:
4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazole-3-carboxylic acid
To a solution of ethyl 4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazole-3-carboxylate (3.5 g, 7.37 mmol) in methanol (50 ml) at room temperature was added potassium hydroxide (830 mg, 14.8 mmol) in one portion. The reaction mixture was warmed to 100°C and then stirred for 5 hours. The resulting solution was cooled down to room temperature and then evaporated the volatile solvent. The residue was acidified with 10% hydrochloric acid and then filtered using water and hexane. The filtrated solid was dried under vacuum to obtain the title compound (3.2 g, 97%) as pale yellow solid. MH+ 446.
Step 2:
2-(4-bromo-5-(4-chIorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-tert-butyl-l,
3,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.50-7.41 (m, 2H), 7.37-7.24 (m, 3H), 7.23-7.19 (m, 2H), 1.57 (s, 9H). MH+ 527.
Example 339 2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-sec-butyl-l,3 ,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.40-7.37 (m, IH), 7.35-7.32 (m, 3H), 7.25-7.21 (m, 2H), 3.14-3.10 (m, IH), 1.96-1.90 (m, IH), 1.79-1.71 (m, IH), 1.43 (dd, J = 2.8, 7.2 Hz, 3H), 0.91 (m, 3H). MH+ 527.
Example 340
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclobutyl-l, 3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 2.0 Hz, IH), 7.38 (d, J = 8.8 Hz, IH), 7.35-7.32 (m, 3H), 7.25-7.21 (m, 2H), 3.87-3.78 (m, IH), 2.60-2.42 (m, 4H), 2.17-2.05 (m, 2H). MH+ 525.
Example 341
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclohexyl-l ,3,4-oxadiazoIe
1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 2.0, 3.6 Hz, IH), 7.38 (dd, J = 3.2, 8.4 Hz, IH), 7.36-7.32 (m, 3H), 7.26-7.21 (m, 2H), 3.04-2.98 (m, IH), 2.16-2.12 (m, 2H), 1.86-1.76 (m, 2H), 1.73-1.67 (m, 3H), 1.45-1.33 (m, 3H). MH+ 553.
Example 342
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-tert-pentyl-l ,3>4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.39 (m, 2H), 7.35-7.32 (m, 3H), 7.23-7.21 (m, 2H),
1.58-1.68 (dq, J = 7.6, 49.2 Hz, 2H), 1.46 (s, 3H), 1.36 (s, 3H), 0.90-0.78 (dt, J = 7.6, 31.6
Hz, 3H).
MH+ 541.
Example 343
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-(2-(4-chloro phenyl)propan-2-yl)-l,354-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.37 (m, IH), 7.35-7.10 (m, 4H), 7.29-7.27 (m, 3H), 7.24-7.18 (m, 2H), 7.12-7.09 (m, IH), 1.88 (s, 3H), 1.72 (s, 3H)
MH+ 623.
Example 344 2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclopropyl)-l,3,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.41 (m, IH), 7.37-7.32 (m, 4H), 7.27-7.24 (m, 3H), 7.21-7.18 (m, 2H), 7.12-7.08 (m, IH), 1.96 (dd, J = 9.2, 6.7 Hz, 2H), 1.45 (dd, J = 9.2, 6.7 Hz, 2H) MH+ 621.
Preparation of 1,3,4-thiadiazole (formula (Ib))
Example 345 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cycIobutyl-l ,3,4-thiadiazole
N-cyclobutanoyl-N'-[5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyra zole-3-carbonyl] -hydrazine (0.14 g, 0.29 mmol) was added to a microwave reactor containing Lawesson's reagent (0.18 g, 0.44 mmol) in 1,4-dioxane (3 mL). The capped reactor was placed into a microwave reactor and the mixture was heated at 180°C for 15 min, and the process was repeated one more time. The reaction mixture was then purified by preparative HPLC to provide the title compound (60 mg, 0.16 mmol, 43%) as yellow solid.
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 2.3 Hz, IH), 7.34-7.28 (m, 4H), 7.13-7.09 (m, 2H), 4.01 (m, IH), 2.62-2.52 (m, 2H), 2.49 (s, 3H), 2.47-2.39 (m, 2H), 2.20-2.00 (m, 2H). MH+ 475.
The following compounds of Examples 346 to 547 were obtained by using corresponding starting materials and repeating the procedure of Example 345.
Example 346
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopentyl- 1 ,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 1.84 Hz, IH), 7.34- 7.28 (m, 4H), 7.11 (dt, J = 2.28, 8.24 Hz, 2H), 3.60 (m, IH), 2.49 (s, 3H), 2.26 (m, 2H), 1.94-1.81 (m, 4H), 1.74 (m, 2H). MH+ 489. Example 347
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-cyclohexyl-l
,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 1.84 Hz, IH), 7.37- 7.29 (m, 4H), 7.11 (dt, J = 2.28, 8.24 Hz, 2H), 2.99 (m, IH), 2.44 (s, 3H), 2.16-2.12 (m, 2H), 1.87-1.81 (m, 2H), 1.78-1.65 (m, 3H), 1.44-1.28 (m, 3H). MH+ 487.
Example 348 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopropyl- 1 ,3?4-thiadiazole
MH+ 461.
Example 349 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(furan-2-yl)- 1,3,4-thiadiazole
MH+ 486.
Example 350 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pyrazin-2-y l)-l,3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 9.64 (d, J = 1.40 Hz, IH), 8.67 (d, J = 2.28 Hz, IH), 8.64 (dd, J = 1.40, 2.32 Hz, IH), 7.44 (d, J = 1.84 Hz, IH). , 7.36-7.29 (m, 4H), 7.15-7.11 (m, 2H), 2.56 (s, 3H). MH+ 499.
Example 351
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyrazol-3-yl)-
5-(thiophen-2-yl)-l,3,4-thiadiazoIe 1H-NMR (400 MHz, CDCl3) δ 7.58 (dd, J = 0.92, 3.68 Hz, IH), 7.50 (dd, J = 1.36, 5.04 Hz, IH), 7.44 (d, J = 1.84 Hz, IH) , 7.36-7.29 (m, 4H), 7.15-7.11 (m, 3H), 2.52 (s, 3H). MH+ 503.
Example 352 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)- 5-(pyridin-2-ylmethyl)-l,3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 8.59 (d, J = 5.04 Hz, IH), 7.66 (dt, J = 1.84, 7.76 Hz, IH) , 7.41 (d, J = 1.84 Hz, IH), 7.36 (d, J = 7.76 Hz, IH), 7.33-7.28 (m, 4H), 7.20 (dd, J = 5.04, 7.32 Hz, IH), 7.13-7.09 (m, 2H), 4.66 (s, 2H), 2.48 (s, 3H). MH+ 512.
Example 353
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)- 5-isopropyl-l,3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.42 (d, J = 1.84 Hz, IH), 7.33-7.28 (m, 3H), 7.13-7.09 (m, 2H), 3.50 (m, IH), 2.49 (s, 3H), 1.47 (d, J = 6.88Hz, 6H). MH+ 463.
Example 354
2-benzyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3>4 -thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.40 (br s, IH), 7.34-7.28 (m, 9H), 7.16-7.12 (m, 2H), 4.45 (s, 2H), 2.48 (s, 3H). MH+ 511.
Example 355
2-Butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-t hiadiazole 1H-NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.34-7.29 (m, 4H), 7.13-7.10 (m, 2H), 3.14 (t, J = 7.8 Hz, 2H), 2.49 (s, 3H), 1.85-1.79 (m, 2H), 1.52-1.42 (m, 2H), 0.97 (t, J = 7.3 Hz, 3H). MH+ 477.
Example 356
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-metliyl-lH-pyrazol-3-yl)-5-plienyl-l,3» 4-thiadiazole
1H-NMR (300 MHz, CDCl3) δ 8.05-8.01 (m, 2H), 7.51-7.48 (m, 3H), 7.45-7.44 (m, IH), 7.35-7.31 (m, 4H), 7.16-7.12 (m, 2H), 2.55 (s, 3H). MH+ 497.
Example 357
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclopenty lmethyl)-l,3,4-thiadiazole
1H-NMR (300 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.35-7.28 (m, 4H), 7.13-7.10 (m, 2H), 3.14 (d, J = 7.5, 2H), 2.50 (s, 3H), 2.36-2.26 (m, IH), 1.88-1.84 (m, 2H), 1.71-1.54 (m, 4H), 1.37-1.25 (m, 2H). MH+ 503.
Example 358
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(tetrahydro
-2H-pyran-4-yl)-l,3.4-thiadiazole
1H-NMR (300 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.35-7.30 (m, 4H), 7.14-7.10 (m, 2H), 4.11-4.07 (m, 2H), 3.63-3.55 (m, 2H), 3.50-3.40 (m, IH), 2.50 (s, 3H), 2.14-2.11 (m, 2H), 2.05-1.92 (m, 2H). MH+ 505.
Example 359 2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(tetrahydro furan-2-yl)-l,3,4-thiadiazole
1H-NMR (300 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.35-7.30 (m, 4H), 7.13-7.10 (m, 2H), 5.43-5.39 (m, IH), 4.11-4.04 (m, IH), 4.00-3.93 (m, IH), 2.52-2.47 (m, IH), 2.49 (s, 3H), 2.37-2.28 (m, IH), 2.09-2.03 (m, 2H). MH+ 491.
Example 360
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-methyl-l,3?4
-thiadiazole 1H-NMR (400 MHz, CDCl3) δ 7.42 (d, J = 1.84 Hz, IH), 7.35-7.29 (m, 4H), 7.13-7.10 (m, 2H), 2.82 (s, 3H), 2.48 (s, 3H). MH+ 435.
Example 361 2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-pentyl-l,3,4 -thiadiazole
1H-NMR (400 MHz, CDCla) δ 7.43-7.42 (m, IH), 7.34-7.29 (m, 4H), 7.13-7.10 (m, 2H), 3.14 (t, J = 7.8 Hz, 2H), 2.49 (s, 3H), 1.88-1.81 (m, 2H), 1.43-1.38 (m, 4H), 0.91 (t, J = 7.3 Hz, 3H). MH+ 491.
Example 362
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cycIoheptyl -1,3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.34-7.31 (m, 4H), 7.13-7.10 (m, 2H), 3.47-3.43 (m, IH), 2.47 (s, 3H), 2.22-2.17 (m, 4H), 1.87-1.79 (m, 4H), 1.70-1.59 (m, 4H). MH+ 517.
Example 363
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2,4-dichlor ophenyl)-l,3,4-thiadiazole
1H-NMR (400 MHz, CDCla) δ 8.40 (d, J = 8.4 Hz, IH), 7.57 (d, J = 2.2 Hz, IH), 7.44 (d, J = 1.8 Hz, IH), 7.42 (d, J =2.2 Hz, IH), 7.37-7.31 (m, 4H), 7.16-7.12 (m, 2H), 2.55 (s, 3H). MH+ 564.
Example 364
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl- 1 ,3,4-thiad iazole 1H-NMR (400 MHz, CDCl3) δ 7.50-7.45 (m, 2H), 7.43-7.42 (m, IH), 7.34-7.28 (m, 2H), 7.07-7.02 (m, 2H), 4.06-3.96 (m, IH), 2.61-2.52 (m, 2H), 2.50 (s, 3H), 2.46-2.38 (m, 2H), 2.18-1.99 (m, 2H). MH+ 519.
Example 365
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclohexyl methyl)-l,3)4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.42 (bs, IH), 7.34-7.29 (m, 4H), 7.12-7.10 (m, 2H), 3.02 (d, J = 6.4 Hz, 2H), 2.50 (s, 3H), 1.82-1.64 (m, 5H), 1.30-1.02 (m, 6H). MH+ 517.
Example 366
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopentyl- 1,3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.43-7.42 (m, IH), 7.34-7.28 (m, 2H),
7.07-7.03 (m, 2H), 3.64-3.57 (m, IH), 2.49 (s, 3H), 2.29-2.21 (m, 2H), 1.94-1.82 (m, 4H),
1.79-1.69 (m, 2H).
MH+ 533.
Example 367
2-sec-Butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,
3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.40-7.28 (m, 4H), 7.13-7.10 (m, 2H), 3.36-3.27 (m, IH), 2.50 (s, 3H), 1.91-1.73 (m, 2H), 1.44 (d, J = 6.9 Hz, 3H), 0.98 (t, J = 7.3
Hz, 3H).
MH+ 477.
Example 368 2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pentan-2-y I)-1, 3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.34-7.28 (m, 4H), 7.13-7.10 (m, 2H), 3.45-3.37 (m, IH), 2.49 (s, 3H), 1.84-1.67 (m, 2H), 1.44 (d, J = 6.9 Hz, 3H), 1.41-1.33 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). MH+ 491.
Example 369
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-butyl-l
,3,4-thiadiazole 1H-NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.43-7.42 (m, IH), 7.33-7.28 (m, 2H), 7.07-7.04 (m, 2H), 2.49 (s, 3H), 1.53 (s, 9H). MH+ 521.
Example 370 2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclopropy lmethyl)-l,3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.34-7.29 (m, 4H), 7.14-7.10 (m, 2H), 3.03 (d, J = 7.3 Hz, 2H), 2.50 (s, 3H), 1.25-1.14 (m, IH), 0.69-0.64 (m, 2H), 0.40-0.35 (m, 2H).
MH+ 475.
Example 371
2-(4-tert-Butylcyclohexyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-p yrazol-3-yl)-l,3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.37-7.28 (m, 4H), 7.13-7.10 (m, 2H),
3.14-3.08 (m, IH), 2.49 (s, 3H), 2.31-2.28 (m, 2H), 1.95-1.92 (m, 2H), 1.66-1.52 (m, 4H),
1.25-1.04 (m, IH), 0.89 (s, 9H).
MH+ 559.
Example 372
2-tert-Butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,
3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.38-7.28 (m, 4H), 7.14-7.10 (m, 2H), 2.50 (s, 3H), 1.53 (s, 9H).
MH+ 477.
Example 373
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl- 1, 3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.50-7.45 (m, 2H), 7.43-7.42 (m, IH), 7.34-7.28 (m, 2H), 7.07-7.03 (m, 2H), 3.22-3.16 (m, IH), 2.49 (s, 3H), 2.22-2.17 (m, 2H), 1.90-1.84 (m, 2H), 1.78-1.28 (m, 6H). MH+ 547.
Example 374
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,
3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.42-7.41 (m, IH), 7.33 (d, J = 8.3 Hz, IH), 7.30-7.28 (m, IH), 7.09-7.05 (m, 2H), 3.21-3.15 (m, IH), 2.95-2.89 (m, 2H), 2.23-2.18 (m, 2H), 1.90-1.84 (m, 2H), 1.78-1.28 (m, 6H), 1.26-1.22 (m, 3H). MH+ 561.
Example 375
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3 ,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.42-7.41 (m, IH), 7.34-7.28 (m, 2H), 7.08-7.05 (m, 2H), 4.05-3.96 (m, IH), 2.95-2.89 (m, 2H), 2.60-2.52 (m, 2H), 2.49-2.39 (m, 2H), 2.18-2.00 (m, 2H), 1.30-1.22 (m, 3H). MH+ 533.
Example 376
2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclopentyl-l, 3,4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.42-7.41 (m, IH), 7.34-7.28 (m, 2H),
7.08-7.05 (m, 2H), 3.64-3.56 (m, IH), 2.95-2.89 (m, 2H), 2.29-2.22 (m, 2H), 1.95-1.82 (m,
4H), 1.79-1.70 (m, 2H), 1.26-1.22 (m, 3H).
MH+ 547.
Example 377 l^S^-BromophenyO-l-CI^-dichloropheny^^-ethyl-lH-pyrazol-S-ylJ-S-tert-butyl-ljS) 4-thiadiazole
1H-NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.42-7.41 (m, IH), 7.34-7.28 (m, 2H), 7.08-7.05 (m, 2H), 2.95-2.89 (m, 2H), 1.56 (s, 9H), 1.28-1.24 (m, 3H).
MH+ 535.
Example 378 2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cycloheptyl- 1, 3,4-thiadiazole
1H-NMR (300 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.43-7.42 (m, IH), 7.35-7.28 (m, 2H), 7.06-7.04 (m, 2H), 3.47-3.37 (m, IH), 2.49 (s, 3H), 2.24-2.18 (m, 2H), 1.87-1.60 (m, 10H). MH+ 561. Example 379
2-(5-(4-ChIorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(hexan-2-yl )-l ,3,4-thiadiazole
1H-NMR (300 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.35-7.28 (m, 4H), 7.13-7.10 (m, 2H), 3.42-3.35 (m, IH), 2.50 (s, 3H), 1.78-1.73 (m, 2H), 1.44 (d, J = 6.7 Hz, 3H), 1.34-1.32 (m, 4H), 0.90-0.85 (m, 3H). MH+ 505.
Example 380 2-(5-(4-Bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(hexan-2-yl) -1,3,4-thiadiazole
1H-NMR (300 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.43-7.42 (m, IH), 7.35-7.28 (m, 2H), 7.07-7.03 (m, 2H), 3.44-3.35 (m, IH), 2.50 (s, 3H), 1.85-1.69 (m, 2H), 4.44 (d, J = 6.7 Hz, 3H), 1.36-1.25 (m, 4H), 0.90-0.85 (m, 3H). MH+ 549.
Example 381
2-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-(l-phenyleth yl)- 1 ,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.40-7.23 (m, 10H), 7.12-7.08 (m, 2H), 4.64 (m, IH), 2.48 (s, 3H), 1.87 (d, J = 7.4 Hz, 3H). MH+ 525.
Example 382 5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-N-cyclohexyl- 1 ,3,4-thiadiazol-2-amine
MH+ 518.
Example 383 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-(cyclohex-3- enyl)-l ,3,4-thiadiazole
MH+ 501.
Example 384 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclopeiit-3 -enyl)-l ,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 1.8 Hz), 7.34-7.28 (m, 4H), 7.15-7.10 (m, 2), 5.80 (s, 2H), 4.05 (m, IH), 4.06 (m, 2H), 4.05 (m, 2H), 2.49 (s, 3H). MH+ 487.
Example 385
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-phenylpr opan-2-yl)-l ,3,4-thiadiazole 1H NMR (300 MHz, CDCl3) δ 7.43 (d, J - 2.34 Hz, 2H), 7.38-7.24 (m, 5H), 7.24-7.19 (m, 3H), 7.12-7.10 (m, 2H), 3.48-3.43 (m, IH), 3.37-3.30 (m, IH), 2.95-2.88 (m, IH), 2.50 (s, 3H), 1.46 (d, J = 6.78 Hz, 3H). MH+ 541.
Example 386
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(cyclohexylme thyl)-l,3,4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.42-7.41 (m, IH), 7.36-7.27 (m, 2H), 7.08-7.05 (m, 2H), 3.02 (d, J = 6.6 Hz, 2H), 2.96-2.88 (m, 2H), 1.85-1.65 (m, 7H), 1.27-1.04 (m, 7H). MH+ 576.
Example 387
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclohexyl methyl)-l,3,4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.50-7.45 (m, 2H), 7.43-7.42 (m, IH), 7.36-7.28 (m, 2H),
7.06-7.03 (m, 2H), 3.03 (d, J = 6.6 Hz, 2H), 2.49 (s, 3H), 1.88-1.62 (m, 7H), 1.23-1.02 (m,
4H).
MH+ 561.
Example 388
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(hexan-2-yl)-l
,3,4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.42-7.41 (m, IH), 7.35-7.27 (m, 2H), 7.09-7.05 (m, 2H), 3.41-3.34 (m, IH), 2.96-2.88 (m, 2H), 1.83-1.73 (m, 2H), 1.44 (d, J = 6.9 Hz, 3H), 1.36-1.23 (m, 7H), 0.90-0.86 (m, 3H). MH+ 563.
Example 389 l-tert-butyl-S-CS^-chloropheny^-l^Z^-dichlorophenyl^-ethyl-lH-pyrazol-S-yO-l^, 4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.35-7.27 (m, 4H), 7.15-7.12 (m, 2H), 2.95-2.88 (m, 2H), 1.53 (s, 9H), 1.26 (t, J = 7.3 Hz, 3H). MH+ 491.
Example 390
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,3
,4-thiadiazole MH+ 517.
Example 391
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-(l-cyclopent ylethyl)-l,3,4-thiadiazole 1H NMR (300 MHz, CDCl3) δ 7.42-7.11 (m, 5H), 7.15-7.11 (m, 2H), 3.12-3.10 (m, IH), 2.44 (s, 3H), 1.90-1.73 (m, IH), 1.70-1.50 (m, 4H), 1.44-1.40 (m, 4H), 1.41 (d, J = 7.0 Hz, 3H). MH+ 519.
Example 392
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-cyclohexy lethyl)-l,3,4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.42-7.11 (m, 5H), 7.09-7.02 (m, 2H), 3.22-3.19 (m, IH), 2.42 (s, 3H), 1.91-1.72 (m, 2H), 1.69-1.50 (m, 5H), 1.44-1.40 (m, 4H), 1.44 (d, J = 7.33 Hz, 3H).
MH+ 531.
Example 393 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-cyclopent ylpropan-2-yl)-l,3,4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.56-7.53 (m, 2H), 7.39-7.33 (m, 2H), 7.25-7.20 (m, 2H), 7.11-7.08 (m, IH), 2.50 (s, 3H), 1.90-1.88 (m, IH), 1.74-1.50 (m, 4H), 1.45 (s, 6H), 1.43-1.40 (m, 4H). MH+ 531.
Example 394
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-cyclohexy lpropan-2-yl)-l,3,4-thiadiazole 1H NMR (300 MHz, CDCl3) θ 7.56-7.53 (m, 2H), 7.38-7.34 (m, 2H), 7.26-7.20 (m, 2H), 7.15-7.12 (m, IH), 2.54 (s, 3H), 1.97-1.87 (m, IH), 1.74-1.50 (m, 6H), 1.44 (s, 6H), 1.43-1.40 (m, 3H). MH+ 547.
Example 395
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,35 4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.35-7.28 (m, 4H), 7.15-7.12 (m, 2H), 4.03-3.98 (m, IH), 2.94-2.89 (m, 2H), 2.60-2.52 (m, 2H), 2.49-2.39 (m, 2H), 2.16-2.01 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H). MH+ 489.
Example 396
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cyclopeiityl-l, 3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.34-7.28 (m, 4H), 7.14-7.12 (m, 2H), 3.62-3.58 (m, IH), 2.94-2.89 (m, 2H), 2.30-2.23 (m, 2H), 1.95-1.70 (m, 6H), 1.25 (t, J = 7.2 Hz, 3H). MH+ 503.
Example 397
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cycloheptyl-l,
3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.34-7.27 (m, 4H), 7.15-7.11 (m, 2H), 3.43-3.38 (m, IH), 2.94-2.89 (m, 2H), 2.24-2.18 (m, 2H), 1.90-1.79 (m, 4H), 1.70-1.57 (m, 6H), 1.24 (t, J = 7.3 Hz, 3H). MH+ 531.
Example 398
2-sec-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,3,4 -thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.34-7.27 (m, 4H), 7.15-7.10 (m, 2H), 3.35-3.26 (m, IH), 2.95-2.89 (m, 2H), 1.92-1.73 (m, 2H), 1.45 (d, J = 6.88 Hz, 3H), 1.25 (t, J = 7.32 Hz, 3H), 0.98 (t, J = 7.36 Hz, 3H). MH+ 491.
Example 399 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-sec-butyl-l,3, 4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.42 (d, J = 1.84 Hz, IH), 7.33 (d, J = 8.28 Hz, IH), 7.29 (dd, J = 8.24, 1.81 Hz, IH), 7.08-7.05 (m, 2H), 3.34-3.28 (m, IH), 2.95-2.89 (m, 2H), 1.90-1.75 (m, 2H), 1.45 (d, J = 6.88 Hz, 3H), 1.25 (t, J = 7.32 Hz, 3H), 1.98 (t, J = 7.32 Hz, 3H). MH+ 535.
Example 400
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-cycloheptyl-l,
3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.41 (d, J = 1.84 Hz, IH), 7.33 (d, J =
8.24 Hz, IH), 7.29 (dd, J = 8.24, 1.84 Hz, IH), 7.10-7.05 (m, 2H), 3.43-3.37 (m, IH),
2.95-2.89 (m, 2H), 2.25-2.19 (m, 2H), 1.90-1.79 (m, 4H), 1.70-1.57 (m, 6H), 1.24 (t, J =
7.32 Hz, 3H).
MH+ 575.
Example 401
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-phenyIpr opan-2-yl)-l,3)4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.38 (m, IH), 7.36-7.27 (m, 7H), 7.26-7.21 (m, IH), 7.11-7.01 (m, 2H), 2.50 (s, 3H), 1.95 (s, 6H). MH+ 539.
Example 402 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazoI-3-yl)-5-(2-(4-chloro phenyl)propan-2-yl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.38 (m, IH), 7.35-7.27 (m, 6H), 7.26-7.21 (m, IH),
7.11-7.09 (m, 2H), 2.50 (s, 3H), 1.91 (s, 6H).
MH+ 575.
Example 403
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-sec-butyl-l,
3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.46 (m, 2H), 7.42 (bs, IH), 7.34-7.29 (m, 2H), 7.06-7.04 (m, 2H), 3.34-3.29 (m, IH), 2.50 (s, 3H), 1.87-1.76 (m, 2H), 1.44 (d, J = 6.8 Hz,
3H), 0.98 (t, J = 7.6 Hz, 3H).
MH+ 522.
Example 404 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(2-phenylprop an-2-yl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.46 (m, 2H), 7.42-7.38 (m, 3H), 7.34-7.30 (m, 2H), 7.27-7.22 (m, 3H), 7.06-7.04 (m, 2H), 2.92-2.90 (m, 2H), 1.94 (s, 6H), 1.27 (t, J = 7.6 Hz, 3H). MH+ 598.
Example 405
2-tert-butyl-5-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4- thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.44-7.24 (m, 6H), 7.18-7.12 (m, 2H), 2.51 (s, 3H), 1.53 (s, 9H). MH+ 443.
Example 406 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazoI-3-yl)-5-(2-methylhe xan-2-yl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (m, IH), 7.35-7.30 (m, 4H), 7.34-7.30 (m, 2H), 2.50 (s, 3H), 1.77 (m, 2H), 1.50 (s, 6H), 1.26 (m, 4H), 0.86 (t, J = 6.8 Hz, 3H). MH+ 519.
Example 407
2-sec-butyl-5-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-t hiadiazole 1H NMR (400 MHz, CDCl3) δ 7.42-7.26 (m, 6H), 7.14-7.09 (m, 2H), 3.31 (sextet, J = 6.8 Hz, IH), 2.50 (s, 3H), 1.80-1.72 (m, 2H), 1.44 (d, J = 7.2 Hz, 3H), 0.97 (t, J = 7.6 Hz, 3H). MH+ 443.
Example 408 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,3,4 -thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.26 (m, 6H), 7.15-7.05 (m, 2H), 3.25-3.17 (m, IH), 2.51 (s, 3H), 2.26-2.17 (m , 2H), 1.93-1.80 (m, 2H), 1.80-1.72 (m, IH), 1.68-1.53 (m, 2H), 1.52-1.38 (m, 2H), 1.38-1.26 (m, IH). MH+ 469.
Example 409
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3)4
-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.43-7.27 (m, 6H), 7.15-7.07 (m, 2H), 4.01 (quintet, J = 8.8 Hz, IH), 2.61-2.38 (m, 7H), 2.19-2.01 (m, 2H). MH+ 441.
Example 410 2-(l-(2-chlorophenyl)-5-(4-chIorophenyl)-4-methyl-lH-pyrazoI-3-yI)-5-tert-peiityl-l,354 -thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.26 (m, 6H), 7.16-7.10 (m, 2H), 2.52 (s, 3H), 1.83 (quartet, J = 7.6 Hz, 2H), 1.46 (s, 6H), 0.87 (t, J = 7.6 Hz, 3H). MH+ 457. Example 411
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(hexan-2-yl)-l,3
,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.42-7.27 (m, 6H), 7.18-7.12 (m, 2H), 3.39 (sextet, J = 6.8 Hz, IH), 2.51 (s, 3H), 1.85-1.69 (m, 3H), 1.44 (d, J = 7.2 Hz, 2H), 1.42-1.25 (m, 4H), 0.89 (t, J = 6.8 Hz, 3H). MH+ 471.
Example 412
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(pentan-2-yl)- 1,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, 2H), 7.34-7.30 (m, 4H), 7.15-7.12 (m, 2H), 3.43-3.38 (m, IH), 2.95-2.90 (m, 2H), 1.84-1.67 (m, 4H), 1.46-1.44 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H), 0.93 (t, J = 7.6 Hz, 3H). MH+ 505.
Example 413
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pentan-2-yl )-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.43-7.42 (m, IH), 7.34-7.31 (m, 2H),
7.06-7.04 (m, 2H), 3.44-3.38 (m, IH), 2.49 (s, 3H), 1.84-1.66 (m, 4H), 1.44 (d, J = 6.8 Hz,
3H), 1.41-1.36 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H).
MH+ 536.
Example 414
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yI)-5-(pentan-2-yl)-
1 ,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.46 (m, 2H), 7.42-7.41 (m, IH), 7.34-7.28 (m, 2H), 7.08-7.06 (m, 2H), 3.43-3.37 (m, IH), 2.95-2.89 (m, 2H), 1.83-1.67 (m, 4H), 1.45-1.43 (d, J
= 6.8 Hz, 3H), 1.41-1.34 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H), 0.93 (t, J = 7.2 Hz, 3H).
MH+ 549.
Example 415 2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-methyIhexan -2-yl)-l ,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.27 (m, 6H), 7.30-7.11 (m, 2H), 2.45 (s, 3H), 1.83-1.74 (m, 2H), 1.47 (s, 6H), 1.33-1.18 (m, 4H), 0.88 (t, J = 6.8 Hz, 3H). MH+ 485.
Example 416
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-phenylpropa n-2-yl)-l,3*4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.43-7.21 (m, 1 IH), 7.19-7.09 (m, 2H), 2.51 (s, 3H), 1.94 (s, 6H). MH+ 505.
Example 417 2-(5-(4-bromophenyl)-l-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl-l,3, 4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.8 Hz, 2H), 7.31 (d, J = 6.4 Hz, 2H), 7.20 (d, J = 6.4 Hz, 2H), 7.08 (d, J = 8.8 Hz, 2H), 2.47 (s, 3H), 1.85 (q, J = 7.2 Hz, 2H), 1.50 (s, 6H), 0.90 (t, J = 7.2 Hz, 3H). MH+ 503.
Example 418
2-(5-(4-bromophenyl)-l-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-sec-butyl-l,3,4-t hiadiazole 1H NMR (400 MHz, CDCl3) δ 7.55-7.53 (m, 2H), 7.35-7.30 (m, 2H), 7.26-7.20 (m, 2H), 7.09-7.06 (m, 2H), 3.35-3.23 (m, IH), 2.46 (s, 3H), 1.97-1.91 (m, 2H), 1.71-1.40 (m, 2H), 1.42 (d, J = 6.8 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H). MH+ 489.
Example 419
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-methoxyp ropan-2-yl)-l,3,4-thiadiazo!e
1H NMR (400 MHz, CDCl3) δ 7.44 (m, IH), 7.36-7.32 (m, 4H), 7.16-7.12 (m, 2H), 7.28 (s, 3H), 2.51 (s, 3H), 1.74 (s, 6H). MH+ 493.
Example 420 l-Cl^^-dichloropheny^^-methyl-S-phenyl-lH-pyrazol-S-yO-S-tert-pentyl-ljS^-thiad iazole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.0 Hz, IH), 7.35-7.32 (m, 3H), 7.31 (s, IH),
7.28 (d, J = 2.0 Hz, IH), 7.21-7.17 (m, 2H), 2.52 (s, 3H), 1.84 (q, J = 8.0 Hz, 2H), 1.49 (s,
6H), 0.88 (t, J = 7.2 Hz, 3H).
MH+ 457.
Example 421
2-tert-butyI-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyI-lH-pyrazol-3-yl)-l,3»4-thiadi azole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.4 Hz, IH), 7.35-7.32 (m, 3H), 7.31 (s, IH), 7.28 (d, J = 2.0 Hz, IH), 7.21-7.17 (m, 2H), 2.51 (s, 3H), 1.53 (s, 9H).
MH+ 443.
Example 422 2-sec-butyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,3,4-thiadia zole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.0 Hz, IH), 7.35-7.32 (m, 3H), 7.31 (s, IH), 7.28 (d, J = 2.0 Hz, IH), 7.21-7.17 (m, 2H), 3.39-3.28 (m, IH), 2.52 (s, 3H), 1.89-1.75 (m, 2H), 1.45 (d, J = 6.8 Hz, 3H), 0.98 (t, J = 7.2 Hz, 3H). MH+ 443.
Example 423
2-cyclobutyl-5-(l-(2,4-dichlorophenyl)-4-methyI-5-phenyI-lH-pyrazol-3-yl)-l,3,4-thiadi azole
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 2.4 Hz, IH), 7.35-7.32 (m, 3H), 7.31 (s, IH), 7.28 (d, J = 2.0 Hz, IH), 7.20-7.17 (m, 2H), 4.05-3.97 (m, IH), 2.61-2.38 (m, 7H), 2.16-2.03
(m, 2H). MH+ 441.
Example 424 2-(5-(4-bromophenyl)-l-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3,4 -thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.55-7.54 (m, 2H), 7.32-7.31 (m, 2H), 7.26-7.20 (m, 2H), 7.08-7.06 (m, 2H), 3.81-3.79 (m, IH), 2.57-2.53 (m, 2H), 2.49-2.45 (m, 2H), 2.42 (s, 3H), 2.17-2.04 (m, 2H). MH+ 487.
Example 425
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-butyl-l,354- thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.43 (m, 3H), 7.41-7.38 (m, IH), 7.36-7.31 (m, 2H), 7.07-7.04 (m, 2H), 2.5 (s, 3H), 1.50 (s, 9H). MH+ 487.
Example 426
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,354 -thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.41 (m, 3H), 7.40-7.38 (m, IH), 7.37-7.32 (m, 2H), 7.07-7.05 (m, 2H), 3.22-3.15 (m, IH), 2.50 (s, 3H), 2.21-2.18 (m, 2H), 1.89-1.84 (m, 2H), 1.77-1.65 (m, IH), 1.64-1.55 (m, 2H), 1.50-1.40 (m, 2H), 1.35-1.29 (m, IH). MH+ 513.
Example 427
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3»4 -thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.31 (m, 6H), 7.07-7.05 (m, 2H), 4.03-3.98 (m, IH), 2.59-2.52 (m, 2H), 2.51 (s, 3H), 2.50-2.40 (m, 2H), 2.16-2.02 (m, 2H). MH+ 485.
Example 428
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-sec-butyl-l,354-t hiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.29 (m, 6H), 7.08-7.05 (m, 2H), 3.34-3.29 (m, IH), 2.50 (s, 3H), 1.89-1.76 (m, IH), 1.44 (d, J = 6.8 Hz, 3H), 0.98 (t, J = 7.6 Hz, 3H). MH+ 487.
Example 429
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl-l,3? 4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.29 (m, 6H), 7.08-7.05 (m, 2H), 2.51 (s, 3H), 1.83 (q, J = 7.6 Hz, 2H), 1.49 (s, 6H), 0.88 (t, J = 7.6 Hz, 3H). MH+ 501.
Example 430
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclopropyl)-l,3»4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-5.28 (m, 9H), 7.15-7.08 (m, 2H), 2.46 (s, 3H), 1.94 (m, 2H), 1.50 (m, 2H). MH+ 571.
Example 431
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-cliloro phenyl)cyclobutyl)-l,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.40 (m, IH), 7.35-7.25 (m, 8H), 7.12-7.08 (m, 2H), 3.08 (m, 2H), 2.85 (m, 2H), 2.49 (s, 3H), 2.38 (m, IH), 2.02 (m, IH). MH+ 585.
Example 432 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chlorop henyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.31 (m, 9H), 7.06-7.02 (m, 2H), 2.87 (q, J = 7.2 Hz, 2H), 1.95 (dd, J = 7.2, 4.8 Hz, 2H), 1.50 (dd, J = 7.2, 4.8 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H). MH+ 629.
Example 433
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chloroplie nyl)cyclopropyl)-l,3>4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.26 (m, 10H), 7.14-7.08 (m, 2H), 2.47 (s, 3H), 1.98-1.92 (m, 2H), 1.54-1.48 (m, 2H). MH+ 536.
Example 434 2-tert-butyl-5-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l, 3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 2.4 Hz, 1.8 Hz, IH), 7.35-7.31 (m, 3H), 7.30-7.24 (m, 2H), 7.22-7.21 (m, IH), 7.05 (dt, J - 8.0 Hz, 1.2 Hz, IH), 2.51 (s, 3H), 1.53 (s, 9H). MH+ 477.
Example 435
2-sec-butyl-5-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,
3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 2.4 Hz, 1.8 Hz, IH), 7.35-7.31 (m, 3H),
7.30-7.26 (m, 2H), 7.22-7.21 (m, IH), 7.03 (dt, J = 7.6 Hz, 1.6 Hz, IH), 3.34-3.29 (m, IH), 2.50 (s, 3H), 1.87-1.76 (m, IH), 1.44 (d, 3H), 0.98 (t, 3H). MH+ 477.
Example 436
2-(5-(3-chIorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l ,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 2.0 Hz, 0.4 Hz, IH), 7.35-7.31 (m, 3H), 7.30-7.24 (m, 2H), 7.22-7.21 (m, IH), 7.04 (dt, J = 7.6 Hz, 1.2 Hz, IH), 4.01 (m, IH), 2.60-2.52 (m, 2H), 2.50 (s, 3H), 2.46-2.41 (m, 2H), 2.41-2.03 (m, 2H). MH+ 475.
Example 437
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-ethoxypr opan-2-y I)-1, 3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (br d, J = 2.0 Hz, IH), 7.36-7.29 (m, 4H), 7.14-7.10 (m, 2H), 3.45 (q, J = 7.2 Hz, 2H), 2.50 (s, 3H), 1.74 (s, 6H), 1.19 (t, J = 7.2 Hz, 3H). MH+ 507. Example 438
2-(5-(3-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyI-
1,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.43 (dd, IH, J = 2.0 Hz, 0.4 Hz), 7.35-7.31 (m, 3H), 7.30-7.24 (m, 2H), 7.22-7.21 (m, IH), 7.04 (dt, IH, J = 7.6 Hz, 1.6 Hz), 3.24-3.16 (m, IH), 2.51 (s, 3H), 2.22-2.02 (m, 2H), 1.90-1.75 (m, 3H), 1.66-1.56 (m, 2H), 1.51-1.26 (m, 3H). MH+ 502.
Example 439 2-(5-(3-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl- 1,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.43 (dd, IH, J = 2.0 Hz, 0.4 Hz), 7.34-7.31 (m, 3H), 7.29-7.24 (m, 2H), 7.22-7.21 (m, IH), 7.04 (dt, IH, J = 7.6 Hz, 1.2 Hz), δ 2.50 (s, 3H), 1.83 (q, 2H, J = 7.6 Hz), 1.49 (s, 6H), 0.88 (t, 3H, J = 7.2 Hz). MH+ 491.
Example 440
2-(5-(4-chlorophenyl)-4-cyclopropyl-l-(2,4-dichlorophenyI)-lH-pyrazoI-3-yl)-5-cyclohe xyl-l,3*4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.55-7.49 (m, 2H), 7.36-7.31 (m, 2H), 7.21-7.16 (m, IH), 7.11-7.01 (m, 2H), 3.14-3.10 (m, IH), 2.14-2.12 (m, 2H), 1.91-1.87 (m, 2H), 1.78-1.70 (m, 2H), 1.44-1.20 (m, 4H), 0.62-0.60 (m, 2H), 0.37-0.34 (m, 2H). MH+ 531.
Example 441
2-tert-butyl-5-(5-(4-chlorophenyl)-4-cyclopropyl-l-(2,4-dichlorophenyl)-lH-pyrazol-3- y I)-1 ,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.56-7.51 (m, 2H), 7.34-7.31 (m, 2H), 7.20-7.17 (m, IH), 7.15-7.11 (m, 2H), 1.44 (m, IH), 1.32 (s, 9H), 0.61-0.59 (m, 2H), 0.37-0.34 (m, 2H). MH+ 505.
Example 442
2-(5-(4-chlorophenyl)-4-cyclopropyl-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclobu tyl- 1 ,3,4-th iadiazole 1H NMR (400 MHz, CDCl3) δ 7.54-7.51 (m, 2H), 7.33-7.31 (m, 2H), 7.22-7.18 (m, IH), 7.14-7.11 (m, 2H), 3.25-2.22 (m, IH), 1.50-1.47 (m, IH), 1.45-1.44 (m, 4H), 1.37-1.30 (m, 2H), 0.60-0.57 (m, 2H), 0.37-0.35 (m, 2H). MH+ 503.
Example 443
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazoI-3-yI)-5-tert-butyI-l,3?4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H), 7.19 (d, J = 9.2 Hz, 2H), 7.15 (d, J = 8.8 Hz, 2H), 2.46 (s, 3H), 1.54 (s, 9H). MH+ 443.
Example 444 2-(l,5-bis(4-chIorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-sec-butyI-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H), 7.19 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 3.37-3.28 (m, IH), 2.46 (s, 3H), 1.91-1.76 (m, 2H), 1.46 (d, J = 7.2 Hz, 3H), 0.99 (t, J = 7.2 Hz, 3H). MH+ 443.
Example 445 2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H), 7.19 (d, J =
8.8 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 4.06-3.08 (m, IH), 2.62-2.54 (m, 2H), 2.52-2.42 (m,
5H), 2.20-2.02 (m, 2H).
MH+ 441.
Example 446
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l,3,4-thiadiazole
1U NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.19 (d, J =
8.8 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 3.24-3.16 (m, IH), 2.46 (s, 3H), 2.24-2.20 (m, 2H), 1.91-1.86 (m, 2H), 1.79-1.74 (m, IH), 1.67-1.57 (m, 2H), 1.52-1.26 (m, 3H).
MH+ 469.
Example 447 2-(l,5-bis(4-chlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclopropyl )-l ,3>4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.8 Hz, 2H), 7.39-7.34 (m, 4H), 7.28-7.24 (m, 2H), 7.14-7.11 (m, 4H), 2.42 (s, 3H), 1.96-1.94 (m, 2H), 1.53-1.50 (m, 2H). MH+ 537.
Example 448
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-pentyl-l,3?4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.8 Hz, 2H), 7.29 (d, J = 11.6 Hz, 2H), 7.19 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 2.46 (s, 3H), 1.84 (q, J = 7.2 Hz, 2H), 1.50 (s, 6H), 0.89 (t, J = 0.90 Hz, 3H). MH+ 457.
Example 449
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-propoxyp ropan-2-yl)-l,3.4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (br d, J = 2.0 Hz, IH), 7.36-7.29 (m, 4H), 7.14-7.10 (m,
2H), 3.35 (t, J = 6.8 Hz, 2H), 2.50 (s, 3H), 1.73 (s, 6H), 1.57 (m, 2H), 0.90 (t, J = 7.2 Hz,
3H).
MH+ 521.
Example 450
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-phenylcycl opropyl)-l ,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.51-7.42 (m, 4H), 7.37-7.27 (m, 6H), 7.05-7.02 (m, 2H), 2.87 (quartet, J = 7.6 Hz, 2H), 1.95 (m, 2H), 1.53 (m, 2H), 1.10 (t, J = 7.6 Hz, 3H).
MH+ 596.
Example 451
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-tert-pentyl-l, 3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.42-7.40 (m, IH), 7.32-7.26 (m, 2H), 7.08-7.03 (m, 2H), 2.91 (quartet, J = 7.2 Hz, 2H), 1.82 (quartet, J = 8.0 Hz, 2H), 1.48 (s, 6H), 1.25 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H). MH+ 550. Example 452
2-(bicyclo[2.2.1]heptan-2-yI)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH- pyrazoI-3-yl)-l,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.49-7.44 (m, 2H), 7.42-7.39 (m, IH), 7.33-7.26 (m, 2H), 7.08-7.04 (m, 2H), 3.35-3.31 (m, IH), 2.90 (quartet, J = 7.6 Hz, 2H), 2.56 (br d, J = 3.6 Hz, IH), 2.49-2.37 (m, IH), 2.20-2.02 (m, IH), 1.95-1.85 (m, IH), 1.70-1.18 (m, 9H). MH+ 574.
Example 453
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-isopropyl-l,35 4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.44 (m, 2H), 7.42-7.39 (m, IH), 7.33-7.26 (m, 2H), 7.08-7.04 (m, 2H), 3.48 (quintet, J = 7.2 Hz, IH), 2.91 (quartet, J = 7.2 Hz, 2H), 1.48 (d, J = 6.8 Hz, 6H), 1.24 (t, J = 7.2 Hz, 3H). MH+ 522.
Example 454
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(pentan-3-yl)- 1,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.45 (m, 2H), 7.41-7.40 (m, IH), 7.33-7.26 (m, 2H),
7.08-7.04 (m, 2H), 3.03-3.01 (m, IH), 2.92 (quartet, J = 7.6 Hz, 2H), 1.80-1.45 (m, 4H),
1.24 (t, J = 7.6 Hz, 3H), 0.92 (t, J = 7.6 Hz, 3H).
MH+ 550.
Example 455
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-methylcycI ohexyl)-l,3?4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.44 (m, 2H), 7.41-7.40 (m, IH), 7.33-7.269 (m, 2H), 7.09-7.04 (m, 2H), 2.91 (quartet, J = 7.6 Hz, 2H), 2.28-2.18 (m, 2H), 1.75-1.45 (m, 8H),
1.41 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H).
MH+ 577.
Example 456 2-(2-(allyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH- pyrazol-3-yl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.30 (m, 5H), 7.14-7.10 (m, 2H), 5.90 (m, IH), 5.30 (br d, J = 17.2 Hz, IH), 5.14 (br d, J = 10.4 Hz, IH), 3.95 (dt, J = 5.2, 1.6 Hz, 2H), 2.50 (s, 3H), 1.77 (s, 6H). MH+ 519.
Example 457
2-(2-butoxypropan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-py razol-3-yl)-l,3>4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (br d, J = 2.0 Hz), 7.37-7.29 (m, 4H), 7.13-7.09 (m, 2H), 3.39 (t, J = 6.8 Hz, 2H), 2.50 (s, 3H), 1.73 (s, 6H), 1.54 (m, 2H), 1.36 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H). ~MH+ 535.
Example 458
2-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-metho xyphenyl)cyclopropyl)-l,3.4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.37 (m, 3H), 7.31-7.24 (m, 4H), 7.07 (m, 2H), 6.87 (m, 2H), 3.79 (s, 3H), 2.45 (s, 3H), 1.92 (dd, J = 7.2, 4.4 Hz, 2H), 1.48 (dd, J = 7.2, 4.4 Hz, 2H). MH+ 567.
Example 459
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(2,4-dichl orophenyl)cyclopropyl)-l,3»4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.42 (m, 2H), 7.38 (t, J = 1.2 Hz, IH), 7.31-7.25 (m,
5H), 7.08 (m, 2H), 2.45 (s, 3H), 2.01 (dd, J = 7.6, 5.2 Hz, 2H), 1.54 (dd, J = 7.6, 5.2 Hz,
2H).
MH+ 605.
Example 460
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-p-tolylcyc lopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.38-7.25 (m, 7H), 7.14 (m, 2H), 7.08 (m, 2H), 2.46 (s, 3H), 2.33 (s, 3H), 1.94 (dd, J = 7.2, 4.4 Hz, 2H), 1.50 (dd, J = 7.2, 4.4 Hz, 2H). MH+ 551.
Example 461 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-(pentylox y)propan-2-yl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 2.0, 0.4 Hz, IH), 7.34-7.28 (m, 4H), 7.11 (m, 2H), 3.36 (t, J = 6.4 Hz, 2H), 2.49 (s, 3H), 1.72 (s, 6H), 1.50 (m, 2H), 1.27 (m, 4H), 0.87 (t, J = 5.2 Hz, 3H). MH+ 549.
Example 462
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(trifluoro methyl)cyclopropyl)-l,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 1.6, 0.8 Hz, IH), 7.33-7.29 (m, 4H), 7.10 (m, 2H), 2.48 (s, 3H), 1.72 (m, 2H), 1.64 (m, 2H). MH+ 529.
Example 463 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chloroph enyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.40 (m, 2H), 7.38-7.36 (m, IH), 7.34-7.27 (m, 4H), 7.26-7.23 (m, 2H), 7.12-7.08 (m, 2H), 2.87 (quartet, J = 7.6 Hz, 2H), 1.93 (m, 2H), 1.50 (m, 2H), 1.23 (t, J = 7.6 Hz, 3H). MH+ 587.
Example 464
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chloropheny l)cyclopropyl)-l,3)4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.45-7.41(m, 4H), 7.37-7.35 (m, 2H), 7.34-7.31 (m, 2H), 7.29-7.24 (m, 2H), 7.05 (d, J = 8.8 Hz, 2H), 2.88 (q, J = 7.2 Hz, 2H), 1.96-1.93 (m, 2H), 1.52-1.49 (m, JAB = 7.2 Hz, 2H), 1.24 (t, J = 7.2 Hz, 3H). MH+ 597. Example 465
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(trifluoro methyl)cyclobutyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (m, IH), 7.34-7.30 (m, 4H), 7.11 (m, 2H), 2.83 (m, 4H), 2.51 (s, 3H), 2.17 (m, 2H). MH+ 543.
Example 466
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2,2,2-trifluo roethyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 1.6, 0.4 Hz, IH), 7.34-7.30 (m, 4H), 7.11 (m, 2H), 4.01 (q, J = 10.0 Hz, 2H), 2.50 (s, 3H). + 503.
Example 467
2-(l-benzylcyclopropyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyr azol-3-yl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.35-7.26 (m, 6H), 7.21-7.17 (m, 3H), 7.10-7.08 (m, 2H), 3.30 (s, 2H), 2.45 (s, 3H), 1.50-1.47 (m, 2H), 1.19-1.16 (m, 2H). MH+ 595.
Example 468
2-(l-benzylcyclopropyl)-5-(5-(4-bromorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-py razol-3-yl)-l,3)4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.46-7.44 (m, 2H), 7.39 (d, J = 1.2 Hz, IH), 7.30-7.23 (m, 6H), 7.21-7.18 (m, IH), 7.05-7.03 (m, 2H), 3.30 (s, 2H), 2.87 (q, J = 7.6 Hz, 2H), 1.51-1.48 (m, 2H), 1.23 (t, J = 7.6 Hz, 3H), 1.19-1.16 (m, 2H). MH+ 611.
Example 469
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-methylcy clopropyl)-l,3)4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (dd, J = 0.8, 2 Hz, 2H), 7.33-7.28 (m, 4H), 7.14-7.09 (m, 2H), 2.47 (s, 3H), 1.64 (s, 3H), 1.42-1.40 (m, 2H), 1.08-1.05 (m, 2H). MH+ 475.
Example 470
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-methylcycl opropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.45 (m, 2H), 7.40 (d, J = 2 Hz, IH), 7.32-7.26 (m, 2H),
7.07-7.05 (m, 2H), 2.90 (q, J - 7.2 Hz, 2H), 1.64 (s, 3H), 1.46-1.40 (m, 2H), 1.23 (t, J = 7.2
Hz, 3H), 1.08-1.06 (m, 2H).
MH+ 535.
Example 471
2-(l-(4-chlorobenzyl)cyclopropyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-meth yl-lH-pyrazol-3-yl)-l,3>4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.41 (m, IH), 7.32-7.28 (m, 4H), 7.23-7.20 (m, 3H), 7.11-7.07 (m, 2H), 3.25(s, 2H), 2.45 (s, 3H), 1.47 (dd, J = 4.8, 6.8 Hz, 2H), 1.72 (dd, J = 4.8,
6.8 Hz, 2H).
MH+ 587.
Example 472 2-(l-(4-chlorobenzyl)cyclopropyl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl -lH-pyrazol-3-yl)-l,3>4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.44 (m, 2H), 7.40-7.39 (m, IH), 7.32-7.26 (m, 3H), 7.23-7.20 (m, 3H), 7.06-7.02 (m, 2H), 3.25(s, 2H), 2.86 (q, J = 7.5 Hz, 2H), 1.49-1.46 (m, 2H), 1.36-1.27 (m, 5H). MH+ 645.
Example 473
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyI-lH-pyrazol-3-yl)-5-(l-(4-methoxy phenyl)cyclopropyl)-l,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.46-7.39 (m, 4H), 7.37 (dd, J = 1.6, 1.2 Hz, IH), 7.25 (m, 2H), 7.04-7.00 (m, 2H), 6.89-6.85 (m, 2H), 3.80 (s, 3H), 2.87 (q, J = 7.6 Hz, 2H), 1.94 (dd, J = 7.2, 4.8 Hz, 2H), 1.49 (dd, J = 7.2, 4.8 Hz, 2H), 1.21 (t, J = 7.6 Hz, 3H). MH+ 625. Example 474
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-p-tolylcyclo propyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.39 (m, 2H), 7.38-7.36 (m, 3H), 7.24 (m, 2H), 7.17-7.14 (m, 2H), 7.06-7.02 (m, 2H), 2.87 (q, J = 7.6 Hz, 2H), 1.96 (dd, J = 7.2, 4.8 Hz, 2H), 1.52 (dd, J = 7.2, 4.8 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H). MH+ 609.
Example 475 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-phenylcycI opropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.50-7.43 (m, 2H), 7.36-7.29 (m, 4H), 7.24 (m, 2H), 7.04-7.02 (m, 2H), 2.87 (q, J = 7.6 Hz, 2H), 1.96 (dd, J = 7.2, 4.8 Hz, 2H), 1.54 (dd, J = 7.2, 4.8 Hz, 2H), 1.22 (t, J = 7.6 Hz, 3H). MH+ 595.
Example 476
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chlorop henyl)cyclobutyl)-l,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.47-7.43 (m, 2H), 7.38 (t, J = 1.2 Hz, IH), 7.30-7.24 (m, 6H), 7.04-7.02 (m, 2H), 3.09 (m, 2H), 2.90 (q, J = 7.6 Hz, 2H), 2.56 (m, 2H), 2.36 (m, IH), 2.02 (m, IH), 1.24 (t, J - 7.6 Hz, 3H). MH+ 643.
Example 477
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyI-lH-pyrazol-3-yI)-5-(l-(4-chIorop henyl)cyclopropyl)-l,3.4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.40 (m, 4H), 7.38 (m, IH), 7.34-7.30 (m, 2H), 7.24 (m, 2H), 7.04-7.02 (m, 2H), 2.87 (q, J = 7.6 Hz, 2H), 1.94 (dd, J = 7.2, 4.8 Hz, 2H), 1.50 (dd, J= 7.2, 4.8 Hz, 2H), 1.22 (t, J = 7.6 Hz, 3H). MH+ 629.
Example 478 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyI-lH-pyrazol-3-yl)-5-(l-(2,4-dichlo rophenyl)cyclopropyl)-l,3>4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.40 (m, 4H), 7.38 (m, IH), 7.28-7.24 (m, 3H), 7.04-7.02 (m, 2H), 2.87 (q, J = 7.6 Hz, 2H), 2.05 (dd, J = 7.2, 4.8 Hz, 2H), 1.54 (dd, J = 7.2, 4.8 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H). MH+ 663.
Example 479
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazoI-3-yl)-5-(l-phenylcyclo propyl)-l,3>4-thiadiazole 1H NMR (300 MHz, CDCl3) δ 7.50 (d, J - 5.5 Hz, 2H), 7.38-7.25 (m, 8H), 7.11 (d, J = 8.5 Hz, 2H), 2.88 (q, J = 7.4 Hz, 2H), 1.99-1.96 (m, 2H), 1.56-1.53 (m, 2H), 1.23 (t, J = 7.4 Hz, 3H). MH+ 553.
Example 480
2-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-p-tolylcyclo propyl)-l,3,4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.39-7.37 (m, 2H), 7.31-7.25 (m, 5H), 7.17-7.14 (m, 2H), 7.11 (d, J = 8.6 Hz, 2H), 2.88 (q, J = 7.4 Hz, 2H), 2.34 (s, 3H), 1.96-1.93 (m, 2H), 1.53-1.49 (m, 2H), 1.23 (t, J = 7.4 Hz, 3H). MH+ 567.
Example 481
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-methoxy phenyl)cyclopropyl)-l,3.4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.43-7.37 (m, 3H), 7.31-7.25 (m, 4H), 7.11 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 3.80 (s, 3H), 2.88 (q, J = 7.4 Hz, 2H), 1.95-1.92 (m, 2H), 1.51-1.48 (m, 2H), 1.23 (t, J = 7.4 Hz, 3H). MH+ 583.
Example 482
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyI-lH-pyrazol-3-yl)-5-(l-(2,4-diclilor ophenyl)cyclopropyl)-l,3)4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.47-7.38 (m, 3H), 7.31-7.25 (m, 5H), 7.11 (d, J = 8.6 Hz, 2H), 2.88 (q, J = 7.4 Hz, 2H), 2.08-2.04 (m, 2H), 1.57-1.53 (m, 2H), 1.23 (t, J = 7.3 Hz,
3H).
MH+ 621.
Example 483
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yI)-5-(l-(4-chloroph enyl)cyclobutyl)-l,3»4-thiadiazole
1H NMR (300 MHz, CDCl3) δ 7.41-7.40 (m, IH), 7.35-7.28 (m, 8H), 7.13 (d, J = 8.4 Hz, 2H), 3.13-3.05 (m, 2H), 2.92 (q, J = 7.4 Hz, 2H), 2.88-2.78 (m, 2H), 2.40-2.30 (m, IH), 2.06-1.95 (m, IH), 1.27 (t, J = 7.4 Hz, 3H). MH+ 601.
Example 484
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-methylcycI opropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 1.6 Hz, IH), 7.33-7.27 (m, 4H), 7.15-7.10 (m,
2H), 2.90 (q, J = 7.2 Hz, 2H), 1.64 (s, 3H), 1.44 (dd, J = 4.4, 6.8 Hz, 2H), 1.24 (t, J = 7.6 Hz,
3H), 1.09 (dd, J = 4.4, 6.8 Hz, 2H).
MH+ 489.
Example 485
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-phenylcycl opentyl)-l,3?4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.41 (m, 4H), 7.37 (m, IH), 7.32-7.24 (m, 4H), 7.23-7.19 (m, IH), 7.04-7.01 (m, 2H), 2.90 (q, J = 7.6 Hz, 2H), 2.83 (m, 2H), 2.31 (m, 2H),
1.85 (m, 4H), 1.23 (t, J = 7.6 Hz, 3H).
MH+ 623.
Example 486 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-chIorop henyl)cyclopentyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.43 (m, 2H), 7.38-7.35 (m, 3H), 7.28-7.25 (m, 4H), 7.05-7.02 (m, 2H), 2.89 (t, J = 7.6 Hz, 2H), 2.82 (m, 2H), 2.27 (m, 2H), 1.86 (m, 4H), 1.23 (t, J = 7.6 Hz, 3H). MH+ 657.
Example 487
2-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyI-lH-pyrazoI-3-yl)-5-(l-phenyIcy clopropyl)-l,3*4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.50-7.47 (m, 2H), 7.38-7.27 (m, 6H), 7.25-7.24 (m, 2H), 7.10-7.04 (m, 2H), 2.45 (s, 3H), 1.98 (d, J = 7.2, 3.6 Hz, 2H), 1.55 (dd, J = 7.2, 3.6Hz, 2H). MH+ 537.
Example 488
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-ethylcycl opropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.34-7.30 (m , 4H), 7.14-7.10 (m, 2H), 2.48 (s, 3H), 1.89 (q, J = 9.7 Hz, 2H), 1.37 (dd, J = 9.3, 6.2 Hz, 2H), 1.11 (t, J = 9.7 Hz, 3H), 1.06 (dd, J = 9.3, 6.2 Hz). MH+ 489.
Example 489
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yI)-5-(l-ethyIcyclop ropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.42 (m, IH), 7.34-7.30 (m , 4H), 7.16-7.11 (m, 2H),
2.87 (q, J = 9.4 Hz, 2H), 1.93 (q, J = 9.7 Hz, 2H), 1.38 (dd, J = 9.3, 6.2 Hz, 2H), 1.27 (t, J =
9.4 Hz, 3H), 1.03 (t, J = 9.7 Hz, 3H), 1.00 (dd, J = 9.3, 6.2 Hz).
MH+ 504.
Example 490
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-ethylcyclop ropyl)-l,3)4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.42-7.41 (m , IH), 7.34-7.29 (m, 2H), 7.10-7.05 (m, 2H), 2.90 (q, J = 9.8 Hz, 2H), 1.90 (q, J = 9.8 Hz, 2H), 1.38 (dd, J = 9.2, 6.2
Hz, 2H), 1.27 (t, J = 9.8 Hz, 3H), 1.10 (t, J = 9.8 Hz, 3H), 1.03 (dd, J = 9.2, 6.2 Hz).
MH+ 547.
Example 491 l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazoI-3-yl)-l,3,4-thiadiaz ol-2-yl)cyclopropanecarbonitrile
1H NMR (400 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.34-7.30 (m, 4H), 7.14-7.11 (m, 2H), 2.88 (q, J = 10.0 Hz, 2H), 2.11-2.05 (m, 2H), 1.99-1.94 (m, 2H), 1.24 (t, J = 10.0 Hz, 3H). MH+ 501.
Example 492
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(4-fluoroph enyl)cyclopropyl)-l,3)4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.45-7.42 (m, IH), 7.35-7.30 (m, 6H), 7.20-7.13 (m, 4H), 2.79 (q, J = 9.8 Hz, 2H), 2.19 (dd, J = 9.4, 6.1, 2H), 2.02 (dd, J = 9.4, 6.1, 2H), 1.21 (t, J = 9.8 Hz, 3H). MH+ 613.
Example 493
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(l-(3-chloro phenyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.44 (m, 2H), 7.39-7.37 (m, IH), 7.36-7.34 (m, IH), 7.33-7.32 (m, IH), 7.29-7.25 (m, 4H), 7.04-7.02 (m, 2H), 2.45 (s, 3H), 1.95 (dd, J = 7.2, 4.4 Hz, 2H), 1.53 (dd, J = 7.2, 4.4 Hz, 2H). MH+ 571.
Example 494
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(3-chloroph enyl)cyclopropyl)-l,354-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.44 (m, 2H), 7.39 (d, J = 2.0 Hz, IH), 7.36-7.32 (m,
2H), 7.30-7.29 (m, IH), 121-125 (m, 4H), 7.04-7.02 (m, 2H), 2.78 (q, J = 7.6 Hz, 2H), 1.79
(dd, J = 7.2, 4.8 Hz, 2H), 1.47 (dd, J = 7.2, 4.8 Hz, 2H), 1.17 (t, J = 7.6 Hz, 3H).
MH+ 586.
Example 495
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(3-chlorop henyl)cyclopropyl)-l,3?4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.43 (m, 3H), 7.39-7.36 (m, 2H), 7.29-7.22 (m, 4H), 7.05-7.03 (m, 2H), 2.88 (q, J = 7.2 Hz, 2H), 1.94 (dd, J = 7.2, 4.0 Hz, 2H), 1.52 (dd, J = 7.2, 4.0 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H). MH+ 629.
Example 496
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-(l-(4-fluoro phenyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.44 (m, 3H), 7.38-7.35 (m, 2H), 7.29-7.22 (m, 4H), 7.04-7.01 (m, 2H), 2.27 (s, 3H), 1.90 (dd, J = 8.3, 6.7 Hz, 2H), 1.44 (dd, J = 8.3, 6.7 Hz, 2H).
MH+ 555.
Example 497
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5-(l-(4-chlo rophenyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.4 Hz, 2H), 7.30-7.19 (m, 5H), 7.14-7.12 (m,
2H), 7.07 (d, J = 8.4 Hz, 2H), 3.51-3.43 (m, IH), 1.90-1.88 (m, 2H), 1.45-1.43 (m, 2H), 1.21
(d, J = 7.2 Hz, 6H).
MH+ 601.
Example 498
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5-(l-(trifluo romethyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.40 (s, IH), 7.31-7.24 (m, 4H), 7.15 (d, J = 8.4 Hz, 2H), 3.59-3.51 (m, IH), 1.76-1.73 (m, 2H), 1.63-1.60 (m, 2H), 1.28 (d, J = 6.8 Hz, 6H).
MH+ 559.
Example 499
2-(5-(4-chIorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5-(l-(trifluoro methyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 (s, IH), 7.32-7.27 (m, 4H), 7.12 (d, J = 8.4 Hz, 2H), 2.87-2.83 (m, 2H), 1.69-1.57 (m, 6H), 0.88 (t, J = 7.6 Hz, 2H). MH+ 559. Example 500
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(trifluorom ethyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.42 (s, IH), 7.32-7.29 (m, 4H), 7.13 (d, J = 8.8 Hz, 2H), 2.90 (q, J = 7.6 Hz, 2H), 1.78-1.72 (m, 2H), 1.64-1.61 (m, 2H), 1.25 (t, J = 7.6 Hz, 3H). MH+ 545.
Example 501
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-ethyl-lH-pyrazol-3-yl)-5-(l-(2-fluoropli enyl)cyclopropyl)-l,3.4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.51-7.44 (m, IH), 7.37-7.22 (m, 6H), 7.15-7.05 (m, 4H), 2.87 (q, J = 7.2 Hz, 2H), 2.05-1.99 (m, 2H), 1.55-1.52 (m, 2H), 1.22 (t, J = 7.6 Hz, 3H). MH+ 571.
Example 502
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-tert-butyl-l,3.4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 8.79 (s, IH), 7.99 (s, IH), 7.45-7.42 (m, 3H), 7.39-7.34 (m, 4H), 5.64 (s, 2H), 1.52 (s, 9H). MH+ 544.
Example 503
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-3-yl)-5-tert-butyl-l,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 8.77 (s, IH), 7.96 (s, IH), 7.53-7.50 (m, 2H), 7.45-7.44 (m, IH), 7.39-7.36 (m, 2H), 7.35-7.30 (m, 2H), 5.63 (s, 2H), 1.52 (s, 9H). MH+ 588.
Example 504 2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-diclilorophenyl)-lH-pyra zol-3-yl)-5-cyclobutyl-l,3.4-thiadiazole
1U NMR 400 MHz, CDCl3) δ 8.82 (s, IH), 7.96 (s, IH), 7.50-7.23 (m, 7H), 5.65 (s, 2H), 4.08-3.93 (m, IH), 2.63-2.51 (m, 2H), 2.50-2.37 (m, 2H), 2.20-2.01 (m, 2H). MH+ 542. Example 505
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-cyclohexyl-l,3>4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 9.16 (s, IH), 8.16 (s, IH), 7.49-7.31 (m, 7H), 5.69 (s, 2H), 3.23-3.12 (m, IH), 2.24-2.15 (m, 2H), 1.98-1.91 (m, 2H), 1.65-1.21 (m, 6H). MH+ 570.
Example 506 2-(4-((lH-l,2,4-triazol-l-yl)methyI)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-(4-chlorophenyl)cydopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 9.07 (s, IH), 8.13 (s, IH), 7.44-7.24 (m, 1 IH), 5.29 (s, 2H),
1.99-1.88 (m, 2H), 1.59-1.51 (m, 2H).
MH+ 638.
Example 507
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-phenylcyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 8.91 (s, IH), 8.05 (s, IH), 7.50-7.46 (m, 2H), 7.42-7.21 (m, 10H), 5.63 (s, 2H), 1.98-1.90 (m, 2H), 1.61-1.53 (m, 2H).
MH+ 604.
Example 508
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-p-tolylcyclopropyI)-l,3j4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 8.89 (s, IH), 8.04 (s, IH), 7.47-7.22 (m, 9H), 7.18-7.10 (m, 2H), 5.62 (s, 2H), 2.33 (s, 3H), 1.95-1.88 (m, 2H), 1.56-1.49 (m, 2H). MH+ 618.
Example 509
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chloroplienyl)-l-(2,4-dichIorophenyl)-lH-pyra zol-3-yl)-5-(l-(4-methoxyphenyl)cyclopropyI)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 9.03 (s, IH), 8.07 (s, IH), 7.49-7.21 (m, 9H), 6.92-6.83 (m, 2H), 5.64 (s, 2H), 3.78 (s, 3H), 1.98-1.87 (m, 2H), 1.65-1.49 (m, 2H). MH+ 634.
Example 510
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-(2,4-dichlorophenyl)cycIopropyl)-l,3»4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 9.03 (s, IH), 8.11 (s, IH), 7.48-7.22 (m, 9H), 5.64 (s, 2H), 2.09-1.99 (m, 2H), 1.65-1.53 (m, 2H). MH+ 672.
Example 511
2-(4-((lH-l,2,4-triazol-l-yl)methyI)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-(trifluoromethyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 8.94 (s, IH), 8.01 (s, IH), 7.48-7.28 (m, 7H), 5.65 (s, 2H), 1.83-1.61 (m, 4H). MH+ 596.
Example 512
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-lH-pyra zol-3-yl)-5-(l-(trifluoromethyl)cyclobutyl)-l,3.4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 9.41 (s, IH), 8.28 (s, IH), 7.47-7.45 (m, IH), 7.43-7.31 (m, 6H), 5.72 (s, 2H), 2.84 (d, J - 8.0 Hz, 4H), 2.20 (m, 2H). MH+ 610.
Example 513 2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-(4-chlorophenyl)cyclobutyI)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 9.41 (s, IH), 8.28 (s, IH), 7.43-7.23 (m, 1 IH), 5.70 (s, 2H), 3.10-3.01 (m, 2H), 2.89-2.78 (m, 2H), 2.42-2.31 (m, IH), 2.10-1.98 (m, IH). MH+ 652.
Example 514
2-(4-((lH-l,2,4-triazoH-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichloroplienyl)-lH-pyra zol-3-yl)-5-(l-phenylcyclopentyl)-l,3.4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 9.56 (s, IH), 8.34 (s, IH), 7.45-7.25 (m, 12H), 5.69 (s, 2H), 2.84-2.75 (m, 2H), 2.41-2.32 (m, 2H), 1.95-1.80 (m, 4H). MH+ 632.
Example 515 2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-(4-chlorophenyl)cyclopentyl)-l,3»4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 9.46 (s, IH), 8.29 (s, IH), 7.43-7.24 (m, 1 IH), 5.68 (s, 2H),
2.82-2.73 (m, 2H), 2.37-2.26 (m, 2H), 1.92-1.80 (m, 4H).
MH+ 666.
Example 516
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyra zol-3-yl)-5-(l-methylcyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 9.13 (s, IH), 8.16 (s, IH), 7.48-7.29 (m, 7H), 5.68 (s, 2H), 1.65 (s, 3H), 1.45-1.39 (m, 2H), 1.16-1.10 (m, 2H).
MH+ 543.
Example 517
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-3-yl)-5-(l-(trifluoromethyl)cyclopropyl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 9.30 (s, IH), 8.25 (s, IH), 7.58-7.54(m, 2H), 7.47 (d, J = 1.6 Hz, IH), 7.39-7.31 (m, 4H), 5.69 (s, 2H), 1.77-1.65 (m, 4H). MH+ 640.
Example 518
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-lH-pyr azol-3-yl)-5-(l-(4-chlorophenyl)cyclopropyl)-l,3»4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 9.15 (s, IH), 8.18 (s, IH), 7.53 (d, J = 8.4 Hz, IH), 7.46-7.40 (m, 2H), 7.38-7.24 (m, 8H), 5.67 (s, 2H), 2.05-1.93 (m, 2H), 1.59-1.52 (m, 2H). MH+ 682.
Example 519
2-(4-((lH-l,2,4-triazol-l-yl)methyl)-l-(2-chlorophenyl)-5-(4-chlorophenyl)-lH-pyrazol-
3-yl)-5-tert-butyl-l,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 9.16 (s, IH), 8.18 (s, IH), 7.47-7.31 (m, 8H), 5.71 (s, 2H), 1.54 (s, 9H). MH+ 510.
Example 520
(5-(4-bromophenyl)-3-(5-tert-butyl-l,3»4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH-py razol-4-yl)methyl acetate
1H NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.44-7.43 (m, IH), 7.32-7.31 (m, 2H), 7.09-7.06 (m, 2H), 5.39 (s, 2H), 2.00 (s, 3H), 1.51 (s, 9H). MH+ 579.
Example 521
(3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-py razol-4-yl)methyl acetate 1H NMR (400 MHz, CDCl3) δ 7.44-7.43 (m, IH), 7.34-7.29 (m, 4H), 7.15-7.12 (m, 2H), 5.40 (s, 2H), 2.00 (s, 3H), 1.52 (s, 9H). MH+ 535.
Example 522 (5-(4-bromophenyl)-3-(5-tert-butyl-l,3j4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH-py razol-4-yl)methanol
1H NMR (400 MHz, CDCl3) δ 7.48-7.45 (m, 2H), 7.44-7.43 (m, IH), 7.30-7.29 (m, 2H),
7.09-7.07 (m, 2H), 4.70 (s, 2H), 1.52 (s, 9H).
MH+ 537.
Example 523
(3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-lH-py razol-4-yl)methanol
1H NMR (400 MHz, CDCl3) δ 7.44-7.43 (m IH), 7.33-7.29 (m, 4H), 7.24-7.12 (m, 2H), 4.70 (s, 2H), 1.54 (2, 9H).
MH+ 493.
Example 524 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-(methoxymethyl)-lH-pyrazol-3-yl)-5-te rt-butyl-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.46 (m, 2H), 7.45-7.44 (m, IH), 7.30-7.29 (m, 2H), 7.19-7.17 (m, 2H), 4.73 (s, 2H), 3.47 (s, 3H), 1.52 (s, 9H). MH+ 551.
Example 525
2-(5-(4-bromophenyl)-l-(2,4-dichIorophenyI)-4-(fluoromethyl)-lH-pyrazol-3-yl)-5-tert- buty 1- 1 ,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.51-7.45 (m, 3H), 7.33-7.32 (m, 2H), 7.17-7.14 (m, 2H), 5.74 (d, J = 48.4 Hz, 2H), 1.53 (s, 9H). MH+ 539.
Example 526
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-((5-(trifluoromethyl)pyridin-2-yloxy)m ethyl)-lH-pyrazol-3-yl)-5-tert-butyl-l,3.4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 8.00-7.99 (m, IH), 7.43-7.40 (m, 3H), 7.34-7.27 (m, 3H), 7.01-6.99 (m, 2H), 6.42-6.40 (m, IH), 5.48 (s, 2H), 1.52 (s, 9H). MH+ 682.
Example 527
5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazoI-2-yl)-l-(2,4-dichlorophenyl)-lH-pyr azole-4-carbaldehyde
1H NMR (400 MHz, CDCl3) δ 10.80 (s, IH), 7.48-7.42 (m, 3H), 7.34-7.26 (m, 2H), 7.20-7.07 (m, 2H), 1.53 (s, 9H). MH+ 535.
Example 528 l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)ethanol 1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.42-7.41 (m, IH), 7.30-7.26 (m, 2H), 7.07-7.04 (m, 2H), 4.83-4.78 (m, IH), 1.59 (d, J = 6.8 Hz, 3H), 1.52 (s, 9H). MH+ 551.
Example 529 l-(3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-p yrazol-4-yl)ethanol
MH+ 507.
Example 530
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-(l-fluoroethyl)-lH-pyrazol-3-yl)-5-tert- butyl-l,3,4-thiadiazole
MH+ 553.
Example 531
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)-5-tert-butyl-l,3, 4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.44 (m, 2H), 7.42-7.40 (m, IH), 7.29-7.21 (m, 3H), 7.15-7.11 (m, 2H), 5.43 (dd, J = 18, 1.6 Hz, IH), 5.22 (dd, J = 11.6, 1.6 Hz, IH), 1.51 (s, 9H).
MH+ 533.
Example 532 Methyl l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)ethylcarbamate
1H NMR (400 MHz, CDCl3) δ 7.51-7.41 (m, 3H), 7.27-7.22 (m, 4H), 5.02 (bs, IH), 3.62 (s,
3H), 1.53 (s, 9H), 1.48 (d, J = 7.2 Hz, 3H).
MH+ 609.
Example 533 l-(5.(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)ethanone
1H NMR (400 MHz, CDCl3) δ 7.46-7.43 (m, 3H), 7.30-7.29 (m, 2H), 7.15-7.12 (m, 2H), 2.53 (s, 3H), 1.52 (s, 9H).
MH+ 549.
Example 534 2-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH- pyrazol-4-yl)propan-2-ol
MH+ 565.
Example 535 2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-(prop-l-en-2-yl)-lH-pyrazol-3-yl)-5-ter t-butyl-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.39 (m, 3H), 7.34 (d, J = 8.4 Hz, IH), 7.31-7.28 (m,
IH), 7.07-7.03 (m, 2H), 5.29-5.24 (m, IH), 4.97-4.96 (m, IH), 2.10 (s, 3H), 1.51 (s, 9H).
MH+ 547.
Example 536
2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclobutyl-l,
3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.38 (m, IH), 7.41-7.34 (m, 4H), 7.25-7.23 (m, 2H), 4.07-4.02 (m, IH), 2.60-2.56 (m, 2H), 2.54-2.48 (m, 2H), 2.18-2.05 (m, 2H).
MH+ 497.
Example 537 2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-tert-pentyI-l ,3>4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.44 (m, IH), 7.38-7.33 (m, 4H), 7.26-7.22 (m, 2H), 1.86 (q, J = 7.6 Hz, 2H), 1.52 (s, 3H), 1.50 (s, 3H), 0.89 (t, J = 7.6 Hz, 3H). MH+ 514.
Example 538
2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-lH-pyrazol-3-yl)-5-cyclohexyl-l, 3,4-thiadiazole
1B. NMR (400 MHz, CDCl3) δ 7.46-7.40 (m, 2H), 7.37-7.32 (m, 3H), 7.26-7.22 (m, 2H), 3.26-3.24 (m, IH), 2.22-1.86 (m, 4H), 1.56-1.44 (m, 6H). MH+ 525.
Example 539
2-sec-butyl-5-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-l,3
,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.46-7.41 (m, 2H), 7.39-7.26 (m, 3H), 7.24-7.20 (m, 2H), 3.36-3.32 (m, IH), 1.87-1.75 (m, 2H), 1.48 (d, J = 6.9 Hz, 3H), 0.99 (t, J = 7.2 Hz). MH+ 499
Example 540
2-tert-butyl-5-(4-chloro-5-(4-chlorophenyI)-l-(2,4-dichlorophenyI)-lH-pyrazol-3-yl)-l, 3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.49-7.41 (m, 2H), 7.38-7.24 (m, 3H), 7.23-7.19 (m, 2H), 1.59 (s, 9H). MH+ 499.
Example 541
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-lH-pyrazol-3-yl)-5-tert-butyl-l,
3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.51-7.48 (m, 2H), 7.38-7.27 (m, 3H), 7.23-7.19 (m, 2H), 1.55 (s, 9H). MH+ 544.
Example 542 2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dicliIorophenyl)-lH-pyrazol-3-yl)-5-sec-butyl-l,3
,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.42 (m, IH), 7.40-7.37 (m, IH), 7.35-7.32 (m, 3H), 7.25-7.21 (m, 2H), 3.37-3.32 (m, IH), 1.87-1.76 (m, 2H), 1.45 (d, J = 6.8 Hz, 3H), 0.91 (t, J = 7.2, 3H). MH+ 543.
Example 543
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclobutyl-l,
3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.44-7.42 (m, IH), 7.37-7.31 (m, 4H), 7.25-7.22 (m, 2H),
4.12-4.01 (m, IH), 2.61-2.57 (m, 2H), 2.53-2.39 (m, 2H), 2.19-2.05 (m, 2H). MH+ 541.
Example 544 2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-cyclohexyl-l ,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.43-7.37 (m, 2H), 7.34-7.31 (m, 3H), 7.25-7.21 (m, 2H), 3.02-2.97 (m, IH), 2.16-2.11 (m, 2H), 1.87-1.76 (m, 2H), 1.73-1.68 (m, 3H), 1.44-1.33 (m, 3H). MH+ 569.
Example 545
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-tert-pentyl-l ,3>4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.43 (m, 2H), 7.38-7.33 (m, 3H), 6.99-6.95 (m, 2H), 1.66 (dq, J - 28.8, 7.2 Hz, 2H), 1.49 (s, 3H), 1.42 (s, 3H), 0.83 (t, J = 18.8, 7.2 Hz, 3H). MH+ 557.
Example 546
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichloroplienyl)-lH-pyrazol-3-yl)-5-(2-(4-chloro phenyl)propan-2-yl)-l,3,4-thiadiazole
1H NMR (400 MHz, CDCl3) δ 7.45-7.41 (m, IH), 7.38-7.33 (m, 4H), 7.27-7.24 (m, 3H), 7.22-7.18 (m, 2H), 7.12-7.08 (m, IH), 1.92 (s, 3H), 1.81 (s, 3H). MH+ 639.
Example 547
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5-(l-(4-chloro phenyl)cyclopropyl)-l,3,4-thiadiazole 1H NMR (400 MHz, CDCl3) δ 7.46-7.42 (m, IH), 7.39-7.36 (m, 4H), 7.27-7.24 (m, 3H), 7.21-7.18 (m, 2H), 7.12-7.08 (m, IH), 2.01 (dd, J = 9.1, 6.7 Hz, 2H), 1.49 (dd, J = 9.1, 6.7 Hz, 2H). MH+ 635.
Preparation of 1,2,4-oxadiazole
Example 548
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l
,2,4-oxadiazole Step 1: 5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazole-3- carboxamide
Thionyl chloride (1.3 ml, 22.0 mmol) was added to a solution of 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazole-3-carboxylic acid (2.09 g, 5.5 mmol) in toluene (50 ml) maintained at room temperature. The mixture was refluxed at 110°C for 2 hours and then cooled to room temperature. The resulting solution was evaporated and dried under a vacuum to produce crude 5-(4-chlorophenyl)-l-(2,4- dichlorophenyl)-4-methyl-lH-pyrazole-3-carbonyl chloride, which are not further purified. 27% aqueous ammonia (2 ml) was added to the solution of crude 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazole-3-carbonyl chloride in methylene chloride (10 ml) at 0°C . After stirring 3 hours at room temperature, the resulting solution was quenched with saturated ammonium chloride which was extracted twice with 50 ml portions of ethyl acetate. After concentrating the extract by evaporation, the crude residue was purified using a silica gel column (hexane/ethyl acetate = 1/1), to obtain the title compound (2.07 g, 99 %) as white solid.
Step 2: 5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazole- 3-carbonitrile
Added dropwise to a solution of 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 4-methyl-lH-pyrazole-3 -carboxamide (1.57 g, 4.1 mmol) obtained in Step 1 dissolved in dimethylformamide (10 ml) at 0°C , was phosphoryl chloride (0.72 ml, 8.2 mmol). The resulting mixture was stirred for 20 minutes at 0°C and then stirred for 1 hour at room temperature. The reaction mixture was quenched with water at 0°C, and an mixture was extracted with ethyl acetate (30 ml twice). After removing the solvent, 5-(4-chloro phenyl)- l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazole-3-carbonitrile was obtained by column chromatography as white solid (1.47g, quantativly).
1H NMR (400 MHz, CDCl3) δ 7.40 (br s, IH), 7.31-7.27 (m, 4H), 7.08-7.03 (m, 2H), 2.33 (s, 3H), 2.31 (t, J = 7.8 Hz, 2H), 1.72 (m, IH), 0.97 (t, J = 7.3 Hz, 3H). MH+ 463.
Step 3 : 5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-N-hydroxy-4-methyl- 1 H- pyrazole-3-carboximidamide Potassium carbonate (0.58 g, 4.14 mmol) was added to a sealed tube containing a solution of 5-(4-chlorophenyl)-l-(2,4- dichlorophenyl)-4-methyl-lH-pyrazole-3-carbonitrile (1.0 g, 2.76 mmol) obtained in Step 2, hydroxylamine hydrochloride (0.39 g, 5.52 mmol) dissolved in MeOH (16 mL). The mixture was stirred vigorously and heated at 100°C for 16 hr. The white precipitate formed was filtered and washed twice with cold water. It was further dried under a high vacuum. The filtrate was extracted with chloroform (30 mL x 2), dried over MgSO4, filtered and evaporated under a vacuum, to obtain the title product in a compound amount of 1.04 g (2.63 mmol, 95%).
1H NMR (400 MHz, DMSO-(I6) δ 9.77 (s, IH), 8.27 (s, IH), 7.69 (d, J = 2.2 Hz, IH), 7.63 (d, J - 8.4 Hz, IH), 7.51 (dd, J = 2.2,, 8.4 Hz, IH), 7.41 (br d, J = 8.6 Hz, 2H), 7.19 (br d, J = 8.6 Hz, 2H), 5.49 (br s, IH), 2.20 (s, 3H). MH+ 395.
Step 4: 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,2,4-oxadiazole
NMM (0.42 mL, 3.77 mmol) was added to a solution of 5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-N-hydroxy-4-methyl- 1 H-pyrazole-3-carboxamid amide (0.30 g, 0.75 mmol) obtained in Step 3, cyclohexylcarboxylic acid (97 mg, 0.75 mmol), HOBt (194 mg, 1.43 mmol) and EDCI (220 mg, 1.13 mmol) dissolved in DCM (7 mL). The mixture was stirred overnight at room temperature. After adding thereto EtOAc (30 mL), the mixture was successively washed with water, saturated NaHCO3 solution (20 mL) and brine (20 mL). The organic layer was isolated, dried over MgSO4, filtered, and concentrated under a vacuum, to obtain 5-(4-chlorophenyl)-N- (cyclohexanecarbonyloxy)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazole-3-carboximidami de as a white solid, which was used in the next step without further purification. The crude material was dissolved in pyridine (4 mL), and was subjected to microwave irradiation at 180°C for 20 min., to remove volatile components under a vacuum. The residue was further purified by reverse phase preparative HPLC, to obtain the title compound as white solid (67 mg, 0.137 mmol, 18% via two steps).
1H NMR (300 MHz, CDCl3) δ 7.42 -7.38 (m, 2H), 7.34-7.28 (m, 3H), 7.14-7.09 (m, 2H), 3.06 (m, IH), 2.39 (s, 3H), 2.14 (m, 2H), 1.88-1.81 (m, 2H), 1.80-1.68 (m, 2H), 1.48-1.25 (m, 4H). (M+Na)+ 509.
The following compounds of Examples 549 to 564 were obtained by using corresponding starting materials and repeating the procedure of Example 548.
Example 549
3-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-cyclopentyl- 1,2,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.42 -7.38 (m, 2H), 7.34-7.28 (m, 3H), 7.14-7.09 (m, 2H), 3.45 (m, IH), 2.39 (s, 3H), 2.20 (m, 2H), 2.06 (m, 2H), 1.86 (m, 2H), 1.72 (m, 2H). (M+Na)+ 495.
Example 550
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pentan-3-yl )-l,2,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.42 -7.38 (m, 2H), 7.34-7.28 (m, 3H), 7.14-7.09 (m, 2H), 3.01 (m, IH), 2.40 (s, 3H), 1.99-1.75 (m, 4H), 0.92 (t, J = 7.5 Hz ,3H). (M+Na)+ 497.
Example 551
5-benzyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,2,4 -oxadiazole
1U NMR (300 MHz, CDCl3) δ 7.41- 7.27 (m, 10H), 7.13-7.09 (m, 2H), 4.33 (s, 2H), 2.38 (s, 3H), 2.67-2.42 (m, 4H), 2.39 (s, 3H), 2.24-2.02 (m, 2H). (M+Na)+ 517.
Example 552
3-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l
,2,4-oxadiazole 1H NMR (300 MHz, CDCl3) δ 7.42 -7.38 (m, 2H), 7.34-7.28 (m, 3H), 7.14-7.10 (m, 2H), 3.86 (m, IH), 2.67-2.42 (m, 4H), 2.39 (s, 3H), 2.24-2.02 (m, 2H). (M+Na)+ 481.
Example 553 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyrazol-3-yl)-5-cycloheptyl- 1,2,4-oxadiazole
1H NMR (300 MHz, CDCl3) δ 7.42 -7.37 (m, 2H), 7.32-7.27 (m, 3H), 7.13-7.10 (m, 2H), 3.25 (m, IH), 2.39 (s, 3H), 2.24-2.15 (m, 2H), 2.01-1.81 (m, 4H), 1.65-1.60 (m, 6H). (M+Na)+ 523.
Example 554
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclopropyl methyl)-l,2,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.41 -7.37 (m, 2H), 7.32-7.27 (m, 3H), 7.13-7.10 (m, 2H), 2.89 (d, J = 6.88 Hz, 2H), 2.40 (s, 3H), 1.26 (m, IH), 0.64 (m, 2H), 0.35 (AB q, J = 5.04 Hz, 2H). MH+ 459.
Example 555
3-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-(cycIopentyl methyl)-l ,2,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 -7.37 (m, 2H), 7.32-7.27 (m, 3H), 7.13-7.10 (m, 2H), 2.98 (d, J = 7.80 Hz, 2H), 2.46 (m, IH), 2.40 (s, 3H), 1.98 (m, IH), 1.91-1.82 (m, 2H), 1.72-1.52 (m, 4H), 1.36-1.25 (m, 2H). MH+ 487.
Example 556
3-(5-(4-chIorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclohexyl methyl)-l,2,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41 -7.37 (m, 2H), 7.32-7.27 (m, 3H), 7.13-7.10 (m, 2H), 2.86 (d, J = 7.36 Hz, 2H), 2.40 (s, 3H), 1.98 (m, IH), 1.80-1.62 (m, 5H), 1.33-1.10 (m, 5H). MH+ 501.
Example 557
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-isopropyl-l, 2,4-oxadiazole
MH+ 447. Example 558
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopropyl-
1,2,4-oxadiazole
MH+ 445.
Example 559
5-sec-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l, 2,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.37 (m, 2H), 7.33-7.28 (m, 3H), 7.14-7.11 (m, 2H), 3.14 (m, IH), 2.40 (s, 3H), 2.95 (m, IH), 1.78 (m, IH), 1.45 (d, J = 6.9 Hz, 3H), 0.97 (t, J = 7.6 Hz, 3H). MH+ 461.
Example 560 3-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(pentan-2-yl )-l,2,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40-7.35 (m, 2H), 7.32-7.27 (m, 3H), 7.14-7.11 (m, 2H), 3.25 (m, IH), 2.39 (s, 3H), 1.91 (m, IH), 1.70 (m, IH), 1.43 (d, J = 7.3 Hz), 1.36 (m, IH), 0.92 (t, J = 7.3 Hz, 3H). MH+ 475.
Example 561
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazoI-3-yl)-5-(liexaii-2-yl) -1 , 2,4-oxadiazole 1H NMR (400 MHz, CDCl3) δ 7.43-7.37 (m, 2H), 7.33-7.28 (m, 3H), 7.14-7.11 (m, 2H), 3.23 (m, IH), 2.40 (s, 3H), 1.98-1.88 (m, IH), 1.77-1.67 (m, IH), 1.44 (d, J = 6.5 Hz, 3H), 1.39-1.23 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H). MH+ 489.
Example 562
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cycIopent-3 -enyl)-l,2,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.37 (m, 2H), 7.34-7.27 (m, 3H), 7.14-7.10 (m, 2H), 5.76 (s, 2H), 3.83 (m, IH), 2.92 (d, J = 8.24 Hz, 4H), 2.39 (s, 3H). MH+ 471.
Example 563
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(2-methylcy clopropyl)-l,2,4-oxadiazole
1H NMR (400 MHz, CDCl3) δ 7.40-7.36 (m, 2H), 7.33-7.27 (m, 3H), 7.12-7.09 (m 2H),
2.37 (s, 3H), 1.99 (m, IH), 1.73 (m, IH), 1.54 (m, IH), 1.23 (d, J = 6.0 Hz, 3H), 1.04 (m,
IH).
MH+ 459.
Example 564
3-benzyI-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazoI-3-yI)-l,2,4
-oxadiazole
MH+ 495.
Preparation of tetrazoles (formula (Ie) and (If))
Example 565
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-propyl-lH-t etrazole
Step 1 : 5-(5-(4-Chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H- tetrazole
A mixture of 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazole- 3-carbonitrile (500 mg, 1.39 mmol), sodium azide (1.08 g, 16.6 mmol) and ammonium chloride (890 mg, 16.6 mmol) dissolved in dimethylformamide (3 ml) was placed in a microwave synthesizer tube, and subjected to microwave irradiation in a Biotage® Initiator was set at 180 °C . After 20 mintues, the mixture was quenched with water and extracted with ethyl acetate. The solvent of the extracted organic layer was evaporated off and the residue was purified by reverse phase preparative HPLC, to obtain 5-(5-(4-chlorophenyl)-l-(2,4- dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- lH-tetrazole (550 mg, 98 %) as white solid.
MH+ 404. Step 2: 5-(5-(4-Chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - propyl- 1 H-tetrazole
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H-tetrazo Ie (150 mg, 0.37 mmol) obtained in Step 1 was dissolved in dimethylfoπnamide (1 ml), and potassium carbonate (250 mg, 1.85 mmol) and 1-iodopropane (0.07 ml, 1.1 mmol) were added thereto at room temperature. After stirring for 5 hours, the resulting solution was quenched with water (1 ml) and the mixture was three time extracted with 5 ml portion of ethyl acetate. The solvent of the extracted organic layer was evaporated under a reduced pressure and the residue was subjected to silica gel column chromatography (hexane/ethyl acetate = 1/7 to hexane/ethyl acetate = 1/5), to obtain two compounds, one of which was the title compound (61 mg, 37 %) in the form of white solid.
1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 2.28 Hz, IH), 7.36-7.32 (m, 2H), 7.29 (dd, J = 8.72, 2.28 Mz, IH), 7.18 (d, J = 8.68 Hz, IH), 7.14-7.10 (m, 2H), 4.78 (t, J = 7.32 Hz, 2H), 2.46 (s, 3H), 2.03-1.93 (m, 20.94 (t, J = 7.32 Hz, 3H). MH+ 447.
Example 566 5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-propyl-2H-t etrazole
The title compound (62 mg, 37 %) was the other compound obtained as white solid in Example 565, which was relatively more polar than the compound of Example 565.
1H NMR (400 MHz, CDCl3) δ 7.41-7.38 (m, 2H), 7.33-7.28 (m, 3H), 7.15-7.12 (m, 2H), 4.66 (t, J = 5.16, 2H), 2.46 (s, 3H), 2.17-2.07 (m, 2H), 1.01 (t, J = 5.52 Hz, 3H). MH+ 447.
The following compounds of Examples 567 to 592 were obtained by using corresponding starting materials and repeating the procedure of Example 565 and 566.
Example 567
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-methyl-lH- tetrazole 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.32 Hz, IH), 7.35-7.22 (m, 4H), 7.14-7.10 (m, 2H), 4.39 (s, 3H), 2.47 (s, 3H). MH+ 419.
Example 568
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-methyl-2H- tetrazole
1H NMR (400 MHz, CDCl3) δ 7.40-7.38 (m, 2H), 7.33-7.27 (m, 3H), 7.14-7.12 (m, 2H), 4.44 (s, 3H), 2.46 (s, 3H). MH+421 .
Example 569
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyrazol-3-yl)-l-ethyI-lH-te trazole 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 1.71 Hz, IH), 7.36-7.28 (m, 3H), 7.20 (d, J = 6.51 Hz, IH), 7.14-7.10 (m, 2H), 4.86 (q, J = 5.52 Hz, 2H), 2.47 (s, 3H), 1.56 (t, J = 5.52 Hz, 3H). MH+ 433.
Example 570
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-etliyl-2H-te trazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.38 (m, 2H), 7.33-7.27 (m, 3H), 7.15-7.12 (m, 2H), 4.75 (q, J = 7.36 Hz, 2H), 2.46 (s, 3H), 1.71 (t, J = 7.36 Hz, 3H). MH+ 433.
Example 571 l-Butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-lH-tet razole 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.32 Hz, IH), 7.35-7.27 (m, 3H), 7.19 (d, J = 8.72 Hz, IH), 7.14-7.10 (m, 2H), 4.82 (t, J = 7.32 Hz, 2H), 2.46 (s, 3H), 1.97-1.89 (m, 2H), 1.55-1.33 (m, 2H), 0.91 (t, J = 7.36 Hz, 3H). MH+ 460. Example 572
2-Butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2H-tet razole
1H NMR (400 MHz, CDCl3) δ 7.41-7.38 (m, 2H), 7.33-7.27 (m, 3H), 7.15-7.12 (m, 2H), 4.70 (t, J = 7.32 Hz, 2H), 2.46 (s, 3H), 2.10-2.03 (m, 2H), 1.44-1.38 (m, 2H), 0.98 (t, J = 7.32 Hz, 3H). MH+ 459.
Example 573 5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-peiityl-lH-t etrazole
1H NMR (300 MHz, CDCl3) δ 7.50 (d, J = 2.22 Hz, IH), 7.36-7.27 (m, 3H), 7.19 (d, J = 11.24 Hz, IH), 7.14-7.10 (m, 2H), 4.81 (t, J = 9.76 Hz, 2H), 2.46 (s, 3H), 1.97-1.83 (m, 2H), 1.32-1.25 (m, 4H), 0.86-81 (m, 3H). MH+ 475.
Example 574
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-pentyl-2H-t etrazole 1H NMR (300 MHz, CDCl3) δ 7.42-7.39 (m, 2H), 7.34-7.27 (m, 3H), 7.15-7.12 (m, 2H), 4.69 (t, J = 7.14 Hz, 2H), 2.46 (s, 3H), 2.11-2.09 (m, 2H), 1.37-1.36 (m, 4H), 0.92-0.88 (m, 3H). MH+ 477.
Example 575
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-isopropyl-l H-tetrazole
1H NMR (300 MHz, CDCl3) δ 7.49 (d, J = 2.19 Hz, IH), 7.36-7.27 (m, 3H), 7.20 (d, J = 8.61 Hz, IH), 7.14-7.10 (m, 2H), 5.68-5.61 (m, IH), 2.44 (s, 3H), 1.66 (s, 3H), 1.63 (s, 3H). MH+ 449.
Example 576
5-(5-(4-Chlorophenyl)-l-(2,4-dichloroplienyl)-4-metliyl-lH-pyrazol-3-yl)-2-isopropyl-2
H-tetrazole 1H NMR (300 MHz, CDCl3) δ 7.42-7.38 (m, 2H), 7.33-7.27 (m, 3H), 7.15-7.12 (m, 2H), 5.22-5.12 (m, IH), 2.46 (s, 3H), 1.74 (s, 3H), 1.72 (s, 3H). MH+ 447.
Example 577
5-(5-(4-ChIorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-cyclopentyl -lH-tetrazole
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.28 Hz, IH), 7.35-7.27 (m, 3H), 7.20 (d, J = 8.72 Hz, IH), 7.14-7.09 (m, 2H), 5.75-5.67 (m, IH), 2.44 (s, 3H), 2.24-2.16 (m, 4H), 2.04-1.98 (m, 2H), 1.78-1.68 (m, 2H). MH+ 473.
Example 578
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-cyclopentyl -2H-tetrazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.36 (m, 2H), 7.33-7.27 (m, 3H), 7.15-7.11 (m, 2H), 5.34-5.27 (m, IH), 2.44 (s, 3H), 2.37-2.24 (m, 4H), 2.04-1.94 (m, 2H), 1.84-1.73 (m, 2H). MH+ 473.
Example 579
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-cyclohexyl- lH-tetrazole
1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 2.28 Hz, IH), 7.36-7.26 (m, 3H), 7.16-7.10 (m, 3H), 5.25-5.17 (m, IH), 2.42 (s, 3H), 2.19-1.30 (m, 10H). MH+ 487.
Example 580
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-cyclohexyl-
2H-tetrazole 1H NMR (400 MHz, CDCl3) δ 7.41-7.38 (m, 2H), 7.35-7.27 (m, 3H), 7.15-7.10 (m, 2H), 4.84-4.76 (m, IH), 2.45 (s, 3H),2.31-1.31 (m, 10H). MH+ 487.
Example 581 l-Benzyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-lH-t etrazole
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.28 Hz, IH), 1.31-126 (m, 8H), 7.19 (d, J = 8.24 Hz, IH), 7.11-7.07 (m, 2H),6.05 (s, 2H), 2.44 (s, 3H). MH+ 496.
Example 582
2-Benzyl-5-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyl-lH-pyrazol-3-yl)-2H-t etrazole 1B. NMR (400 MHz, CDCl3) δ 7.45-7.43 (m, 2H), 7.39-7.27 (m, 8H), 7.13-7.10 (m, 2H), 5.85 (s, 2H), 2.43 (s, 3H). MH+ 497.
Example 583 2-((5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-lH-tetraz ol-l-yl)methyl)pyridine
1H NMR (400 MHz, CDCl3) δ 8.52 (d, J = 4.53, IH), 7.61-7.57 (m, IH), 7.42 (d, J = 2.32 Hz, IH), 7.33-7.30 (m, 2H), 7.27-7.24 (m, 2H), 7.20-7.17 (m, 2H), 7.11-7.05 (m, 3H), 7.00 (d, J = 7.80 Hz, IH), 6.21 (s, 2H), 2.48 (s, 3H). MH+ 496.
Example 584
2-((5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2H-tetraz ol-2-yl)methyl)pyridine 1H NMR (400 MHz, CDCl3) δ 8.61-8.59 (m, IH), 7.71-7.66 (m, IH), 7.40-7.37 (dd, J = 5.04, 2.72 Hz, 2H), 7.33-7.26 (m, 4H), 7.18 (d, J = 8.24 Hz, IH), 7.14-7.11 (m, 2H), 6.03 (s, 2H), 2.45 (s, 3H). MH+ 498.
Example 585
3-((5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-lH-tetraz ol-l-yl)methyl)pyridine
1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 1.84, IH), 8.54 (dd, J = 4.56, 1.36 Hz, IH), 7.23-7.70 (m, IH), 7.50 (d, J = 2.32 Hz, IH), 7.35-7.31 (m, 3H), 7.26-7.20 (m, 2H), 7.11-7.08 (m, 2H), 6.09 (s, 2H), 2.46 (s, 3H). MH+ 496.
Example 586 3-((5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-2H-tetraz ol-2-yl)methyl)pyridine
1U NMR (400 MHz, CDCl3) δ 8.76 (d, J = 1.84 Hz, IH), 8.62 (dd, J = 5.04, 1.84 Hz, IH), 7.79-7.76 (m, IH), 7.39-7.36 (m, 2H), 7.33-7.27 (m, 4H), 7.13-7.10 (m, 2H), 5.88 (s, 2H), 2.43 (s, 3H). MH+ 498.
Example 587
4-((5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-lH-tetraz ol-l-yl)methyl)pyridine 1H NMR (400 MHz, CDCl3) δ 8.54-8.52 (m, 2H), 7.48 (d, J = 2.28 Hz, IH), 7.34-7.28 (m, 3H), 7.14-7.07 (m, 5H), 6.07 (s, 2H), 2.47 (s, 3H). MH+ 496.
Example 588 4-((5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2H-tetraz ol-2-yl)methyl)pyridine
1H NMR (400 MHz, CDCl3) δ 8.64-8.62 (m, 2H), 7.40-7.13 (m, 7H), 7.14-7.11 (m, 2H), 5.87 (s, 2H), 2.45 (s, 3H). MH+ 496.
Example 589
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-(cyclohexyl methyl)-lH-tetrazole
1H NMR (300 MHz, CDCl3) δ 7.51 (d, J = 2.4 Hz, IH), 7.36-7.26 (m, 3H), 7.18-7.09 (m, 3H), 4.68 (d, J = 7.32 Hz, 2H), 2.46 (s, 3H), 2.04-2.00 (m, IH), 1.68-0.90 (m, 10H).
MH+ 501.
Example 590 5-(5-(4-Chlorophenyl)-l-(2,4-dichloroplienyl)-4-methyl-lH-pyrazol-3-yl)-2-(cyclohexyl methyl)-2H-tetrazole
1H NMR (300 MHz, MeOH-d,) δ 7.58-7.55 (m, 2H), 7.47-7.44 (m, IH), 7.41-7.37 (m, 2H), 7.27-7.23 (m, 2H), 4.60 (d, J = 7.14 Hz, 2H), 2.39 (s, 3H), 2.18-2.02 (m, IH), 1.77-0.86 (m, 10H). MH+ 501.
Example 591
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-phenethyl-l
H-tetrazoIe 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J = 2.37 Hz, IH), 7.36-7.07 (m, HH), 5.04 (t, J = 7.68 Hz, 2H), 3.24 (t, J = 7.86 Hz, 2H), 2.39 (s, 3H). MH+ 508.
Example 592 5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazoI-3-yl)-2-phenethyI-2 H-tetrazole
1H NMR (300 MHz, CDCla) δ 7.42-7.39 (m, 2H), 7.34-7.,26 (m, 6H), 7.25-7.19 (m, 2H), 7.16-7.11 (m, 2H), 4.92 (t, J = 7.68 Hz, 2H), 3.41 (t, J = 7.89 Hz, 2H), 2.45 (2, 3H). MH+ 509.
Example 593
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazoI-3-yl)-l-(furan-2-yl methyl)-lH-tetrazole
A mixture of 5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-
3-yl)-l H-tetrazole (113 mg, 0.28 mmol) obtained in Step 1 of Example 52, furfuryl alcohol (0.05 ml, 0.56 mmol) and triphenylphosphine (146 mg, 0.56 mmol) was dissolved in tetrahydronfuran (3 ml) and cooled down to 0 "C . Then, diisopropyl azodicarboxylate (0.11 ml, 0.56 mmol) was slowly added thereto at 0°C . After stirring for 2 hours at room temperature, the resulting solution was quenched with saturated ammonium chloride solution (1 ml). The mixture was extracted with ethyl acetate, and then the solvent of the organic layer was removed under a reduced pressure. The residue contained two regioisomers were separated by silica gel column chromatography (hexane/ethyl acetate = 1/5), and repurified by reverse phase preparative HPLC, to obtain two compound, one of which was the title compound (22 mg, 16 %).
1H NMR (400 MHz, CDCl3) δ 7.50-7.47 (m, IH), 7.35-7.23 (m, 6H), 7.14-7.10 (m, 3H), 6.07 (s, 2H), 2.46 (s, 3H). MH+ 484.
Example 594
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-(furan-2-yl methyl)-2H-tetrazole
The title compound (24 mg, 18 %) was the other regioisomer obtained as white solid in Example 593, which is relatively more polar than the compound of Example 593.
1H NMR (400 MHz, CDCl3) δ 7.48-7.27 (m, 7H), 7.14-7.10 (m, 3H), 5.86 (s, 2H), 2.43 (s, 3H).
MH+ 485.
The following compounds of Examples 595 to 598 were obtained by using corresponding starting materials and repeating the procedure of Example 593 and 594.
Example 595
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-l-(furan-3-yl methyl)-lH-tetrazole
1H NMR (400 MHz, CDCl3) δ 7.50-7.51 (m IH), 7.46 (s, IH), 7.36-7.31 (m, 4H), 7.25-7.23 (m, IH), 7.14-7.10 (m, 2H), 6.46 (s, IH), 5.91 (s, 2H), 2.47 (s, 3H).
MH+ 484.
Example 596
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-(furan-3-yl methyl)-2H-tetrazole
1H NMR (400 MHz, CDCl3) δ 7.61 (s, IH), 7.41-7.37 (m, 3H), 7.32-7.27 (m, 3H), 7.14-7.10 (m, 2H), 6.52 (m, 2H), 5.73 (s, 2H), 2.44 (s, 3H). MH+ 484. Example 597
5-(5-(4-Chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyI-lH-pyrazol-3-yl)-l-(thiophen-3 -y lmethy I)- 1 H-tetrazole
1H NMR (300 MHz, CDCl3) δ 7.51 (d, J = 2.19 Hz, IH), 7.35-7.30 (m, 4H), 7.26-7.21 (m, 2H), 7.13-7.09 (m, 3H), 6.06 (s, 2H), 2.45 (s, 3H). MH+ 501.
Example 598
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2-(thiophen-3 -ylmethyl)-2H-tetrazole
1H NMR (300 MHz, CDCl3) δ 7.43-7.41 (m, IH), 7.40-737 (m, 2H), 7.33-7.27 (m, 4H), 7.18 (dd, J = 4.95, 1.29 Hz, IH), 7.14-7.10 (m, 2H), 5.87 (s, 2H), 2.44 (s, 3H). MH+ 501.
Example 599
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-cyclopropyl -1 H-tetrazole
Crude 5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazole- 3-carbonyl chloride (150 mg, 0.37 mmol) was dissolved in methylene chloride (3 ml) at 0°C , and triethyl amine (0.05 ml, 1.11 mmol) and cyclopropyl amine (0.03 ml, 0.56 mmol) were slowly added thereto. The resulting solution was stirred at room temperature for 3 hours, quenched with saturated ammonium chloride solution, extracted with ethyl acetate and filtrated with magnesium sulfate. The crude solution was evaporated and dried under a reduced pressure, to obtain 5-(4-chlorophenyl)-N- cyclopropyl- 1 -(2,4-dichlorophenyl)-
4-methyl-lH-pyrazole-3-carboxamide, which are not further purified. The resulting product was dissolved in benzene (3 ml), and phosphorus pentachloride (85 mg, 0.41 mmol) was added thereto at room temperature. The solution was stirred for 20 minutes, hydroazoic aicd (1.0 ml, 2.0 M solution in benzene) was added thereto and maintained room temperature for overnight. For completion of the reaction, reaction solution was refluxed for 10 minutes and purified by reverse phase preparative HPLC, to obtain the title compound (83 mg, 50 %) as white solid.
1H NMR (300 MHz, CDCl3) δ 7.49-7.47 (m, IHO, 7.34-7.22 (4H), 7.14-7.11 (m, 2H), 4.44 (m, IH), 2.44 (s, 3H), 1.46-1.40 (m, 2H), 1.24-1.18 (m, 2H). MH+ 445.
The following compounds of Examples 600 to 610 were obtained by using corresponding starting material and repeating the procedure of Example 599.
Example 600
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyrazol-3-yI)-l-cyclobutyl- lH-tetrazole 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 2.32 Hz, IH), 7.35-7.29 (m, 3H), 7.22 (d, J =
8.24 Hz, IH), 7.13-7.09 (m, 2H), 5.75-5.67 (m, IH), 2.86-2.75 (m, 2H), 2.62-2.53 (m, 2H), 2.43 (s, 3H), 2.03-1.85 (m, 2H).
MH+ 459.
Example 601
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-cycloheptyl -lH-tetrazole
1H NMR (300 MHz, CDCl3) δ 7.42 (m, IH), 7.36-7.26 (m, 3H), 7.07-7.04 (m, 2H), 6.91-6.88 (m, IH), 4.13 (m, IH), 2.37 (s, 3H), 2.08-2.02 (m, 2H), 1.75-1.52 (m, 8H), 1.27-1.22 (m, 3H), 0.93-0.82 (m, 3H). MH+ 500.
Example 602 l-tert-Butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-l H-tetrazole
1H NMR (300 MHz, CDCl3) δ 7.44-7.43 (m, IH), 7.34-7.26 (m, 4H), 7.07-7.03 (m, 2H),
2.25 (s, 3H), 1.58 (s, 9H). MH+ 460.
Example 603
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-hexyl-lH-te trazole
1H NMR (300 MHz, CDCl3) δ 7.43-7.42 (m, IH), 7.32-7.23 (m, 2H), 7.07-7.04 (m, 2H), 6.94 (m, 1H),3.41 (q, J = 6.96 Hz, 2H), 2.38 (s, 3H), 1.63-1.25 (m, 7H), 0.91-0.85 (m, 4H). MH+ 489.
Example 604
5-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-l-octyl-lH-tet razole
1H NMR (300 MHz, CDCl3) δ 7.43-7.41 (m, IH), 7.31-7.24 (m, 3H), 7.10-7.03 (m, 2H), 6.94-6.92 (m, IH), 3.41 (q, J = 7.14 Hz, 2H), 2.38 (s, 3H), 1.62-0.85 (m, 15H). MH+ 516.
Example 605 l-Adamantyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)- lH-tetrazole
1H NMR (300 MHz, CDCl3) δ 7.47 (d, J = 2.22 Hz, IH), 7.34-7.28 (m, 4H), 7.15-7.12 (m, 2H), 2.42 (s, 6H), 2.20 (br, 3H), 2.12 (s, 3H), 1.76 (m, 6H). MH+ 541.
Example 606
S^S^-bromopheny^-l^l^-diclilorophenyl^-methyl-lH-pyrazol-S-yO-l-cyclopentyl- lH-tetrazole 1H NMR (400 MHz, CDCl3) δ 7.50-7 '.47 (m, 3H), 7.31-7.28 (m, IH), 7.20 (d, J = 8.8 Hz, IH), 7.06-7.03 (m, 2H), 5.73-5.69 (m, IH), 2.43 (s, 3H), 2.27-2.16 (m, 4H), 2.06-1.96 (m, 2H), 1.77-1.67 (m, 2H). MH+ 517.
Example 607
5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-cycloliexyl-l H-tetrazole
1H NMR (400 MHz, CDCl3) δ 7.52-7.48 (m, 3H), 7.29-7.26 (m, IH), 7.15 (d, J = 8.4 Hz, IH), 7.06-7.04 (m, 2H), 5.23-5.18 (m, IH), 2.42 (s, 3H), 2.18-2.15 (m, 2H), 2.03-2.00 (m, 2H), 1.93-1.90 (m, 2H), 1.41-1.34 (m, 4H). MH+ 531.
Example 608 5-(S-(4-bromophenyl)-l-(2,4-diclilorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-cyclolieptyl- lH-tetrazole '
1R NMR (400 MHz, CDCl3) δ 7.51-7.47 (m, 3H), 7.27 (dd, J - 8.4 Hz, J = 2.4 Hz, IH), 7.15 (d, J = 8.4 Hz, IH), 7.05-7.03 (m, 2H), 5.43-5.41 (m, IH), 2.41 (s, 3H), 2.21-2.15 (m, 4H), 1.86-1.82 (m, 2H), 1.66-1.63 (m, 4H), 1.51-1.49 (m, 2H). MH+ 545.
Example 609
5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l-cyclopentyl-l
H-tetrazole 1H NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 3H), 7.29-7.26 (m, IH), 7.20 (d, J = 8.8 Hz, IH), 7.08-7.04 (m, 2H), 5.72-5.65 (m, IH), 2.88-2.82 (m, 2H), 2.22-2.16 (m, 4H), 2.02-1.96 (m, 2H), 1.74-1.67 (m, 2H), 1.16 (t, J = 7.6 Hz, 3H). MH+ 531.
Example 610
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l-cyclopentyl-l H-tetrazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.46 (m, IH), 7.34-7.30 (m, 2H), 7.28-7.26 (m, IH), 7.20 (d, J = 8.4 Hz, IH), 7.14-7.11 (m, 2H), 5.71-5.67 (m, IH), 2.85 (q, J = 7.6 Hz, 2H), 2.22-2.16 (m, 4H), 2.02-1.97 (m, 2H), 1.73-1.69 (m, 2H), 1.16 (t, J = 7.6 Hz, 3H). MH+ 487.
Preparation of triazole (formula (Id))
Example 611
3-(5-(4-ChIorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyrazol-3-yl)-5-cyclopentyl -lH-l,2,4-triazole
A solution of 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazole- 3-carbonitrile (300 mg, 0.83 mmol), cyclopentanecarbohydrazide (116 mg, 0.90 mmol) and potassium carbonate (57 mg, 0.41 mmol) dissolved in 1-butanol (2 ml) was placed in a sealed tube, stirred at room temperature for 10 minutes and then refluxed at 150°C for 1 day. The mixture was cooled down to room temperature and methanol (4 ml) was added thereto, followed by filtering. The filtrate was purified by reverse phase preparative HPLC, to obtain the title compound as white solid.
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 2.32 Hz, IH), 7.35-7.27 (m, 3H), 7.07-7.03 (m, 2H), 3.32-3.23 (m, IH), 2.25 (s, 3H), 2.17-2.08 (m, 2H), 1.98-1.78 (m, 4H), 1.74-1.67 (m, 2H). MH+ 472.
The following compounds of Examples 612 to 636 were obtained by using corresponding starting materials and repeating the procedure of Example 611.
Example 612
3-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-cyclohexyl- lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.39-7.35 (m, 2H), 7.32-7.27 (m, 3H), 7.12-7.09 (m, 2H), 2.91-2.84 (m, IH), 2.43 (s, 3H), 2.17-2.10 (m, 2H), 1.87-1.83 (m, 2H), 1.75-1.73 (m, IH),
1.67-1.58 (m, 3H), 1.46-1.28 (m, 2H).
MH+ 486.
Example 613 3-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-phenyl-lH- 1,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 8.21-8.18 (m, 2H), 7.47-7.42 (m, 4H), 7.35-7.29 (m, 4H),
7.14-7.12 (m, 2H), 2.54 (s, 3H).
MH+ 480.
Example 614
3-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(thiophen-2
-yl)-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.44-7.43 (m, IH), 7.35-7.81 (m, 4H), 7.31-7.29 (m, IH), 7.14-7.11 (m, 2H), 7.07-7.03 (m, 2H), 2.25 (s, 3H).
MH+ 486.
Example 615 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cycloheptyl- lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.40-7.35 (m, 2H), 7.32-7.27 (m, 3H), 7.12-7.09 (m 2H), 3.11-3.04 (m, IH), 2.43 (s, 3H), 2.18-2.12 (m, 2H), 1.89-1.80 (m, 4H), 1.70-1.55 (m, 6H). MH+ 502.
Example 616
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(furan-2-yl)- lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.43 (m, IH), 7.34-7.27 (m, 5H), 7.14-7.10 (m, 2H), 7.07-7.04 (m, 2H), 2.25 (s, 3H). MH+Na 493.
Example 617
3-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-propyl-lH-l ,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.32 (m, 2H), 7.34-7.27 (m, 3H), 7.08-7.05 (m, 2H), 2.57-2.50 (m, 2H), 2.15 (s, 3H), 1.70-1.65 (m, 2H), 1.01-0.98 (m, 3H). MH+ 445.
Example 618
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-isopropyl-l H-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.40-7.26 (m, 5H), 7.12-7.09 (m 2H), 3.23-3.18 (m, IH), 2.44 (s, 3H), 1.43 (s, 3H), 1.41 (s, 3H). MH+ 447.
Example 619
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopropyl- lH-l,2,4-triazole 1H NMR (400 MHz, CDCl3) δ 7.40-7.27 (m, 5H), 7.12-7.09 (m, 2H), 2.41 (s, 3H), 2.10-2.04 (m, IH), 1.34-1.10 (m, 2H), 1.04-0.99 (m, 2H). MH+ 445.
Example 620 3-(5-(4-chlorophenyI)-l-(2,4-dichIorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-(cyclopropyl methyl)-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.42-7.26 (m, 5H), 7.14-7.08 (m, 2H), 2.97-2.80 (m, 2H), 1.58-1.48 (m, IH), 1.33-1.09 (m, 2H), 1.04-1.00 (m, 2H). MH+ 458.
Example 621
3-(5-(4-chlorophenyI)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-cyclobutyl-l
H-l,2,4-triazole 1H NMR (400 MHz, CDCl3) δ 7.46-7.43 (m, 2H), 7.34-7.27 (m, 3H), 7.07-7.04 (m, 2H), 3.51-3.47 (m, IH), 2.57-2.52 (m, 2H), 2.38-2.29 (m, 2H), 2.25 (s, 3H), 2.25-1.93 (m, 2H). MH+ 459.
Example 622 5-sec-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l H-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.40-7.27 (m, 5H), 7.13-7.09 (m, 2H), 3.10-2.93 (m, IH), 2.44 (s, 3H), 1.93-1.83 (m, IH), 1.76-1.67 (m, IH), 1.39 (d, J = 6.9 Hz, 3H), 0.93 (t, J = 7.3 Hz, 3H). MH+ 460.
Example 623
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopentyl- l-methyl-lH-l,2,4-triazole
A solution of 3-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol- 3-yl)-5-cyclopentyl-lH-l,2,4-triazole (400 mg, 0.82 mmol), iodomethane (0.19 ml, 2.5 mmol) and potassium hydroxide (138 mg, 2.5 mmol) dissolved in methanol (3 ml) was placed in a round bottom flask, stirred at room temperature for 1 day. After evaporation of the volatile solvent, the crude residue was purified by column chromatography to obtain the title compound (33Omg, 80%) as white solid.
1H NMR (400 MHz, CDCl3) δ 7.46-7.45 (m, IH), 7.33-7.27 (m, 3H), 7.22-7.20 (d, J = 8.7 Hz, IH), 7.11-7.08 (m, 2H), 4.11 (s, 3H), 3.28-3.20 (m, IH), 2.35 (s, 3H), 2.12-2.06 (m, 2H), 1.97-1.78 (m, 2H), 1.73-1.63 (m, 2H). MH+ 486.
Example 624 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l -methyl-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.45 (d, J = 2.32 Hz, IH), 7.33-7.27 (m, 3H), 7.22-7.20 (d, J = 8.2 Hz, IH), 7.11-7.08 (m, 2H), 4.12 (s, 3H), 2.83-2.77 (m, IH), 2.35 (s, 3H), 2.11-2.06 (m, 2H), 1.87-1.82 (m, 2H), 1.74-1.67 (m, 2H), 1.67-1.57 (m, 2H), 1.46-1.28 (m, 4H).
MH+ 500.
Example 625
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexyl-l -ethyl-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.46 (d, J = 2.3 Hz, IH), 7.33-7.27 (m, 3H), 7.20-7.18 (d, J = 8.2 Hz, IH), 7.11-7.07 (m, 2H), 4.55-4.50 (q, J = 6.9 Hz, 3H), 2.83-2.77 (m, IH), 2.35 (s, 3H), 2.11-2.05 (m, 2H), 1.87-1.82 (m, 2H), 1.75-1.67 (m, 2H), 1.67-1.57 (m, 2H), 1.47-1.44 (t, J = 7.4 Hz, 3H), 1.44-1.28 (m, 4H). MH+ 515.
Example 626
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cycIoliexyl-l
-isopropyl-lH-l,2,4-triazole 1H NMR (400 MHz, CDCl3) δ 7.46-7.45 (d, J = 2.3 Hz, IH), 7.33-7.25 (m, 3H), 7.21-7.19
(d, J = 8.2 Hz, IH), 7.11-7.07 (m, 2H), 5.28-5.22 (m, IH), 2.85-2.79 (m, IH), 2.31 (s, 3H),
2.07-2.03 (m, 2H), 1.89-1.81 (m, 2H), 1.73-1.62 (m, 2H), 1.51-1.49 (d, J = 6.4 Hz, 6H),
1.49-1.25 (m, 5H).
MH+ 530.
Example 627
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-metliyl-lH-pyrazol-3-yl)-5-cyclohexyl-l
-isopropyl-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.45 (d, J = 2.3 Hz, IH), 7.33-7.25 (m, 3H), 7.21-7.19 (d, J = 8.2 Hz, IH), 7.11-7.07 (m, 2H), 5.28-5.22 (m, IH), 2.85-2.79 (m, IH), 2.31 (s, 3H), 2.07-2.03 (m, 2H), 1.89-1.81 (m, 2H), 1.73-1.62 (m, 2H), 1.51-1.49 (d, J = 6.4 Hz, 6H), 1.49-1.25 (m, 5H). MH+ 530.
Example 628
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopropyl- l-methyl-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.46 (d, J = 2.3 Hz, IH), 7.34-7.25 (m, 3H), 7.20-7.17 (d, J = 8.1 Hz, IH), 7.10-7.08 (m, 2H), 4.1 (s, 3H), 2.32 (s, 3H), 2.12-2.07 (m, IH), 1.55-1.04 (m, 2H), 1.00-0.96 (m, 2H). MH+ 459.
Example 629 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)-5-cyclopropyl- l-ethyl-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.46 (d, J = 2.3 Hz, IH), 7.33-7.25 (m, 3H), 7.20-7.17 (d, J = 8.2 Hz, IH), 7.10-7.08 (m, 2H), 4.53-4.78 (q, J = 7.3 Hz, 2H), 2.32 (s, 3H), 2.12-2.07 (m, IH), 1.47-1.44 (t, J = 7.4 Hz, 3H), 1.54-1.03 (m, 2H), 1.00-0.96 (m, 2H). MH+ 473.
Example 630
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopropyl- l-isopropyl-lH-l,2,4-triazole 1H NMR (400 MHz, CDCl3) δ 7.46-7.45 (d, J = 2.3 Hz, IH), 7.33-7.25 (m, 3H), 7.20-7.18 (d, J = 8.2 Hz, IH), 7.10-7.08 (m, 2H), 5.28-5.24 (m, IH) 2.23 (s, 3H), 2.14-2.10 (m, IH), 1.51-1.49 (d, J = 6.4 Hz, 6H), 1.07-1.30 (m, 2H), 0.99-0.95 (m, 2H). MH+ 487.
Example 631
5-sec-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l- methyl-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.44 (d, J = 2.3 Hz, IH), 7.32-7.24 (m, 3H), 7.20-7.18 (d, J = 8.6 Hz, IH), 7.11-7.08 (m, 2H), 4.15 (s, 3H), 2.92-2.87 (m, IH), 2.34 (s. 3H), 1.91-1.83 (m, IH), 1.71-1.64 (m, IH), 1.37-1.36 (d, J = 7.3 Hz), 0.94 (t, J = 7.3 Hz, 3H). MH+ 475.
Example 632 5-sec-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyl-lH-pyrazol-3-yl)-l- ethyl-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.47-7.46 (d, J = 2.3 Hz, IH), 7.33-7.24 (m, 3H), 7.20-7.18 (d, J = 8.7 Hz, IH), 7.11-7.08 (m, 2H), 4.55-4.50 (q, J = 6.9 Hz, 2H), 2.92-2.87 (m, IH), 2.34 (s. 3H), 1.91-1.83 (m, IH), 1.71-1.64 (m, IH), 1.47-1.44 (t, J = 6.8 Hz, 3H), 1.37-1.35 (d, J = 7.4 Hz), 0.95-0.91 (t, J = 7.3 Hz, 3H). MH+ 489.
Example 633 5-sec-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l-i sopropyl-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 1.8 Hz, IH), 7.34-7.22 (m, 3H), 7.21-7.19 (d, J = 8.2 Hz, IH), 7.10-7.08 (m, 2H), 5.26-5.22 (m, IH), 2.91-2.88 (m, IH), 2.30 (s. 3H), 1.89-1.82 (m, IH), 1.70-1.64 (m, IH), 1.51-1.49 (d, 6.4 Hz, 6H), 1.36-1.34 (d, J = 7.3 Hz), 0.93-0.90 (t, J = 7.3 Hz, 3H). MH+ 503.
Example 634
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yI)-5-isopropyl-l- methyl-lH-l,2,4-triazole 1H NMR (400 MHz, CDCl3) δ 7.47-7.50 (d, J = 2.3 Hz, IH), 7.33-7.23 (m, 3H), 7.22-7.20 (m, IH), 7.11-7.08 (m, 2H), 4.12 (s, 3H), 3.14-3.08 (m, IH), 2.37 (s. 3H), 1.40-1.38 (d, J = 6.9 Hz, 6H). MH+ 461.
Example 635
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-isopropyl-l- ethyl-lH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.48-7.47 (d, J = 2.3 Hz, IH), 7.33-7.23 (m, 3H), 7.22-7.20 (d, J = 8.7 Hz, IH), 7.11-7.08 (m, 2H), 4.54-4.49 (q, J = 7.4 Hz, 2H), 3.20-3.15 (m, IH), 2.32 (s. 3H), 1.49-1.45 (t, J = 7.3 Hz, 3H), 1.41-1.39 (d, J = 6.9 Hz, 6H). MH+ 475.
Example 636 3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,5-diisopropy MH-l,2,4-triazole
1H NMR (400 MHz, CDCl3) δ 7.46-7.45 (d, J = 2.3 Hz, IH), 7.33-7.23 (m, 3H), 7.21-7.19 (d, J = 8.2 Hz, IH), 7.11-7.08 (m, 2H), 5.26-5.23 (m, IH), 3.17-3.10 (m, IH), 2.31 (s. 3H), 1.51-1.49 (d, J = 6.9 Hz, 6H), 1.39-1.37 (d, J = 7.3 Hz, 6H). MH+ 488.
Preparation of pyrazole (formula (89))
Example 637 5l-tert-butyl-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH,lΗ-3,3'-bipyrazo Ie
Step 1:
(Z)-l-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-3-hydroxy -4,4-dimethylpent-2-en-l-one (87)
To a solution of sodium amide (215 mg, 5.5 mmol) in THF (5 mL) was added pinacolone (1.0 M THF solution, 5 mL, 5.0 mmol). The reaction mixture was refluxed at 80 °C for 30 min and then ethyl 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazole-3-carboxylate (4) (2.05 g, 5.0 mmol) in THF (15 mL) was added. The resulting solution was stirred and refluxed at 80 °C overnight. HCl aquous solution (1.0M, 50 mL) was added and extracted organic layer with ethyl acetate (50 mL twice). The combined organic phase was evaporated under vacuum. The crude residue was further purified by prep HPLC to provide 0.862 g (1.86 mmol, 37%) of the title compound.
1H NMR (400 MHz, CDCl3) δ 7.44-41 (m, IH), 7.35-7.21 (m, 4H), 7.08-7.03 (m, 2H), 6.54 (s, IH), 2.36 (s, 3H), 1.24 (s, 9H). MH+ 463. Step 2:
5'-/ert-butyl-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH,lΗ-3,3'-bipyrazol e (89)
To a suspension of l-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazol-3-yl)-4,4-dimethylpentane-l,3-dione (555 mg, 1.20 mmol) (B) in EtOH (5.5 mL) was added hydrazine monohydrate (0.12 g, 2.4 mmol). The reaction mixture was refluxed at 90 °C for 6 hours. After cooled down to room temperature, the resulting suspension was dissolved by addition of THF (15 mL) and further purified by prep HPLC to provide 350 mg (0.761 mmol, 63%) of the title compound.
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.8 Hz, IH), 7.35-7.25 (m, 4H), 7.11 (d, J = 11.2 Hz, 2H), 6.54 (br s, IH), 2.33 (s, 3H), 1.38 (s, 9H). MH+ 459.
Preparation of oxazole (formula Ig))
Example 638 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexylo xazole
Step 1: tert-Butyl 2-(methoxy(methyl)amino)-2-oxoethylcarbamate
To a 2-(ter/-butoxycarbonylamino)acetic acid (800 mg, 4.57 mmol), N,O-dimethylhydroxylamine hydrochloride (535 mg, 5.48 mmol), EDCI (1.05 g, 5.48 mmol), HOBt (740 mg, 5.48 mmol) in DCM (25 mL) was added NMM (2.77 g, 27.42 mmol) at it. The reaction mixture was stirred overnight. After the reaction was completed, DCM was evaporated in vacuo. The residue was dissolved in MeOH, filtered through a syringe filter, and then purified by reverse-phase prep HPLC to provide the desired product (705 mg, 71 %) as white solid
Step 2: tert-Butyl 2-cyclohexyl-2-oxoethylcarbamate
To a tert-butyl 2-(methoxy(methyl)amino)-2-oxoethylcarbamate (400 mg, 1.83 mmol) in THF (10 mL) was added cyclohexylmagnesium chloride (4.12 mL, 8.24 mmol) portionwise at room temperature under N2 atmosphere. As addition of the Grignard reagent was completed, the reaction mixture was stirred and heated to reflux for an hour. Then the mixture was allowed to cool down to room temperature. The reaction was quenched by adding water (10 mL) slowly. IN HCl solution (30 mL) was added to the mixture, and extracted with EtOAc (20 mL x 3). The combined organic layers were collected and evaporated in vacuo. The crude material was purified by column chromatography (hexane: EtOAc = 10:1 to 5:1) to yield the desired product (110 mg, 25%).
Step3:
5-(4-chlorophenyl)-N-(2-cyclohexyl-2-oxoethyl)-l-(2,4-dichIorophenyl)-4-methyl-lH-py razole-3-carboxamide
To a ter/-butyl 2-cyclohexyl-2-oxoethylcarbamate (228 mg, 0.946 mmol) in DCM (5 mL) was added 4M HCl in 1,4-dioxane (5 mL) at room temperature. The reaction continued for an hour at room temperature. The volatiles were removed under vacuum.
To the residue (2-amino-l-cyclohexylethanone hydrochloric acid),
5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazole-3-carboxylic acid (361 mg, 0.946 mmol), EDCI (272 mg, 1.429 mmol), HOBt (192 mg, 1.429 mmol) in DMF (9 mL) was added NMM (1.0 mL, 9.46 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The residue was purified by reverse-phase prep
HPLC to afford the title compound (232 mg, 49%).
Step 4: 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexylo xazole
5-(4-chlorophenyl)-N-(2-cyclohexyl-2-oxoethyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazole-3-carboxamide (116 mg, 0.23 mmol) obtained in Step 3 was added to a microwave reactor containing Burgess reagent (165 mg, 0.689 mmol) in THF (2 mL). The capped reactor was placed in a microwave reactor and the mixture was irradiated at 160°C for 20 min. The reaction product was purified by reverse-phase prep HPLC to provide the title compound (62 mg, 55%) as white solid.
1H NMR (400 MHz, CDCl3) δ 7.40-7.26 (m, 5H), 7.13-7.09 (m, 2H), 6.86 (d, J = 0.93 Hz, IH), 2.78 (m, IH), 2.42 (s, 3H), 2.10 (m, 2H), 1.83-1.68 (m, 3H), 1.51-1.25 (m, 5H). MH+ 486.
The following compounds of Examples 639 to 644 were obtained by using corresponding starting materials and repeating the procedure of Example 638.
Example 639 5-butyI-2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyI)-4-methyl-lH-pyrazol-3-yl)oxazole
1H NMR (300 MHz, CDCl3) δ 7.40-7.28 (m, 5H), 7.14-7.09 (m, 2H), 6.91 (t, J = 1.0 Hz, IH), 2.74 (t, J = 7.6 Hz, 2H), 2.42 (s, 3H), 1.70 (m, 2H), 1.40 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). MH+ 460.
Example 640 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-ethyloxazole
1H NMR (400 MHz, CDCl3) δ 7.40-7.28 (m, 5H), 7.13-7.09 (m, 2H), 6.91 (t, J = 1.2 Hz, IH), 2.78 (q, J = 7.5Hz, 2H), 2.43 (s, 3H), 1.31 (t, J = 7.5 Hz, 3H). MH+ 432 .
Example 641
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-isobutyloxaz ole
1H NMR (400 MHz, CDCl3) δ 7.40-7.28 (m, 5H), 7.13-7.09 (m, 2H), 6.92 (br s, IH), 2.61 (d, J = 6.7 Hz, 2H), 2.43 (s, 3H), 2.05 (m, IH), 0.97 (d, J = 6.6 Hz, 6H). MH+ 460.
Example 642
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-4,5,6,7-tetrahy drobenzo [d] oxazole 1H NMR (400 MHz, CDCl3) δ 7.40-7.27 (m, 5H), 7.14-7.10 (m, 2H), 2.71 (m, 2H), 2.64 (m, 2H), 2.43 (s, 3H), 1.87-1.80 (m, 4H). MH+ 458.
Example 643 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopentylo xazole
1H NMR (400 MHz, CDCl3) δ 7.40-7.37 (m, 2H), 7.34-7.28 (m, 3H), 7.14-7.08 (m, 2H), 6.89 (s, IH), 3.21 (m, IH), 2.42 (s, 3H), 2.07 (m, 2H), 1.80-1.60 (m, 6H). MH+ 472.
Example 644
5-tert-butyl-2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)ox azole 1H NMR (400 MHz, CDCl3) δ 7.42-7.38 (m, 2H), 7.33-7.26 (m, 3H), 7.12-7.08 (m, 2H), 6.85 (d, J = 0.4 Hz, IH), 2.41 (s, 3H), 1.37 (s, 9H). MH+ 460.
Preparation of thiazole (formula (Ih))
Example 645
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclohexylth iazole
5-(4-chlorophenyl)-N-(2-cyclohexyl-2-oxoethyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1
H-pyrazole-3-carboxamide (116 mg, 0.23 mmol) obtained in Step 3 of preparation of oxazole was added to a microwave reactor containing Lawesson's reagent (186 mg, 0.46 mmol) in THF (2 mL). The capped reactor was placed in a microwave reactor and the mixture was irradiated at 1860°C for 30 min. The reaction product was purified by reverse-phase prep HPLC to provide the title compound (88 mg, 76%) as white solid.
1H NMR (400 MHz, CDCl3) δ 7.59 (br d, J = 0.8 Hz, IH), 7.40 (d, J = 2.0 Hz, IH), 7.37-7.27 (m, 4H), 7.13-7.08 (m, 2H), 2.89 (m, IH), 2.43 (s, 3H), 2.07 (m, 2H), 1.85-1.71 (m, 3H), 1.53-1.34 (m, 5H). MH+ 502.
The following compounds of Examples 646 to 649 were obtained by using corresponding starting materials and repeating the procedure of Example 645. Example 646
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-isobutylthia zole
1H NMR (400 MHz, CDCl3) δ 7.56 (s, IH), 7.40-7.26 (m, 5H), 7.12-7.09 (m, 2H), 2.73 (d, J = 7.0 Hz, 2H), 2.44 (s, 3H), 1.90 (m, IH), 0.97 (d, J = 6.8 Hz, 6H). MH+ 476.
Example 647
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-4,5,6,7-tetrahy drobenzo[d]thiazole
1H NMR (400 MHz, CDCl3) δ 7.41-7.37 (m, 2H), 7.34-7.25 (m, 3H), 7.12-7.08 (m, 2H), 2.84 (d, J = 18.8 Hz, 4H), 2.41 (s, 3H), 1.90 (m, 4H). MH+ 474.
Example 648
2-(5-(4-chlorophenyl)-l-(2,4-dichIorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-cyclopentylt hiazole
1H NMR (400 MHz, CDCl3) δ 7.60 (s, IH), 7.42-7.26 (m, 5H), 7.14-7.09 (m, 2H), 3.31 (m, IH), 2.44 (s, 3H), 2.16 (m, 2H), 1.90-1.60 (m, 6H). MH+ 488.
Example 649
5-tert-butyl-2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)tlii azole 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 0.4 Hz, IH), 7.42-7.27 (m, 5H), 7.14-7.10 (m, 2H),, 2.44 (s, 3H), 1.43 (s, 9H). MH+ 476.
Preparation of isoxazole (formula (90) and (91))
A solution of diketone (87) (200 mg, 0.43 mmol) and hydroxylamine hydrochloride (60 mg, 0.86 mmol) in EtOH (5 mL) was irradiated in a microwave reactor (Biotage) for 20 min. at 140 °C . Purification by Prep-LC (Gilson) provided 67 mg (34 %) of 5-t-butylisoxazole and 28 mg (14 %) of 3-t-butylisoxazole as solid. Example 650
5-tert-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyI-lH-pyrazol-3-yl)iso xazole (90) 1H NMR (400 MHz, CDCl3) δ 7.41(d, J = 2.4 Hz, IH), 7.31-7.29(m, 4H), 7.10(d, J = 9.6 Hz, 2H), 6.47(s, IH), 2.38(s, 3H), 1.38(s, 9H). MH+ 460.
Example 651 3-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)iso xazole (91)
1H NMR (400 MHz, CDCl3) δ 7.41(d, J = 1.6 Hz, IH), 7.32-7.29(m, 4H), 7.09(d, J = 4.4 Hz, 2H), 6.62(s, IH), 2.36(s, 3H), 1.38(s, 9H). MH+ 460.
Preparation of isothiazole
Example 652
5-tert-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)iso thiazole
A solution of diketone (20 mg, 0.043 mmol), hydroxylamine hydrochloride (9 mg, 0.13 mmol) and Lawesson reagent (52 mg, 0.13 mmol) in 1,4-dioxane (4 mL) was irradiated in a microwave reactor (Biotage) for 20 min. at 140°C . Purification by Prep-LC (Gilson) provided 1 mg (5 %) of desired isothiazole as solid.
1H NMR (400 MHz, CDCl3) δ 7.52(s, IH), 7.40(d, J = 2.0 Hz, IH), 7.35-7.28(m, 4H), 7.09(d, J = 6.4 Hz, 2H), 2.28(s, 3H), 1.41(s, 9H). MH+ 476.
Experiment 1 (Pharmacological Test): In vitro Activity Analysis
The compounds of the present invention were analyzed for their binding characteristics for CBi and CB2 and the pharmacological activity thereof in accordance with the method disclosed in [Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS and Howlett AC, Determination and characterization of a cannabinoid receptor in rat brain, MoI. Pharmacol, 34(5): 605-13(1998)]. The analysis was performed using [3H]CP-55940 which is a selectively radioactivity-labeled 5-(l,l-dimethyheptyl)-2[5-hydroxy-2- (3-hydroxypropyl)-cyclohexyl]-phenol, purchased from PerkinElmer Life Sciences, Inc. (Boston, Massachusetts, U.S.A.), through a rat CB-I receptor binding protocol as follows.
The tissue obtained from the brain of SD rats was homogenized with a Dounce homogenate system in TME(50 mM Tris, 3 mM MgCl2 and 1 mM EDTA, pH 7.4) at 4°C, and the homogenate was centrifuged at 48,00Og for 30 min. at 4°C . The pellet was resuspended in 5m£ of TME and the suspension was divided into aliquots and stored at -70 "C until its use in the following assay.
2 μi of the test compound was diluted in dimethylsulphoxide and was added to a deep well of a polypropylene plate, to which 50μC of [3H]CP-55940 diluted in a ligand buffer solution (0.1 % bovine serum albumin(BAS)+TME) was added. The tissue concentrations were determined by Bradford protein analysis, and 148 μi of brain tissue of the required concentration was added to the plate. The plate was covered and placed in a 30 °C incubator for 60 min, and then transformed on GF/B fϊltermat pretreated in polyethylenimine (PEI) using a cell harvester. Each filter was washed five times and dried at 60 °C for 1 hr. Then, the degree of radioactivity retained by the filter was measured using Wallac Microbeta™ (PerkinElmer Life Sciences, Inc., Massachusetts, U.S.A.) and the activity of the compound for inhibiting CB1 receptor was determined therefrom.
The examples of the present invention were tested in the cannabinoid- 1 receptor (CBlR) binding affinity assay (Table 1). AU of the preferred examples were shown to have binding affinities in the range of CBlR IC50 < 1.0 uM. Among them, more than twenty and less than thirty examples of the present invention were shown to have binding affinities in the range of IC50 < 3.0 nM, while rimonabant (SR141716) showed binding affinity in the range of IC50 = 5.O nM. Table 1. Cannabinoid-1 receptor (CBlR) binding affinity assay
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Experiment 2. Measurements of in vivo Activity Analysis
Male C57BL/6J mice weighing over 38 g were housed 1 per cage on a 12-/12-h light/dark cycle, had free access to food (rodent sterilizable diet) and water, and were experimentally native before testing. Mice were allowed at least 7 days to habituate to the experimental room prior to testing, and testing was conducted during the light period. Mice were maintained and experiments were conducted in accordance with the Institutional Animal Care.
The reference (rimonabant) and the inventive compounds of Examples 132, 155 and 502 were prepared fresh daily by dissolving it in deionized water containing 10% DMSO. By oral administration, animals received at a volume of 10 ml/kg for 14 days. All control animals received 10% DMSO dissolved in deionized water.
The vehicles 10% DMSO treated group were comprised of 5 mice in oral test.
There were 6 mice in each of the other experimental groups (n = 6 in each group). By oral administration, the losing weight was checked everyday for the drug treated group and the control group.
Fig. 1 shows chronic effects of compounds of Examples 132, 155, 502 and rimonabant in DIO mice. Body weight change from day 0 was observed on all days at 10 mg/kg of Example 132 compound, at 10 mg/kg of Example 155 compound, at 10 mg/kg of Example 502 compound, and at 10 mg/kg of rimonabant.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000241_0001
wherein:
Ri is hydrogen, C1-5 alkyl, substituted C1-5 alkyl, C2-4 alkenyl, substituted C2-4 alkenyl, C2-4 alkynyl, substituted C2-4 alkynyl, halogen, or -(CH2)n-C3-5 carbocycle, n being 0 or 1 ;
R2 is hydrogen, NR3R4, carbocycle, substituted carbocycle, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, C1-8 alkyl optionally substituted with hydroxy, acyloxy, Ci-6 alkoxy, substituted C1-6 alkoxy; C3-5 alkenyloxy, substituted C3-5 alkenyloxy; C3-5 alkynyloxy, substituted C3-5 alkynyloxy; aryloxy, substituted aryloxy; heteroaryloxy, substituted heteroaryloxy or halogen, C2-6 alkenyl optionally substituted with alkoxy or halogen, C2-6 alkynyl optionally substituted with alkoxy or halogen, -(CH2)m-C3-6 carbocycle optionally substituted with alkoxy or halogen, or -(CH2)m-R5, m being 1 or 2;
R3 and R4 are each independently hydrogen, Ci-6 alkyl, substituted Cj-6 alkyl, C3-7 cycloalkyl, substituted C3-7 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl; or
R3 and R4, together with the nitrogen atom to which they are bonded, form a 4- to 10-membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more Cj-3 alkyl, benzyl, phenyl, Ci-3 alkoxy or halogen;
R5 is phenyl, furanyl, benzofuranyl, thienyl, benzothienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridizinyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, 1 ,4-benzodioxanyl or benzo[l,3]dioxolyl, each being optionally substituted with one or more halogen, Ci-3 alkyl and Ci-2 alkoxy, each optionally having one to three fluorine substitutes;
R6, R7, R8, Rς>, Rio and Rn are each independently hydrogen, halogen, Ci-3 alkyl, Ci-3 alkoxy or trifluoromethyl; -C(Ri2)=, -O-, -N=, -N(Ri3)- and -S- to form an aromatic heterocycle together with Q and T;
Q and T are each independently ™~ or ^ , with the proviso that both
Q and T can not be simultaneously <*~ ; and
Ri2 and R13 are each independently hydrogen, NR3R4, carbocycle, substituted carbcycle, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, Ci-8 alkyl optionally substituted with alkoxy or halogen, C2-6 alkenyl optionally substituted with alkoxy or halogen, C2-6 alkynyl optionally substituted with alkoxy or halogen, -(CH2)m-C3-6 carbocycle optionally substituted with alkoxy or halogen, or -(CH2)m-R5, m being 1 or 2, and R3 s R4, and R5 having the same meaning as defined above; or
R2 and R12 are bonded together to form a 4- to 10-membered saturated or unsaturated carbocyclic or heterocyclic ring which is optionally substituted with one or more Ci-3 alkyl, benzyl, phenyl, Ci-3 alkoxy or halogen.
2. The compound of claim 1, which is a compound of formula (Ia), (Ib), (Id), (Ie), (If), (Ig) or (Di):
Figure imgf000242_0001
Figure imgf000243_0001
wherein R1, R2, R3, R4, R6, R7, Rs, R9, Rio, Rn, R12 and Ri3 have the same meanings as defined in claim 1 ; with the proviso that when the compound of claim 1 is a compound of formula (Ia) and R1 is Ci-5 alkyl, R2 represents (i) or (ii)
Figure imgf000244_0001
(i) wherein Rla is C1-6 alkyl, substituted Cj-6 alkyl; C2-4 alkenyl, substituted C2-4 alkenyl; C2-4 alkynyl, substituted C2-4 alkynyl; CN, carboxy, aminocarbonyl; aryl, substituted aryl; heteroaryl, substituted heteroaryl;
Figure imgf000244_0002
(ϋ) wherein R^ is hydrogen, acyl, C1-6 alkyl, substituted C1-6 alkyl; C3-5 alkenyl, substituted C3-5 alkenyl; C3-5 alkynyl, substituted C3-5 alkynyl; aryl, substituted aryl; heteroaryl, substituted heteroaryl.
3. A compound according to claim 1 selected from the group consisting of:
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (pyridin-4-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5-methyl- 1,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- cyclopentyl- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3 ,4-thiadiazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - ethyl- 1 H-tetrazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-5- (furan-2-yl)- 1 ,3 ,4-oxadiazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclopentyl- 1 H-tetrazole,
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- cyclopentyl-2H-tetrazole,
1 -benzyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- lH-tetrazole,
2-benzyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 2H-tetrazole,
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- cyclohexyl-2H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclohexyl- 1 H-tetrazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (pyrazin-2-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (pyrazin-2-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (thiophen-2-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (thiophen-2-yl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (pyridin-2-ylmethyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- isopropyl- 1 ,3 ,4-thiadiazole,
2-benzyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1,3,4-thiadiazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)- 1 - propyl- 1 H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-2- propyl-2H-tetrazole,
3-((5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H- tetrazol- 1 -yl)methyl)pyridine,
3-((5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-2H- tetrazol-2-yl)methyl)pyridine,
2-((5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H-tetrazol- 1 -yl)methyl)pyridine,
2-((5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2H- tetrazol-2-yl)methyl)pyridine, 4-((5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H- tetrazol- 1 -yl)methyl)pyridine,
4-((5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2H- tetrazol-2-yl)methyl)pyridine,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - (furan-2-ylmethyl)- 1 H-tetrazole,
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- (furan-2-ylmethyl)- 1 H-tetrazole,
2-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)- 1,3,4-thiadiazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - (furan-3-ylmethyl)-lH-tetrazole,
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- (furan-3 -ylmethyl)-2H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - phenyl- 1 H-tetrazole,
1 -butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 H-tetrazole,
2-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 2H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - pentyl- 1 H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-2- pentyl-2H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)- 1 - isopropyl- 1 H-tetrazole,
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- isopropyl-2H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)- 1 - (cyclohexylmethyl)- 1 H-tetrazole,
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- (cyclohexylmethyl)-2H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)- 1 - (thiophen-3-ylmethyl)- 1 H-tetrazole,
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-2- (thiophen-3-ylmethyl)-2H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cycloheptyl- 1 H-tetrazole,
1 -tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - octyl- 1 H-tetrazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- phenyl- 1 ,3 ,4-thiadiazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - hexyl- 1 H-tetrazole,
1 -Adamantyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclopropyl- 1 H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - phenethyl- 1 H-tetrazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-2- phenethyl-2H-tetrazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclopentylmethyl)- 1 ,3 ,4-thiadiazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclobutyl- 1 H-tetrazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentyl- IH-1 ,2,4-triazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (tetrahydro-2H-pyran-4-yl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (tetrahydrofuran-2-yl)- 1 ,3,4-thiadiazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- phenyl- 1 H- 1 ,2,4-triazole,
2-(benzofuran-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazol-3-yl)-l,3,4-oxadiazole, 2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- pentyl- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- cycloheptyl- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2,4-dichlorophenyl)- 1 ,3,4-thiadiazole,
3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (thiophen-2-yl)- 1 H- 1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cycloheptyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (furan-2-yl)- 1 H- 1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- propyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- isopropyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopropyl-lH-l,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclopropylmethyl)- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- cyclobutyl- IH-1 ,2,4-triazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclopentylmethyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (tetrahydro-2H-pyran-4-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (tetrahydrofuran-2-yl)- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentyl-1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -phenylethyl)- 1 ,3 ,4-thiadiazole,
2-sec-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (pentan-2-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- tert-butyl- 1 ,3,4-thiadiazole,
5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-N- cyclohexyl- 1 ,3 ,4-thiadiazol-2-amine,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclohex-3-enyl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5 - (cyclohex-3-enyl)-l,3,4-thiadiazole,
5-sec-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazol-3-yl)- 1 H- 1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 -isopropyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopropyl- 1 -methyl- IH-1 ,2,4-triazole,
4-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)- 1 - cyclopentyl- IH-1 ,2,3 -triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentyl- 1 -methyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 -methyl- IH-1 ,2,4-triazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclopropylmethyl)- 1 ,3 ,4-thiadiazole,
2-(4-tert-butylcyclohexyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4- methyl-lH-pyrazol-3-yl)-l,3,4-thiadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclopropylmethyl)- 1 ,3,4-oxadiazole, 2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- cyclohexyl- 1 ,3 ,4-thiadiazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopropyl- 1 -ethyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopropyl- 1 -isopropyl- IH-1 ,2,4-triazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- cyclohexyl- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclopent-3 -enyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclopent-3-enyl)-l,3,4-thiadiazole,
5-sec-butyl-3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 -methyl- IH-1 ,2,4-triazole,
5-sec-butyl-3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 -ethyl- IH-1 ,2,4-triazole,
5-sec-butyl-3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)- 1 -isopropyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- isopropyl- 1 -methyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - ethyl-5 -isopropyl- IH-1 ,2,4-triazole,
3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,5- diisopropyl- IH-1 ,2,4-triazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- cyclopentyl- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cycloheptyl-1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (hexan-2-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (hexan-2-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -phenylpropan-2-yl)- 1 ,3 ,4-thiadiazole,
5-butyl-2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3- yl)oxazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ethyloxazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- isobutyloxazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- isobutylthiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -cyclobutylpropan-2-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexyloxazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclohexylthiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (cyclohexylmethyl)- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (hexan-2-yl)-l ,3,4-thiadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)- 1,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5 ,6- dihydro-4H-cyclopenta[d]thiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-4,5,6,7- tetrahydrobenzo[d]oxazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-4,5,6,7- tetrahydrobenzo [d] thiazole, 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-5- cyclopentyloxazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclopentylthiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -cyclopentylethyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chloropheηyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -cyclopentylethyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -cyclohexylethyl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (1 -cyclohexylethyl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5 - (2-cyclopentylpropan-2-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-cyclopentylpropan-2-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-cyclohexylpropan-2-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-cyclohexylpropan-2-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2,2-dichloro-l-methylcyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- lH-pyrazol-3-yl)-5- cyclobutyl-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- cyclopentyl-1 ,3,4-thiadiazole,
5-tert-butyl-2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazol-3-yl)oxazole,
5-tert-butyl-2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH- pyrazol-3 -yl)thiazole ,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- cycloheptyl- 1 ,3 ,4-thiadiazole,
2-sec-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)- 1,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- sec-butyl- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- cycloheptyl- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-phenylpropan-2-yl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-(4-chlorophenyl)propan-2-yl)-l,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- sec-butyl-1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (2-phenylpropan-2-yl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-(pyridin-2-yloxy)propan-2-yl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-l H-pyrazol-3 -yl)-5- (2-(5-(trifluoromethyl)pyridin-2-yloxy)propan-2-yl)-l,3,4-oxadiazole,
2-tert-butyl-5-( 1 -(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5 - (2-methylhexan-2-yl)- 1 ,3 ,4-thiadiazole,
2-sec-butyl-5-( 1 -(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1,3,4-thiadiazole,
2-( 1 -(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5- cyclohexyl- 1 ,3 ,4-thiadiazole,
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole,
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole,
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (hexan-2-yl)- 1 ,3,4-thiadiazole, 2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (pentan-2-yl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (pentan-2-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (pentan-2-yl)- 1 ,3,4-thiadiazole,
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-methylhexan-2-yl)- 1 ,3 ,4-thiadiazole,
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-phenylpropan-2-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- sec-butyl-l,3,4-thiadiazole,
2-(l -(allyloxy)-2-methylpropan-2-yl)-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 4-methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-methoxypropan-2-yl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-methoxypropan-2-yl)- 1 ,3,4-oxadiazole,
2-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-5-tert-pentyl-l,3,4- thiadiazole,
2-tert-butyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,3,4- thiadiazole,
2-sec-butyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,3,4- thiadiazole,
2-cyclobutyl-5-(l-(2,4-dichlorophenyl)-4-methyl-5-phenyl-lH-pyrazol-3-yl)-l,3,4- thiadiazole,
2-(5-(4-bromophenyl)- 1 -(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- cyclohexyl-1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- cyclobutyl-1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2-chlorophenyl)-4-methyl- lH-pyrazol-3-yl)-5- sec-butyl- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2-chlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole,
(3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl acetate,
(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl benzoate,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclobutyl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-thiadiazole,
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
2-tert-butyl-5-(5-(3-chlorophenyl)- 1 -(2,4-dichloroρhenyl)-4-methyl- 1 H- pyrazol-3-yl)-l ,3,4-thiadiazole,
2-sec-butyl-5-(5-(3-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)-l ,3,4-thiadiazole,
2-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-ethoxypropan-2-yl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-ethoxypropan-2-yl)- 1 ,3,4-oxadiazole, 2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(fluoromethyl)-lH- pyrazol-3-yl)-l ,3,4-oxadiazole,
2-(4-(butoxymethyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3-yl)- 5-tert-butyl-l,3,4-oxadiazole,
(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methanol,
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole,
2-(5-(3-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3,4-thiadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(methoxymethyl)- 1 H- pyrazol-3-yl)- 1 ,3,4-oxadiazole,
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5-tert-butyl- 1,3,4- thiadiazole,
2-(l ,5-bis(4-chlorophenyl)-4-methyl- lH-pyrazol-3-yl)-5-sec-butyl- 1 ,3,4- thiadiazole,
2-(l,5-bis(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-thiadiazole,
2-( 1 ,5-bis(4-chlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)-5 -tert-pentyl- 1,3,4- thiadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(phenoxymethyl)- 1 H- pyrazol-3 -yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-propoxypropan-2-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-propoxypropan-2-yl)- 1 ,3 ,4-thiadiazole,
3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazole-4-carbaldehyde,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-((pyridin-2- yloxy)methyl)- 1 H-pyrazol-3-yl)- 1 ,3,4-oxadiazole,
2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-oxadiazole,
2-(4-chloro-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3-yl)-5- cyclobutyl- 1 ,3 ,4-thiadiazole,
2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3,4-oxadiazole,
2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3,4-thiadiazole,
2-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3,4-oxadiazole,
2-(4-chloro-5-(4-chlorophenyl)-l -(2,4-dichlorophenyl)- lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3 ,4-thiadiazole,
2-sec-butyl-5-(4-chloro-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3 - yl)- 1 ,3 ,4-oxadiazole,
2-sec-butyl-5-(4-chloro-5-(4-chlorophenyl)-l-(2,4-dictøorophenyl)-lH-pyrazol-3- yl)- 1 ,3 ,4-thiadiazole,
2-tert-butyl-5-(4-chloro-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3- yl)- 1 ,3 ,4-oxadiazole,
2-tert-butyl-5-(4-chloro-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3- yl)- 1 ,3,4-thiadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(difluoromethyl)-lH- pyrazol-3-yl)-l ,3,4-oxadiazole,
2-tert-butyl-5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-( 1 -methoxyethyl)- 1 H- pyrazol-3-yl)-l ,3,4-oxadiazole, l-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanone,
2-tert-butyl-5-(l-(2,4-dichlorophenyl)-5-(4-(methylthio)phenyl)-4- (methylthiomethyl)-lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(piperidin-l-ylmethyl)- 1 H-pyrazol-3 -yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-phenylcyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole,
2-(bicyclo[2.2.1]heptan-2-yl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl- lH-pyrazol-3-yl)-l,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- isopropyl- 1 ,3 ,4-thiadiazole, 2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (pentan-3-yl)-l ,3,4-thiadiazole,
2-(5-(4-Bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (1 -methylcyclohexyl)- 1 ,3,4-thiadiazole,
(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methylcarbamate,
N-((3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl) - 1 H-pyrazol-4-yl)methyl)-N-methylethanamine,
5'-tert-butyl-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H, 1 Η-3,3'- bipyrazole,
2-(4-(( 1 H-imidazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-oxadiazole,
5-tert-butyl-3-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3- yl)isoxazole,
3-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3- yl)isoxazole,
2-(l-(benzyloxy)pentyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-l,3,4-thiadiazole, l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4- oxadiazol-2-yl)pentan- 1 -ol,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(pyrrolidin-l- ylmethyl)- 1 H-pyrazol-3 -yl)- 1 ,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole, l-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl)pyrrolidine-2,5-dione,
1 -(3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanol,
2-tert-butyl-5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-( 1 -fluoroethyl)- 1 H- pyrazol-3-yl)-l ,3,4-oxadiazole, l-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl)pyrτolidin-2-one,
3-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl)oxazolidin-2-one,
S-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methyl ethanethioate,
4-((3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl)morpholine,
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-oxadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l -(2,4-dichlorophenyl)- lH-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- sec-butyl- 1 ,3,4-oxadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- sec-butyl- 1 ,3,4-thiadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-oxadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- cyclobutyl- 1 ,3,4-thiadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- cyclohexyl- 1 ,3 ,4-oxadiazole,
2-(4-bromo-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3-yl)-5- cyclohexyl- 1 ,3 ,4-thiadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3,4-oxadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- tert-pentyl- 1 ,3 ,4-thiadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-lH-pyrazol-3-yl)-5- (2-(4-chlorophenyl)propan-2-yl)- 1 ,3,4-oxadiazole,
2-(4-bromo-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3-yl)-5 - (2-(4-chlorophenyl)propan-2-yl)- 1 ,3 ,4-thiadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)- 1,3,4-oxadiazole,
2-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)propan-2-ol, (( 1 R,2S)-2-(5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H- pyrazol-3-yl)-l,3,4-oxadiazol-2-yl)cyclopropyl)(piperidin-l-yl)methanone,
2-(2-butoxypropan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-(2-butoxypropan-2-yl)- 5 -(5 -(4-chlorophenyl)- 1 -(2 ,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3,4-thiadiazole,
2-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (l-p-tolylcyclopropyl)-l,3,4-oxadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(prop- 1 -en-2-yl)- 1 H- pyrazol-3-yl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-p-tolylcyclopropyl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-(pentyloxy)propan-2-yl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2-(pentyloxy)propan-2-yl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(trifluoromethyl)cyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethyOcyclopropyl)- 1 ,3 ,4-thiadiazole ,
5-tert-butyl-3-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3- yl)isothiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
(3-(5-tert-butyl- 1 ,3, 4-oxadiazol-2-yl)-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methanethiol,
2-(4-(( 1 H-pyrazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-thiadiazole,
3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-4-yl acetate,
(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl acetate,
2-(4-(( 1 H-pyrrol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-oxadiazole,
2-(4-bromo-5-(4-chlorophenyl)-l -(2,4-dichlorophenyl)- lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(4-bromo-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-3 -yl)-5 - ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(trifluoromethyl)cyclobutyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (1 -(trifluoromethyl)cyclobutyl)- 1 ,3,4-thiadiazole,
2-(2-(benzyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4- methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2,2,2-trifluoroethyl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2,2,2-trifluoroethyl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,3-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole,
2-(l-(4-chlorophenyl)cyclopropyl)-5-(l-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)- 4-methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,3-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)acetonitrile, 2-(l -(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(l-(2-chlorophenyl)-5-(4-chlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclobutyl)-l,3,4-oxadiazole,
N-((3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl) - 1 H-pyrazol-4-yl)methyl)-2-methylpropan-2-amine,
N-((3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl) - 1 H-pyrazol-4-yl)methyl)propan-2-amine,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-p-tolylcyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (1 -(trifluoromethyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (l-(3-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (l-(3-chlorophenyl)cyclopropyl)-l, 3 ,4-oxadiazole,
2-( 1 -allylcyclopropyl)-5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H- pyrazol-3-yl)-l ,3,4-oxadiazole,
5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclopentyl- 1 H-tetrazole,
5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cyclohexyl- 1 H-tetrazole,
5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 - cycloheptyl- 1 H-tetrazole,
2-(l-(2-bromophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole,
2-(l-(2-bromophenyl)-5-(4-chlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,6-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,6-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclobutyl)-l,3,4-oxadiazole,
(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methanol,
5-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3 -yl)- 1 - cyclopentyl- 1 H-tetrazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-(fluoromethyl)- 1 H-pyrazol-3-yl)-5- tert-butyl- 1 ,3,4-oxadiazole,
5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)- 1 - cyclopentyl- 1 H-tetrazole,
5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazole-4-carbaldehyde,
2-(4-(( 1 H- 1 ,2,3-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,5-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,5-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethynyl-lH-pyrazol-3- yl)- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3 -yl)-5- ( 1 -propylcyclopropyl)- 1 ,3,4-oxadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(prop- 1 -ynyl)- IH- pyrazol-3-yl)-l ,3,4-oxadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-(3-(trimethylsilyl)prop- 2-ynyl)-lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-(4-(( 1 H-tetrazol- 1 -yl)methyl)-5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole, 2-(4-(( 1 H-tetrazol-5-yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-oxadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(propa- 1 ,2-dienyl)- 1 H- pyrazol-3 -yl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)propan-2-ol,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-(prop- 1 -en-2-yl)- 1 H-pyrazol-3-yl)- 5-tert-butyl- 1 ,3,4-oxadiazole,
2-( 1 -(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethytycyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (1 -p-tolylcyclopropyl)- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-( 1 -fluoroethyl)- 1 H-pyrazol-3-yl)-5- tert-butyl- 1 ,3,4-oxadiazole, l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanol,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)-5-tert-butyl- 1,3,4-oxadiazole,
1 -(5-(4-bromophenyl)-3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethylcarbamate,
1 -(5-(4-bromophenyl)-3-(5-tert-butyl- 1 ,3,4-oxadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanone, l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-oxadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanone, l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4- oxadiazol-2-yl)cyclopropanecarbonitrile,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -(pyridin-2-yl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-isopropyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-propyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-oxadiazole,
(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl acetate,
(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methanol,
2-(l-benzylcyclopropyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-(l-benzylcyclopropyl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3 -yl)- 1 ,3 ,4-oxadiazole,
2-(l-benzylcyclopropyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl- lH-pyrazol-3-yl)-l,3,4-thiadiazole,
2-(l-benzylcyclopropyl)-5-(5-(4-bromorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl- lH-pyrazol-3-yl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (l-methylcyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-methylcyclopropyl)-l,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3 -yl)-5- ( 1 -methylcyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -methylcyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(l -(4-chlorobenzyl)cyclopropyl)-5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4- methyl-lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-(l-(4-chlorobenzyl)cyclopropyl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4- methyl- 1 H-pyrazol-3-yl)- 1 ,3,4-thiadiazole,
2-(l-(4-chlorobenzyl)cyclopropyl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4- ethyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole,
2-(l-(4-chlorobenzyl)cyclopropyl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4- ethyl-lH-pyrazol-3-yl)-l,3,4-thiadiazole, 2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-(methoxymethyl)- 1 H-pyrazol-3-yl) -5-tert-butyl- 1 ,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (l-p-tolylcyclopropyl)-l,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopropyl)-l,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(2,4-dichlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (l-phenylcyclopropyl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (1 -p-tolylcyclopropyl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-methoxyphenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (l-(2,4-dichlorophenyl)cyclopropyl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclobutyl)- 1 ,3,4-thiadiazole,
(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)-l- (2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methyl acetate,
(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)-l- (2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methanol,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(fluoromethyl)- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)-l- (2,4-dichlorophenyl)- 1 H-pyrazole-4-carbaldehyde,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -methylcyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-methylcyclopropyl)-l,3,4-thiadiazole,
1 -(I -(5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazol-2-yl)cyclopropyl)ethanone,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-(fluoromethyl)-lH-pyrazol-3-yl)-5- tert-butyl-l,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-((5-(trifluoromethyl)pyridin-2- yloxy)methyl)-lH-pyrazol-3-yl)-5-tert-butyl-l,3,4-thiadiazole,
2-(4-(( IH- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3 -yl)-5 -tert-butyl- 1 ,3 ,4-thiadiazole,
5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)-lH -pyrazole-4-carbaldehyde,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-cyclobutyl-l,3,4-oxadiazole,
2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-cyclohexyl-l,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-( 1 -phenylcyclopropyl)- 1 ,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -p-tolylcyclopropyl)-l ,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -(4-methoxyphenyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(2,4-dichlorophenyl)cyclopropyl)-l,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-cyclobutyl- 1 ,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-cyclohexyl-l,3,4-thiadiazole,
2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -phenylcyclopropyl)- 1 ,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-p-tolylcyclopropyl)-l,3,4-thiadiazole,
2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-methoxyphenyl)cyclopropyl)-l,3,4-thiadiazole, 2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(2,4-dichlorophenyl)cyclopropyl)-l,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(trifluoromethyl)cyclopropyl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -ethylcyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -ethylcyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (l-ethylcyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopentyl)- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-phenylcyclopentyl)-l,3,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopentyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(4-chlorophenyl)cyclopentyl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -phenylcyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -ethylcyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -ethylcyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -ethylcyclopropyl)- 1 ,3 ,4-thiadiazole, l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,3,4- oxadiazol-2-yl)cyclopropanecarbonitrile, l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-l,3,4- thiadiazol-2-yl)cyclopropanecarbonitrile,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(trifluoromethyl)cyclobutyl)-l,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclobutyl)-l,3,4-oxadiazole,
2-(4-((1H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-S-yO-S-Cl-phenylcyclopenty^-ljS^-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclopentyl)-l,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(trifluoromethyl)cyclobutyl)-l,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclobutyl)-l,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-phenylcyclopentyl)-l,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l-(4-chlorophenyl)cyclopentyl)-l,3,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- (1 -(4-fluorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(4-fluorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(3-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(3-chlorophenyl)cyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- lH-pyrazol-3-yl)-5- ( 1 -(3-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(3-chlorophenyl)cyclopropyl)- 1 ,3,4-thiadiazole,
5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazole-4-carbaldehyde,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-(prop- 1 -en-2-yl)- 1 H-pyrazol-3-yl)- 5-tert-butyl-l ,3,4-thiadiazole,
2-(4-((2H-tetrazol-2-yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole,
2-(4-(( 1 H-tetrazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-fluorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (l-(4-fluorophenyl)cyclopropyl)-l,3,4-thiadiazole, 2-(l-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3- yl)- 1 ,3,4-oxadiazol-2-yl)cyclopropyl)propan-2-ol,
1 -( 1 -(5 -(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 - yl)- 1 ,3 ,4-oxadiazol-2-yl)cyclopropyl)ethanol,
2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4- oxadiazol-2-yl)-2-methylpropyl acetate,
2-(5-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -y I)- 1 ,3,4- oxadiazol-2-yl)-2-methylpropan- 1 -ol,
2-(5-(4-Chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)-5- (2-(2-fluorobenzyloxy)propan-2-yl)- 1 ,3,4-oxadiazole,
2-(2-(3-Chlorobenzyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)- 1 - (2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-ethyl- lH-pyrazol-3-yl)-l,3,4-oxadiazole,
3-(2-(5-(5-(4-bromophenyl)-l -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3 -yl)- 1 ,3,4- oxadiazol-2-yl)propan-2-yloxy)propan- 1 -ol,
2-(2-(allyloxy)propan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4- ethyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-((2-methyl-2H- tetrazol-5-yl)methyl)- 1 H-pyrazol-3-yl)- 1 ,3,4-oxadiazole,
2-tert-butyl-5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-((l-methyl-lH- tetrazol-5-yl)methyl)-lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)- 1 -(2-chlorophenyl)-5-(4-chlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl- 1 ,3,4-oxadiazole, l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l- (2,4-dichloro phenyl)- 1 H-pyrazol-4-yl)ethanol,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-( 1 -fluoroethyl)- 1 H-pyrazol-3-yl)-5- tert-butyl- 1 ,3 ,4-thiadiazole,
2-(5-(4-bromophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)-5-tert-butyl -1,3,4-thiadiazole,
1 -(5-(4-bromophenyl)-3-(5-tert-butyl- 1 ,3,4-thiadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethylcarbamate, l-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanone,
2-(l-(Benzyloxy)-2-methylpropan-2-yl)-5-(5-(4-chlorophenyl)-l-(2,4- dichlorophenyl)-4-methyl- 1 H-pyrazol-3-yl)- 1 ,3 ,4-oxadiazole, l-(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanol,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-(difluoromethyl)- 1 H-pyrazol-3-yl)- 5 -( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-isopropyl- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-isopropyl- 1 H-pyrazol-3-yl)-5- ( 1 -(trifluoromethy^cyclopropyl)- 1 ,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-isopropyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethytycyclopropyl)- 1 ,3 ,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5- ( 1 -(trifluoromethyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-propyl-lH-pyrazol-3-yl)-5- (1 -(trifluoromethyl)cyclopropyl)-l ,3,4-thiadiazole,
2-(5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-( 1 -fluoroethyl)- 1 H-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
1 -(5-(4-chlorophenyl)-3 -(5-( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethanone,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(trifluoromethyl)cyclopropyl)-l,3,4-thiadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- ( 1 -(2-fluorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(2-fluorophenyl)cyclopropyl)-l,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-tert-butyl-l,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)- 1 -(2-chlorophenyl)-5-(4-chlorophenyl)- 1 H-pyr azol-3-yl)-5-tert-butyl-l,3,4-thiadiazole,
(3-(5-tert-butyl- 1 ,3,4-thiadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- lH-pyrazol-4-yl)methyl acetate,
(3-(5-tert-butyl- 1 ,3,4-thiadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)methanol,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-vinyl-lH-pyrazol-3-yl)-5- ( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3 ,4-oxadiazole, l-(5-(4-chlorophenyl)-3-(5-(l-(4-chlorophenyl)cyclopropyl)-l,3,4-oxadiazol-2-yl)- 1 -(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)ethylcarbamate,
2-(5-(5 -(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methyl- 1 H-pyrazol-3 -yl)- 1,3,4- oxadiazol-2-yl)propan-2-yl acetate,
2-(5-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4- oxadiazol-2-yl)propan-2-ol,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -methylcyclopropyl)-l ,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- IH- pyrazol-3-yl)-5-(l -(trifluoromethyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-( 1 -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-oxadiazole,
2-(4-(( IH- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-( 1 -methylcyclopropyl)- 1 ,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -(trifluoromethyl)cyclopropyl)- 1 ,3,4-thiadiazole,
2-(4-(( 1 H- 1 ,2,4-triazol- 1 -yl)methyl)-5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)- 1 H- pyrazol-3-yl)-5-(l -(4-chlorophenyl)cyclopropyl)- 1 ,3,4-thiadiazole,
2-(5-(4-Chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- (2 -methyl- 1 -(4-(trifluoromethyl)benzyloxy)propan-2-yl)- 1 ,3 ,4-oxadiazole,
2-(l-(4-Chlorobenzyloxy)-2-methylpropan-2-yl)-5-(5-(4-chlorophenyl)-l- (2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-l,3,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-lH-pyrazol-3-yl)-5- ( 1 -( 1 -fluoroethyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-ethyl-lH-pyrazol-3-yl)-5- (l-(cyclopropylmethyl)cyclopropyl)-l,3,4-oxadiazole,
2-(5-(4-bromophenyl)- 1 -(2,4-dichlorophenyl)-4-ethyl- 1 H-pyrazol-3-yl)-5- ( 1 -(cyclopropylmethyl)cyclopropyl)- 1 ,3 ,4-oxadiazole,
2-(5-(4-bromophenyl)-3-(5-tert-butyl-l,3,4-thiadiazol-2-yl)-l-(2,4-dichlorophenyl)- 1 H-pyrazol-4-yl)propan-2-ol,
1 -(3-(5-tert-butyl- 1 ,3,4-thiadiazol-2-yl)-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)- lH-pyrazol-4-yl)ethanol, and a pharmaceutically acceptable salt thereof.
4. A method for preparing the compound of formula (Ia), which comprises (i) reacting a carboxylic acid derivative of formula (5) with a hydrazide compound of formula (7) or a semicarbazide compound of formula (12) in the presence of a coupling reagent in a solvent, or reacting a hydrazide derivative of formula (A) with a carboxylic acid derivative in the presence of a coupling reagent, and (ii) cyclizing the resulting product using a dehydrating agent:
Figure imgf000273_0001
O
R2- N H (7)
Figure imgf000273_0002
wherein Ri, R2, R3, R4, R6, R7, Rs, R9, Rio and Rn have the same meanings as defined in claim 1.
5. A method for preparing the compound of formula (Ib), which comprises (i) reacting a carboxylic acid of formula (5) with a hydrazide compound of formula (7) in the presence of coupling agents in a solvent, or reacting a hydrazide derivative of formula (A) with a carboxylic acid derivative in the presence of a suitable coupling reagent and (ii) cyclizing the resulting product using a Lawesson's reagent:
Figure imgf000274_0001
wherein R1, R2, R6, R7, R8, R9, R10 and Rn have the same meanings as defined in claim 1.
6. A method for preparing the compound of formula (Id), which comprises reacting a nitrile intermediate of formula (19) with a hydrazide compound of formula (7) in the presence of a catalyst in a solvent:
Figure imgf000275_0001
wherein R1, R2, R6, R7, R8, R9, Rj0, Rj 1 and R13 have the same meanings as defined in claim 1.
7. A method for preparing the compound of formula (Ie) or (If), which comprises reacting a nitrile intermediate of formula (19) with sodium azide in the presence of a base in a solvent and optionally alkylating or acylating the resulting product:
Figure imgf000275_0002
Figure imgf000276_0001
wherein R1, R2, R6, R7, R8, R9, Rio, Rn and R13 have the same meanings as defined in claim 1.
8. A method for preparing the compound of formula (Ig), which comprises reacting a carboxylic acid intermediate (5) with an aminoketone in the presence of a coupling reagent and cyclizing the resulting product using a dehydrating agent:
Figure imgf000276_0002
wherein R1, R2, R6, R7, R8, R9, R10, Rn and Ri2 have the same meanings as defined in claim 1.
9. A method for preparing the compound of formula (Ih), which comprises reacting a carboxylic acid intermediate (5) with an aminoketone in the presence of a coupling reagent and cyclizing the resulting product using a Lawesson's reagent:
Figure imgf000277_0001
wherein R1, R2, R6, R7, R8, R9, Rio, Rn and R12 have the same meanings as defined in claim 1.
10. A pharmaceutical composition comprising the compound of formula (I) of claim 1 as an active ingredient and a pharmaceutically acceptable carrier.
11. A method for preventing or treating obesity or an obesity-related metabolic disorders in a mammal, which comprises administering the compound of formula (I) of claim 1 to the mammal.
12. A method for inhibiting cannabinoid CBj receptor in a mammal, which comprises administering the compound of formula (I) of claim 1 to the mammal.
PCT/KR2007/004754 2006-09-29 2007-09-28 Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists WO2008039023A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07833072A EP2097410A4 (en) 2006-09-29 2007-09-28 Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists
KR1020097008743A KR101100028B1 (en) 2006-09-29 2007-09-28 Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists
JP2009530273A JP5269795B2 (en) 2006-09-29 2007-09-28 Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
CN2007800363304A CN101528740B (en) 2006-09-29 2007-09-28 Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/541,269 US20080081815A1 (en) 2006-09-29 2006-09-29 Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
US11/541,269 2006-09-29
KR20060132606 2006-12-22
KR10-2006-0132606 2006-12-22

Publications (1)

Publication Number Publication Date
WO2008039023A1 true WO2008039023A1 (en) 2008-04-03

Family

ID=39234790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/004754 WO2008039023A1 (en) 2006-09-29 2007-09-28 Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists

Country Status (5)

Country Link
EP (1) EP2097410A4 (en)
JP (1) JP5269795B2 (en)
KR (1) KR101100028B1 (en)
CN (1) CN101528740B (en)
WO (1) WO2008039023A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2012147764A1 (en) * 2011-04-27 2012-11-01 塩野義製薬株式会社 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity
US20130178457A1 (en) * 2011-07-05 2013-07-11 Lupin Limited Cannabinoid receptor modulators
WO2015162452A1 (en) * 2014-04-23 2015-10-29 Piramal Enterprises Limited Substituted pyrazole compounds as cb1 receptor antagonists and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5539322B2 (en) * 2008-04-22 2014-07-02 イーライ リリー アンド カンパニー 1,5-Diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
JP5539323B2 (en) * 2008-04-22 2014-07-02 イーライ リリー アンド カンパニー 1,5-Diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
CA2900295C (en) 2013-03-14 2021-04-27 Hunter Douglas Inc. Methods and apparatus to control an architectural opening covering assembly
CN108586436A (en) * 2018-07-06 2018-09-28 南京大学 Bishydrazide derivative of one kind skeleton containing indoles and its preparation method and application

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906252A1 (en) * 1979-02-19 1980-08-28 Merck Patent Gmbh PYRAZOLE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF
EP0418845A1 (en) * 1989-09-22 1991-03-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US5462960A (en) 1993-12-17 1995-10-31 Sanofi Pyrazole-3-carboxamide derivatives, process for their preparation and pharmaceutical compositions in which they are present
WO2004035566A1 (en) * 2002-10-18 2004-04-29 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
WO2005032550A2 (en) 2002-12-18 2005-04-14 Smithkline Beecham Corporation Peptide deformylase inhibitors
WO2005058848A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2006087480A1 (en) * 2005-02-21 2006-08-24 Sanofi-Aventis (1,5-diphenyl-1h-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
AU2001267824A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cancer
AU2002313633B2 (en) * 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP1732904B1 (en) * 2004-03-29 2014-03-19 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906252A1 (en) * 1979-02-19 1980-08-28 Merck Patent Gmbh PYRAZOLE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF
EP0418845A1 (en) * 1989-09-22 1991-03-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US5462960A (en) 1993-12-17 1995-10-31 Sanofi Pyrazole-3-carboxamide derivatives, process for their preparation and pharmaceutical compositions in which they are present
WO2004035566A1 (en) * 2002-10-18 2004-04-29 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
WO2005032550A2 (en) 2002-12-18 2005-04-14 Smithkline Beecham Corporation Peptide deformylase inhibitors
WO2005058848A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2006087480A1 (en) * 2005-02-21 2006-08-24 Sanofi-Aventis (1,5-diphenyl-1h-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRUNO P. IMBIMBO ET AL., J. MED. CHEM., vol. 48, 2005, pages 5707 - 5720
HENRYK KRAWCZYK ET AL., SYNLETT, vol. 17, 2005, pages 2648 - 2652
J. MED. CHEM., vol. 42, 1999, pages 769 - 776
KRAWCZYK, H., SYNLEN., vol. 17, 2005, pages 2648 - 2652
See also references of EP2097410A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2012147764A1 (en) * 2011-04-27 2012-11-01 塩野義製薬株式会社 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity
US8916594B2 (en) 2011-04-27 2014-12-23 Shionogi & Co., Ltd. 5-membered ring heteroaromatic derivatives having NPY Y5 receptor antagonistic activity
RU2605207C2 (en) * 2011-04-27 2016-12-20 Шионоги Энд Ко., Лтд. Heterocyclic derivative with aromatic 5-member cycle possessing npy y5 receptor antagonist activity
KR101893237B1 (en) 2011-04-27 2018-08-29 시오노기세야쿠 가부시키가이샤 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity
US20130178457A1 (en) * 2011-07-05 2013-07-11 Lupin Limited Cannabinoid receptor modulators
US9006442B2 (en) * 2011-07-05 2015-04-14 Lupin Limited Cannabinoid receptor modulators
WO2015162452A1 (en) * 2014-04-23 2015-10-29 Piramal Enterprises Limited Substituted pyrazole compounds as cb1 receptor antagonists and uses thereof

Also Published As

Publication number Publication date
EP2097410A1 (en) 2009-09-09
KR101100028B1 (en) 2011-12-29
KR20090061076A (en) 2009-06-15
CN101528740A (en) 2009-09-09
JP2010504961A (en) 2010-02-18
JP5269795B2 (en) 2013-08-21
CN101528740B (en) 2012-09-19
EP2097410A4 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
WO2008039023A1 (en) Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists
AU2011287574B2 (en) N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein
CA2483159C (en) Triazole derivatives as tachykinin receptor antagonists
JP6244365B2 (en) [Orthobi- (hetero-) aryl]-[2- (methabi- (hetero-) aryl) -pyrrolidin-1-yl] -methanone derivatives orexin receptor antagonists
AU2007303889B2 (en) mGluR5 modulators
TWI808305B (en) Substituted bicyclic compounds as farnesoid x receptor modulators
IL238044A (en) 2-chloro-4-(1h-pyrazol-5-yl)benzonitrile and (s)-4-(1-(2-aminopropyl)-1h-pyrazol-3-yl)-2-chlorobenzonitrile as intermediates in the process for preparing (s)-3-acetyl-n-(1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)propan-2-yl)-1h-pyrazole-5-carboxamide
AU2007333992A1 (en) Compounds and compositions as inhibitors of Cannabinoid Receptor 1 activity
WO2012020820A1 (en) Heteroaryl-pyrazole derivative
AU2006331437A1 (en) Aryl-Isoxazol-4-yl-Imidazole derivatives
JP2018522893A5 (en)
US7875647B2 (en) Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
WO2008105607A1 (en) Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists
WO2009078498A1 (en) Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands
US20080081815A1 (en) Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
US8309584B2 (en) Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists
WO2013111796A1 (en) N-substituted pyrazole derivative
US20080207705A1 (en) Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780036330.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07833072

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2009530273

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007833072

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2724/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020097008743

Country of ref document: KR